1 00:00:05,760 --> 00:00:10,760 WELCOME TO THE 148th MEETING 2 00:00:10,760 --> 00:00:12,400 OF THE NATIONAL ADVISORY COUNCIL 3 00:00:12,400 --> 00:00:14,240 ON AGING. 4 00:00:14,240 --> 00:00:16,880 MY NAME IS KEN SANTORA, THE 5 00:00:16,880 --> 00:00:18,760 DIRECTOR OF THE DIVISION OF 6 00:00:18,760 --> 00:00:20,960 EXTRAMURAL ACTIVITIES HERE AT 7 00:00:20,960 --> 00:00:25,000 NIA AND THE EXECUTIVE COUNCIL. 8 00:00:25,000 --> 00:00:26,200 FIRST OFF, BEFORE I TURN THE 9 00:00:26,200 --> 00:00:28,600 MEETING OVER TO OUR DIRECTOR, 10 00:00:28,600 --> 00:00:32,640 DR. RICHARD HODES, I'M GOING TO 11 00:00:32,640 --> 00:00:34,120 DO A ROLL CALL OF OUR COUNCIL 12 00:00:34,120 --> 00:00:34,320 MEMBERS. 13 00:00:34,320 --> 00:00:37,000 WHEN I CALL YOUR NAME, IF YOU 14 00:00:37,000 --> 00:00:38,120 COULD PLEASE INTRODUCE YOURSELF, 15 00:00:38,120 --> 00:00:41,600 GIVE YOUR NAME AND AFFILIATIONS 16 00:00:41,600 --> 00:00:44,200 AND WE'LL GO FROM THERE. 17 00:00:44,200 --> 00:00:47,560 SO STARTING OFF, DR. BAKER. 18 00:00:47,560 --> 00:00:49,800 >>OKAY, DARIN BAKER, MAYO 19 00:00:49,800 --> 00:00:50,400 CLINICMENT ASSOCIATE PROFESSOR 20 00:00:50,400 --> 00:00:53,280 OF BIOCHEMISTRY AND MOLECULAR 21 00:00:53,280 --> 00:00:55,760 BEAMINGY AND PEDIATRIC MEDICINE, 22 00:00:55,760 --> 00:00:57,840 VERY FUNNY AS BEING PART OF THE 23 00:00:57,840 --> 00:00:58,440 NATIONAL ADVISORY COUNCIL ON 24 00:00:58,440 --> 00:00:59,080 AGING. 25 00:00:59,080 --> 00:01:00,200 I HAVE BEEN HERE ROUGHLY A 26 00:01:00,200 --> 00:01:02,200 LITTLE OVER A YEAR AT THIS 27 00:01:02,200 --> 00:01:02,720 POINT. 28 00:01:02,720 --> 00:01:07,120 >>THANK YOU, DARIN. 29 00:01:07,120 --> 00:01:13,000 SHELLY? 30 00:01:13,000 --> 00:01:13,880 >>SHELLY, PROFESSOR OF MEDICINE 31 00:01:13,880 --> 00:01:15,840 AT HARVARD MEDICAL SCHOOL. 32 00:01:15,840 --> 00:01:17,840 I'M AN ENDOCRINOLOGIST BY 33 00:01:17,840 --> 00:01:19,680 TRAINING BUT MUCH OF MY RECENT 34 00:01:19,680 --> 00:01:24,600 WORK HAS BEEN IN AGING BIOLOGY. 35 00:01:24,600 --> 00:01:26,800 >>THANK YOU. 36 00:01:26,800 --> 00:01:33,520 DR. CASE. 37 00:01:33,520 --> 00:01:35,120 >>I'M ANN CASE, AN ECONOMIST AT 38 00:01:35,120 --> 00:01:36,480 PRINCETON UNIVERSITY AND MOST OF 39 00:01:36,480 --> 00:01:38,560 MY RECENT WORK HAS BEEN ON MID 40 00:01:38,560 --> 00:01:42,480 LIFE MORBIDITY AND MORTALITY AND 41 00:01:42,480 --> 00:01:45,120 ITS MOVEMENT INTO OLD AGE. 42 00:01:45,120 --> 00:01:49,160 >>THANK YOU. 43 00:01:49,160 --> 00:01:49,480 DR. CRUISE. 44 00:01:49,480 --> 00:01:52,520 >>GOOD MORNING. 45 00:01:52,520 --> 00:01:53,920 I AM THE PRESIDENT AND CEO FOR 46 00:01:53,920 --> 00:01:55,400 THE NATIONAL HISPANIC COUNCIL ON 47 00:01:55,400 --> 00:01:56,240 AGING. 48 00:01:56,240 --> 00:01:58,400 I HAVE A DOCTORATE IN PUBLIC 49 00:01:58,400 --> 00:02:02,040 HEALTH AND MOST OF MY WORK IS 50 00:02:02,040 --> 00:02:04,240 FOCUSED ON HISPANIC ISSUES AND 51 00:02:04,240 --> 00:02:06,040 OLDER ADULTS. 52 00:02:06,040 --> 00:02:07,880 >>THANK YOU. 53 00:02:07,880 --> 00:02:08,200 DR. DRISCOL. 54 00:02:08,200 --> 00:02:09,680 >>HI, GOOD MORNING. 55 00:02:09,680 --> 00:02:11,600 MONICA DRISCOL. 56 00:02:11,600 --> 00:02:13,000 DISTINGUISHED PROFESSOR IN THE 57 00:02:13,000 --> 00:02:13,920 DEPARTMENT OF MOLECULAR BIOLOGY 58 00:02:13,920 --> 00:02:16,480 AND BIOCHEMISTRY AT RUTGERS. 59 00:02:16,480 --> 00:02:18,200 MY RESEARCH INTERESTS ARE IN THE 60 00:02:18,200 --> 00:02:21,440 VERY FUNDAMENTAL BIOLOGY OF 61 00:02:21,440 --> 00:02:25,000 AGING AND NEURODEGENERATION. 62 00:02:25,000 --> 00:02:26,360 >>THANK YOU. 63 00:02:26,360 --> 00:02:26,680 DR. GREENSPAN. 64 00:02:26,680 --> 00:02:28,280 >>HI, I'M SUSAN GREENSPAN, 65 00:02:28,280 --> 00:02:29,800 PROFESSOR OF MEDICINE AT 66 00:02:29,800 --> 00:02:31,200 UNIVERSITY OF PITTSBURGH. 67 00:02:31,200 --> 00:02:34,080 I'M TRAINED ENDOCRINOLOGIST AND 68 00:02:34,080 --> 00:02:36,800 GERIATRICIAN AND MY FOCUS HAS 69 00:02:36,800 --> 00:02:41,080 BEEN ON FRAILTY, FALLS AND 70 00:02:41,080 --> 00:02:41,880 FRACTURES. 71 00:02:41,880 --> 00:02:44,680 >>THANK YOU. 72 00:02:44,680 --> 00:02:44,960 DR. WONG? 73 00:02:44,960 --> 00:02:46,720 I'M NOT SURE IF YOU CAN 74 00:02:46,720 --> 00:02:47,760 INTRODUCE -- 75 00:02:47,760 --> 00:02:53,600 >>I HOPE -- I GET BETTER TODAY. 76 00:02:53,600 --> 00:02:56,840 SENIOR INVESTIGATOR AT -- AND 77 00:02:56,840 --> 00:03:04,760 PROFESSOR AT UROLOGY UCSF. 78 00:03:04,760 --> 00:03:06,600 >>THANK YOU. 79 00:03:06,600 --> 00:03:10,040 >>I'M CYNTHIA HUMBLE, RETIRED 80 00:03:10,040 --> 00:03:12,000 PRESBYTERIAN PASTOR. 81 00:03:12,000 --> 00:03:13,280 ALZHEIMER'S AND DEMENTIA 82 00:03:13,280 --> 00:03:15,680 ADVOCATE AND I HAVE BEEN A 83 00:03:15,680 --> 00:03:16,280 RESEARCH PARTICIPANT FOR MORE 84 00:03:16,280 --> 00:03:25,880 THAN 13 YEARS. 85 00:03:25,880 --> 00:03:26,360 THANK YOU DR. WONGO? 86 00:03:26,360 --> 00:03:26,680 FRANK? 87 00:03:26,680 --> 00:03:36,600 ARE YOU ON? 88 00:03:36,600 --> 00:03:39,040 WE'LL COME BACK TO HIM. 89 00:03:39,040 --> 00:03:39,400 DR. MANLY. 90 00:03:39,400 --> 00:03:40,720 >>JENNIFER MANLY. 91 00:03:40,720 --> 00:03:44,320 I AM A NEUROPSYCHOLOGIST AND A 92 00:03:44,320 --> 00:03:47,200 PROFESSOR IN THE DEPARTMENT OF 93 00:03:47,200 --> 00:03:48,440 NEUROLOGY AT COLUMBIA 94 00:03:48,440 --> 00:03:48,720 UNIVERSITY. 95 00:03:48,720 --> 00:03:51,360 AND MY RESEARCH IS ON LIFE 96 00:03:51,360 --> 00:03:54,000 COURSE STRUCTURAL AND SOCIAL 97 00:03:54,000 --> 00:03:55,400 INFLUENCES ON COGNITIVE AGING 98 00:03:55,400 --> 00:04:00,120 AND ALZHEIMER'S DISEASE. 99 00:04:00,120 --> 00:04:01,960 >>THANK YOU. 100 00:04:01,960 --> 00:04:02,320 DR. PETERSEN? 101 00:04:02,320 --> 00:04:03,080 >>GOOD MORNING. 102 00:04:03,080 --> 00:04:04,240 I'M CHARLOTTE PETERSON, 103 00:04:04,240 --> 00:04:07,200 PROFESSOR AT THE UNIVERSITY OF 104 00:04:07,200 --> 00:04:08,760 KENTUCKY AND MY RESEARCH -- I'M 105 00:04:08,760 --> 00:04:10,240 A MOLECULAR AND CELLULAR 106 00:04:10,240 --> 00:04:13,200 BIOLOGIST WITH FOCUS ON MUSCLE 107 00:04:13,200 --> 00:04:14,440 WASTING, SARK PENIA AND LOSS OF 108 00:04:14,440 --> 00:04:15,560 FUNCTIONAL INDEPENDENCE WITH 109 00:04:15,560 --> 00:04:17,080 AGE. 110 00:04:17,080 --> 00:04:19,040 >>THANK YOU. 111 00:04:19,040 --> 00:04:20,600 DR. RUBIN. 112 00:04:20,600 --> 00:04:21,480 >>I'M DAVE RUBIN, GERIATRICIAN 113 00:04:21,480 --> 00:04:23,880 BASED AT UCLA AND MOST OF MY 114 00:04:23,880 --> 00:04:28,080 WORK HAS BEEN ON HEALTH SERVICES 115 00:04:28,080 --> 00:04:30,200 RESEARCH, INCLUDING 116 00:04:30,200 --> 00:04:31,120 IMPLEMENTATION AND SOME LARGE 117 00:04:31,120 --> 00:04:33,440 CLINICAL TRIALS, INCLUDING WITH 118 00:04:33,440 --> 00:04:34,760 SHALLY. 119 00:04:34,760 --> 00:04:36,600 AND THEN MY CURRENT WORK FOCUSES 120 00:04:36,600 --> 00:04:38,800 ALMOST EXCLUSIVELY ON DEMENTIA 121 00:04:38,800 --> 00:04:43,240 AND IMPROVING THE CARE OF PEOPLE 122 00:04:43,240 --> 00:04:44,400 WHO HAVE DEMENTIA. 123 00:04:44,400 --> 00:04:47,760 I HAVE A VERY CLINICAL TRIAL 124 00:04:47,760 --> 00:04:50,240 WITH PCORI AT NIA WE ARE IN THE 125 00:04:50,240 --> 00:04:52,040 MIDST OF. 126 00:04:52,040 --> 00:04:56,560 >>THANK YOU. 127 00:04:56,560 --> 00:04:58,240 DR. SNYDER? 128 00:04:58,240 --> 00:04:59,480 >>GOOD MORNING, EVERYBODY. 129 00:04:59,480 --> 00:05:04,080 I'M JULIE SNYDER. 130 00:05:04,080 --> 00:05:06,520 -- DEPARTMENT OF PATHOLOGY. 131 00:05:06,520 --> 00:05:10,200 IN OR ABOUTO PATHOLOGIST AND 132 00:05:10,200 --> 00:05:10,760 ENDOCRINOLOGIST -- DISEASE 133 00:05:10,760 --> 00:05:13,800 CENTER WHERE STUDY MOSTLY THE 134 00:05:13,800 --> 00:05:16,320 NEUROPATHOLOGY BASIS OF DECLINE 135 00:05:16,320 --> 00:05:17,760 AND MOTOR DECLINE WITH AGING. 136 00:05:17,760 --> 00:05:21,160 ESPECIALLY INTERESTED IN 137 00:05:21,160 --> 00:05:22,760 TRANSLATIONAL EFFORTS AND 138 00:05:22,760 --> 00:05:28,080 BIOMARKERS AND MECHANISMS, 139 00:05:28,080 --> 00:05:30,080 ESPECIALLY 140 00:05:30,080 --> 00:05:33,960 [ INAUDIBLE ] 141 00:05:33,960 --> 00:05:34,320 >>DR. BEN? 142 00:05:34,320 --> 00:05:35,560 >>I'M LINDA VANELEDDIC, 143 00:05:35,560 --> 00:05:37,240 DIRECTOR OF THE BROWN CENTER ON 144 00:05:37,240 --> 00:05:39,320 AGING AND THE UNIVERSITY OF 145 00:05:39,320 --> 00:05:41,320 KENTUCKY ALZHEIMER'S DISEASE 146 00:05:41,320 --> 00:05:42,560 CENTER AND PROFESSOR OF 147 00:05:42,560 --> 00:05:42,920 NEUROSCIENCE. 148 00:05:42,920 --> 00:05:46,040 MY OWN RESEARCH IS ON 149 00:05:46,040 --> 00:05:47,240 TRANSLATIONAL NEUROSCIENCE IN 150 00:05:47,240 --> 00:05:50,600 TERMS OF DYSREGULATED BRAIN 151 00:05:50,600 --> 00:05:53,640 INFLAMMATION AND USING THAT AS 152 00:05:53,640 --> 00:05:55,440 THERAPEUTIC TARGETS SO I BROUGHT 153 00:05:55,440 --> 00:05:58,080 COMPOUNDS INTO HUMAN TRIALS. 154 00:05:58,080 --> 00:05:59,120 >>THANK YOU. 155 00:05:59,120 --> 00:06:01,880 AND DR. WE'RE. 156 00:06:01,880 --> 00:06:02,360 >>I'M DAVID WE'RE. 157 00:06:02,360 --> 00:06:03,760 A PROFESSOR IN THE INSTITUTE FOR 158 00:06:03,760 --> 00:06:05,080 SOCIAL RESEARCH AT THE 159 00:06:05,080 --> 00:06:06,480 UNIVERSITY OF MICHIGAN AND 160 00:06:06,480 --> 00:06:08,920 DIRECTOR OF THE HEALTH AND 161 00:06:08,920 --> 00:06:09,320 RETIREMENT STUDY. 162 00:06:09,320 --> 00:06:09,960 I'M INTERESTED IN JUST ABOUT 163 00:06:09,960 --> 00:06:11,880 ANYTHING WE CAN LEARN ABOUT THE 164 00:06:11,880 --> 00:06:14,960 LIVES OF OLDER PEOPLE. 165 00:06:14,960 --> 00:06:16,440 >>THANK YOU. 166 00:06:16,440 --> 00:06:18,080 AND DR. WET FIELD. 167 00:06:18,080 --> 00:06:21,280 >>MORNING, EVERYONE. 168 00:06:21,280 --> 00:06:21,760 I'M KEITH WHITFIELD. 169 00:06:21,760 --> 00:06:24,480 I'M PROFESSOR OF PSYCHOLOGY, 170 00:06:24,480 --> 00:06:25,080 PROFESSOR OF BRAIN HEALTH AS 171 00:06:25,080 --> 00:06:27,240 WELL AS THE PRESIDENT OF THE 172 00:06:27,240 --> 00:06:29,480 UNIVERSITY OF LAS VEGAS. 173 00:06:29,480 --> 00:06:32,040 MY RESEARCH IS ON COGNITIVE 174 00:06:32,040 --> 00:06:33,240 AGING IN AFRICAN-AMERICANS AS 175 00:06:33,240 --> 00:06:35,280 WELL AS LONGEVITY IN 176 00:06:35,280 --> 00:06:36,360 AFRICAN-AMERICANS. 177 00:06:36,360 --> 00:06:37,280 THANK YOU. 178 00:06:37,280 --> 00:06:38,520 >>THANK YOU. 179 00:06:38,520 --> 00:06:42,520 AND BACK TO DR. LONGO. 180 00:06:42,520 --> 00:06:43,320 >>MORNING, EVERYONE. 181 00:06:43,320 --> 00:06:45,400 I'M FRANK LONG OH, NEUROLOGIST. 182 00:06:45,400 --> 00:06:48,040 I CHAIR THE DEPARTMENT OF 183 00:06:48,040 --> 00:06:49,160 NEUROLOGY AT STAMFORD. 184 00:06:49,160 --> 00:06:52,080 MY RESEARCH IS FOCUSED ON 185 00:06:52,080 --> 00:06:54,040 MECHANISM ELUCIDATION RELEVANT 186 00:06:54,040 --> 00:06:55,360 TO SYNAPSE DEGENERATION, 187 00:06:55,360 --> 00:06:56,920 ESPECIALLY IN CREATING SMALL 188 00:06:56,920 --> 00:06:59,800 MOLECULE APPROACHES TO TARGET 189 00:06:59,800 --> 00:07:00,480 THOSE MECHANISMS AND WE HAVE 190 00:07:00,480 --> 00:07:02,560 BROUGHT COMPOUNDS FROM IN VITRO 191 00:07:02,560 --> 00:07:05,800 THROUGH MICE AND INTO HUMAN 192 00:07:05,800 --> 00:07:06,040 TRIALS. 193 00:07:06,040 --> 00:07:07,440 >>THANK YOU. 194 00:07:07,440 --> 00:07:12,160 WE ALSO HAVE OUR EX-OFFICIO 195 00:07:12,160 --> 00:07:15,320 MEMBERS, DR. VAHALLA. 196 00:07:15,320 --> 00:07:18,280 >>HI, GOOD MORNING. 197 00:07:18,280 --> 00:07:21,000 I'M HOLLY FROM THE NATIONAL 198 00:07:21,000 --> 00:07:21,920 INSTITUTE ON DISABILITY AND 199 00:07:21,920 --> 00:07:23,240 INDEPENDENT LIVING AND 200 00:07:23,240 --> 00:07:24,640 REHABILITATION RESEARCH. 201 00:07:24,640 --> 00:07:28,080 THANK YOU. 202 00:07:28,080 --> 00:07:30,800 >>THANK YOU. 203 00:07:30,800 --> 00:07:31,000 DR. . 204 00:07:31,000 --> 00:07:32,240 >>ANN ORD WAY, PROGRAM 205 00:07:32,240 --> 00:07:33,840 SPECIALIST AT THE NATIONAL 206 00:07:33,840 --> 00:07:34,360 INSTITUTE ON DISABILITY 207 00:07:34,360 --> 00:07:35,440 INDEPENDENT LIVING AND 208 00:07:35,440 --> 00:07:37,160 REHABILITATION RESEARCH AND I 209 00:07:37,160 --> 00:07:38,840 LEAD THE RESEARCH PORTFOLIO AT 210 00:07:38,840 --> 00:07:39,560 THE INTERSECTION OF DISABILITY 211 00:07:39,560 --> 00:07:41,680 AND AGING. 212 00:07:41,680 --> 00:07:42,680 >>THANK YOU. 213 00:07:42,680 --> 00:07:45,280 AND FINALLY WE HAVE A FEW AD-HOC 214 00:07:45,280 --> 00:07:45,920 MEMBERS. 215 00:07:45,920 --> 00:07:49,880 THESE MEMBERS WILL BE OUR -- 216 00:07:49,880 --> 00:07:51,680 SOON ON-BOARDED AND BE OUR 217 00:07:51,680 --> 00:07:53,800 COUNCIL MEMBERS COME MAY. 218 00:07:53,800 --> 00:07:58,520 SO WE'LL INTRODUCE THEM. 219 00:07:58,520 --> 00:07:59,040 DR. SPANNA? 220 00:07:59,040 --> 00:08:01,200 >>GOOD MORNING. 221 00:08:01,200 --> 00:08:03,200 SANJAY, UNIVERSITY 222 00:08:03,200 --> 00:08:05,360 WISCONSIN-MADISON. 223 00:08:05,360 --> 00:08:08,760 I'M -- PROFESSOR OF MEDICINE IN. 224 00:08:08,760 --> 00:08:10,480 [ BACKGROUND NOISE ] 225 00:08:10,480 --> 00:08:12,560 AT THE MEDICAL SCHOOL. 226 00:08:12,560 --> 00:08:14,880 ALSO DIRECTSOR OF THE WIG 227 00:08:14,880 --> 00:08:16,080 CONSIN -- AND HEAD AT THE 228 00:08:16,080 --> 00:08:16,560 MEDICAL SCHOOL. 229 00:08:16,560 --> 00:08:19,360 MY RESEARCH INTERESTS ARE IN 230 00:08:19,360 --> 00:08:21,320 PRE-CLINICAL BIOMARKERS OF 231 00:08:21,320 --> 00:08:22,120 ALZHEIMER'S DISEASE AND I HAVE 232 00:08:22,120 --> 00:08:24,760 DONE A NUMBER OF CLINICAL TRIALS 233 00:08:24,760 --> 00:08:27,240 INVOLVING HORMONES, COGNITION 234 00:08:27,240 --> 00:08:31,760 AND DEMENTIA. 235 00:08:31,760 --> 00:08:33,160 >>THANK YOU. 236 00:08:33,160 --> 00:08:34,160 DR.-- 237 00:08:34,160 --> 00:08:36,120 >>GOOD MORNING. 238 00:08:36,120 --> 00:08:37,480 I AM -- LA BETTERO. 239 00:08:37,480 --> 00:08:39,160 I'M NOT A DOCTOR YET, STILL 240 00:08:39,160 --> 00:08:42,040 WORKING ON MY DISSERTATION. 241 00:08:42,040 --> 00:08:47,520 I AM PROFOUNDLY GRATEFUL TO BE 242 00:08:47,520 --> 00:08:48,000 HERE. 243 00:08:48,000 --> 00:08:50,040 AND STRENGTH END BY ALL YOUR 244 00:08:50,040 --> 00:08:51,120 EXPERTISE AND INTERESTS. 245 00:08:51,120 --> 00:08:57,000 I AM A LONG -- LIFELONG, I WOULD 246 00:08:57,000 --> 00:09:00,160 SAY, CAREGIVER AND CARE PARTNER 247 00:09:00,160 --> 00:09:03,560 FOR MY FAMILY AND MY MOTHER. 248 00:09:03,560 --> 00:09:05,240 CURRENTLY WHO IS IN A NURSING 249 00:09:05,240 --> 00:09:05,440 HOME. 250 00:09:05,440 --> 00:09:08,360 AND I AM A PATIENT ADVOCATE, 251 00:09:08,360 --> 00:09:11,640 SUPPORTER AND MY INTERESTS IN 252 00:09:11,640 --> 00:09:13,000 RESEARCH ARE CONTRIBUTING ALL I 253 00:09:13,000 --> 00:09:17,000 CAN TO MOVE FORWARD RESEARCH 254 00:09:17,000 --> 00:09:20,000 THAT WILL GIVE US A BETTER 255 00:09:20,000 --> 00:09:21,600 TREATMENT AND HOPEFULLY SOME DAY 256 00:09:21,600 --> 00:09:22,080 A CURE. 257 00:09:22,080 --> 00:09:22,680 THANK YOU. 258 00:09:22,680 --> 00:09:24,160 FOR ALZHEIMER'S DISEASE. 259 00:09:24,160 --> 00:09:28,760 THANK YOU. 260 00:09:28,760 --> 00:09:30,840 >>THANK YOU. 261 00:09:30,840 --> 00:09:31,120 DR. ANONI? 262 00:09:31,120 --> 00:09:32,720 >>YES, HI. 263 00:09:32,720 --> 00:09:34,800 I'M SHARON AND I AM REALLY 264 00:09:34,800 --> 00:09:35,240 HONORED TO BE HERE. 265 00:09:35,240 --> 00:09:37,840 I'M A PROFESSOR OF MEDICINE AT 266 00:09:37,840 --> 00:09:39,520 HARVARD MEDICAL SCHOOL. 267 00:09:39,520 --> 00:09:41,160 I'M TRAINED AS A GERIATRICIAN 268 00:09:41,160 --> 00:09:43,880 AND CLINICAL EPIDEMIOLOGIST. 269 00:09:43,880 --> 00:09:45,440 I'M BASED AT THE MARCUS 270 00:09:45,440 --> 00:09:49,000 INSTITUTE FOR AGING RESEARCH. 271 00:09:49,000 --> 00:09:52,720 AND MY RESEARCH FOCUSES ON 272 00:09:52,720 --> 00:09:53,840 REVERSIBLE CONTRIBUTORS TO 273 00:09:53,840 --> 00:09:56,160 COGNITIVE IMPAIRMENT, MOST 274 00:09:56,160 --> 00:09:57,880 SPECIFICALLY THE INTERFACE OF 275 00:09:57,880 --> 00:09:59,720 DELIRIUM AND DEMENTIA. 276 00:09:59,720 --> 00:10:03,000 AND I DO STUDIES RANGING FROM 277 00:10:03,000 --> 00:10:07,200 CLINICAL TO TRANSLATIONAL AND 278 00:10:07,200 --> 00:10:08,840 IMPLEMENTATION RESEARCH. 279 00:10:08,840 --> 00:10:10,520 THANK YOU. 280 00:10:10,520 --> 00:10:13,160 >>THANK YOU. 281 00:10:13,160 --> 00:10:16,520 DR. COLIN? 282 00:10:16,520 --> 00:10:18,440 >>HI, GOOD MORNING. 283 00:10:18,440 --> 00:10:21,880 I'M DR. KAHN. 284 00:10:21,880 --> 00:10:24,880 AND THIS IS A EXTREMELY 285 00:10:24,880 --> 00:10:26,640 IMPRESSIVE PANEL. 286 00:10:26,640 --> 00:10:28,280 FOR THE LAST TWO DAYS I'M 287 00:10:28,280 --> 00:10:29,920 THINKING WHAT AM I DOING HERE? 288 00:10:29,920 --> 00:10:33,160 BUT A LITTLE BIT ABOUT ME. 289 00:10:33,160 --> 00:10:36,960 I AM A TRAINED EPIDEMIOLOGIST. 290 00:10:36,960 --> 00:10:38,320 WENT TO MED SCHOOL AND HAVE BEEN 291 00:10:38,320 --> 00:10:41,160 WORKING WITH CHEROKEES FOR 29 292 00:10:41,160 --> 00:10:41,360 YEARS. 293 00:10:41,360 --> 00:10:43,840 SO THE REASON FOR ME BEING HERE 294 00:10:43,840 --> 00:10:47,720 IS TO REPRESENT THE ISSUES 295 00:10:47,720 --> 00:10:53,160 FACING THE CHEROKEES AND AI IN 296 00:10:53,160 --> 00:10:53,440 COMMUNITIES. 297 00:10:53,440 --> 00:10:54,680 AND EVERY NOW AND THEN YOU WILL 298 00:10:54,680 --> 00:10:57,040 SEE MY COMMENTS THERE ARE UNIQUE 299 00:10:57,040 --> 00:10:58,960 ABOUT THEIR POINT OF VIEW AND 300 00:10:58,960 --> 00:11:01,880 PERSPECTIVE AND NEEDS IN TERMS 301 00:11:01,880 --> 00:11:03,680 OF RESEARCH. 302 00:11:03,680 --> 00:11:05,280 ALZHEIMER'S IS AN ISSUE AND 303 00:11:05,280 --> 00:11:07,680 AGING AND LIMITED RESOURCES AND 304 00:11:07,680 --> 00:11:09,880 I HAVE BEEN WORKING THERE FOR 305 00:11:09,880 --> 00:11:12,000 QUITE A LONG TIME. 306 00:11:12,000 --> 00:11:13,920 LIVED THERE IN RURAL OKLAHOMA. 307 00:11:13,920 --> 00:11:18,520 SO I BRING THAT PERSPECTIVE AND 308 00:11:18,520 --> 00:11:20,800 THE UNIQUE THING ABOUT ME YOU'LL 309 00:11:20,800 --> 00:11:22,000 FIND OUT PRETTY SOON, I'M NOT 310 00:11:22,000 --> 00:11:25,280 SHY ABOUT SHARING MY THOUGHTS. 311 00:11:25,280 --> 00:11:28,680 >>VERY GOOD, THANK YOU. 312 00:11:28,680 --> 00:11:34,760 AND FINALLY NANCY LYNDEN BERG. 313 00:11:34,760 --> 00:11:35,200 >>HI, I'M NANCY. 314 00:11:35,200 --> 00:11:36,760 CEO OF THE AMERICAN GERIATRIC 315 00:11:36,760 --> 00:11:39,080 SOCIETY AND A RECOVERING 316 00:11:39,080 --> 00:11:39,840 CAREGIVER. 317 00:11:39,840 --> 00:11:41,280 AND A NOD TO MARISA. 318 00:11:41,280 --> 00:11:43,720 I THINK A LOT OF US SHARE THAT 319 00:11:43,720 --> 00:11:46,200 DUTY AND SOMETIMES BURDEN. 320 00:11:46,200 --> 00:11:48,880 I AM A LAYPERSON SO I FEEL LIKE 321 00:11:48,880 --> 00:11:51,080 THIS -- YESTERDAY WAS SORT OF 322 00:11:51,080 --> 00:11:53,000 FUNNELING INTO THE INNER 323 00:11:53,000 --> 00:11:56,840 WORKINGS OF THE NIA BUT ALSO I 324 00:11:56,840 --> 00:12:00,680 WOULD SAY THAT I'M A FIERCE 325 00:12:00,680 --> 00:12:01,760 CHAMPION FOR ADVANCING THE WORK 326 00:12:01,760 --> 00:12:04,440 THAT IS DONE WITH FUNDING FOR 327 00:12:04,440 --> 00:12:07,920 NIA INTO CLINICAL PRACTICE AND 328 00:12:07,920 --> 00:12:09,120 REALLY LOOK FORWARD TO LEARNING 329 00:12:09,120 --> 00:12:13,040 AND COLLABORATING WITH ALL OF 330 00:12:13,040 --> 00:12:13,560 YOU. 331 00:12:13,560 --> 00:12:14,120 >>GREAT. 332 00:12:14,120 --> 00:12:14,520 THANK YOU VERY MUCH. 333 00:12:14,520 --> 00:12:18,720 AND WELCOME TO OUR NEW MEMBERS. 334 00:12:18,720 --> 00:12:21,680 ALL RIGHT, LET'S SEE. 335 00:12:21,680 --> 00:12:23,320 NEXT UP, I'LL INTRODUCE 336 00:12:23,320 --> 00:12:26,320 DR. RICHARD HODES, OUR DIRECTOR 337 00:12:26,320 --> 00:12:27,320 OF THE NATIONAL INSTITUTE AGING. 338 00:12:27,320 --> 00:12:34,440 SO I'LL TURN IT OVER TO RICHARD. 339 00:12:34,440 --> 00:12:35,000 >>DR. HODES: THANK YOU. 340 00:12:35,000 --> 00:12:36,440 I WILL ADD MY APPRECIATION TO 341 00:12:36,440 --> 00:12:37,240 OUR CURRENT AND IN-COMING 342 00:12:37,240 --> 00:12:38,160 COUNCIL MEMBERS. 343 00:12:38,160 --> 00:12:39,320 IT IS AN INVESTED GROUP. 344 00:12:39,320 --> 00:12:40,880 AND IMPRESSIVE EVERY TIME I SEE 345 00:12:40,880 --> 00:12:42,400 THE GALLERY COME BY. 346 00:12:42,400 --> 00:12:44,080 I'D LIKE TO OPEN THIS SESSION 347 00:12:44,080 --> 00:12:47,440 HERE NOW BY A BRIEF STATUS 348 00:12:47,440 --> 00:12:48,920 REPORT OF SOME OF THE EVENTS 349 00:12:48,920 --> 00:12:50,760 THAT HAPPENED SINCE OUR LAST 350 00:12:50,760 --> 00:12:51,840 MEETING. 351 00:12:51,840 --> 00:12:53,000 NEXT SLIDE, PLEASE. 352 00:12:53,000 --> 00:12:54,600 FIRST, WE WANT TO INTRODUCE TO 353 00:12:54,600 --> 00:12:57,000 YOU, AND SHE CAN PLEASE GO ON 354 00:12:57,000 --> 00:12:57,640 CAMERA AMY. 355 00:12:57,640 --> 00:12:58,680 I THINK BY NOW A LOT OF YOU GOT 356 00:12:58,680 --> 00:12:59,920 TO KNOW HER. 357 00:12:59,920 --> 00:13:02,680 AMY KELLY IS OUR DEPUTY DIRECTOR 358 00:13:02,680 --> 00:13:03,840 SINCE SEPTEMBER AND HAS BEEN 359 00:13:03,840 --> 00:13:07,480 FANTASTIC IN THESE FIRST MONTHS. 360 00:13:07,480 --> 00:13:09,680 SHE CAME TO US FROM MOUNT SINAI 361 00:13:09,680 --> 00:13:12,160 WITH HER BACKGROUND IN HEALTH 362 00:13:12,160 --> 00:13:13,440 POLICY, IN PARTICULAR GERIATRICS 363 00:13:13,440 --> 00:13:14,800 AND PALLIATIVE CARE. 364 00:13:14,800 --> 00:13:16,880 AMY, SAY HELLO. 365 00:13:16,880 --> 00:13:18,480 >>AMY: GOOD MORNING, EVERYBODY. 366 00:13:18,480 --> 00:13:20,920 IT'S WONDERFUL TO SEE YOU ALL 367 00:13:20,920 --> 00:13:22,200 AND JUST FANTASTIC OPPORTUNITY 368 00:13:22,200 --> 00:13:24,320 TO GET TO KNOW OUR NEW MEMBERS. 369 00:13:24,320 --> 00:13:26,880 SOME ARE FAMILIAR WITH ME 370 00:13:26,880 --> 00:13:29,280 ALREADY AND JUST THANK YOU ALL 371 00:13:29,280 --> 00:13:33,040 FOR SUPPORTING NIA. 372 00:13:33,040 --> 00:13:36,600 >>DR. HODES: THANK YOU, AMY. 373 00:13:36,600 --> 00:13:37,600 NEXT SLIDE. 374 00:13:37,600 --> 00:13:42,320 SO THIS IS THE FIRST COUNCIL 375 00:13:42,320 --> 00:13:42,920 MEETING WE'VE HAD SINCE WE HAD 376 00:13:42,920 --> 00:13:44,600 THE PASSAGE OF OUR LAST 377 00:13:44,600 --> 00:13:47,600 APPROPRIATION THE FY2023 BUDGET. 378 00:13:47,600 --> 00:13:51,680 IT SAW IN KEYS IN TOTAL NIH, 379 00:13:51,680 --> 00:13:53,640 47.7 BILLION DOLLARS FOR NIA 380 00:13:53,640 --> 00:13:56,760 WITH INCREASE TO 4.4 BILLION 381 00:13:56,760 --> 00:13:57,000 DOLLARS. 382 00:13:57,000 --> 00:13:58,800 THERE WERE SEVERAL TARGET 383 00:13:58,800 --> 00:14:00,160 INCREASES IN THE NIH BUDGET, ONE 384 00:14:00,160 --> 00:14:02,800 OF THE LARGEST WAS AGAIN FOR AD 385 00:14:02,800 --> 00:14:06,040 AND ADRD RESEARCH, TOTAL OF 226 386 00:14:06,040 --> 00:14:08,800 MILLION DOLLARS, 151 MILLION 387 00:14:08,800 --> 00:14:11,200 DOLLARS TO NIA, 75 MILLION 388 00:14:11,200 --> 00:14:13,240 DOLLARS OF WHICH TO OUR GREAT 389 00:14:13,240 --> 00:14:17,840 PARTNER IN THESE EFFORTS, NINDS; 390 00:14:17,840 --> 00:14:18,080 PLEASE. 391 00:14:18,080 --> 00:14:19,960 WE WERE ALSO ABLE TO ANNOUNCE 392 00:14:19,960 --> 00:14:21,960 THAT THE POINT IN THE YEAR, OUR 393 00:14:21,960 --> 00:14:23,880 PAY LINE. 394 00:14:23,880 --> 00:14:24,480 SO FAR BESIDES PROJECTIONS NOW 395 00:14:24,480 --> 00:14:26,840 THAT WE KNOW OUR FUNDING AND 396 00:14:26,840 --> 00:14:27,320 BUDGET. 397 00:14:27,320 --> 00:14:28,960 AND BREAKING IT DOWN AS YOU SEE 398 00:14:28,960 --> 00:14:31,440 HERE FIRST FOR THE CSR REVIEWED 399 00:14:31,440 --> 00:14:33,200 APPLICATIONS WHICH RECEIVED 400 00:14:33,200 --> 00:14:34,600 PERCENTILES, THERE IS A GENERAL 401 00:14:34,600 --> 00:14:38,320 PAY LINE WHICH MEANS THAT 402 00:14:38,320 --> 00:14:38,800 UNTARGETED RESEARCH NOT 403 00:14:38,800 --> 00:14:42,240 SPECIFIED FOR ADADRD, FOR THE 404 00:14:42,240 --> 00:14:45,000 MOST COMMON APPLICATIONS FALLS 405 00:14:45,000 --> 00:14:46,040 UNDER $500,000. 406 00:14:46,040 --> 00:14:47,680 WE HAVE THAT THE POINT A PAY 407 00:14:47,680 --> 00:14:50,120 LINE OF UPON 15 PERCENTILE. 408 00:14:50,120 --> 00:14:52,320 FOR NEW INVESTIGATORS AND 409 00:14:52,320 --> 00:14:53,560 EARLY-STAGE INVESTIGATORS, 410 00:14:53,560 --> 00:14:56,200 RESPECTIVELY, THE PAY LINES WILL 411 00:14:56,200 --> 00:14:59,680 18-20 PERCENTILE WHICH REFLECT 412 00:14:59,680 --> 00:15:00,280 OUR CONTINUING PRIORITY TO NEW 413 00:15:00,280 --> 00:15:02,120 PEOPLE ENTERING THE FIELD. 414 00:15:02,120 --> 00:15:03,880 THE GENERAL PAY LINE FOR THE 415 00:15:03,880 --> 00:15:06,240 MORE EXPENSIVE APPLICATIONS 416 00:15:06,240 --> 00:15:08,200 GREATER THAN $500,000 SET A 417 00:15:08,200 --> 00:15:09,720 HIGHER BAR IN EACH CATEGORY. 418 00:15:09,720 --> 00:15:15,760 IF WE LOOK AT AD/ADRD PAY LINES, 419 00:15:15,760 --> 00:15:16,920 WE HAVE AGAIN FOR APPLICATIONS 420 00:15:16,920 --> 00:15:19,400 EITHER BEFORE OR UNDER OR OVER 421 00:15:19,400 --> 00:15:21,280 500K THEY ARE REALLY THE SAME, 422 00:15:21,280 --> 00:15:24,440 THE 25th PER CERTAINLY TILE, 423 00:15:24,440 --> 00:15:26,680 28 AND 30 PERCENTILE IS FOR NEW 424 00:15:26,680 --> 00:15:28,520 INVESTIGATORS AND ESIs. 425 00:15:28,520 --> 00:15:29,880 THAT THE POINT OF THE YEAR, IT'S 426 00:15:29,880 --> 00:15:31,040 POSSIBLE AS WE LEARN MORE, WE 427 00:15:31,040 --> 00:15:34,080 WILL BE ABLE TO MODIFY, 428 00:15:34,080 --> 00:15:34,680 HOPEFULLY IN THE DIRECTION OF 429 00:15:34,680 --> 00:15:35,560 INCREASING FURTHER OUR PAY 430 00:15:35,560 --> 00:15:35,880 LINES. 431 00:15:35,880 --> 00:15:37,720 BUT THESE ARE OUR ALLOCATIONS AT 432 00:15:37,720 --> 00:15:38,640 THIS POINT. 433 00:15:38,640 --> 00:15:40,960 AND THE NEXT SLIDE DEALS WITH 434 00:15:40,960 --> 00:15:43,040 THOSE PAY LINES WHICH ARE FOR 435 00:15:43,040 --> 00:15:44,200 NON CSR. 436 00:15:44,200 --> 00:15:46,360 THEY ARE NIA REVIEWED 437 00:15:46,360 --> 00:15:47,800 APPLICATION AND RECEIVED IMPACT 438 00:15:47,800 --> 00:15:49,440 SCORE RATHER THAN PRIORITY SCORE 439 00:15:49,440 --> 00:15:50,960 AND YOU CAN SEE HERE AGAIN THE 440 00:15:50,960 --> 00:15:53,840 GENERAL AND ADA PAY LINES FOR 441 00:15:53,840 --> 00:15:57,240 PROGRAM PROJECTS OTHER THAN NIA 442 00:15:57,240 --> 00:15:57,600 RESEARCH. 443 00:15:57,600 --> 00:15:59,040 FUNDED RESEARCH, CAREER 444 00:15:59,040 --> 00:16:02,400 DEVELOPMENT OF A HIGHER AND 445 00:16:02,400 --> 00:16:02,960 FELLOWSHIP AWARDS AT HIGHER 446 00:16:02,960 --> 00:16:06,360 STILL PAY LINE IN BOTH 447 00:16:06,360 --> 00:16:08,520 CATEGORIES. 448 00:16:08,520 --> 00:16:09,160 NEXT, PLEASE. 449 00:16:09,160 --> 00:16:10,920 THIS IS JUST TO REMIND US ALL OF 450 00:16:10,920 --> 00:16:12,240 THE INCREASE WE HAVE BEEN SEEING 451 00:16:12,240 --> 00:16:15,400 IN THE NIA APPROPRIATION FROM 452 00:16:15,400 --> 00:16:16,920 2014 TO THE PRESENT. 453 00:16:16,920 --> 00:16:20,560 AND 2015 WE WERE AT ONE BILLION 454 00:16:20,560 --> 00:16:21,520 DOLLAR LEVELED AND NOW 4.4 455 00:16:21,520 --> 00:16:22,200 BILLION DOLLARS. 456 00:16:22,200 --> 00:16:24,320 GOOD BIT OF THIS DUE TO THE 457 00:16:24,320 --> 00:16:27,120 TARGET INCREASE IN ADADRD 458 00:16:27,120 --> 00:16:29,720 RESEARCH BUT NOT ENTIRELY -- 459 00:16:29,720 --> 00:16:31,120 SUBSTANTIAL INCREASE ACROSS OUR 460 00:16:31,120 --> 00:16:33,000 GENERAL COMPONENT OF OUR 461 00:16:33,000 --> 00:16:35,040 APPROPRIATION AS WELL. 462 00:16:35,040 --> 00:16:37,040 NEXT, PLEASE. 463 00:16:37,040 --> 00:16:37,720 SOME UPDATES. 464 00:16:37,720 --> 00:16:40,280 WE WANTED TO SUMMARIZE FOR YOU 465 00:16:40,280 --> 00:16:44,320 THE ACTIVITY IN NIA FUNDED A. 466 00:16:44,320 --> 00:16:45,640 AND ADRD CLINICAL TRIALS. 467 00:16:45,640 --> 00:16:47,400 THIS IS UPDATE OF THE ACTIVE 468 00:16:47,400 --> 00:16:48,680 SUPPORTIVE TRIALS RIGHT NOW. 469 00:16:48,680 --> 00:16:51,800 A TOTAL OF 459, A STRIKING 470 00:16:51,800 --> 00:16:52,040 NUMBER. 471 00:16:52,040 --> 00:16:55,040 THEY ARE DIVIDED AS YOU WILL SEE 472 00:16:55,040 --> 00:16:59,440 HERE, FOR PHARMACOLOGIC AND NON 473 00:16:59,440 --> 00:17:00,040 PHARMACOLOGIC TREATMENTS AIMED 474 00:17:00,040 --> 00:17:02,120 AT PREVENTING TREATING, SLOWING 475 00:17:02,120 --> 00:17:03,320 PROGRESSION OF ALZHEIMER'S. 476 00:17:03,320 --> 00:17:05,560 66 PHARMACOLOGIC, ONE HUNG 52 477 00:17:05,560 --> 00:17:08,480 NON PHARMACOLOGIC AND 210 THAT 478 00:17:08,480 --> 00:17:11,120 ARE TARGETED AT DEMENTIA CARE 479 00:17:11,120 --> 00:17:13,360 AND CARE GIVING AS WELL AS 480 00:17:13,360 --> 00:17:14,720 STUDIES AIMED AT 481 00:17:14,720 --> 00:17:16,080 NEUROPSYCHIATRIC SYMPTOMS AND 482 00:17:16,080 --> 00:17:17,720 DIAGNOSTIC AND ASSESSMENT AND 483 00:17:17,720 --> 00:17:20,960 IMAGING TOOLS. 484 00:17:20,960 --> 00:17:22,280 NEXT SLIDE. 485 00:17:22,280 --> 00:17:24,920 JUST TO GIVE YOU REVEALING 486 00:17:24,920 --> 00:17:26,160 COMPONENTS OF WHERE THESE FALL. 487 00:17:26,160 --> 00:17:28,800 FOR 66 PHARMACOLOGIC TRIALS, YOU 488 00:17:28,800 --> 00:17:33,000 LOOK FIRST AT THE 7 TRIALS THAT 489 00:17:33,000 --> 00:17:34,160 ARE PHASE II OR PHASE III. 490 00:17:34,160 --> 00:17:36,000 THESE ARE ADVANCED TRIALS 491 00:17:36,000 --> 00:17:37,400 POTENTIALLY DEFINITIVE IN 492 00:17:37,400 --> 00:17:39,760 IDENTIFYING EFFECTIVE 493 00:17:39,760 --> 00:17:40,080 INTERVENTIONS. 494 00:17:40,080 --> 00:17:42,520 OF THE 7, 4 ARE AMYLOID 495 00:17:42,520 --> 00:17:42,800 TARGETED. 496 00:17:42,800 --> 00:17:49,760 3 ARE NOT AS YOU CAN SEE. 497 00:17:49,760 --> 00:17:50,960 THESE REFLECT THE PREDOMINANCE 498 00:17:50,960 --> 00:17:53,240 OF AMYLOID AS A TARGET STUDY 499 00:17:53,240 --> 00:17:54,400 OVER PAST YEARS AND THE NUMBER 500 00:17:54,400 --> 00:17:57,360 OF YEARS IT TAKES TO PROGRESS 501 00:17:57,360 --> 00:17:59,280 FROM STAGE TO STAGE IN THESE 502 00:17:59,280 --> 00:17:59,520 STUDIES. 503 00:17:59,520 --> 00:18:00,440 IF YOU LOOK AT THE EARLIER PHASE 504 00:18:00,440 --> 00:18:02,280 TRIALS, PHASE I AND PHASE II, 505 00:18:02,280 --> 00:18:04,400 SOME 59 OF THEM, YOU WILL SEE 506 00:18:04,400 --> 00:18:06,880 340s OF THEM ARE TO TARGETS 507 00:18:06,880 --> 00:18:08,640 OTHER THAN AMYLOID. 508 00:18:08,640 --> 00:18:10,080 AMYLOID REMAINS IMPORTANT BUT 509 00:18:10,080 --> 00:18:11,520 THIS REFLECTS THE DIVERSITY OF 510 00:18:11,520 --> 00:18:13,640 WHAT WE HAVE LEARNED THAT THE 511 00:18:13,640 --> 00:18:15,280 UNDERLYING PATHOPHYSIOLOGY OF 512 00:18:15,280 --> 00:18:17,360 ALZHEIMER'S AND OUR ABILITY TO 513 00:18:17,360 --> 00:18:19,080 TARGET THOSE COMPONENTS, THESE 514 00:18:19,080 --> 00:18:23,000 WILL BE IN THE NEXT GENERATIONS 515 00:18:23,000 --> 00:18:23,560 AS THEY MOVE TO PHASE II AND 516 00:18:23,560 --> 00:18:25,080 PHASE III STUDIES SHOULD THEY 517 00:18:25,080 --> 00:18:27,440 PROVE PROMISING AND PHASE I AND 518 00:18:27,440 --> 00:18:27,920 PHASE II. 519 00:18:27,920 --> 00:18:32,400 NON PHARMACOLOGIC TRIALS, 152 520 00:18:32,400 --> 00:18:33,040 BROKEN DOWN HERE BY CATEGORIES 521 00:18:33,040 --> 00:18:34,440 INCLUDING EXERCISE AND IN OR 522 00:18:34,440 --> 00:18:37,000 ABOUTO STIMULATION, COGNITIVE 523 00:18:37,000 --> 00:18:38,040 TRAINING, SLEEP-RELATED TRIALS 524 00:18:38,040 --> 00:18:41,160 AND SO ON. 525 00:18:41,160 --> 00:18:42,960 SO A DIVERSITY WHICH EFFECTS A 526 00:18:42,960 --> 00:18:45,360 CONVICTION OF THE FACT THAT THE 527 00:18:45,360 --> 00:18:46,200 ADADRD PROCESS ITSELF IS A 528 00:18:46,200 --> 00:18:47,880 COMPLEX ONE. 529 00:18:47,880 --> 00:18:48,880 AND THAT BEING ABLE TO ADDRESS 530 00:18:48,880 --> 00:18:49,760 MULTIPLE TARGETS ARE GOING TO 531 00:18:49,760 --> 00:18:52,600 GIVE US THE BEST OPPORTUNITY TO 532 00:18:52,600 --> 00:18:54,920 FIND THE BEST INDIVIDUAL OR 533 00:18:54,920 --> 00:18:55,560 COMBINATION THERAPIES FOR GIVEN 534 00:18:55,560 --> 00:18:57,440 INDIVIDUALS AS WE LEARN MORE AND 535 00:18:57,440 --> 00:18:59,760 MORE ABOUT THE HETEROGENEITY IN 536 00:18:59,760 --> 00:19:03,240 THE DISEASE PROCESSES. 537 00:19:03,240 --> 00:19:03,920 NEXT, PLEASE. 538 00:19:03,920 --> 00:19:05,440 AMONG THE DEMENTIA CARE AND CARE 539 00:19:05,440 --> 00:19:06,400 GIVING TRIALS. 540 00:19:06,400 --> 00:19:08,800 AGAIN, YOU'LL SEE THE 541 00:19:08,800 --> 00:19:09,520 SUBCATEGORIES SHOWN HERE RANGING 542 00:19:09,520 --> 00:19:11,000 FROM FORMAL CARE TO IMPROVING 543 00:19:11,000 --> 00:19:12,720 CAREGIVER HEALTH AND WELL-BEING. 544 00:19:12,720 --> 00:19:15,480 AND AGAIN THE DIVERSITY MUCH 545 00:19:15,480 --> 00:19:15,960 EXPANDED. 546 00:19:15,960 --> 00:19:17,080 EVERY BIT AS IMPORTANT AND 547 00:19:17,080 --> 00:19:19,000 RIGOROUS AS WE TRY TO DEAL WITH 548 00:19:19,000 --> 00:19:21,000 THE BEST APPROACHES AND 549 00:19:21,000 --> 00:19:22,000 INDIVIDUALS CURRENT LEAD LIVING 550 00:19:22,000 --> 00:19:23,840 WITH DEMENTIA, EVEN AS WE TRY TO 551 00:19:23,840 --> 00:19:25,360 REDUCE THE NUMBER THROUGH 552 00:19:25,360 --> 00:19:27,320 PREVENTION IN OUR STUDIES TO 553 00:19:27,320 --> 00:19:29,040 UNDERSTAND BETTER THE UNDERLYING 554 00:19:29,040 --> 00:19:29,360 PATHOGENESIS. 555 00:19:29,360 --> 00:19:31,120 AND IMPORTANT AREAS OF 556 00:19:31,120 --> 00:19:32,920 DIAGNOSTIC TOOL DEVELOPMENT AND 557 00:19:32,920 --> 00:19:34,320 ASSESSMENT AND TREATMENT FOR 558 00:19:34,320 --> 00:19:36,720 NEUROPSYCHIATRIC SYMPTOMS. 559 00:19:36,720 --> 00:19:37,600 NEXT, PLEASE. 560 00:19:37,600 --> 00:19:41,040 WOULD I WANT TO POINT YOU TO THE 561 00:19:41,040 --> 00:19:43,600 ADADRD PROGRESS REPORT MOST 562 00:19:43,600 --> 00:19:44,600 RECENTLY RELEASED IN NOVEMBER. 563 00:19:44,600 --> 00:19:47,000 THIS IS A SUMMARY EACH YEAR OF 564 00:19:47,000 --> 00:19:48,600 SCIENCE ADVANCES ACROSS MULTIPLE 565 00:19:48,600 --> 00:19:50,160 RESEARCH TOPICS. 566 00:19:50,160 --> 00:19:52,480 LINKS SHOWN HERE AND WE INVITE 567 00:19:52,480 --> 00:19:53,800 YOU TO LOOK AT WHAT WE THINK ARE 568 00:19:53,800 --> 00:19:57,040 VERY IMPRESSIVE ASPECTS OF CARE 569 00:19:57,040 --> 00:19:58,480 SERVICES, UNDERLYING 570 00:19:58,480 --> 00:19:59,800 PATHOPHYSIOLOGY, ADVANCES IN ALL 571 00:19:59,800 --> 00:20:02,760 THESE AREAS. 572 00:20:02,760 --> 00:20:04,800 NEXT, PLEASE. 573 00:20:04,800 --> 00:20:07,880 AN UPDATE ON ONE OF THE NEWER 574 00:20:07,880 --> 00:20:10,760 ACTIVITIES HERE AT NIA AND NIH. 575 00:20:10,760 --> 00:20:12,600 THE NIH CENTER FOR ALZHEIMER'S 576 00:20:12,600 --> 00:20:16,120 RELATED DEMENTIAS ARE HARD. 577 00:20:16,120 --> 00:20:18,400 THIS IS ESTABLISHED THE 578 00:20:18,400 --> 00:20:18,920 COLLABORATION BETWEEN. 579 00:20:18,920 --> 00:20:21,840 THIS IA AND NINDS AS PART OF OUR 580 00:20:21,840 --> 00:20:22,440 INTRAMURAL PROGRAM N SEPTEMBER 581 00:20:22,440 --> 00:20:24,960 WE HAD A REALLY WONDERFUL 582 00:20:24,960 --> 00:20:26,520 DEDICATION CEREMONY ON CAMPUS AS 583 00:20:26,520 --> 00:20:27,440 IT WAS NAMED THE ROY BLUNT 584 00:20:27,440 --> 00:20:29,200 CENTER FOR ALZHEIMER'S DISEASE 585 00:20:29,200 --> 00:20:31,160 RELATED DEMENTIAS RESEARCH. 586 00:20:31,160 --> 00:20:33,760 ROY BLUNT WHO HAS BEEN A 587 00:20:33,760 --> 00:20:35,560 LONGSTANDING CHAMPION FOR 588 00:20:35,560 --> 00:20:38,400 RESEARCH AT NIH VERY MUCH 589 00:20:38,400 --> 00:20:42,760 INCLUDING NIA AND RESEARCH. 590 00:20:42,760 --> 00:20:45,360 PRIMARY ASPECTS OF THIS CENTER 591 00:20:45,360 --> 00:20:45,960 ARE A STRONG COMMITMENT TO 592 00:20:45,960 --> 00:20:48,400 RESOURCE SHARING WITH NEW ONLINE 593 00:20:48,400 --> 00:20:50,120 PORTAL TO DEVELOP A INITIATIVES 594 00:20:50,120 --> 00:20:53,400 AS THEY COME FORWARD. 595 00:20:53,400 --> 00:20:54,600 INFRASTRUCTURE AND 596 00:20:54,600 --> 00:20:57,200 IDENTIFICATION OF RESEARCH TOOLS 597 00:20:57,200 --> 00:21:01,320 SUCH AS THE INTRODUCTION OF A 598 00:21:01,320 --> 00:21:04,680 PANEL OF INDUCED POTENTIAL STEM 599 00:21:04,680 --> 00:21:05,040 CELLS. 600 00:21:05,040 --> 00:21:06,440 LIBRARY BECOMES AVAILABLE TO THE 601 00:21:06,440 --> 00:21:08,040 RESEARCH COMMUNITY AND SOME 602 00:21:08,040 --> 00:21:09,840 UNIQUE PREMIER DEVELOPMENT 603 00:21:09,840 --> 00:21:10,280 EXPERIENCE AS WELL. 604 00:21:10,280 --> 00:21:11,800 AS WE ATTEMPT TO BRING IN NOT 605 00:21:11,800 --> 00:21:16,360 JUST A FACULTY BUT AN ONGOING 606 00:21:16,360 --> 00:21:16,920 PASSTHROUGH OF INDEPENDENT 607 00:21:16,920 --> 00:21:18,760 SCIENTISTS WHO MAY SPEND PARTS 608 00:21:18,760 --> 00:21:21,840 OF THEIR TIME AT CARD AND THEN 609 00:21:21,840 --> 00:21:25,960 ARE PROVIDED WITH TRANSITION TO 610 00:21:25,960 --> 00:21:27,600 OTHER ASPECTS OF NIH RESEARCH 611 00:21:27,600 --> 00:21:33,360 AND EVEN THE CAREERS BEYOND NIH. 612 00:21:33,360 --> 00:21:34,080 NEXT, PLEASE. 613 00:21:34,080 --> 00:21:36,000 IN TERMS OF OUR COMMUNITY, 614 00:21:36,000 --> 00:21:37,400 PROGRESS AND POTENTIAL IN 615 00:21:37,400 --> 00:21:38,480 ALZHEIMER'S, ONE OF OUR 616 00:21:38,480 --> 00:21:41,120 COMMUNICATION STRATEGIES HAS 617 00:21:41,120 --> 00:21:43,520 BEEN TOW PUT TOGETHER A SERIES 618 00:21:43,520 --> 00:21:45,680 OF VERY EFFECTIVE VIDEOS. 619 00:21:45,680 --> 00:21:48,120 AND SINCE ONE OF THE AUTHORS, 620 00:21:48,120 --> 00:21:49,960 ONE OF THE SPOKESPERSONS SHEAR 621 00:21:49,960 --> 00:21:51,200 WITH US AS A COUNCIL MEMBER, WE 622 00:21:51,200 --> 00:21:53,040 CAN SEE IF WE TAKE A MINUTE TO 623 00:21:53,040 --> 00:21:55,960 SHOW YOU A PART OF JENNIFER 624 00:21:55,960 --> 00:21:58,680 MANLY'S PRESENTATION. 625 00:21:58,680 --> 00:22:04,200 [ MUSIC PLAYING ] 626 00:22:04,200 --> 00:22:05,320 >>FOR ABOUT 25 YEARS, I HAVE 627 00:22:05,320 --> 00:22:07,920 BEEN WORKING WITH 628 00:22:07,920 --> 00:22:11,360 COMMUNITY-BASED COHORTS OF OLDER 629 00:22:11,360 --> 00:22:15,080 ADULTS THAT LIVE AROUND COLUMBIA 630 00:22:15,080 --> 00:22:15,920 UNIVERSITY IRVINE MEDICAL 631 00:22:15,920 --> 00:22:16,120 CENTER. 632 00:22:16,120 --> 00:22:18,320 THIS IS A REALLY DIVERSE 633 00:22:18,320 --> 00:22:19,280 NEIGHBORHOOD, REALLY INTERESTING 634 00:22:19,280 --> 00:22:23,360 NEIGHBORHOOD AND AN EPIC ENCLAVE 635 00:22:23,360 --> 00:22:24,760 FOR CARIBBEAN HISPANICS OR 636 00:22:24,760 --> 00:22:26,160 LATINX PEOPLE. 637 00:22:26,160 --> 00:22:28,200 THERE IS ALSO A LONG HISTORY OF 638 00:22:28,200 --> 00:22:31,600 PEOPLE WHO ARE AFRICAN-AMERICAN, 639 00:22:31,600 --> 00:22:33,720 AND THEN THERE IS A GROUP OF 640 00:22:33,720 --> 00:22:35,960 PEOPLE WHO DESCRIBE THEMSELVES 641 00:22:35,960 --> 00:22:38,320 AS NON-HISPANIC AND WHITE. 642 00:22:38,320 --> 00:22:40,200 AFRICAN-AMERICANS AND HISPANICS 643 00:22:40,200 --> 00:22:45,880 ARE 1.5-TWO TIMES MORE LIKELY TO 644 00:22:45,880 --> 00:22:46,720 DEVELOP ALZHEIMER'S DISEASE AND 645 00:22:46,720 --> 00:22:47,600 DEMENTIA. 646 00:22:47,600 --> 00:22:50,600 AND YET, THEY REPRESENT NO MORE 647 00:22:50,600 --> 00:22:56,000 THAN 2% OF PARTICIPANTS IN 648 00:22:56,000 --> 00:22:57,160 ALZHEIMER'S DISEASE CLINICAL 649 00:22:57,160 --> 00:22:57,400 TRIALS. 650 00:22:57,400 --> 00:23:00,880 PROGRESS IN ALZHEIMER'S DISEASE 651 00:23:00,880 --> 00:23:02,360 RESEARCH, IT WON'T BE AS 652 00:23:02,360 --> 00:23:06,640 RELEVANT AND IT WON'T BE USEFUL 653 00:23:06,640 --> 00:23:09,440 UNLESS IT IS ABLE TO INCLUDE 654 00:23:09,440 --> 00:23:11,480 PEOPLE WHO ARE REPRESENTATIVE OF 655 00:23:11,480 --> 00:23:12,560 OLDER ADULTS IN THE UNITED 656 00:23:12,560 --> 00:23:12,800 STATES. 657 00:23:12,800 --> 00:23:17,520 AND IT ALSO WON'T BE AS USEFUL 658 00:23:17,520 --> 00:23:19,080 IF THEIR -- 659 00:23:19,080 --> 00:23:22,400 >>THANK YOU. 660 00:23:22,400 --> 00:23:23,680 SO SORRY TO KEEP CUT YOU OFF. 661 00:23:23,680 --> 00:23:25,200 WE WANTED TO PROVIDE AN EXAMPLE 662 00:23:25,200 --> 00:23:28,560 OF SOME VERY EFFECTIVE 663 00:23:28,560 --> 00:23:30,960 COMMUNICATIONS TO OUR PUBLIC BY 664 00:23:30,960 --> 00:23:35,000 IN ALL RESPECT ARES, A DIVERSE 665 00:23:35,000 --> 00:23:35,560 GROUP OF INVESTIGATORS. 666 00:23:35,560 --> 00:23:37,880 I URGE YOU TO ENJOY CLICKING ON 667 00:23:37,880 --> 00:23:41,880 THESE LINKS AS WE GO FORWARD. 668 00:23:41,880 --> 00:23:42,080 NEXT. 669 00:23:42,080 --> 00:23:45,480 ALSO NOTEWORTHY -- SO FORMS ARE 670 00:23:45,480 --> 00:23:47,880 RELEASED LIST OF WORLD'S TOP 671 00:23:47,880 --> 00:23:50,480 FEMALEANIST 2022. 672 00:23:50,480 --> 00:23:53,000 -- FEMALE SCIENTISTS. 673 00:23:53,000 --> 00:23:54,360 AMONG IN THE LIST, INCLUDED 674 00:23:54,360 --> 00:23:57,000 AMONG THE TOP 10 ARE THREE WHO 675 00:23:57,000 --> 00:24:00,120 ARE SUPPORTED BY OR MEMBERS OF 676 00:24:00,120 --> 00:24:02,040 PRIOR NAI. 677 00:24:02,040 --> 00:24:05,320 SO VIRGINIA LEE, NEUROSCIENTIST 678 00:24:05,320 --> 00:24:07,560 AT UPENN AND FORMER COUNCIL 679 00:24:07,560 --> 00:24:07,800 MEMBER. 680 00:24:07,800 --> 00:24:08,960 TERRY MOFFITT, SIMILARLY AND 681 00:24:08,960 --> 00:24:10,960 TAMARA HARRIS, A LONG TIME 682 00:24:10,960 --> 00:24:13,000 LEADER IN THE INTRAMURAL 683 00:24:13,000 --> 00:24:13,200 PROGRAM. 684 00:24:13,200 --> 00:24:14,400 THERE ARE MANY MORE AS WE GO 685 00:24:14,400 --> 00:24:17,040 DOWN THE LIST BUT IT'S REALLY 686 00:24:17,040 --> 00:24:18,560 GRATIFYING AND TESTIMONY TO OUR 687 00:24:18,560 --> 00:24:20,080 ABILITY TO RECRUIT THESE 688 00:24:20,080 --> 00:24:21,680 OUTSTANDING PEOPLE TO OUR 689 00:24:21,680 --> 00:24:21,920 PROGRAMS. 690 00:24:21,920 --> 00:24:24,560 SO CONGRATULATIONS TO YOU AND TO 691 00:24:24,560 --> 00:24:27,840 ALL IN THIS. 692 00:24:27,840 --> 00:24:29,000 NEXT, PLEASE. 693 00:24:29,000 --> 00:24:30,040 IN TERMS OF OUR COMMUNICATING 694 00:24:30,040 --> 00:24:31,760 WITH THE PUBLIC, THIS IS JUST A 695 00:24:31,760 --> 00:24:32,680 LISTING BY THE NUMBERS OF THE 696 00:24:32,680 --> 00:24:35,560 NUMBER OF RELEASES WE HAVE HAD 697 00:24:35,560 --> 00:24:38,360 AND RESEARCH HIGHLIGHTS AND 698 00:24:38,360 --> 00:24:39,040 BLOGS, ANNOUNCEMENTS. 699 00:24:39,040 --> 00:24:41,400 IN TERMS OF THE ACTIVITIES FROM 700 00:24:41,400 --> 00:24:44,600 MYSELF AND I GUESS NOW IT'S 701 00:24:44,600 --> 00:24:47,480 DOCTOR KELLY AND AMY AND MELANED 702 00:24:47,480 --> 00:24:47,960 OVER THIS PAST MONTH. 703 00:24:47,960 --> 00:24:51,160 THESE ARE OUR CONVERSATIONS WITH 704 00:24:51,160 --> 00:24:52,800 STAKEHOLDER ADVOCACY GROUPS AS 705 00:24:52,800 --> 00:24:56,560 WELL AS OUR SIX CONGRESSIONAL 706 00:24:56,560 --> 00:25:04,440 BRIEFINGS WITH MORE TO COME. 707 00:25:04,440 --> 00:25:05,720 MANY OF YOU INVOLVED WITH 708 00:25:05,720 --> 00:25:07,160 RESEARCH ARE VERY, PERHAPS ALL 709 00:25:07,160 --> 00:25:09,560 TOO AWARE OF THE IMPACT THAT WE 710 00:25:09,560 --> 00:25:11,240 ARE GOING TO HAVE POSITIVELY AND 711 00:25:11,240 --> 00:25:14,000 WITH THE COST IN TERMS OF 712 00:25:14,000 --> 00:25:15,720 EFFORT, OF ENACTING THE NIH 713 00:25:15,720 --> 00:25:19,600 POLICY FOR DATA MANAGEMENT AND 714 00:25:19,600 --> 00:25:21,160 SHARING. 715 00:25:21,160 --> 00:25:23,240 PRINCIPLES ARE, WITHOUT DEBATE, 716 00:25:23,240 --> 00:25:23,760 CRITICAL AND IMPORTANT. 717 00:25:23,760 --> 00:25:25,520 THAT IS TO MAKE MOST BROADLY 718 00:25:25,520 --> 00:25:29,080 AVAILABLE THE OUTCOMES OF OUR 719 00:25:29,080 --> 00:25:30,920 RESEARCH TO THE BIOMEDICAL 720 00:25:30,920 --> 00:25:31,200 COMMUNITY. 721 00:25:31,200 --> 00:25:33,480 IT APPLIES TO ALL RESEARCH 722 00:25:33,480 --> 00:25:34,600 FUNDED BY NIH. 723 00:25:34,600 --> 00:25:36,120 TWO KEY REQUIREMENTS ARE 724 00:25:36,120 --> 00:25:37,560 SUBMISSION OF THE DATA 725 00:25:37,560 --> 00:25:39,040 MANAGEMENT AND SHARING PLAN. 726 00:25:39,040 --> 00:25:43,360 THAT'S A PART OF APPLICATIONS 727 00:25:43,360 --> 00:25:43,840 COMING FROM EXTRAMURAL 728 00:25:43,840 --> 00:25:44,520 SCIENTISTS. 729 00:25:44,520 --> 00:25:47,600 AND THIS IS ALSO NOW WORK, OUR 730 00:25:47,600 --> 00:25:49,160 INTRAMURAL SCIENTISTS ARE 731 00:25:49,160 --> 00:25:49,960 ENGAGED IN AS WELL. 732 00:25:49,960 --> 00:25:52,200 AND THEN COMPLIANCE ULTIMATELY 733 00:25:52,200 --> 00:25:52,800 WITH A PLAN THAT IS APPROVED. 734 00:25:52,800 --> 00:25:54,040 IT WILL BE A LOT OF WORK TO 735 00:25:54,040 --> 00:25:55,680 BRING IT TOGETHER AND WE'LL DO 736 00:25:55,680 --> 00:25:58,040 OUR VERY BEST TO GUIDE THE 737 00:25:58,040 --> 00:26:00,240 RESEARCH COMMUNITY IN AN 738 00:26:00,240 --> 00:26:01,120 EXTRAORDINARILY VALUABLE 739 00:26:01,120 --> 00:26:02,040 ENHANCEMENT OF COMMUNICATION OF 740 00:26:02,040 --> 00:26:03,720 OUR DATA GENERATED THROUGH 741 00:26:03,720 --> 00:26:05,080 RESEARCH. 742 00:26:05,080 --> 00:26:07,400 NEXT, PLEASE. 743 00:26:07,400 --> 00:26:11,160 NIH WIDE STRATEGIC PLAN FOR 744 00:26:11,160 --> 00:26:13,000 DEIA. 745 00:26:13,000 --> 00:26:14,320 THAT'S A DIVERSITY EQUITY AND 746 00:26:14,320 --> 00:26:15,040 INCLUSION AND ACCESSIBILITY. 747 00:26:15,040 --> 00:26:16,800 IT'S BEEN DEVELOPED OVER THESE 748 00:26:16,800 --> 00:26:21,040 PAST MONTHS AND IT IS -- WE ARE 749 00:26:21,040 --> 00:26:22,840 HERE AT PHASE V, DUE TO BE 750 00:26:22,840 --> 00:26:23,920 RELEASED. 751 00:26:23,920 --> 00:26:25,480 THIS IS NOT THE BEGINNING. 752 00:26:25,480 --> 00:26:27,400 IT'S THE CULMINATION OF A 753 00:26:27,400 --> 00:26:32,160 PLANNING PROCESS AND A FURTHER 754 00:26:32,160 --> 00:26:32,760 SERBALLIZATION AND COMMITMENT 755 00:26:32,760 --> 00:26:36,440 ACROSS ALL OF NIH, THE 756 00:26:36,440 --> 00:26:38,120 PRIORITIES OF DEIMENTED A. 757 00:26:38,120 --> 00:26:39,080 VERBALIZATION. 758 00:26:39,080 --> 00:26:46,480 IN TERMS OF TURNOVER AT NIH. 759 00:26:46,480 --> 00:26:47,680 WITHOUT EXAGGERATION THE EVENT 760 00:26:47,680 --> 00:26:50,560 WAS THE RETIREMENT OF TONY FAUCI 761 00:26:50,560 --> 00:26:52,720 AS NIAID DIRECTOR N THAT 762 00:26:52,720 --> 00:26:54,800 POSITION FOR 38 YEARS. 763 00:26:54,800 --> 00:26:57,440 ADVISED AND SERVED SEVEN 764 00:26:57,440 --> 00:26:58,640 PRESIDENTS ACROSS BOTH PARTIES. 765 00:26:58,640 --> 00:26:59,120 EXTRAORDINARY. 766 00:26:59,120 --> 00:27:03,040 THE DEPUTY DIRECTOR AT NIAID IS 767 00:27:03,040 --> 00:27:04,960 CURRENTLY ACTING CAPACITY AND WE 768 00:27:04,960 --> 00:27:07,760 ARE IN THE PROCESS NOW RAFT 769 00:27:07,760 --> 00:27:10,440 SEARCH FOR A NEW DIRECTOR OF 770 00:27:10,440 --> 00:27:10,640 NIAID. 771 00:27:10,640 --> 00:27:12,400 IT'S BEEN IMPORTANT TO THE 772 00:27:12,400 --> 00:27:14,640 NATION AND A DEPARTMENT PARTNER 773 00:27:14,640 --> 00:27:15,040 WITH NI. 774 00:27:15,040 --> 00:27:17,720 IN AGE-RELATED RESEARCH. 775 00:27:17,720 --> 00:27:19,640 NEXT, PLEASE. 776 00:27:19,640 --> 00:27:21,560 ANOTHER NEW APPOINTMENT NAMED 777 00:27:21,560 --> 00:27:23,560 THE INAUGURAL DIRECTOR OF ARMA 778 00:27:23,560 --> 00:27:24,000 H. 779 00:27:24,000 --> 00:27:25,720 AND AS YOU WILL SEE IN THE 780 00:27:25,720 --> 00:27:28,560 PROGRAM, AND HAVE A CHANCE TO 781 00:27:28,560 --> 00:27:31,200 SPEAK WITH THE FIRST FOUNDING 782 00:27:31,200 --> 00:27:33,120 DEPUTY DIRECTOR TO LEARN MORE 783 00:27:33,120 --> 00:27:33,840 ABOUT THE PROGRAM. 784 00:27:33,840 --> 00:27:37,840 JUST A WAY IN WHICH OUR TWO 785 00:27:37,840 --> 00:27:40,120 AGENCIES ARE GOING TO INTERACT 786 00:27:40,120 --> 00:27:41,360 AND DEVELOP OVER TIME BUT A 787 00:27:41,360 --> 00:27:43,600 CRITICAL OPPORTUNITY TO EXPAND 788 00:27:43,600 --> 00:27:47,480 OUR OVERALL RESEARCH EFFORTS. 789 00:27:47,480 --> 00:27:49,320 UP COMING EVENTS. 790 00:27:49,320 --> 00:27:53,000 POINT YOU TO COMING UP QUICKLY, 791 00:27:53,000 --> 00:27:54,960 MARCH, THE CARE AND SERVICES FOR 792 00:27:54,960 --> 00:27:57,160 PERSONS LIVING WITH DEMENTIA AND 793 00:27:57,160 --> 00:27:58,480 THEIR PARTNERS. 794 00:27:58,480 --> 00:28:00,880 THIS WILL BE A VIRTUAL MEETING 795 00:28:00,880 --> 00:28:04,720 AND I ENCOURAGE THOSE OF YOU TO 796 00:28:04,720 --> 00:28:06,040 REGISTER AND PARTICIPATE. 797 00:28:06,040 --> 00:28:07,840 IT'S A MEANS FOR HUNDREDS OF 798 00:28:07,840 --> 00:28:09,640 HAVINGS FROM PROFESSIONAL TO LAY 799 00:28:09,640 --> 00:28:11,040 AND THOSE INTERESTED. 800 00:28:11,040 --> 00:28:13,080 MAKE THEIR CONTRIBUTIONS THROUGH 801 00:28:13,080 --> 00:28:13,720 THE AIRPORT GREATED PLANNING 802 00:28:13,720 --> 00:28:14,680 EFFORTS FOR RESEARCH IN THIS 803 00:28:14,680 --> 00:28:14,880 FIELD. 804 00:28:14,880 --> 00:28:16,880 AND THE YEARS TO COME, WE'LL 805 00:28:16,880 --> 00:28:19,240 HAVE THE OTHER SUMMITS, THE 806 00:28:19,240 --> 00:28:20,720 ALZHEIMER'S RESEARCH SUMMIT AND 807 00:28:20,720 --> 00:28:23,880 THE ALZHEIMER'S RELATED DEMENTIA 808 00:28:23,880 --> 00:28:27,360 RESEARCH SUMMIT. 809 00:28:27,360 --> 00:28:30,000 NEXT, PLEASE. 810 00:28:30,000 --> 00:28:32,120 THE FOURTH SUM LIT OCCUR THIS 811 00:28:32,120 --> 00:28:32,320 YEAR. 812 00:28:32,320 --> 00:28:34,320 IT IS SCHEDULED TO BE IN PERSON 813 00:28:34,320 --> 00:28:37,080 AND HYBRID ON THE NIH BETHESDA 814 00:28:37,080 --> 00:28:38,200 CAMPUS IN APRIL. 815 00:28:38,200 --> 00:28:39,960 YOU SHOULD SOON BE SEEING THE 816 00:28:39,960 --> 00:28:41,480 AGENDA AND ENCOURAGE 817 00:28:41,480 --> 00:28:42,840 PARTICIPATION HERE. 818 00:28:42,840 --> 00:28:45,640 THIS INVOLVES NOT JUST NIA BUT A 819 00:28:45,640 --> 00:28:47,480 CONSORTIUM OF MOST OF THE 820 00:28:47,480 --> 00:28:49,680 INSTITUTES ACROSS NIH WITH NIA 821 00:28:49,680 --> 00:28:51,440 DOING AN IMPORTANT ROLE IN 822 00:28:51,440 --> 00:28:51,840 LEADERSHIP. 823 00:28:51,840 --> 00:28:54,840 I TRIED TO TIE THE BIOLOGY, 824 00:28:54,840 --> 00:28:58,120 BEHAVIOR OF AGING IN A WAY WHICH 825 00:28:58,120 --> 00:29:00,160 IT TIES TO THE RISKS AND 826 00:29:00,160 --> 00:29:02,160 PREVENTION OF DISEASE AND 827 00:29:02,160 --> 00:29:05,120 DISORDERS. 828 00:29:05,120 --> 00:29:07,960 NEXT, PLEASE. 829 00:29:07,960 --> 00:29:08,600 WILLIAM SCHOLARS PROGRAM WILL BE 830 00:29:08,600 --> 00:29:10,200 OCCURRING AGAIN THIS YEAR. 831 00:29:10,200 --> 00:29:11,120 FOR THE PAST TWO YEARS IT 832 00:29:11,120 --> 00:29:13,880 OCCURRED REMOTELY AND IT HAS 833 00:29:13,880 --> 00:29:15,720 BEEN SUCCESSFUL IN THAT 834 00:29:15,720 --> 00:29:16,040 CAPACITY. 835 00:29:16,040 --> 00:29:20,040 IT'S SCHEDULED FOR AUGUST 23-25. 836 00:29:20,040 --> 00:29:21,720 APPLICATIONS ARE DUE APRIL 21. 837 00:29:21,720 --> 00:29:23,760 WE ARE ENCOURAGING JUNIOR 838 00:29:23,760 --> 00:29:24,680 FACULTY AND RESEARCHERS IN THE 839 00:29:24,680 --> 00:29:27,200 FIELD OF AGING TO PARTICIPATE IN 840 00:29:27,200 --> 00:29:30,120 WHAT HAS BEEN AN OUTSTANDING, 841 00:29:30,120 --> 00:29:33,160 PRODUCTIVE COUNTRY-DEFINING 842 00:29:33,160 --> 00:29:33,760 EVENT AND PATRICIA JONES IS 843 00:29:33,760 --> 00:29:34,960 TAKING A LEAD IN THIS. 844 00:29:34,960 --> 00:29:36,920 AND WE WILL BE DELIGHTED TO HEAR 845 00:29:36,920 --> 00:29:38,040 IF YOU HAVE QUESTIONS. 846 00:29:38,040 --> 00:29:41,920 THE LINK IS HERE. 847 00:29:41,920 --> 00:29:42,520 AND THE APPLICATIONS ARE BEING 848 00:29:42,520 --> 00:29:43,440 RECEIVED. 849 00:29:43,440 --> 00:29:45,000 NEXT, PLEASE. 850 00:29:45,000 --> 00:29:48,000 AND NOW, WE TURN TO SOMETHING IN 851 00:29:48,000 --> 00:29:50,880 PERSON AND HAVE A CHANCE TO LET 852 00:29:50,880 --> 00:29:54,120 THE NEW RECRUITS, STAND UP AND 853 00:29:54,120 --> 00:29:54,760 INTRODUCE THEMSELVES BUT WE'LL 854 00:29:54,760 --> 00:29:56,080 DO IT ALL REMOTELY. 855 00:29:56,080 --> 00:30:00,680 SO WE'LL DO THIS DIVISION BY 856 00:30:00,680 --> 00:30:02,120 DIVISION. 857 00:30:02,120 --> 00:30:03,560 WE'LL START WITH THE AB. 858 00:30:03,560 --> 00:30:05,360 >>SHOULD I DO THAT, RICHARD? 859 00:30:05,360 --> 00:30:06,400 >>YES, PLEASE. 860 00:30:06,400 --> 00:30:07,720 >>THANK YOU. 861 00:30:07,720 --> 00:30:09,960 SO WE WELCOME TWO NEW PROGRAM 862 00:30:09,960 --> 00:30:12,120 OFFICERS TO THE DIVISION OF 863 00:30:12,120 --> 00:30:15,920 AGING BIOLOGY. 864 00:30:15,920 --> 00:30:18,360 DR. FU JOIN US IN SEPTEMBER OF 865 00:30:18,360 --> 00:30:19,360 2022 TO MANAGE RESEARCH 866 00:30:19,360 --> 00:30:22,200 PORTFOLIO FOCUSED ON MOLECULAR 867 00:30:22,200 --> 00:30:23,960 EPIDEMIOLOGY IN AGING WHICH 868 00:30:23,960 --> 00:30:25,840 TIMES BROADEN THE UNDERSTANDING 869 00:30:25,840 --> 00:30:28,120 OF AGING AS A RISK FACTOR FOR 870 00:30:28,120 --> 00:30:28,960 FUNCTIONAL DECLINE. 871 00:30:28,960 --> 00:30:32,080 AND THAT WAS FUNCTIONAL DECLINES 872 00:30:32,080 --> 00:30:33,840 PERMISSIVE OR CONTRIBUTE TO 873 00:30:33,840 --> 00:30:35,000 DYSFUNCTION DEFICIT, 874 00:30:35,000 --> 00:30:38,520 ACCUMULATION AND MORBIDITIES. 875 00:30:38,520 --> 00:30:40,120 PREVIOUSLY, SHE HELD POSITIONS 876 00:30:40,120 --> 00:30:42,360 AT THE OFFICE OF BIOSTATISTICS 877 00:30:42,360 --> 00:30:45,000 RESEARCH AT THE NATIONAL HEART 878 00:30:45,000 --> 00:30:46,760 AND LUNG BLOOD INSTITUTE AND 879 00:30:46,760 --> 00:30:48,080 ALSO WORKED EXTENSIVELIED IN 880 00:30:48,080 --> 00:30:52,120 ANALYSIS OF THE FRAMINGHAM HEART 881 00:30:52,120 --> 00:30:53,440 STUDY. 882 00:30:53,440 --> 00:30:55,640 SHE RECEIVED HER DOCTORATE IN 883 00:30:55,640 --> 00:30:57,520 EPIDEMIOLOGY FROM UNIVERSITY OF 884 00:30:57,520 --> 00:31:01,480 OF TEXAS AT HOUSTON AND 885 00:31:01,480 --> 00:31:03,040 POSTDOCTORAL RESEARCH AT THE 886 00:31:03,040 --> 00:31:05,120 NATIONAL CANCER INSTITUTE. 887 00:31:05,120 --> 00:31:07,880 DR. AMANDA BOYS IS A NEW BRANCH 888 00:31:07,880 --> 00:31:08,720 CHIEF FOR THE AGING PHYSIOLOGY 889 00:31:08,720 --> 00:31:10,360 BRANCH IN THE DIVISION OF AGING 890 00:31:10,360 --> 00:31:10,760 BIOLOGY. 891 00:31:10,760 --> 00:31:13,520 SHE RECEIVED HER BACHELOR'S 892 00:31:13,520 --> 00:31:15,000 DEGREE FROM THE UNIVERSITY OF 893 00:31:15,000 --> 00:31:16,560 TEXAS AT AUSTIN AND COMPLETED 894 00:31:16,560 --> 00:31:19,840 HER PH.D. IN CELL BIOLOGY AND 895 00:31:19,840 --> 00:31:21,240 RESEARCH AT THE UNIVERSITY OF 896 00:31:21,240 --> 00:31:23,160 ALABAMA AT BIRMINGHAM. 897 00:31:23,160 --> 00:31:25,000 AND THEN POSTDOCTORAL RESEARCH 898 00:31:25,000 --> 00:31:28,280 AT THE NATIONAL INSTITUTED OF 899 00:31:28,280 --> 00:31:30,280 ARTHRITIS AND MUFFIN LOW 900 00:31:30,280 --> 00:31:31,800 SKELETAL AND SKIN DECEASES WHERE 901 00:31:31,800 --> 00:31:32,400 SHE WAS INTRAMURAL RESEARCHER 902 00:31:32,400 --> 00:31:35,000 FOR A NUMBER OF YEARS AND THEN 903 00:31:35,000 --> 00:31:38,480 CAME TO THE PROGRAM SIDE N2006 904 00:31:38,480 --> 00:31:41,840 SHE CAME TO US IN 2022. 905 00:31:41,840 --> 00:31:45,200 SHE HAS A PORTFOLIO OF 906 00:31:45,200 --> 00:31:46,840 NEUROMUSCULAR AND CONNECTIVE 907 00:31:46,840 --> 00:31:52,080 TISSUE WHICH HAS EMPHASIS ON 908 00:31:52,080 --> 00:31:52,600 MUSCLE FUNCTIONING AND THE 909 00:31:52,600 --> 00:31:55,560 DECLINE IN MUSCLE FUNCTIONING IN 910 00:31:55,560 --> 00:31:57,600 AGING. 911 00:31:57,600 --> 00:31:59,840 THANK YOU. 912 00:31:59,840 --> 00:32:02,240 >>HELLO, EVERYONE I OF I'M LIZ 913 00:32:02,240 --> 00:32:02,800 NIELSEN FROM THE DIVISION OF 914 00:32:02,800 --> 00:32:03,440 BEHAVIORAL AND SOCIAL RESEARCH. 915 00:32:03,440 --> 00:32:04,440 IT'S MY PLEASURE TO INTRODUCE 916 00:32:04,440 --> 00:32:06,280 OUR NEW STAFF. 917 00:32:06,280 --> 00:32:10,240 THE FIRST IS -- WHO JOINED VSR 918 00:32:10,240 --> 00:32:12,480 AS A PROGRAM OFFICER IN THE 919 00:32:12,480 --> 00:32:15,080 PROCESSES BRANCH TO MANAGE A 920 00:32:15,080 --> 00:32:15,960 PORTFOLIO IN OUR GROWING 921 00:32:15,960 --> 00:32:17,840 COGNITIVE AGING PROGRAM SPREAD 922 00:32:17,840 --> 00:32:19,240 ACROSS SEVERAL PROGRAM DIRECTORS 923 00:32:19,240 --> 00:32:19,720 IN THE DIVISION. 924 00:32:19,720 --> 00:32:24,200 SHE COMES TO US FROM NCCIH WHERE 925 00:32:24,200 --> 00:32:24,760 SHE SUPPORTED TRAINING AND 926 00:32:24,760 --> 00:32:25,400 CAREER DEVELOPMENT INITIATIVES. 927 00:32:25,400 --> 00:32:28,040 SHE COMPLETED A POSTDOCTORAL 928 00:32:28,040 --> 00:32:29,400 FELLOWSHIP AT THE NATIONAL 929 00:32:29,400 --> 00:32:30,000 CANCER INSTITUTE AND RECEIVED 930 00:32:30,000 --> 00:32:33,000 HER PH.D. IN COGNITIVE 931 00:32:33,000 --> 00:32:33,640 PSYCHOLOGY FROM THE UNIVERSITY 932 00:32:33,640 --> 00:32:34,440 OF HOUSTON. 933 00:32:34,440 --> 00:32:36,520 HER WORK HAS FOCUSED ON BRIDGING 934 00:32:36,520 --> 00:32:37,600 THE GAP BETWEEN BASIC COGNITIVE 935 00:32:37,600 --> 00:32:38,960 SCIENCE AND CLINICAL 936 00:32:38,960 --> 00:32:40,720 NEUROPSYCHOLOGY TO ADVANCE 937 00:32:40,720 --> 00:32:41,640 COGNITIVE MEASUREMENT, 938 00:32:41,640 --> 00:32:43,560 PARTICULARLY FOCUSED ON CANCER 939 00:32:43,560 --> 00:32:43,840 SURVIVORS. 940 00:32:43,840 --> 00:32:45,520 AND SHE SERVES AS A 941 00:32:45,520 --> 00:32:46,280 REPRESENTATIVE TO THE COGNITIVE 942 00:32:46,280 --> 00:32:48,120 SCIENCE AND CANCER-RELATED 943 00:32:48,120 --> 00:32:51,400 COGNITIVE IMPAIRMENT NETWORK. 944 00:32:51,400 --> 00:32:53,160 SECOND PROGRAM OFFICER ALSO IN 945 00:32:53,160 --> 00:32:54,240 THE INDIVIDUAL BEHAVIORAL 946 00:32:54,240 --> 00:32:57,360 PROCESS BRANCH IS ELISE RICE WHO 947 00:32:57,360 --> 00:32:58,840 JOINS FROM THE BEHAVIORAL AND 948 00:32:58,840 --> 00:33:00,040 SOCIAL RESEARCH BRANCH AT THE 949 00:33:00,040 --> 00:33:03,200 NATIONAL INSTITUTE OF DENTAL AND 950 00:33:03,200 --> 00:33:03,720 CRANIOFACIAL RESEARCH. 951 00:33:03,720 --> 00:33:05,560 SHE HAS BEEN HIRED TO HELP US 952 00:33:05,560 --> 00:33:09,360 DEVELOP OUR PORTFOLIO IN 953 00:33:09,360 --> 00:33:09,960 COMMUNICATEDY AND BEHAVIORAL 954 00:33:09,960 --> 00:33:10,600 ENTER VENTIONS ALIGNED WITH THE 955 00:33:10,600 --> 00:33:11,760 NIH STAGE MODEL. 956 00:33:11,760 --> 00:33:15,520 SHE SERVES ALSO AS CO-LEAD ON 957 00:33:15,520 --> 00:33:17,760 THE NIH HEALTH BEHAVIOR THEORIES 958 00:33:17,760 --> 00:33:20,000 WORKING GROUP OUT OF OBSSR. 959 00:33:20,000 --> 00:33:22,480 SHE EARNED HER PH.D. IN 960 00:33:22,480 --> 00:33:24,160 PSYCHOLOGY FROM THE UNIVERSITY 961 00:33:24,160 --> 00:33:24,840 OF NORTH CAROLINA AT CHAPEL HILL 962 00:33:24,840 --> 00:33:27,440 AND WILL A POSTDOCTORAL 963 00:33:27,440 --> 00:33:28,240 FELLOWSHIP AT THE NATIONAL 964 00:33:28,240 --> 00:33:31,120 CANNER INSTITUTE, A THEME WE ARE 965 00:33:31,120 --> 00:33:33,400 HEARING IN OUR NEW STAFF. 966 00:33:33,400 --> 00:33:35,800 WE THANK NCI FOR SENDING US 967 00:33:35,800 --> 00:33:36,800 THEIR GREAT POSTDOCS. 968 00:33:36,800 --> 00:33:39,400 HER RESEARCH GREW OUT OF SOCIAL 969 00:33:39,400 --> 00:33:43,760 PSYCHOLOGY AND FOCUSED ON HOW 970 00:33:43,760 --> 00:33:44,360 POSITIVE SPONTANEOUS THOUGHTS 971 00:33:44,360 --> 00:33:45,040 UNDERLIE APPROACH MOTIVATION FOR 972 00:33:45,040 --> 00:33:45,800 HEALTH BEHAVIORS AND OTHER 973 00:33:45,800 --> 00:33:47,560 ASPECTS OF EVERYDAY LIFE. 974 00:33:47,560 --> 00:33:49,800 NEXT SLIDE, PLEASE. 975 00:33:49,800 --> 00:33:52,280 ALSO LIKE TO INTRODUCE DR. JOHN 976 00:33:52,280 --> 00:33:55,360 WHO IS AN ASSISTANT PROFESSOR IN 977 00:33:55,360 --> 00:33:56,520 THE HEALTH SCIENCES AT 978 00:33:56,520 --> 00:33:58,520 NORTHEASTERN UNIVERSITY AND WHO 979 00:33:58,520 --> 00:34:01,480 HAS JOINED US IN NOVEMBER AS ANG 980 00:34:01,480 --> 00:34:02,880 IPA IN THE INDIVIDUAL BEHAVIORAL 981 00:34:02,880 --> 00:34:04,040 PROCESS BRANCH TO HELP US 982 00:34:04,040 --> 00:34:07,080 DEVELOP OUR DIGITAL HEALTH 983 00:34:07,080 --> 00:34:08,160 PORTFOLIO. 984 00:34:08,160 --> 00:34:10,960 DR. JOHN IS A TRAINED EXERCISE 985 00:34:10,960 --> 00:34:12,160 PHYSIOLOGIST AND EXPERT IN THE 986 00:34:12,160 --> 00:34:14,880 APPLICATION OF WEARABLE SENSORS 987 00:34:14,880 --> 00:34:16,280 TO MEASURE AND MODIFY PHYSICAL 988 00:34:16,280 --> 00:34:17,920 DAVE AND HOW TO ACCURATELY 989 00:34:17,920 --> 00:34:20,920 QUANTIFY PHYSICAL ACTIVITY AND 990 00:34:20,920 --> 00:34:21,560 SEDENTARY BEHAVIOR. 991 00:34:21,560 --> 00:34:22,920 HE WILL BE REPRESENTING US ON 992 00:34:22,920 --> 00:34:24,280 MULTIPLE DIGITAL HEALTH WORKING 993 00:34:24,280 --> 00:34:25,840 GROUPS, INCLUDING COLLABORATIONS 994 00:34:25,840 --> 00:34:27,640 WITH NSF ON SMART AND CONNECTED 995 00:34:27,640 --> 00:34:29,000 HEALTH AND HELPING TO SUPPORT 996 00:34:29,000 --> 00:34:31,960 OUR GROWING SBIR PROGRAM OF 997 00:34:31,960 --> 00:34:32,920 TECHNOLOGICAL SOLUTIONS TO 998 00:34:32,920 --> 00:34:34,120 SUPPORT ADAPTIVE AGING. 999 00:34:34,120 --> 00:34:37,800 AND THEN LAST BUT NOT LEAST, 1000 00:34:37,800 --> 00:34:38,360 DORI SULLIVAN JOINED US IN 1001 00:34:38,360 --> 00:34:40,240 NOVEMBER AS A PATHWAYS INTERN 1002 00:34:40,240 --> 00:34:41,920 WORKING WITH OUR ADMINISTRATIVE 1003 00:34:41,920 --> 00:34:42,200 TEAM. 1004 00:34:42,200 --> 00:34:44,200 SHE IS CURRENTLY PURSUING HER 1005 00:34:44,200 --> 00:34:47,400 MPH AT THE GEORGE WASHINGTON 1006 00:34:47,400 --> 00:34:48,000 UNIVERSITY SCHOOL OF PUBLIC 1007 00:34:48,000 --> 00:34:50,960 HEALTH AND PRIOR TO JOINING, SHE 1008 00:34:50,960 --> 00:34:52,240 RECEIVED HER BS IN BEHAVIORAL 1009 00:34:52,240 --> 00:34:54,120 COMMUNITY HEALTH AT THE 1010 00:34:54,120 --> 00:34:54,720 UNIVERSITY OF MARYLAND AND WAS 1011 00:34:54,720 --> 00:34:57,040 PREVIOUSLY AN INTERN WITH NIA'S 1012 00:34:57,040 --> 00:35:01,000 OFFICE OF PLANNING,INALIS AND 1013 00:35:01,000 --> 00:35:05,040 EVALUATION. 1014 00:35:05,040 --> 00:35:07,600 THANK YOU. 1015 00:35:07,600 --> 00:35:08,000 >>GOOD MORNING. 1016 00:35:08,000 --> 00:35:10,360 I'M FROM THE DIVISION OF 1017 00:35:10,360 --> 00:35:12,720 NEUROSCIENCE IT'S ALSO MY 1018 00:35:12,720 --> 00:35:14,160 PLEASURE TO WELCOME THE NEW TEAM 1019 00:35:14,160 --> 00:35:17,480 MEMBERS TO THE DIVISION OF 1020 00:35:17,480 --> 00:35:18,520 NEUROSCIENCE. 1021 00:35:18,520 --> 00:35:22,440 FIRST, RICHARD KWOK WHO JOINED 1022 00:35:22,440 --> 00:35:24,840 THE POPULATION STUBBEDDIES ON 1023 00:35:24,840 --> 00:35:27,720 GENETICS BRANCH. 1024 00:35:27,720 --> 00:35:29,760 RICHARD COMES NIHS AND HAS 1025 00:35:29,760 --> 00:35:32,840 TREMENDOUS EXPERIENCE ON 1026 00:35:32,840 --> 00:35:39,960 ENVIRONMENTAL EXPOSURE RESEARCH 1027 00:35:39,960 --> 00:35:40,400 EXPOSOME RESEARCH. 1028 00:35:40,400 --> 00:35:43,360 HE IS WORKING ON MANAGING A 1029 00:35:43,360 --> 00:35:46,240 PORTFOLIO THAT IS RELATED TO 1030 00:35:46,240 --> 00:35:48,480 EPIDEMIOLOGY OF ENVIRONMENTAL 1031 00:35:48,480 --> 00:35:50,600 EXPOSURE, GLOBAL HEALTH, 1032 00:35:50,600 --> 00:35:54,360 POPULATION STUDIES AND SO FORTH. 1033 00:35:54,360 --> 00:35:57,480 AND ALSO JOINING THE DIVISION OR 1034 00:35:57,480 --> 00:36:00,840 THE POPULATION STUDIES AND 1035 00:36:00,840 --> 00:36:04,360 GENETICS BRANCH IS DR. GHALEH. 1036 00:36:04,360 --> 00:36:06,800 SHE COMES FROM NINDS ALSO WITH A 1037 00:36:06,800 --> 00:36:09,560 VERY STRONG BACKGROUND IN 1038 00:36:09,560 --> 00:36:12,160 RESEARCH AND NEUROSCIENCES. 1039 00:36:12,160 --> 00:36:15,160 AND SHE WILL BE MANAGING 1040 00:36:15,160 --> 00:36:18,160 PORTFOLIOS ON EPIDEMIOLOGY OF 1041 00:36:18,160 --> 00:36:19,240 ALZHEIMER'S DISEASE AS WELL AS 1042 00:36:19,240 --> 00:36:21,120 GLOBAL HEALTH. 1043 00:36:21,120 --> 00:36:24,080 BOTH OF THEM COME TO 1044 00:36:24,080 --> 00:36:27,880 TREMENDOUSLY REINFORCE OUR 1045 00:36:27,880 --> 00:36:29,000 EFFORTS TOWARD EXPANDING 1046 00:36:29,000 --> 00:36:33,840 POPULATION STUDIES IN ADADRD. 1047 00:36:33,840 --> 00:36:38,600 AND NEXT, ALSO JOINING THE 1048 00:36:38,600 --> 00:36:41,880 DIVISION, SASHA. 1049 00:36:41,880 --> 00:36:46,120 SHE COMES FROM NIMH AND SASHA 1050 00:36:46,120 --> 00:36:47,520 JOINED AS PART OF THE TEAM 1051 00:36:47,520 --> 00:36:50,960 MANAGING THE ALZHEIMER'S DISEASE 1052 00:36:50,960 --> 00:36:52,000 RESEARCH CENTER, THE CENTERS 1053 00:36:52,000 --> 00:36:54,960 HAVE CONTINUED TO GROW 1054 00:36:54,960 --> 00:36:59,000 TREMENDOUSLY, NOW UP TO 35 1055 00:36:59,000 --> 00:36:59,480 CENTERS. 1056 00:36:59,480 --> 00:37:02,080 AND SHE ALSO WILL BE HELPING IN 1057 00:37:02,080 --> 00:37:04,240 THE IMPLEMENTATION OF THE DATA 1058 00:37:04,240 --> 00:37:09,040 MANAGEMENT AND SHARING PLANS AND 1059 00:37:09,040 --> 00:37:11,840 ALL CLINICAL RESEARCH RELATED TO 1060 00:37:11,840 --> 00:37:13,320 NEUROSCIENCE IN THE CONTEXT OF 1061 00:37:13,320 --> 00:37:16,080 THE ALZHEIMER'S STANDARDS. 1062 00:37:16,080 --> 00:37:18,560 AND IN TERMS OF THE NEUROBIOLOGY 1063 00:37:18,560 --> 00:37:24,040 OF AGING AND NEURODEGENERATION 1064 00:37:24,040 --> 00:37:27,560 BRANCH, JOE POTTACKAL RECENTLY 1065 00:37:27,560 --> 00:37:27,880 JOINED US. 1066 00:37:27,880 --> 00:37:30,600 HE CAME FROM A UNIVERSITY OF 1067 00:37:30,600 --> 00:37:33,280 MARYLAND, ALSO WITH A BACKGROUND 1068 00:37:33,280 --> 00:37:37,040 IN NEUROSCIENCE, VERY STRONG 1069 00:37:37,040 --> 00:37:37,840 BACKGROUND NEUROSCIENCES. 1070 00:37:37,840 --> 00:37:42,720 AND HE IS GOING TO BE WORKING ON 1071 00:37:42,720 --> 00:37:48,240 THE BRANCH PROVIDING SUPPORT ON 1072 00:37:48,240 --> 00:37:48,840 PROGMALTIC RESEARCH ON VARIOUS 1073 00:37:48,840 --> 00:37:52,360 AREAS OF NEUROBIOLOGY OF AGING, 1074 00:37:52,360 --> 00:37:56,480 ALZHEIMER'S DISEASE AND ADRD IN 1075 00:37:56,480 --> 00:37:58,200 SUPPORT OF THE OVERALL EFFORTS 1076 00:37:58,200 --> 00:37:58,880 OF THE BRANCH. 1077 00:37:58,880 --> 00:38:03,360 AND FINALLY, JERRY BOWER IS OUR 1078 00:38:03,360 --> 00:38:05,760 NEW PATHWAY INTERN. 1079 00:38:05,760 --> 00:38:08,640 HE ALSO COMES FROM A UNIVERSITY 1080 00:38:08,640 --> 00:38:12,200 OF MARYLAND BALTIMORE COUNTY. 1081 00:38:12,200 --> 00:38:16,680 AND HE WILL BE WORKING ON OUR 1082 00:38:16,680 --> 00:38:18,320 ADMINISTRATIVE PROGRAMS AND 1083 00:38:18,320 --> 00:38:25,240 SUPPORT AS A PATHWAY FELLOW. 1084 00:38:25,240 --> 00:38:27,720 THANK YOU. 1085 00:38:27,720 --> 00:38:30,160 >>ALL RIGHT, SO IT'S MY 1086 00:38:30,160 --> 00:38:31,960 PLEASURE TO INTRODUCE THE NEW 1087 00:38:31,960 --> 00:38:33,800 MEMBERS TO THE DIVISION OF 1088 00:38:33,800 --> 00:38:35,320 EXTRAMURAL ACTIVITY. 1089 00:38:35,320 --> 00:38:37,600 FIRST, IN OUR OFFICE OF CLINICAL 1090 00:38:37,600 --> 00:38:39,640 RESEARCH, WE HAVE TWO NEW 1091 00:38:39,640 --> 00:38:41,280 FEDERAL EMPLOYEES. 1092 00:38:41,280 --> 00:38:43,840 FIRST IS DR. SHAH. 1093 00:38:43,840 --> 00:38:46,720 SHE IS GOING TO BE A SUPERVISORY 1094 00:38:46,720 --> 00:38:47,080 PROGRAM OFFICER. 1095 00:38:47,080 --> 00:38:52,280 SHE IS JOINING US FROM NIAID, 1096 00:38:52,280 --> 00:38:56,040 ALLERGY AND INFECTIOUS DISEASE. 1097 00:38:56,040 --> 00:38:57,840 IN THEIR DIVISION OF AIDS 1098 00:38:57,840 --> 00:38:59,520 RESEARCH AND SHE IS GOING TO BE 1099 00:38:59,520 --> 00:39:02,960 PROVIDING A LOT OF SUPPORT FOR 1100 00:39:02,960 --> 00:39:04,560 OUR CLINICAL RESEARCH OFFICE, 1101 00:39:04,560 --> 00:39:08,760 ESPECIALLY IN REGULATORY AFFA 1102 00:39:08,760 --> 00:39:09,480 AFFAIRS. 1103 00:39:09,480 --> 00:39:11,800 WE ALSO HAVE GENE JAHVARIS 1104 00:39:11,800 --> 00:39:12,000 GIBSON. 1105 00:39:12,000 --> 00:39:13,600 SHE IS GOING TO BE A HEALTH 1106 00:39:13,600 --> 00:39:15,840 COMMUNICATION SPECIALIST AND SHE 1107 00:39:15,840 --> 00:39:18,640 HAS BEEN PREVIOUSLY A CONTRACTOR 1108 00:39:18,640 --> 00:39:21,080 WITH US IN THE OFFICE OF 1109 00:39:21,080 --> 00:39:22,080 CLINICAL RESEARCH BUT CONVERTED 1110 00:39:22,080 --> 00:39:24,200 TO FEDERAL EMPLOYEE, FINALLY. 1111 00:39:24,200 --> 00:39:27,240 AND SHE IS GOING TO HELP DEVELOP 1112 00:39:27,240 --> 00:39:30,880 MATERIALS FOR ONE OF OUR MAJOR 1113 00:39:30,880 --> 00:39:32,920 TOOLS FOR RECRUITMENT OUTREACH 1114 00:39:32,920 --> 00:39:33,280 PRO. 1115 00:39:33,280 --> 00:39:36,640 AND HELP OTHER CLINICAL TRIAL 1116 00:39:36,640 --> 00:39:39,160 WORKGROUP STRATEGIES WITHIN THE 1117 00:39:39,160 --> 00:39:39,400 OFFICE. 1118 00:39:39,400 --> 00:39:41,040 NEXT SLIDE. 1119 00:39:41,040 --> 00:39:43,960 WE HAVE TWO NEW SROs, 1120 00:39:43,960 --> 00:39:45,000 SCIENTIFIC REVIEW OFFICERS IN 1121 00:39:45,000 --> 00:39:48,600 THE SCIENTIFIC REVIEW BRANCH. 1122 00:39:48,600 --> 00:39:52,480 FIRST WE HAVE -- JOINING US FROM 1123 00:39:52,480 --> 00:39:53,680 BAILOR SCOTT AND LIGHT HEALTH. 1124 00:39:53,680 --> 00:39:56,720 SHE IS GOING TO BE ONE OF THE 1125 00:39:56,720 --> 00:39:59,720 TWO NEW SCIENTIFIC REVIEW 1126 00:39:59,720 --> 00:40:00,120 OFFICERS. 1127 00:40:00,120 --> 00:40:03,080 ALSO WE HAVE IVAN REBUSTINI. 1128 00:40:03,080 --> 00:40:06,480 HE IS JOIN US US FROM THE EYE 1129 00:40:06,480 --> 00:40:10,120 INSTITUTE AS A SCIENTIFIC REVIEW 1130 00:40:10,120 --> 00:40:10,920 OFFICER. 1131 00:40:10,920 --> 00:40:11,120 NEXT. 1132 00:40:11,120 --> 00:40:12,800 AND ALSO WE HAVE TWO NEW MEMBERS 1133 00:40:12,800 --> 00:40:15,800 OF OUR OFFICE OF STRATEGIC 1134 00:40:15,800 --> 00:40:16,840 EXTRAMURAL PROGRAMS. 1135 00:40:16,840 --> 00:40:19,200 THIS IS THE OFFICE THAT HANDLES 1136 00:40:19,200 --> 00:40:22,480 OUR SMALL BUSINESS AND OUR 1137 00:40:22,480 --> 00:40:23,160 TRAINING PROGRAMS. 1138 00:40:23,160 --> 00:40:25,120 FIRST WE HAVE DR. JOSHUA HOOKS. 1139 00:40:25,120 --> 00:40:28,920 HE IS A AAAS SCIENCE AND 1140 00:40:28,920 --> 00:40:29,800 TECHNOLOGY POLICY FELLOW AND HE 1141 00:40:29,800 --> 00:40:33,080 IS JOINING US FROM JOHNS HOPKINS 1142 00:40:33,080 --> 00:40:34,480 UNIVERSITY SCHOOL OF MEDICINE. 1143 00:40:34,480 --> 00:40:36,680 SO SHE GOING TO BE WORKING WITH 1144 00:40:36,680 --> 00:40:38,760 US ON OUR VARIOUS TRAINING 1145 00:40:38,760 --> 00:40:43,360 PROGRAMS FOR SMALL BUSINESS AND 1146 00:40:43,360 --> 00:40:43,960 START UPS FOR NEW ENTREPRENEURS 1147 00:40:43,960 --> 00:40:45,720 AND HE WILL DO A LOT OF OUR 1148 00:40:45,720 --> 00:40:47,920 EVALUATION FOR OUR PROGRAMS, 1149 00:40:47,920 --> 00:40:49,720 ESPECIALLY TO DIVERSIFY OUR 1150 00:40:49,720 --> 00:40:52,600 AGING TECHNOLOGY AND RESEARCH 1151 00:40:52,600 --> 00:40:53,120 WORKFORCE. 1152 00:40:53,120 --> 00:40:58,960 WE ALSO, JUST THIS WEEK, STARTS 1153 00:40:58,960 --> 00:40:59,240 DR. KUMAR. 1154 00:40:59,240 --> 00:41:03,280 HE IS JOINING US FROM LAYOLA 1155 00:41:03,280 --> 00:41:03,720 UNIVERSITY MARYLAND. 1156 00:41:03,720 --> 00:41:06,680 HE IS GOING TO BE COORDINATING 1157 00:41:06,680 --> 00:41:09,560 OUR SMALL BUSINESS FUNDING 1158 00:41:09,560 --> 00:41:11,200 OPPORTUNITIES AND HE IS GOING TO 1159 00:41:11,200 --> 00:41:14,400 HELP WITH IDENTIFYING BIOMEDICAL 1160 00:41:14,400 --> 00:41:16,840 INNOVATIONS AND DEVELOP NEW 1161 00:41:16,840 --> 00:41:19,720 INITIATIVES FOR SMALL BUSINESS. 1162 00:41:19,720 --> 00:41:23,840 NEXT SLIDE. 1163 00:41:23,840 --> 00:41:26,200 WE HAVE ONE NEW MEMBER IN OUR 1164 00:41:26,200 --> 00:41:28,600 CONTRACTS MANAGEMENT BRANCH. 1165 00:41:28,600 --> 00:41:33,040 WE WELCOME LAURA PEOPLE WHO WILL 1166 00:41:33,040 --> 00:41:34,240 BE A SUPERVISOR, GRANTS 1167 00:41:34,240 --> 00:41:34,720 MANAGEMENT SPECIALIST. 1168 00:41:34,720 --> 00:41:38,400 SHE IS ALSO JOINING US FROM NI 1169 00:41:38,400 --> 00:41:41,280 AIA AND SHE IS GOING TO BE 1170 00:41:41,280 --> 00:41:44,120 SUPERVISING SEVERAL OF OUR GRANT 1171 00:41:44,120 --> 00:41:45,200 SPECIALISTS BUT ALSO COORDINATE 1172 00:41:45,200 --> 00:41:49,160 A LOT OF OUR COMPLEX GRANT 1173 00:41:49,160 --> 00:41:53,080 PORTFOLIO THAT WE MANAGE IN OUR 1174 00:41:53,080 --> 00:41:57,560 GRANTS PROGRAM. 1175 00:41:57,560 --> 00:41:59,640 THANK YOU. 1176 00:41:59,640 --> 00:42:02,080 >>GOOD MORNING, PATRICK IN THE 1177 00:42:02,080 --> 00:42:02,480 EXECUTIVE OFFICE. 1178 00:42:02,480 --> 00:42:05,120 TWO NEW MEMBERS TO OUR FINANCIAL 1179 00:42:05,120 --> 00:42:07,720 MANAGEMENT BRANCH. 1180 00:42:07,720 --> 00:42:09,680 LAURA LAIN AND CUDDY COBARNETT. 1181 00:42:09,680 --> 00:42:11,080 THESE ARE THE FOLKS THAT MAKE 1182 00:42:11,080 --> 00:42:17,920 SURE THAT THE DATA THAT WE 1183 00:42:17,920 --> 00:42:19,800 PROVIDES IN ANALYSIS IS 1184 00:42:19,800 --> 00:42:21,240 ACCURATE, TIMELY AND AVAILABLE 1185 00:42:21,240 --> 00:42:21,920 FOR RICHARD AND AMY. 1186 00:42:21,920 --> 00:42:24,080 WE ARE EXCITED TO HAVE THEM. 1187 00:42:24,080 --> 00:42:25,600 LAUREN JOINS US FROM THE 1188 00:42:25,600 --> 00:42:28,040 CLINICAL CENTER AT NIHED AND HE 1189 00:42:28,040 --> 00:42:30,240 JOINS US FROM THE NAVAL RESEARCH 1190 00:42:30,240 --> 00:42:35,720 LABORATORY OPERATIONS. 1191 00:42:35,720 --> 00:42:38,080 THE NEXT BRANCH, WORKFORCE 1192 00:42:38,080 --> 00:42:38,920 ADMINISTRATOR MANAGEMENT BRANCH, 1193 00:42:38,920 --> 00:42:40,880 AS YOU'RE SEEING THIS, A LOT OF 1194 00:42:40,880 --> 00:42:42,480 HIRING AND STAFFING GOING ON 1195 00:42:42,480 --> 00:42:44,680 ACROSS THE NIA IN SUPPORT OF THE 1196 00:42:44,680 --> 00:42:46,720 IMPORTANT MISSION WE HAVE AND 1197 00:42:46,720 --> 00:42:50,040 ANDREA AND BETH ARE IN THAT TEAM 1198 00:42:50,040 --> 00:42:51,920 AND OPPORTUNITY WORK TO MAKE 1199 00:42:51,920 --> 00:42:52,520 SURE WE CAN ON BOARD AND BRING 1200 00:42:52,520 --> 00:42:58,120 THE STAFF NECESSARY TO SUPPORT 1201 00:42:58,120 --> 00:43:00,120 THE ACTIVITIES BOTH INTERN TO 1202 00:43:00,120 --> 00:43:02,040 SUPPORT STAFF AND GET NEW FOLKS 1203 00:43:02,040 --> 00:43:02,320 ONBOARD. 1204 00:43:02,320 --> 00:43:06,360 SO THANK YOU. 1205 00:43:06,360 --> 00:43:07,400 EXCITED TO HAVE THEM. 1206 00:43:07,400 --> 00:43:10,000 THIS IS A NEW OPERATION THAT WE 1207 00:43:10,000 --> 00:43:13,920 STOOD UP WITH CONTRACTS 1208 00:43:13,920 --> 00:43:18,080 ACCUSATION AND PROCUREMENT 1209 00:43:18,080 --> 00:43:18,400 BRANCH. 1210 00:43:18,400 --> 00:43:21,160 THESE ARE FOLKS THAT ARE 1211 00:43:21,160 --> 00:43:22,280 PREPARING TO SEE INCREASES IN 1212 00:43:22,280 --> 00:43:25,640 OUR WORKLOAD REACTED TO R&D 1213 00:43:25,640 --> 00:43:27,200 CONTRACTS, SO OUTWARD FACING, AS 1214 00:43:27,200 --> 00:43:28,600 WELL AS CONTRACTS WE NEED 1215 00:43:28,600 --> 00:43:31,560 INTERNALLY TO SUPPORT THE 1216 00:43:31,560 --> 00:43:31,760 GROWTH. 1217 00:43:31,760 --> 00:43:34,880 AND TONY AND DIANA COME FROM 1218 00:43:34,880 --> 00:43:37,080 OTHER PARTS OF THE NIH. 1219 00:43:37,080 --> 00:43:38,600 AND MICHELLE IS A BRAND NEW FAN 1220 00:43:38,600 --> 00:43:40,400 AND LOOKING FORWARD TO HER 1221 00:43:40,400 --> 00:43:44,080 CREATIVITY AND INNOVATION IN 1222 00:43:44,080 --> 00:43:48,040 THIS SPACE. 1223 00:43:48,040 --> 00:43:48,680 AND OUR INFORMATION TECHNOLOGY 1224 00:43:48,680 --> 00:43:50,440 BRANCH HAS A COUPLE OF NEW 1225 00:43:50,440 --> 00:43:50,640 FOLKS. 1226 00:43:50,640 --> 00:43:52,640 THESE ARE THE TEAMS THAT SUPPORT 1227 00:43:52,640 --> 00:43:53,480 MEETINGS LIKE THIS ACROSS THE 1228 00:43:53,480 --> 00:43:54,920 ORGANIZATION AND SUPPORT OUR 1229 00:43:54,920 --> 00:43:56,800 WORKPLACE FLEXIBILITY DURING THE 1230 00:43:56,800 --> 00:43:57,080 PANDEMIC. 1231 00:43:57,080 --> 00:43:59,520 WE HAVE A NEW INFORMATION 1232 00:43:59,520 --> 00:44:01,600 SECURITY SYSTEMS OVERS, DAVE. 1233 00:44:01,600 --> 00:44:04,560 HE COMES FROM US FROM THE 1234 00:44:04,560 --> 00:44:05,160 OUTSIDE AS A CONTRACTOR. 1235 00:44:05,160 --> 00:44:06,800 WE ARE EXCITED TO HAVE HIM JOIN 1236 00:44:06,800 --> 00:44:09,440 US WITH HIS EXPERIENCE AND 1237 00:44:09,440 --> 00:44:11,400 SELENA COMES TO US AGAIN FROM AN 1238 00:44:11,400 --> 00:44:12,160 OUTSIDE COMPANY WITH HER 1239 00:44:12,160 --> 00:44:17,040 CREATIVITY AND VISION TO SUPPORT 1240 00:44:17,040 --> 00:44:18,080 FUTURE AUTOMATION AND 1241 00:44:18,080 --> 00:44:20,120 DIGITIZATION ACROSS THE NIH 1242 00:44:20,120 --> 00:44:21,040 OPERATIONS. 1243 00:44:21,040 --> 00:44:23,480 THANK YOU. 1244 00:44:23,480 --> 00:44:25,080 >>THANK YOU. 1245 00:44:25,080 --> 00:44:25,600 MY NAME IS OLIVIA KENT. 1246 00:44:25,600 --> 00:44:28,120 I LEAD THE DIGITAL MEDIA BRANCH 1247 00:44:28,120 --> 00:44:28,800 IN THE OFFICE OF COMMUNICATIONS 1248 00:44:28,800 --> 00:44:30,960 AND PUBLIC LIASON AT NIA. 1249 00:44:30,960 --> 00:44:33,000 I'M EXCITED TO INTRODUCE DERRICK 1250 00:44:33,000 --> 00:44:34,640 WHO JOINED THE TEAM THE WEEK OF 1251 00:44:34,640 --> 00:44:36,280 THANKSGIVING AND HAS ALREADY 1252 00:44:36,280 --> 00:44:38,400 BEEN MAKING AN IMPACT IN MANY 1253 00:44:38,400 --> 00:44:38,760 AREAS. 1254 00:44:38,760 --> 00:44:40,720 HE HAS A BACKGROUND IN GRAPHIC 1255 00:44:40,720 --> 00:44:43,440 AND WEB DESIGN SO SHE OUR 1256 00:44:43,440 --> 00:44:45,560 FIRST-EVER IN HOUSE GRAPHIC 1257 00:44:45,560 --> 00:44:45,800 DESIGNER. 1258 00:44:45,800 --> 00:44:47,800 AND YOU WILL LIKELY SEE THE 1259 00:44:47,800 --> 00:44:50,120 OUTPUT OF HIS WORK AT THE NEXT 1260 00:44:50,120 --> 00:44:50,480 MEETING. 1261 00:44:50,480 --> 00:44:52,440 HE IS ALREADY WORKING ON AN 1262 00:44:52,440 --> 00:44:54,040 UPDATED SLIDE PRESENTATION DECK 1263 00:44:54,040 --> 00:44:56,880 AS WELL AS A COUPLE OF OTHER WEB 1264 00:44:56,880 --> 00:44:58,320 PROJECTS AROUND DOING CONTENT 1265 00:44:58,320 --> 00:44:59,520 AUDITING FOR US. 1266 00:44:59,520 --> 00:45:01,400 SO VERY HAPPY TO HAVE DERRICK 1267 00:45:01,400 --> 00:45:11,560 ONBOARD. 1268 00:45:12,360 --> 00:45:12,480 >>-- 1269 00:45:12,480 --> 00:45:12,840 [ INAUDIBLE ] 1270 00:45:12,840 --> 00:45:17,160 I'M GOING TO PRESENT THE FIVE 1271 00:45:17,160 --> 00:45:20,320 PEOPLE THAT WILL JOIN TODAY -- 1272 00:45:20,320 --> 00:45:23,120 LET ME GET THIS OPPORTUNITY TO 1273 00:45:23,120 --> 00:45:25,480 WISH YOU HAPPY NEW YEAR. 1274 00:45:25,480 --> 00:45:28,560 SO NATALIE LANDECK FORMERLY WAS 1275 00:45:28,560 --> 00:45:31,520 A FELLOW IN THE LABORATORY OF 1276 00:45:31,520 --> 00:45:36,400 NEUROGENETICS FOCUSING ON 1277 00:45:36,400 --> 00:45:38,000 INNOVATION HOW PARKINSON'S 1278 00:45:38,000 --> 00:45:39,000 DISEASE AFFECT NEURONAL FUNCTION 1279 00:45:39,000 --> 00:45:44,480 AND IS BECOMING A RESEARCH 1280 00:45:44,480 --> 00:45:46,360 FELLOW. 1281 00:45:46,360 --> 00:45:47,080 AND THEN CHELSEA WALTER AND 1282 00:45:47,080 --> 00:45:50,600 MONICA SULLIVAN, THE FIRST 1283 00:45:50,600 --> 00:45:51,800 COMING FROM THE ADMINISTRATION 1284 00:45:51,800 --> 00:45:55,640 WHERE SHE WAS A SUPPORT 1285 00:45:55,640 --> 00:45:57,640 ASSISTANT AND FREQUENTLY MEDICAL 1286 00:45:57,640 --> 00:45:59,840 INSTITUTE WHERE SHE WAS 1287 00:45:59,840 --> 00:46:02,520 PROVIDING ADMINISTRATIVE HELP. 1288 00:46:02,520 --> 00:46:05,360 AND THEY ARE BOTH SUPPORTIVE 1289 00:46:05,360 --> 00:46:07,760 OFFICERS THAT WILL BE MOSTLY 1290 00:46:07,760 --> 00:46:12,120 FOCUSING ON HANDLING TRAVEL, AND 1291 00:46:12,120 --> 00:46:18,960 SOME TRAINING FOR EMPLOYEES. 1292 00:46:18,960 --> 00:46:21,760 NEXT SLIDE. 1293 00:46:21,760 --> 00:46:24,880 ALSO A POSTDOCTORAL FELLOW. 1294 00:46:24,880 --> 00:46:30,960 HE IS AN EXPERT IN HEMATOPOIETIC 1295 00:46:30,960 --> 00:46:35,840 STEM CELL IN GENERAL. 1296 00:46:35,840 --> 00:46:38,960 ALSO IN HUMAN AND FOCUSING ON EP 1297 00:46:38,960 --> 00:46:39,240 GENOMICS. 1298 00:46:39,240 --> 00:46:41,800 AND HE WILL BE REALLY HELPING 1299 00:46:41,800 --> 00:46:46,000 THE ENTIRE TEAM AND TRAINING 1300 00:46:46,000 --> 00:46:47,920 POSTDOC AND WITH MANUSCRIPT 1301 00:46:47,920 --> 00:46:49,640 WRITING AND REVIEWING. 1302 00:46:49,640 --> 00:46:53,440 AND HE IS NOW RESEARCH FELLOW. 1303 00:46:53,440 --> 00:46:57,760 THE LAST BUT NOT LEAST, DAHLIA 1304 00:46:57,760 --> 00:46:59,280 MARZOUK, THE NEW ADMINISTRATIVE 1305 00:46:59,280 --> 00:47:02,640 MANAGER OF THE LABORATORY OF 1306 00:47:02,640 --> 00:47:05,240 CARDIOVASCULAR SCIENCE AND SHE 1307 00:47:05,240 --> 00:47:07,880 BASICALLY HANDLES THE ENTIRE 1308 00:47:07,880 --> 00:47:10,040 INFRASTRUCTURE OF THE LABORATORY 1309 00:47:10,040 --> 00:47:16,280 BY LOOKING AT TRAVEL PLANS AND 1310 00:47:16,280 --> 00:47:17,840 SUPERVISING ALL THE 1311 00:47:17,840 --> 00:47:18,840 ADMINISTRATION PERSONNEL THAT IS 1312 00:47:18,840 --> 00:47:22,400 IN THE LABORATORY. 1313 00:47:22,400 --> 00:47:26,160 AND SHE JOINS US IN SAINT LUKE'S 1314 00:47:26,160 --> 00:47:31,800 HEALTH SYSTEM. 1315 00:47:31,800 --> 00:47:36,120 >>LET ME JUST PAUSE AT THIS 1316 00:47:36,120 --> 00:47:36,880 POINT TO EXPRESS OUR EXCITEMENT 1317 00:47:36,880 --> 00:47:39,680 AND ENTHUSIASM FOR THE FACT WE 1318 00:47:39,680 --> 00:47:41,840 HAVE BEEN ABLE TO RECRUIT 1319 00:47:41,840 --> 00:47:42,480 TALENTED AND COMMITTED PEOPLE TO 1320 00:47:42,480 --> 00:47:43,080 THE INSTITUTE. 1321 00:47:43,080 --> 00:47:44,680 THEY WILL JUST ADD TO THE 1322 00:47:44,680 --> 00:47:48,800 RICHNESS OF OUR CREATIVITY AND 1323 00:47:48,800 --> 00:47:49,400 PRODUCTIVITY AND WELCOME ALL 1324 00:47:49,400 --> 00:47:49,600 AGAIN. 1325 00:47:49,600 --> 00:47:50,720 WISH THEY WERE HERE IN THE ROOM 1326 00:47:50,720 --> 00:47:53,000 FOR A ROUND OF PLAYS AND SOME 1327 00:47:53,000 --> 00:47:54,040 FURTHER RECOGNITION, BUT WE LOOK 1328 00:47:54,040 --> 00:47:55,520 FORWARD TO YOUR CHANCE TO 1329 00:47:55,520 --> 00:47:57,640 INTERACT WITH THEM IN THE TIMES 1330 00:47:57,640 --> 00:47:59,040 COMING. 1331 00:47:59,040 --> 00:48:00,920 FINALLY WE HAVE HERE SOME OF THE 1332 00:48:00,920 --> 00:48:02,560 LINKS TO WAYS IN WHICH YOU CAN 1333 00:48:02,560 --> 00:48:05,240 STAY INFORMED WITH WHAT NIA IS 1334 00:48:05,240 --> 00:48:05,520 DOING. 1335 00:48:05,520 --> 00:48:09,400 FIRST OF THOSE IS FOR ALL ACTIVE 1336 00:48:09,400 --> 00:48:11,720 FUNDING OPPORTUNITIES. 1337 00:48:11,720 --> 00:48:15,200 HERE THEY ARE FOR YOU TO PERUSE 1338 00:48:15,200 --> 00:48:17,000 AND CONFORM YOUR OWN RESEARCH 1339 00:48:17,000 --> 00:48:18,080 DECISIONS AND PLANS. 1340 00:48:18,080 --> 00:48:19,480 AND THEN LATEST APPROVED 1341 00:48:19,480 --> 00:48:21,280 CONCEPTS, MANY OF COME WILL BE 1342 00:48:21,280 --> 00:48:23,600 FINALIZING IN TERMS OF CONCEPT 1343 00:48:23,600 --> 00:48:24,880 APPROVAL THAT THE COUNCIL. 1344 00:48:24,880 --> 00:48:26,360 THESE ARE CONCEPTS APPROVED TO 1345 00:48:26,360 --> 00:48:26,920 GO FORWARD. 1346 00:48:26,920 --> 00:48:29,720 MANY OF THEM WILL TURN INTO 1347 00:48:29,720 --> 00:48:30,160 FUNDING OPPORTUNITIES. 1348 00:48:30,160 --> 00:48:31,240 AND THEN AS THE MOST PROACTIVE 1349 00:48:31,240 --> 00:48:34,360 WAY TO KEEP IN TOUCH WITH WHAT 1350 00:48:34,360 --> 00:48:35,040 IS HAPPENING AT THE INSTITUTE, I 1351 00:48:35,040 --> 00:48:36,040 ENCOURAGE YOU TO SUBSCRIBE TO 1352 00:48:36,040 --> 00:48:38,120 THE BLOG SO IT COMES TO YOU 1353 00:48:38,120 --> 00:48:40,600 GENERALLY WEEKLY BASIS. 1354 00:48:40,600 --> 00:48:43,120 DESCRIBING A LOT OF THE LATEST 1355 00:48:43,120 --> 00:48:45,040 INFORMATION OF RELEVANCE TO THE 1356 00:48:45,040 --> 00:48:48,000 RESEARCH COMMUNITY AND THE 1357 00:48:48,000 --> 00:48:48,600 BROADER PUBLIC. 1358 00:48:48,600 --> 00:48:51,800 THANK YOU. 1359 00:48:51,800 --> 00:48:54,280 I'M HAPPY TO ADDRESS ANY 1360 00:48:54,280 --> 00:48:56,720 QUESTIONS YOU MAY HAVE. 1361 00:48:56,720 --> 00:48:58,920 OTHERWISE IT'S BACK TO A TALK 1362 00:48:58,920 --> 00:49:04,160 ABOUT FUTURE MEETINGS AND WHAT 1363 00:49:04,160 --> 00:49:05,560 COMES NEXT. 1364 00:49:05,560 --> 00:49:05,960 >>THANK YOU. 1365 00:49:05,960 --> 00:49:16,360 ANY QUESTIONS FOR DR. HOSED? 1366 00:49:16,360 --> 00:49:17,240 HE WILL BE ON HAND THROUGHOUT 1367 00:49:17,240 --> 00:49:17,920 THE MEETING. 1368 00:49:17,920 --> 00:49:20,840 IF YOU HAVE ANY QUESTIONS LET US 1369 00:49:20,840 --> 00:49:22,040 KNOW AND WE'LL CONTINUE ON. 1370 00:49:22,040 --> 00:49:23,480 FOR EVERYONE'S KNOWLEDGE, OUR 1371 00:49:23,480 --> 00:49:26,920 FUTURE MEETINGS FOR 2023 AND 1372 00:49:26,920 --> 00:49:30,000 2024 ARE POSTED HERE. 1373 00:49:30,000 --> 00:49:33,120 WE WILL BE HAVING AN IN-PERSON 1374 00:49:33,120 --> 00:49:33,320 MEETING. 1375 00:49:33,320 --> 00:49:35,360 OUR ATTEMPT IS FOR MAY AND 1376 00:49:35,360 --> 00:49:35,800 SEPTEMBER COUNCILS. 1377 00:49:35,800 --> 00:49:37,960 THIS WILL BE ON OUR MAIN CAMPUS 1378 00:49:37,960 --> 00:49:41,560 BUILDING 45 HERE AT THE NIH 1379 00:49:41,560 --> 00:49:41,800 CAMPUS. 1380 00:49:41,800 --> 00:49:44,000 WE LOOK FORWARD TO MEETING 1381 00:49:44,000 --> 00:49:46,840 PEOPLE IN PERSON IN THE NEAR 1382 00:49:46,840 --> 00:49:48,400 FUTURE. 1383 00:49:48,400 --> 00:49:49,280 NEXT UP -- 1384 00:49:49,280 --> 00:49:50,280 >>CAN I ASK A QUESTION BEFORE 1385 00:49:50,280 --> 00:49:51,680 YOU MOVE ON FROM THAT? 1386 00:49:51,680 --> 00:49:54,200 >>SURE, GO AHEAD. 1387 00:49:54,200 --> 00:49:56,040 >>SO, SOME OF US NEVER HAD AN 1388 00:49:56,040 --> 00:49:58,120 IN-PERSON AS PART OF THE COUNCIL 1389 00:49:58,120 --> 00:49:58,360 BEFORE. 1390 00:49:58,360 --> 00:50:01,480 AND SO RELATED TO ALL OF THE 1391 00:50:01,480 --> 00:50:02,560 TRAVEL THAT WOULD BE ASSOCIATED 1392 00:50:02,560 --> 00:50:05,920 WITH THAT, THAT WOULD ALL BE 1393 00:50:05,920 --> 00:50:07,000 FIRST ORIGINATING FROM PEOPLE AT 1394 00:50:07,000 --> 00:50:09,120 NIA COMING TO US OR SHOULD WE DO 1395 00:50:09,120 --> 00:50:12,920 THINGS ON OUR OWN SIDE? 1396 00:50:12,920 --> 00:50:13,360 >>ABSOLUTELY. 1397 00:50:13,360 --> 00:50:16,400 YES, SO YOU WILL BE RECEIVING A 1398 00:50:16,400 --> 00:50:21,000 DETAILED E-MAIL FROM LINDA 1399 00:50:21,000 --> 00:50:23,840 ADDISON HARVEY FROM OUR TEAM AND 1400 00:50:23,840 --> 00:50:24,080 JASMINE. 1401 00:50:24,080 --> 00:50:25,480 AND IT WILL OUTLINE EXACTLY WHAT 1402 00:50:25,480 --> 00:50:27,440 YOU NEED TO DO FOR TRAVEL. 1403 00:50:27,440 --> 00:50:29,240 AND THEY WILL BE HANDLING THE 1404 00:50:29,240 --> 00:50:29,480 TRAVEL. 1405 00:50:29,480 --> 00:50:30,960 >>BUT WAIT FOR IT TO ORIGINATE 1406 00:50:30,960 --> 00:50:32,400 FROM YOUR SIDE BEFORE DOING 1407 00:50:32,400 --> 00:50:32,960 ANYTHING? 1408 00:50:32,960 --> 00:50:33,640 >>YES, CORRECT. 1409 00:50:33,640 --> 00:50:34,400 >>GOT IT. 1410 00:50:34,400 --> 00:50:36,720 THANK YOU. 1411 00:50:36,720 --> 00:50:38,880 >>KEN ALSO IN THE CHAT, MARISA 1412 00:50:38,880 --> 00:50:41,200 IS ASKING ABOUT AVAILABILITY OF 1413 00:50:41,200 --> 00:50:42,440 THESE SLIDES AND LINKS. 1414 00:50:42,440 --> 00:50:43,640 ABSOLUTELY WE WILL SEE THAT 1415 00:50:43,640 --> 00:50:47,600 THESE ARE MADE AVAILABLE. 1416 00:50:47,600 --> 00:50:47,880 >>YES. 1417 00:50:47,880 --> 00:50:51,440 ABSOLUTELY. 1418 00:50:51,440 --> 00:50:52,920 NEXT UP, IT'S OUR CONSIDERATION 1419 00:50:52,920 --> 00:50:55,800 OF THE MINUTES FROM OUR LAST 1420 00:50:55,800 --> 00:50:59,200 SEPTEMBER 2022 COUNCIL. 1421 00:50:59,200 --> 00:51:03,440 THESE ARE AVAILABLE IN THE 1422 00:51:03,440 --> 00:51:03,920 ELECTRONIC COUNCIL BOOK. 1423 00:51:03,920 --> 00:51:06,000 I JUST LIKE TO THEN GET A MOTION 1424 00:51:06,000 --> 00:51:07,640 TO APPROVE THE MINUTES FROM THE 1425 00:51:07,640 --> 00:51:09,920 LAST MEETING. 1426 00:51:09,920 --> 00:51:12,160 >>SO MOVED. 1427 00:51:12,160 --> 00:51:12,720 >>SECOND? 1428 00:51:12,720 --> 00:51:13,000 >>SECOND. 1429 00:51:13,000 --> 00:51:16,840 >>ALL IN FAVOR. 1430 00:51:16,840 --> 00:51:17,120 >>AYE. 1431 00:51:17,120 --> 00:51:19,720 >>ANY OPPOSED? 1432 00:51:19,720 --> 00:51:21,560 NOT HEARING ANY. 1433 00:51:21,560 --> 00:51:22,760 WE HAVE APPROVAL OF THE MINUTES. 1434 00:51:22,760 --> 00:51:27,480 R. FROM THE 2022 SEPTEMBER 1435 00:51:27,480 --> 00:51:29,640 COUNCIL. 1436 00:51:29,640 --> 00:51:30,120 THANK YOU VERY MUCH. 1437 00:51:30,120 --> 00:51:32,680 NEXT UP IS OUR REPORT FROM OUR 1438 00:51:32,680 --> 00:51:34,440 TASK FORCE ON MINORITY AGING. 1439 00:51:34,440 --> 00:51:40,760 I'M TURN THIS OVER TO DR. MANLY. 1440 00:51:40,760 --> 00:51:42,560 >>DR. MANLY: I'M GOING TO SHARE 1441 00:51:42,560 --> 00:51:46,760 SOME SLIDES, IF THAT'S OKAY. 1442 00:51:46,760 --> 00:51:48,720 HOPEFULLY IF YOU CAN SEE MY 1443 00:51:48,720 --> 00:51:50,760 SCREEN RIGHT NOW -- 1444 00:51:50,760 --> 00:51:51,040 >>YES. 1445 00:51:51,040 --> 00:51:55,920 >>DR. MANLY: AND JUST WANT TO 1446 00:51:55,920 --> 00:51:56,640 ORIENT LISTENERS THAT JUST LIKE 1447 00:51:56,640 --> 00:52:07,320 THE NACA COUNCIL ADVISES THE 1448 00:52:07,320 --> 00:52:07,840 SECRETARY OF HHS, THE DIRECTOR 1449 00:52:07,840 --> 00:52:10,480 OF NIH AND DR. HOSED ON NIA'S 1450 00:52:10,480 --> 00:52:13,480 MISSION, THE TASK FORCE FOR 1451 00:52:13,480 --> 00:52:14,160 MINORITYEDS AGING RESEARCH 1452 00:52:14,160 --> 00:52:17,080 COMMITTEE IS A SUBCOMMITTEE OF 1453 00:52:17,080 --> 00:52:17,320 NACA. 1454 00:52:17,320 --> 00:52:19,680 ALL COUNCIL MEMBERS ARE ACTIVE 1455 00:52:19,680 --> 00:52:22,440 MEMBERS OF OUR TASK FORCE 1456 00:52:22,440 --> 00:52:25,800 SUBCOMMITTEE AND THE TASK FORCE 1457 00:52:25,800 --> 00:52:31,840 HAS A SPECIAL ROLE TO ADVISE NIH 1458 00:52:31,840 --> 00:52:34,240 AND DR. HOEDS ABOUT OUR 1459 00:52:34,240 --> 00:52:35,840 UNDERSTANDING OF HOW AGING 1460 00:52:35,840 --> 00:52:39,040 RESEARCH CAN ADDRESS HEALTH 1461 00:52:39,040 --> 00:52:41,680 INEQUALITIES FOR MINORITY WOMEN, 1462 00:52:41,680 --> 00:52:43,560 MINORITY GROUPS AND PEOPLE WITH 1463 00:52:43,560 --> 00:52:44,160 DISABILITIES. 1464 00:52:44,160 --> 00:52:47,120 WE HAVE DR. PATRICIA JONES, THE 1465 00:52:47,120 --> 00:52:48,320 DIRECTOR OF THE NIA OFFICE OF 1466 00:52:48,320 --> 00:52:50,880 SPECIAL POPULATIONS WHO WORKS 1467 00:52:50,880 --> 00:52:53,640 WITH THE TASK FORCE TO ACHIEVE 1468 00:52:53,640 --> 00:53:01,680 ITS GOALS, AND DR. YANIRA CRUZ 1469 00:53:01,680 --> 00:53:05,240 ARE THE CO-CHAIRS. 1470 00:53:05,240 --> 00:53:06,200 DR. HEALTH WHITFIELD THIS IS HIS 1471 00:53:06,200 --> 00:53:07,320 LAST MEETING AT COUNCIL, WHICH 1472 00:53:07,320 --> 00:53:11,760 IS A VERY SAD THING. 1473 00:53:11,760 --> 00:53:17,080 BUT DR. CRUZ IS STEPPING UP TO 1474 00:53:17,080 --> 00:53:19,680 TAKE PART IN AS A CO-CHAIR. 1475 00:53:19,680 --> 00:53:22,920 AND WHAT WE DO IN THE TASK 1476 00:53:22,920 --> 00:53:24,920 FORCE, IS WE TRY TO HIGHLIGHT 1477 00:53:24,920 --> 00:53:26,960 INNOVATIVE AND IMPACTFUL HEALTH 1478 00:53:26,960 --> 00:53:30,200 RESEARCH FUNDED BY NIA 1479 00:53:30,200 --> 00:53:31,480 THROUGHOUT EACH OF THE 1480 00:53:31,480 --> 00:53:32,160 DIVISIONS, ESPECIALLY THE 1481 00:53:32,160 --> 00:53:34,200 RESEARCH THAT USES THE NIA 1482 00:53:34,200 --> 00:53:35,360 HEALTH DISPARITIES FRAMEWORK. 1483 00:53:35,360 --> 00:53:38,200 AND WE ALSO TRY TO ENGAGE IN A 1484 00:53:38,200 --> 00:53:39,800 DISCUSSION ABOUT SUPPORT FOR 1485 00:53:39,800 --> 00:53:41,720 TRAINING AND OTHER NIA RESOURCES 1486 00:53:41,720 --> 00:53:43,640 THAT CAN HELP TO ACCELERATE AND 1487 00:53:43,640 --> 00:53:44,640 ADVANCE HEALTH AND AGING 1488 00:53:44,640 --> 00:53:45,440 RESEARCH. 1489 00:53:45,440 --> 00:53:48,680 AND SO, PRIOR TO EVERY NACA 1490 00:53:48,680 --> 00:53:49,600 MEETING, THE CO-CHAIRS AND 1491 00:53:49,600 --> 00:53:51,600 DR. JONES MEET TO TRY TO COME UP 1492 00:53:51,600 --> 00:53:55,040 WITH WHAT WE ARE GOING TO DO AT 1493 00:53:55,040 --> 00:53:55,360 THIS MEETING. 1494 00:53:55,360 --> 00:53:57,880 AND THIS TIME WE CHOSE TWO 1495 00:53:57,880 --> 00:54:01,640 SPEAKERS TO PRESENT TO COUNCIL 1496 00:54:01,640 --> 00:54:06,080 TO HIGHLIGHT THE CONTRIBUTION OF 1497 00:54:06,080 --> 00:54:09,360 BIOLOGICAL RESEARCH OR BASIC 1498 00:54:09,360 --> 00:54:13,520 BIOLOGY RESEARCH AND BIOLOGICAL 1499 00:54:13,520 --> 00:54:15,440 MECHANISMS TO UNDERSTANDING 1500 00:54:15,440 --> 00:54:16,280 HEALTH AND AGING DISPARITIES 1501 00:54:16,280 --> 00:54:17,040 RESEARCH. 1502 00:54:17,040 --> 00:54:18,200 SO LET ME TELL YOU ABOUT THOSE 1503 00:54:18,200 --> 00:54:19,840 TALKS RIGHT NOW AND I'M GOING 1504 00:54:19,840 --> 00:54:21,720 SHOW YOU SLIDES FROM THE 1505 00:54:21,720 --> 00:54:22,040 PRESENTERS. 1506 00:54:22,040 --> 00:54:23,680 THESE ARE NOT MY SLIDES. 1507 00:54:23,680 --> 00:54:25,000 THESE ARE SLIDES FROM THE 1508 00:54:25,000 --> 00:54:25,280 PRESENTERS. 1509 00:54:25,280 --> 00:54:28,640 OUR FIRST TALK WAS FROM 1510 00:54:28,640 --> 00:54:29,680 DR. CHANTAL MARTIN WHO IS AN 1511 00:54:29,680 --> 00:54:31,040 ASSISTANT PROFESSOR OF 1512 00:54:31,040 --> 00:54:34,080 EPIDEMIOLOGY AT THE GILLINGS 1513 00:54:34,080 --> 00:54:34,640 SCHOOL OF GLOBAL AND PUBLIC 1514 00:54:34,640 --> 00:54:34,880 HEALTH. 1515 00:54:34,880 --> 00:54:36,600 SHE IS A SOCIAL EPIDEMIOLOGIST 1516 00:54:36,600 --> 00:54:39,920 WHO FOCUSES ON SOCIAL AND 1517 00:54:39,920 --> 00:54:42,560 STRUCTURAL DRIVERS OF HEALTH AND 1518 00:54:42,560 --> 00:54:44,000 EQUALITIES IN COGNITIVE DISEASE 1519 00:54:44,000 --> 00:54:47,600 RISK ACROSS THE LIFE COURSE. 1520 00:54:47,600 --> 00:54:48,640 AND THE POTENTIAL UNDERLYING 1521 00:54:48,640 --> 00:54:49,120 BIOLOGICAL MECHANISMS. 1522 00:54:49,120 --> 00:54:51,680 AND SHE BEGAN HER TALK BY 1523 00:54:51,680 --> 00:54:53,440 PROVIDING AN OVERVIEW FOR US OF 1524 00:54:53,440 --> 00:54:55,520 STRUCTURAL RACISM AS A 1525 00:54:55,520 --> 00:54:57,760 FUNDAMENTAL CAUSE OF HEALTH 1526 00:54:57,760 --> 00:54:58,080 DISPARITIES. 1527 00:54:58,080 --> 00:55:02,880 SHE PROVIDED A QUOTE TO US FROM 1528 00:55:02,880 --> 00:55:04,040 ZIN WE HAVE BAILEY, AN EXPERT ON 1529 00:55:04,040 --> 00:55:09,000 STRUCTURAL RACISM AND HEALTH AND 1530 00:55:09,000 --> 00:55:09,760 THAT BASICALLY SAYS THAT 1531 00:55:09,760 --> 00:55:11,600 STRUCTURAL RACISM IS 1532 00:55:11,600 --> 00:55:12,440 INTERCONNECTED INSTITUTIONS 1533 00:55:12,440 --> 00:55:15,160 WHOSE LINKAGES ARE HISTORICALLY 1534 00:55:15,160 --> 00:55:17,400 ROOTED AND CULTURALLY ENFORCED. 1535 00:55:17,400 --> 00:55:20,000 IT'S THE TOTALITY OF WAYS IN 1536 00:55:20,000 --> 00:55:23,960 WHICH THE SOCIETIES FOSTER 1537 00:55:23,960 --> 00:55:24,560 RACIAL DISCRIMINATION THROUGH 1538 00:55:24,560 --> 00:55:26,640 MUTUALLY REINFORCING I BELIEVE 1539 00:55:26,640 --> 00:55:29,960 EQUITABLE SYSTEMS AND -- 1540 00:55:29,960 --> 00:55:33,280 INEQUITABLE SYSTEMS AND 1541 00:55:33,280 --> 00:55:34,400 REINFORCE DISCRIMINATORY 1542 00:55:34,400 --> 00:55:35,720 BELIEFS, VALUES AND DISTRIBUTION 1543 00:55:35,720 --> 00:55:37,560 OF RESOURCES WHICH TOGETHER 1544 00:55:37,560 --> 00:55:39,080 AFFECT THE RISK OF ADVERSE 1545 00:55:39,080 --> 00:55:39,440 HEALTH OUTCOMES. 1546 00:55:39,440 --> 00:55:41,160 SO DR. MARTIN DESCRIBED HER WORK 1547 00:55:41,160 --> 00:55:42,600 TO US TO UNDERSTAND HOW 1548 00:55:42,600 --> 00:55:44,360 STRUCTURAL RACISM THAT I JUST 1549 00:55:44,360 --> 00:55:47,280 GAVE YOU A DEFINITION FOR, IN 1550 00:55:47,280 --> 00:55:49,960 PARTICULAR RESIDENTIAL 1551 00:55:49,960 --> 00:55:51,960 SEGREGATION INFLUENCES CHANGES 1552 00:55:51,960 --> 00:55:55,840 IN BIOLOGICAL, PHYSIOLOGICAL, 1553 00:55:55,840 --> 00:55:57,080 PSYCHOLOGICAL, BEHAVIORAL AND 1554 00:55:57,080 --> 00:56:00,000 SOCIAL FUNCTIONING. 1555 00:56:00,000 --> 00:56:01,640 ONE OF THE INNOVATIVE WAYS THAT 1556 00:56:01,640 --> 00:56:04,280 RESEARCHERS HAVE BEEN TRYING TO 1557 00:56:04,280 --> 00:56:05,480 UNDERSTAND THESE INFLUENCES IS 1558 00:56:05,480 --> 00:56:07,720 BY MEASURING BIOLOGICAL AGING 1559 00:56:07,720 --> 00:56:09,760 AND ESSENTIALLY THIS IS 1560 00:56:09,760 --> 00:56:12,360 BIOMARKERS THAT PREDICT THE 1561 00:56:12,360 --> 00:56:13,280 FUNCTIONAL CAPABILITY OF A 1562 00:56:13,280 --> 00:56:15,720 PERSON OR THEIR ORGANS AND HOW 1563 00:56:15,720 --> 00:56:17,800 IT CHANGES WITH AGE. 1564 00:56:17,800 --> 00:56:20,920 SO, COMMON MEASURES OF 1565 00:56:20,920 --> 00:56:22,200 BIOLOGICAL AGING INCLUDE ALOE 1566 00:56:22,200 --> 00:56:26,560 STATIC LOAD, TELOMERE LENGTH AND 1567 00:56:26,560 --> 00:56:27,040 IMMEW MUNE FUNCTION BUT 1568 00:56:27,040 --> 00:56:30,200 DR. MARTIN TOLD US ABOUT DNA 1569 00:56:30,200 --> 00:56:31,600 METHYLATION WHICH IS BIOMARKER 1570 00:56:31,600 --> 00:56:34,080 OF BIOLOGICAL AGING THAT IS 1571 00:56:34,080 --> 00:56:37,680 RESPONSIVE TO ENVIRONMENTAL 1572 00:56:37,680 --> 00:56:37,960 STRESSORS. 1573 00:56:37,960 --> 00:56:40,160 IT OFFERS INSIGHT INTO POTENTIAL 1574 00:56:40,160 --> 00:56:44,040 MOLECULAR PATHWAYS THAT LINK 1575 00:56:44,040 --> 00:56:48,520 STRESS AND THE ENVIRONMENT TO 1576 00:56:48,520 --> 00:56:49,840 HEALTH IN THE BODY. 1577 00:56:49,840 --> 00:56:51,040 AND LET PLEASE JUST QUICKLY SHOW 1578 00:56:51,040 --> 00:56:53,720 YOU SOME OF HER RESULTS. 1579 00:56:53,720 --> 00:56:55,360 SHE LOOKED AT THE ASSOCIATION -- 1580 00:56:55,360 --> 00:56:58,240 ASKED THE QUESTION HOW IS THIS 1581 00:56:58,240 --> 00:57:01,600 TO STRUCTURAL RACISM AND ADVERSE 1582 00:57:01,600 --> 00:57:02,520 NEIGHBORHOOD CONDITIONS 1583 00:57:02,520 --> 00:57:04,520 CONTRIBUTE TO EP GENELNETIC 1584 00:57:04,520 --> 00:57:07,480 CHANGES AND ACCELERATED AGING 1585 00:57:07,480 --> 00:57:08,360 THROUGHOUT THE LIFE COURSE. 1586 00:57:08,360 --> 00:57:10,560 SHE FOUND USING THE DETROIT 1587 00:57:10,560 --> 00:57:11,880 NEIGHBORHOOD HEALTH AND AGING 1588 00:57:11,880 --> 00:57:13,360 STUDY THAT NEIGHBORHOOD QUALITY 1589 00:57:13,360 --> 00:57:17,160 WAS ASSOCIATED WITH ACCELERATED 1590 00:57:17,160 --> 00:57:21,000 DNA METHYLATION AGING. 1591 00:57:21,000 --> 00:57:22,960 IN MODELS THAT WERE STRATIFIED 1592 00:57:22,960 --> 00:57:24,000 ON SOCIAL COHESION, THE 1593 00:57:24,000 --> 00:57:25,360 ASSOCIATION OF NEIGHBORHOOD 1594 00:57:25,360 --> 00:57:27,720 DISORDER WITH DNA METHYLATION 1595 00:57:27,720 --> 00:57:28,880 REMAINED ELEVATED FOR PEOPLE 1596 00:57:28,880 --> 00:57:32,560 LIVING IN NEIGHBORHOODS WITH 1597 00:57:32,560 --> 00:57:33,600 LOWER SOCIAL COHESION BUT WERE 1598 00:57:33,600 --> 00:57:34,840 NULL FOR PEOPLE WHO LIVED IN 1599 00:57:34,840 --> 00:57:38,480 NEIGHBORHOODS WITH HIGHER SOCIAL 1600 00:57:38,480 --> 00:57:38,760 COHESION. 1601 00:57:38,760 --> 00:57:42,640 SO, DR. MARTIN'S RESEARCH 1602 00:57:42,640 --> 00:57:43,520 SUGGESTED THAT LIVING IN AN 1603 00:57:43,520 --> 00:57:44,520 ADVERSE NEIGHBORHOOD ENVIRONMENT 1604 00:57:44,520 --> 00:57:46,640 CAN SPEED UP THIS EPIGENETIC 1605 00:57:46,640 --> 00:57:49,080 AGING WHILE POSITIVE 1606 00:57:49,080 --> 00:57:49,880 NEIGHBORHOOD ATTRIBUTES MAY 1607 00:57:49,880 --> 00:57:51,400 BUFFER THOSE EFFECTS. 1608 00:57:51,400 --> 00:57:53,360 LET ME MOVE ON QUICKLY TO THE 1609 00:57:53,360 --> 00:57:55,920 NEXT TALK THAT WE HEARD 1610 00:57:55,920 --> 00:57:56,680 YESTERDAY. 1611 00:57:56,680 --> 00:57:57,960 DR. GERMANE DAVIS IS AN 1612 00:57:57,960 --> 00:57:58,720 ASSISTANT PROFESSOR IN THE 1613 00:57:58,720 --> 00:58:01,040 DEPARTMENT OF BIOCHEMISTRY, 1614 00:58:01,040 --> 00:58:03,120 CANCER BIOLOGY AND NEUROSCIENCE 1615 00:58:03,120 --> 00:58:05,040 AT THE HARRY MEDICAL COLLEGE AND 1616 00:58:05,040 --> 00:58:07,200 IS A MEMBER OF THE CENTER FOR 1617 00:58:07,200 --> 00:58:08,280 STRUCTURAL BIOLOGY AT 1618 00:58:08,280 --> 00:58:08,640 VANDERBILT. 1619 00:58:08,640 --> 00:58:11,800 HE IS A PH.D. IN BIOCHEMISTRY 1620 00:58:11,800 --> 00:58:13,560 AND MOLECULAR BIOPHYSICS AND IS 1621 00:58:13,560 --> 00:58:16,160 AN ALUMNUS AT THE BUTLER WILLIAM 1622 00:58:16,160 --> 00:58:18,000 SCHOLAR PROGRAM, ONE OF THE KEY 1623 00:58:18,000 --> 00:58:20,360 ACTIVITIES OF THE OFFICE OF 1624 00:58:20,360 --> 00:58:23,480 SPECIAL PROGRAMS AT NIA. 1625 00:58:23,480 --> 00:58:26,640 AND ONE IMPORTANT PART OF WHAT 1626 00:58:26,640 --> 00:58:28,880 DR. DAVIS DOES IS TRIES TO 1627 00:58:28,880 --> 00:58:30,520 UNDERSTAND THE CONTRIBUTION OF 1628 00:58:30,520 --> 00:58:33,960 GENETICS TO THE DISPARITY IN 1629 00:58:33,960 --> 00:58:36,880 ALZHEIMER'S DISEASE RISK BETWEEN 1630 00:58:36,880 --> 00:58:38,920 AFRICAN-AMERICANS AND 1631 00:58:38,920 --> 00:58:41,720 NON-HISPANIC WHITES, WHICH VIDEO 1632 00:58:41,720 --> 00:58:43,320 ME JUST SAID ABOUT 20 MINUTES 1633 00:58:43,320 --> 00:58:46,640 AGO, 20 OR 30 MINUTES AGO, IN 1634 00:58:46,640 --> 00:58:48,560 THE VIDEO. 1635 00:58:48,560 --> 00:58:52,080 AND DR. DAVIS IS TRYING TO 1636 00:58:52,080 --> 00:58:52,840 UNDERSTAND GENETIC VARIANTS THAT 1637 00:58:52,840 --> 00:58:54,480 ARE ASSOCIATED WITH ALZHEIMER'S 1638 00:58:54,480 --> 00:58:58,640 DISEASE THAT ARE MORE PREVALENT 1639 00:58:58,640 --> 00:59:00,680 IN EUROPEANS OF AFRICAN DECENT 1640 00:59:00,680 --> 00:59:03,800 THAN THEY ARE IN PEOPLE OF 1641 00:59:03,800 --> 00:59:04,560 EUROPEAN ANCESTRY. 1642 00:59:04,560 --> 00:59:09,120 SO HE IS TRYING TO UNDERSTAND 1643 00:59:09,120 --> 00:59:10,280 THIS A7 GENE, WHICH HAS BEEN 1644 00:59:10,280 --> 00:59:11,920 SHOWN TO HAVE STRONGER 1645 00:59:11,920 --> 00:59:15,240 ASSOCIATIONS WITH AD RISK IN 1646 00:59:15,240 --> 00:59:17,000 PEOPLE WITH AFRICAN ANCESTRY 1647 00:59:17,000 --> 00:59:19,840 THAN IN PEOPLE WITH EUROPEAN 1648 00:59:19,840 --> 00:59:20,840 ANCESTRY. 1649 00:59:20,840 --> 00:59:24,480 IN FACT, IT HAS A STRONGER 1650 00:59:24,480 --> 00:59:29,640 EFFECT ON AD RISK THANG THE 1651 00:59:29,640 --> 00:59:33,440 APOE4 GENE OR ALLELE IN 1652 00:59:33,440 --> 00:59:33,840 AFRICAN-AMERICANS. 1653 00:59:33,840 --> 00:59:36,320 SO HE IS TRYING TO UNDERSTAND 1654 00:59:36,320 --> 00:59:38,480 THIS TRANSMEMBRANE PROTEIN 1655 00:59:38,480 --> 00:59:43,040 THAT'S INVOLVED IN LIPID 1656 00:59:43,040 --> 00:59:45,840 HOMEOSTAYSIS AND PHAGOCYTOSIS, 1657 00:59:45,840 --> 00:59:49,680 AND THE DYSFUNCTION OF THE ABC 1658 00:59:49,680 --> 00:59:51,320 A7 JEAN IS ASSOCIATED WITH 1659 00:59:51,320 --> 00:59:54,040 INCREASED AMYLOID BETA 1660 00:59:54,040 --> 00:59:55,440 PRODUCTION, REDUCED AMYLOID BETA 1661 00:59:55,440 --> 00:59:58,240 CLEARS, IMPAIRED MICROGLIAL 1662 00:59:58,240 --> 01:00:01,480 RESPONSE TO INFLAMMATION AND 1663 01:00:01,480 --> 01:00:03,840 ENDOPLASMIC RETICULUM STRESS. 1664 01:00:03,840 --> 01:00:07,320 SO, LET ME SHOW YOU MY LAST 1665 01:00:07,320 --> 01:00:10,240 SLIDE, WHICH IS ALSO FROM 1666 01:00:10,240 --> 01:00:10,680 DR. DAVIS'S TALKS. 1667 01:00:10,680 --> 01:00:13,440 SO THIS IS DR. DAVIS'S SLIDE AND 1668 01:00:13,440 --> 01:00:13,720 DATA. 1669 01:00:13,720 --> 01:00:17,520 SOME OF IT WAS PRESENTED IN 1670 01:00:17,520 --> 01:00:18,000 AAIC. 1671 01:00:18,000 --> 01:00:20,880 AND THE QUESTION THAT HE HAS 1672 01:00:20,880 --> 01:00:24,440 WAS, HOW A7 CONTRIBUTES A DO. 1673 01:00:24,440 --> 01:00:25,560 A MOLECULAR LEVEL. 1674 01:00:25,560 --> 01:00:28,160 HE SHOWED US HOW HE ISUDING A 1675 01:00:28,160 --> 01:00:28,760 COMBINATION OF STRUCTURAL AND 1676 01:00:28,760 --> 01:00:32,280 CELL BIOLOGY TECHNIQUES TO DO 1677 01:00:32,280 --> 01:00:33,280 THIS. 1678 01:00:33,280 --> 01:00:38,920 HE IS LOOKING AT HOW THE ABC A7 1679 01:00:38,920 --> 01:00:39,360 VARIANT MAY CONTRIBUTE 1680 01:00:39,360 --> 01:00:42,640 ALZHEIMER'S DISEASE BY REDUCING 1681 01:00:42,640 --> 01:00:43,680 THE LEVEL OF THIS SUBSTANCE 1682 01:00:43,680 --> 01:00:46,160 CALLED, PIP 2 IT'S A 1683 01:00:46,160 --> 01:00:48,160 PHOSPHOLIPID REPORTED TO BE 1684 01:00:48,160 --> 01:00:52,640 DECREASED IN THE AD BRAIN. 1685 01:00:52,640 --> 01:00:53,320 SO THAT VERY INTERESTING WORK 1686 01:00:53,320 --> 01:00:55,000 WAS PRESENTED BY HIM YESTERDAY. 1687 01:00:55,000 --> 01:00:56,440 IN ADDITION TO THE CAREFUL AND 1688 01:00:56,440 --> 01:00:58,160 INNOVATIVE WORK HE IS DOING TO 1689 01:00:58,160 --> 01:01:02,400 UNDERSTAND THESE GENETIC 1690 01:01:02,400 --> 01:01:03,440 CONTRIBUTIONS, THE KNACK COUNCIL 1691 01:01:03,440 --> 01:01:05,000 WAS VERY IMPRESSED WITH HIS 1692 01:01:05,000 --> 01:01:06,320 EMPHASIS ON COMMUNITY 1693 01:01:06,320 --> 01:01:06,880 ENGAGEMENT. 1694 01:01:06,880 --> 01:01:09,840 -- NACA -- THIS IS A RESEARCHER 1695 01:01:09,840 --> 01:01:11,320 WHO ALWAYS KEEPS IT REAL WITH 1696 01:01:11,320 --> 01:01:12,360 THE COMMUNITY. 1697 01:01:12,360 --> 01:01:14,800 HE ENGAGES THEM ABOUT HIS 1698 01:01:14,800 --> 01:01:17,600 RESEARCH AND RESEARCH 1699 01:01:17,600 --> 01:01:19,920 PARTICIPATION, AND THROUGH THE 1700 01:01:19,920 --> 01:01:24,400 MEMBERS OF HIS LAB AND HIS WORK, 1701 01:01:24,400 --> 01:01:26,320 HE EMPHASIZES THE IMPORTANCE OF 1702 01:01:26,320 --> 01:01:28,000 EMBEDDING HIS SCIENCE IN THE 1703 01:01:28,000 --> 01:01:28,720 CONCERNS OF THE COMMUNITIES WE 1704 01:01:28,720 --> 01:01:31,640 ARE TRYING TO SERVE. 1705 01:01:31,640 --> 01:01:33,000 SO THAT IS MY REPORT. 1706 01:01:33,000 --> 01:01:35,960 LET ME JUST ASK DR. CRUZ IF YOU 1707 01:01:35,960 --> 01:01:38,920 HAVE ANYTHING TO ADD? 1708 01:01:38,920 --> 01:01:40,000 >>THANK YOU DR. MANLY. 1709 01:01:40,000 --> 01:01:42,680 I THINK YOU HAVE DONE A VERY 1710 01:01:42,680 --> 01:01:45,200 NICE JOB JUST COVERING WHAT WE 1711 01:01:45,200 --> 01:01:45,960 HEARD YESTERDAY. 1712 01:01:45,960 --> 01:01:48,080 IT WAS FASCINATING PRESENTATION 1713 01:01:48,080 --> 01:01:50,600 AND I THINK A GREAT OPPORTUNITY 1714 01:01:50,600 --> 01:01:52,720 TO CONTINUE TO DO GOOD WORK TO 1715 01:01:52,720 --> 01:01:56,560 ADDRESS HEALTH EQUITIES IN OUR 1716 01:01:56,560 --> 01:01:57,840 SOCIETY. 1717 01:01:57,840 --> 01:02:00,160 >>DR. MANLY: THANK YOU. 1718 01:02:00,160 --> 01:02:04,360 >>THANK YOU DR. MANLY AND 1719 01:02:04,360 --> 01:02:10,800 DR. CRUZ. 1720 01:02:10,800 --> 01:02:11,440 ANY OTHER COMMENTS OR QUESTIONS 1721 01:02:11,440 --> 01:02:13,000 FROM OUR PANEL? 1722 01:02:13,000 --> 01:02:14,680 >>THIS IS SANJAY. 1723 01:02:14,680 --> 01:02:17,360 THAT WAS A BEAUTIFUL SUMMARY, 1724 01:02:17,360 --> 01:02:17,640 JENNIFER. 1725 01:02:17,640 --> 01:02:19,200 JUST A COMMENT AND I THINK MANY 1726 01:02:19,200 --> 01:02:21,960 OF YOU ARE AWARE THAT SOME WORK 1727 01:02:21,960 --> 01:02:25,400 BY DR. AMY KLEIN HAS SHOWN THAT 1728 01:02:25,400 --> 01:02:28,240 PEOPLE WHO RESIDE IN POOR 1729 01:02:28,240 --> 01:02:29,520 NEIGHBORHOODS ACTUALLY HAVE 1730 01:02:29,520 --> 01:02:33,200 WORSE COGNITIVE PERFORMANCE, 1731 01:02:33,200 --> 01:02:34,720 CARDIOATROPHY ON MRI SCANS AND 1732 01:02:34,720 --> 01:02:38,160 ALSO INCREASED AMYLOID BURDEN AS 1733 01:02:38,160 --> 01:02:39,840 A MEASURE TO BIOMARKER. 1734 01:02:39,840 --> 01:02:45,400 THERE SEEMS TO BE DIRECT 1735 01:02:45,400 --> 01:02:45,840 RELATIONSHIP BETWEEN 1736 01:02:45,840 --> 01:02:47,000 NEIGHBORHOOD DISADVANTAGE AND 1737 01:02:47,000 --> 01:02:47,840 SOME BIOLOGY AS WELL. 1738 01:02:47,840 --> 01:02:50,200 IT NEEDS TO BE CONFIRMED IN 1739 01:02:50,200 --> 01:02:55,520 ADDITIONAL STUDIES. 1740 01:02:55,520 --> 01:02:57,120 I WONDER IF YOU MIGHT HAVE SOME 1741 01:02:57,120 --> 01:02:58,640 INSIGHT INTO THE -- DR. MARTIN'S 1742 01:02:58,640 --> 01:02:58,960 PRESENTATION. 1743 01:02:58,960 --> 01:03:03,920 I WONDER IF AS PEOPLE MOVE FROM 1744 01:03:03,920 --> 01:03:04,480 ONE NEIGHBORHOOD TO ANOTHER 1745 01:03:04,480 --> 01:03:09,000 DURING THEIR LIFE COURSE, AND IF 1746 01:03:09,000 --> 01:03:09,600 THEIR LIVING CONDITIONS IMPROVE, 1747 01:03:09,600 --> 01:03:11,920 WOULD THAT AFFECT THE BIOLOGICAL 1748 01:03:11,920 --> 01:03:14,480 AGING MARKERS THAT DR. MARTIN 1749 01:03:14,480 --> 01:03:15,440 TALKED ABOUT? 1750 01:03:15,440 --> 01:03:17,240 WILL YOU HAVE ANY SENSE ABOUT 1751 01:03:17,240 --> 01:03:17,760 THAT? 1752 01:03:17,760 --> 01:03:22,480 >>DR. MANLY: I MEAN, I THINK 1753 01:03:22,480 --> 01:03:24,320 WHAT I WOULD SAY IS THAT I DON'T 1754 01:03:24,320 --> 01:03:27,600 THINK WE KNOW THE ANSWER TO YOUR 1755 01:03:27,600 --> 01:03:32,160 QUESTION YET. 1756 01:03:32,160 --> 01:03:33,520 AND PART OF WHAT OUR DISCUSSION 1757 01:03:33,520 --> 01:03:37,040 IS MOVING FORWARD IS, WHAT 1758 01:03:37,040 --> 01:03:39,200 CAN -- WHAT OPPORTUNITIES, WHAT 1759 01:03:39,200 --> 01:03:42,000 STUDIES CAN BE LEVERAGED? 1760 01:03:42,000 --> 01:03:45,800 SO YOU SAW DR. MARTIN LEVERAGE 1761 01:03:45,800 --> 01:03:48,120 THE DETROIT STUDY. 1762 01:03:48,120 --> 01:03:50,760 SHE IS ALSO A FREQUENT USER OF 1763 01:03:50,760 --> 01:03:53,320 THE ADD HEALTH STUDY, WHICH IS A 1764 01:03:53,320 --> 01:03:56,520 LONGITUDINAL STUDY OF 1765 01:03:56,520 --> 01:03:56,840 ADOLESCENTS. 1766 01:03:56,840 --> 01:03:58,960 THESE FOLKS ARE GETTING UP THERE 1767 01:03:58,960 --> 01:03:59,160 NOW. 1768 01:03:59,160 --> 01:04:08,560 I THINK THAT IT ARE ABOUT MY 1769 01:04:08,560 --> 01:04:08,720 AGE. 1770 01:04:08,720 --> 01:04:09,320 SO THESE ARE THE KINDS OF DATA 1771 01:04:09,320 --> 01:04:09,840 RESOURCES THAT WE NEED TO 1772 01:04:09,840 --> 01:04:11,800 UNDERSTAND THE ANSWER TO YOUR 1773 01:04:11,800 --> 01:04:12,080 QUESTION. 1774 01:04:12,080 --> 01:04:14,520 OBVIOUSLY IF WE HAVE A GROUP OF 1775 01:04:14,520 --> 01:04:16,600 PEOPLE WHO ARE IDENTIFIED WHO 1776 01:04:16,600 --> 01:04:18,600 LIVE IN A PARTICULAR 1777 01:04:18,600 --> 01:04:20,280 NEIGHBORHOOD LIKE THE ONE THAT I 1778 01:04:20,280 --> 01:04:22,160 WORK IN IN WASHINGTON HEIGHTS, 1779 01:04:22,160 --> 01:04:23,880 THERE ARE PEOPLE WHO ARE THERE 1780 01:04:23,880 --> 01:04:25,080 WHO LIVED THERE THEIR WHOLE 1781 01:04:25,080 --> 01:04:27,560 LIVES AND THERE ARE PEOPLE WHO 1782 01:04:27,560 --> 01:04:30,160 MOVED THERE FROM THE SOUTH OR 1783 01:04:30,160 --> 01:04:32,040 IMMIGRATED FROM OTHER COUNTRIES. 1784 01:04:32,040 --> 01:04:34,800 AND SOY, THIS IS THE RICH KIND 1785 01:04:34,800 --> 01:04:37,760 OF LIFE COURSE TRAJECTORY WE 1786 01:04:37,760 --> 01:04:38,640 NEED TO UNDERSTAND. 1787 01:04:38,640 --> 01:04:40,840 AND ONE KEY PART OF THAT IS TO 1788 01:04:40,840 --> 01:04:44,000 GET A RESIDENTIAL HISTORY FROM 1789 01:04:44,000 --> 01:04:44,200 PEOPLE. 1790 01:04:44,200 --> 01:04:45,680 AND THAT TAKES A WHILE. 1791 01:04:45,680 --> 01:04:49,000 SO THAT TAKES RESOURCES. 1792 01:04:49,000 --> 01:04:52,320 AND THE FLIP SIDE IS TO BE ABLE 1793 01:04:52,320 --> 01:04:54,760 TO LINK PEOPLE TO ADMINISTRATIVE 1794 01:04:54,760 --> 01:04:58,480 RECORDS OF WHERE THEY HAVE LIVED 1795 01:04:58,480 --> 01:05:00,360 AND THEN ONE OTHER -- LIKE ADD 1796 01:05:00,360 --> 01:05:01,760 HEALTH, WHICH IS ESSENTIALLY 1797 01:05:01,760 --> 01:05:03,880 FOLLOW PEOPLE FROM A VERY YOUNG 1798 01:05:03,880 --> 01:05:07,800 AGE, VISIT THEM EVERY 2-3 YEARS 1799 01:05:07,800 --> 01:05:10,200 AND FIND OUT -- MEASURE DIRECTLY 1800 01:05:10,200 --> 01:05:10,480 FROM THEM. 1801 01:05:10,480 --> 01:05:11,800 THAT'S HOW I WOULD ANSWER YOUR 1802 01:05:11,800 --> 01:05:13,000 QUESTION. 1803 01:05:13,000 --> 01:05:15,880 AND I SEE THAT THERE IS ANOTHER 1804 01:05:15,880 --> 01:05:16,960 HAND UP. 1805 01:05:16,960 --> 01:05:21,880 >>HI, JENNIFER. 1806 01:05:21,880 --> 01:05:23,360 WONDERFUL FEATURING OF THIS 1807 01:05:23,360 --> 01:05:24,240 EXCITING WORK. 1808 01:05:24,240 --> 01:05:26,440 I WAS WONDERING, AD-HOC RIGHT 1809 01:05:26,440 --> 01:05:28,240 NOW, I DIDN'T HAVE ACCESS TO THE 1810 01:05:28,240 --> 01:05:33,200 BRIEFING BOOK, BUT WILL WE GET, 1811 01:05:33,200 --> 01:05:34,000 AS COUNCIL MEMBERS, FILLED IN ON 1812 01:05:34,000 --> 01:05:40,440 HOW NIA IS DOING ON DEIA 1813 01:05:40,440 --> 01:05:43,120 INITIATIVES AND JUST IN GRANTS 1814 01:05:43,120 --> 01:05:48,720 THAT ARE FUNDED ACROSS THE 1815 01:05:48,720 --> 01:05:49,760 ORGANIZATION ABOUT INVESTIGATORS 1816 01:05:49,760 --> 01:05:52,640 AT DIFFERENT STAGES OF THEIR 1817 01:05:52,640 --> 01:05:52,880 CAREERS? 1818 01:05:52,880 --> 01:05:54,800 IS THAT SOMETHING WE WILL BE 1819 01:05:54,800 --> 01:05:56,920 GETTING BRIEFED ON? 1820 01:05:56,920 --> 01:05:57,560 >>DR. MANLY: YES, BUT I THINK 1821 01:05:57,560 --> 01:05:59,360 IT'S ALSO SOMETHING THAT COUNCIL 1822 01:05:59,360 --> 01:06:02,720 MEMBERS NEED TO ASK FOR. 1823 01:06:02,720 --> 01:06:03,360 AND SINCE WE ARE ALL MEMBERS OF 1824 01:06:03,360 --> 01:06:06,120 THIS TASK FORCE, WE NEED TO SORT 1825 01:06:06,120 --> 01:06:10,800 OF ASK SPECIFICALLY FOR 1826 01:06:10,800 --> 01:06:12,280 INFORMATION ABOUT THESE 1827 01:06:12,280 --> 01:06:12,800 PROGRAMS. 1828 01:06:12,800 --> 01:06:14,800 AND ASK FOR THE LEVEL OF DETAIL 1829 01:06:14,800 --> 01:06:17,000 THAT WE NEED TO UNDERSTAND 1830 01:06:17,000 --> 01:06:18,600 WHETHER THERE HAS BEEN PROGRESS 1831 01:06:18,600 --> 01:06:25,160 AND WHAT HAS BEEN EFFECTIVE. 1832 01:06:25,160 --> 01:06:27,160 SO LET'S TALK SOME MORE. 1833 01:06:27,160 --> 01:06:29,960 ANY FEEDBACK THAT COUNCIL 1834 01:06:29,960 --> 01:06:34,040 MEMBERS HAVE FOR US ABOUT WHAT 1835 01:06:34,040 --> 01:06:34,920 FUTURE AGENDA SHOULD BE FOR THE 1836 01:06:34,920 --> 01:06:43,840 TASK FORCE, WE WOULD LOVE THAT. 1837 01:06:43,840 --> 01:06:44,120 DR. KAHN? 1838 01:06:44,120 --> 01:06:46,520 >>DR. KAHN: DR. MANLY, I WAS 1839 01:06:46,520 --> 01:06:48,720 CURIOUS IF ANY COMPARABLE 1840 01:06:48,720 --> 01:06:53,040 RESEARCH HAS BEEN DONE IN RURAL 1841 01:06:53,040 --> 01:06:55,560 COMMUNITIES, ESPECIALLY 1842 01:06:55,560 --> 01:06:56,080 UNDERSERVED COMMUNITIES. 1843 01:06:56,080 --> 01:06:56,760 JUST THIS MORNING I GOT THE WORD 1844 01:06:56,760 --> 01:06:59,640 THAT ONE OF MY CHEROKEE FRIENDS, 1845 01:06:59,640 --> 01:07:03,840 HER MOM, PASSED AWAY AND SHE WAS 1846 01:07:03,840 --> 01:07:05,560 SUFFERING FROM ALZHEIMER'S FOR 1847 01:07:05,560 --> 01:07:05,760 YEARS. 1848 01:07:05,760 --> 01:07:06,560 AND I KNOW THE STRUGGLE OF HER 1849 01:07:06,560 --> 01:07:12,680 AND HER FAMILY GETTING CARE FOR 1850 01:07:12,680 --> 01:07:12,880 HER. 1851 01:07:12,880 --> 01:07:13,960 ANY SUPPORT WAS JUST QUITE AN 1852 01:07:13,960 --> 01:07:15,480 EXPERIENCE FOR THEM. 1853 01:07:15,480 --> 01:07:17,320 SO JUST CURIOUS TO KNOW. 1854 01:07:17,320 --> 01:07:19,280 >>DR. MANLY: ABSOLUTELY. 1855 01:07:19,280 --> 01:07:26,320 AND I'M VERY SORRY ABOUT YOUR 1856 01:07:26,320 --> 01:07:27,800 FRIEND'S LOSS. 1857 01:07:27,800 --> 01:07:29,960 I THINK THAT THERE ARE A NUMBER 1858 01:07:29,960 --> 01:07:30,800 OF INITIATIVES. 1859 01:07:30,800 --> 01:07:32,520 I'M A PART OF ONE AND I'LL JUST 1860 01:07:32,520 --> 01:07:37,080 TALK ABOUT THAT VERY QUICKLY. 1861 01:07:37,080 --> 01:07:38,960 THE -- AND I THINK SOMEBODY PUT 1862 01:07:38,960 --> 01:07:39,440 SOMETHING IN THE CHAT. 1863 01:07:39,440 --> 01:07:41,720 LET ME READ THAT IN A MINUTE. 1864 01:07:41,720 --> 01:07:47,560 BUT THE REGARD STUDY, IS AN 1865 01:07:47,560 --> 01:07:48,680 NINDS-FUNDED STUDY. 1866 01:07:48,680 --> 01:07:54,080 IT HAS NIA SUPPORT AS WELL TO 1867 01:07:54,080 --> 01:07:56,320 LOOK AT BRAIN HEALTH IN PEOPLE 1868 01:07:56,320 --> 01:07:57,360 WHO LIVE ACROSS THE UNITED 1869 01:07:57,360 --> 01:07:57,800 STATES. 1870 01:07:57,800 --> 01:08:00,600 AND THEY OVERSAMPLE PEOPLE IN 1871 01:08:00,600 --> 01:08:04,680 THE STROKE BELT, MUCH OF WHICH 1872 01:08:04,680 --> 01:08:05,520 IS RURAL. 1873 01:08:05,520 --> 01:08:06,880 AND ONE OF THE SPIN OFF STUDIES 1874 01:08:06,880 --> 01:08:10,640 FROM THAT IS CALLED, RURAL, THE 1875 01:08:10,640 --> 01:08:15,120 RURAL STUDY, TO UNDERSTAND 1876 01:08:15,120 --> 01:08:17,240 HEALTH IN RURAL ENVIRONMENTS. 1877 01:08:17,240 --> 01:08:20,040 LET ME READ THIS CHAT JUST IN 1878 01:08:20,040 --> 01:08:20,760 CASE. 1879 01:08:20,760 --> 01:08:22,240 OKAY, LIZ, THANK YOU. 1880 01:08:22,240 --> 01:08:23,600 COMES TO THE RESCUE. 1881 01:08:23,600 --> 01:08:25,720 INTERDISCIPLINARY NETWORK ON 1882 01:08:25,720 --> 01:08:27,840 RURAL POPULATION HEALTH AND 1883 01:08:27,840 --> 01:08:29,560 AGING. 1884 01:08:29,560 --> 01:08:30,560 SHE PROVIDES A LINK FOR THAT. 1885 01:08:30,560 --> 01:08:34,160 BUT, RURAL RESIDENTS IS ONE OF 1886 01:08:34,160 --> 01:08:38,600 THOSE KEY SORT OF FUNDAMENTAL 1887 01:08:38,600 --> 01:08:41,800 GEOGRAPHIC PLACE AND SPACE 1888 01:08:41,800 --> 01:08:43,400 DRIVERS OF HEALTH. 1889 01:08:43,400 --> 01:08:44,640 AND SO IT'S SOMETHING THAT I 1890 01:08:44,640 --> 01:08:46,320 THINK THERE IS A NUMBER OF 1891 01:08:46,320 --> 01:08:49,960 PEOPLE OUT THERE TRYING TO 1892 01:08:49,960 --> 01:08:54,080 UNDERSTAND THOSE MECHANISMS. 1893 01:08:54,080 --> 01:08:55,280 >>ALL RIGHT. 1894 01:08:55,280 --> 01:08:57,840 THANK YOU VERY MUCH, JEN. 1895 01:08:57,840 --> 01:09:00,240 APPRECIATE THE RESPONSES TO THE 1896 01:09:00,240 --> 01:09:00,520 COMMENTS. 1897 01:09:00,520 --> 01:09:03,040 I THINK WE WILL MOVE ON. 1898 01:09:03,040 --> 01:09:06,000 NEXT UP WE HAVE A REPORT ON 1899 01:09:06,000 --> 01:09:06,840 WORKING GROUP ON PROGRAM. 1900 01:09:06,840 --> 01:09:12,800 SO I'LL TURN THIS OVER TO MONICA 1901 01:09:12,800 --> 01:09:13,200 DRISCOLL. 1902 01:09:13,200 --> 01:09:13,400 MONICA? 1903 01:09:13,400 --> 01:09:15,400 >>DR. DRISCOLL: THANK YOU VERY 1904 01:09:15,400 --> 01:09:15,800 MUCH. 1905 01:09:15,800 --> 01:09:18,120 SO, YESTERDAY WE STARTED OFF OUR 1906 01:09:18,120 --> 01:09:25,280 WORK WITH A PRESENTATION FROM 1907 01:09:25,280 --> 01:09:27,520 STEVE WHO IS KIND OF OVERSEEING 1908 01:09:27,520 --> 01:09:28,040 THE EFFORT TO REVIEW THE 1909 01:09:28,040 --> 01:09:29,000 DIVISION OF GERIATRICS AND 1910 01:09:29,000 --> 01:09:30,520 CLINICAL GERONTOLOGY. 1911 01:09:30,520 --> 01:09:32,920 SO I THINK WE WERE ALL IMPRESSED 1912 01:09:32,920 --> 01:09:36,760 WITH THE PANEL CREDENTIALS AND 1913 01:09:36,760 --> 01:09:37,240 THEIR EXPERIENCE, THE 1914 01:09:37,240 --> 01:09:39,160 ORGANIZATION AND THE PROGRESS 1915 01:09:39,160 --> 01:09:45,600 THAT THIS GROUP HAS MADE AND 1916 01:09:45,600 --> 01:09:46,920 WITH THE FINAL ANTICIPATED 1917 01:09:46,920 --> 01:09:47,760 REPORT FOR MAY. 1918 01:09:47,760 --> 01:09:50,400 SO YOU CAN ALL HAVE THAT TO LOOK 1919 01:09:50,400 --> 01:09:52,720 FORWARD TO AT THE NEXT MEETING. 1920 01:09:52,720 --> 01:09:55,080 WE THEN TURNED TO CONCEPT 1921 01:09:55,080 --> 01:09:55,400 CLEARANCES. 1922 01:09:55,400 --> 01:09:56,920 AND AGAIN I'LL JUST START BY 1923 01:09:56,920 --> 01:09:59,280 THINKING THE NIA FOR PUTTING 1924 01:09:59,280 --> 01:10:01,800 TOGETHER A REALLY TERRIFIC SET 1925 01:10:01,800 --> 01:10:04,920 OF EXCITING AND IMPORTANT 1926 01:10:04,920 --> 01:10:07,200 INITIATIVES AND THANKING THE 1927 01:10:07,200 --> 01:10:09,720 COUNCIL MEMBERS FOR THEIR HARD 1928 01:10:09,720 --> 01:10:10,960 WORK AND THOUGHTFUL COMMENTS. 1929 01:10:10,960 --> 01:10:13,520 WHAT WE'LL DO TODAY IS JUST, 1930 01:10:13,520 --> 01:10:16,960 I'LL CALL ON THE PRIMARY 1931 01:10:16,960 --> 01:10:20,720 REVIEWER TO REVIEW THE -- 1932 01:10:20,720 --> 01:10:21,240 SUMMARIZE THE DISCUSSION. 1933 01:10:21,240 --> 01:10:23,640 AND THEN WE WILL VOTE AT THE END 1934 01:10:23,640 --> 01:10:25,840 ON BLOCK FOR THE ACCEPTANCE OF 1935 01:10:25,840 --> 01:10:27,480 THESE. 1936 01:10:27,480 --> 01:10:28,680 SO, LET'S BEGIN WITH THE 1937 01:10:28,680 --> 01:10:32,080 DIVISION OF BEHAVIORAL AND 1938 01:10:32,080 --> 01:10:34,640 SOCIAL RESEARCH ON THE INITIAL 1939 01:10:34,640 --> 01:10:35,440 CONCEPT CLEARANCE CALLED 1940 01:10:35,440 --> 01:10:36,280 BEHAVIORAL AND SOCIAL RESEARCH 1941 01:10:36,280 --> 01:10:38,120 ON THE ROLE OF IMMIGRATION ON 1942 01:10:38,120 --> 01:10:39,720 LIFE COURSE HEALTH AND AGING 1943 01:10:39,720 --> 01:10:42,320 INCLUDING AD/ADRD. 1944 01:10:42,320 --> 01:10:46,960 THE PRIMARY VIEWER OF DR. MANLY, 1945 01:10:46,960 --> 01:10:48,200 SECONDED WAS DR. WE'RE. 1946 01:10:48,200 --> 01:10:49,200 DR. MANLY IF YOU COULD SUMMARIZE 1947 01:10:49,200 --> 01:10:50,320 FOR US. 1948 01:10:50,320 --> 01:10:54,080 >>DR. MANLY: SURE, SO THIS WAS 1949 01:10:54,080 --> 01:10:55,840 AN EXCELLENT CONCEPT CLEARANCE, 1950 01:10:55,840 --> 01:10:59,040 VERY CLEARLY WRITTEN AND 1951 01:10:59,040 --> 01:10:59,480 JUSTIFIED. 1952 01:10:59,480 --> 01:11:02,840 IT WOULD BE A NEW INITIATIVE FOR 1953 01:11:02,840 --> 01:11:04,680 OUR PHASE FOR RESEARCH ON LIFE 1954 01:11:04,680 --> 01:11:06,560 COURSE SOCIAL AND STRUCTURAL 1955 01:11:06,560 --> 01:11:09,480 FACTORS THAT SHAPE AGING, HEALTH 1956 01:11:09,480 --> 01:11:12,640 AND ALZHEIMER'S DISEASE AND 1957 01:11:12,640 --> 01:11:14,200 RELATED DISORDERS AMONG BLACK, 1958 01:11:14,200 --> 01:11:16,040 LATINO AND ASIAN IMMIGRANT 1959 01:11:16,040 --> 01:11:20,360 GROUPS IN THE UNITED STATES. 1960 01:11:20,360 --> 01:11:22,320 THERE WAS A RECENT NATIONAL 1961 01:11:22,320 --> 01:11:23,760 ACADEMY OF SCIENCES WORKSHOP 1962 01:11:23,760 --> 01:11:25,400 THAT RECOMMENDED THAT IN ORDER 1963 01:11:25,400 --> 01:11:27,320 TO UNDERSTAND INEQUALITIES AND 1964 01:11:27,320 --> 01:11:29,680 HEALTH AND AGING, NOT ONLY DO WE 1965 01:11:29,680 --> 01:11:31,520 NEED A TRANSDISCIPLINARY LENSE 1966 01:11:31,520 --> 01:11:34,040 AND LIFE COURSE MODELS BUD ALSO 1967 01:11:34,040 --> 01:11:37,360 RESEARCH THAT DISAGGREGATES MY 1968 01:11:37,360 --> 01:11:40,160 NORMAL TIESED GROUPINGS BEYOND 1969 01:11:40,160 --> 01:11:41,200 SOCIOECONOMIC STATUS. 1970 01:11:41,200 --> 01:11:42,880 SO THE DIVISION OF SOCIAL AND 1971 01:11:42,880 --> 01:11:44,680 BEHAVIORAL RESEARCH HAS DECIDED 1972 01:11:44,680 --> 01:11:48,320 THAT ONE WAY TO DO THAT IN ORDER 1973 01:11:48,320 --> 01:11:50,560 TO RESPOND TO THAT REPORT, IS TO 1974 01:11:50,560 --> 01:11:54,800 FOCUS ON THE ROLE OF IMMIGRA 1975 01:11:54,800 --> 01:11:55,120 IMMIGRATION. 1976 01:11:55,120 --> 01:11:58,960 AS ONE ASPECT OF THAT 1977 01:11:58,960 --> 01:11:59,320 DISAGGREGATION. 1978 01:11:59,320 --> 01:11:59,920 MANY PEOPLE WHO ARE LISTENING 1979 01:11:59,920 --> 01:12:02,800 MAY KNOW THAT THERE ARE 1980 01:12:02,800 --> 01:12:04,520 SOMETHING CALLED THE IMMIGRANT 1981 01:12:04,520 --> 01:12:06,040 HEALTH PARADOX, WHICH IS THAT 1982 01:12:06,040 --> 01:12:08,120 MORE RECENT IMMIGRANTS HAVE 1983 01:12:08,120 --> 01:12:10,160 BETTER HEALTH THAN PEOPLE WHO 1984 01:12:10,160 --> 01:12:13,400 ARE U.S. BORN OR IMMIGRATED 1985 01:12:13,400 --> 01:12:15,720 LATER IN LIFE. 1986 01:12:15,720 --> 01:12:17,720 BUT AS OUR RESEARCH IN THIS AREA 1987 01:12:17,720 --> 01:12:21,160 GROWS, THERE IS SOME STUDIES 1988 01:12:21,160 --> 01:12:22,320 THAT SHOW THE OPPOSITE, WHICH IS 1989 01:12:22,320 --> 01:12:24,040 THAT RECENT IMMIGRANTS, HEALTH 1990 01:12:24,040 --> 01:12:25,680 IS WORSE AND IT DEPENDS ON WHAT 1991 01:12:25,680 --> 01:12:27,520 THE HEALTH OUTCOME IS, HOW YOU 1992 01:12:27,520 --> 01:12:31,760 STUDY IT, WHEN YOU STUDY IT. 1993 01:12:31,760 --> 01:12:33,640 SO THIS NEEDS TO BE LOOKED INTO 1994 01:12:33,640 --> 01:12:34,040 FURTHER. 1995 01:12:34,040 --> 01:12:36,840 AND THAT IS WHAT IS CALLED FOR 1996 01:12:36,840 --> 01:12:40,440 IN THE CONCEPT CLEARANCE. 1997 01:12:40,440 --> 01:12:45,000 THE CONCEPT CLEARANCE IS FOR 1998 01:12:45,000 --> 01:12:48,280 BOTH RO1 AND R21 MECHANISMS WITH 1999 01:12:48,280 --> 01:12:50,480 A STRONG RATIONAL FOR EACH 2000 01:12:50,480 --> 01:12:52,120 MECHANISM BEING USEFUL IN 2001 01:12:52,120 --> 01:12:54,040 CONDUCTING THIS WORK. 2002 01:12:54,040 --> 01:12:56,920 R21s MAY BE USEFUL IN DOING 2003 01:12:56,920 --> 01:12:59,160 SOME OF THE COMMUNITY-BASED AND 2004 01:12:59,160 --> 01:13:02,240 MIXED METHODS APPROACHES THAT 2005 01:13:02,240 --> 01:13:04,360 MAYBE MOST IDEALLY SUITED TO 2006 01:13:04,360 --> 01:13:05,600 UNDERSTAND SOME OF THE 2007 01:13:05,600 --> 01:13:07,000 MEASUREMENT ISSUES IN THE 2008 01:13:07,000 --> 01:13:10,160 POPULATION AND THE CONCEPT ALSO 2009 01:13:10,160 --> 01:13:12,840 ENCOURAGED LEVERAGING OF 2010 01:13:12,840 --> 01:13:15,680 EXISTING NIA STUDIES LIKE THE 2011 01:13:15,680 --> 01:13:18,320 HEALTH AND RETIREMENT STUDY AND 2012 01:13:18,320 --> 01:13:20,680 THE HARMONIZED COGNITIVE 2013 01:13:20,680 --> 01:13:21,720 ASSESSMENT PROTOCOL, HAD. 2014 01:13:21,720 --> 01:13:25,760 RS SISTER STUDIES AROUND THE 2015 01:13:25,760 --> 01:13:27,280 WORLD AND ADD HEALTH. 2016 01:13:27,280 --> 01:13:28,880 BUT PRIMARY DATA COLLECTION IS 2017 01:13:28,880 --> 01:13:32,360 ALSO POSSIBLE. 2018 01:13:32,360 --> 01:13:33,760 THIS CONCEPT INDIVIDUAL A SET 2019 01:13:33,760 --> 01:13:35,440 ASIDE FUNDS AND ALSO A 2020 01:13:35,440 --> 01:13:36,200 SPECIALIZED REVIEW. 2021 01:13:36,200 --> 01:13:38,200 AND THIS IS IMPORTANT BECAUSE 2022 01:13:38,200 --> 01:13:42,680 THE CONCEPT CLEARANCE SHOWED 2023 01:13:42,680 --> 01:13:45,720 DATA AT THE LAST TIME NIA SIGNED 2024 01:13:45,720 --> 01:13:47,880 ON TO A ANNOUNCEMENT, FUNDING 2025 01:13:47,880 --> 01:13:49,320 ANNOUNCEMENT TO ADDRESS HEALTH 2026 01:13:49,320 --> 01:13:52,720 DISPARITIES AMONG IMMIGRANT 2027 01:13:52,720 --> 01:13:53,680 POPULATIONS. 2028 01:13:53,680 --> 01:13:56,640 VERY FEW APPLICATIONS WERE SENT 2029 01:13:56,640 --> 01:13:59,240 IN FOR THAT THAT WERE NIA, 2030 01:13:59,240 --> 01:13:59,560 FOCUSED. 2031 01:13:59,560 --> 01:14:01,520 ALL THE STUDIES WENT TO EXISTING 2032 01:14:01,520 --> 01:14:03,320 STUDY SECTIONS AND ALL OF THEM 2033 01:14:03,320 --> 01:14:05,040 WERE SCORED ABOVE THE CURRENT 2034 01:14:05,040 --> 01:14:06,640 PAY LINE. 2035 01:14:06,640 --> 01:14:08,720 SO THIS IS AN OPPORTUNITY FOR 2036 01:14:08,720 --> 01:14:10,160 PEOPLE WHO ARE DOING RESEARCH OR 2037 01:14:10,160 --> 01:14:13,840 WHO WANT TO DO RESEARCH IN 2038 01:14:13,840 --> 01:14:17,840 IMMIGRANT GROUPS TO HAVE THIS 2039 01:14:17,840 --> 01:14:20,000 OPPORTUNITY TO SUBMIT TO SPECIAL 2040 01:14:20,000 --> 01:14:21,800 REVIEW GROUP. 2041 01:14:21,800 --> 01:14:24,280 AND THE COUNCIL WAS ENTHUSIASTIC 2042 01:14:24,280 --> 01:14:29,680 ABOUT THIS CONCEPT CLEARANCE. 2043 01:14:29,680 --> 01:14:30,280 >>GREAT, THANK YOU VERY MUCH. 2044 01:14:30,280 --> 01:14:31,480 THE SECOND CONCEPT THAT WE 2045 01:14:31,480 --> 01:14:33,800 CONSIDERED WAS ENHANCING USE OF 2046 01:14:33,800 --> 01:14:34,440 HCAP DATA. 2047 01:14:34,440 --> 01:14:37,880 THE PRIMARY REVIEWER OF 2048 01:14:37,880 --> 01:14:40,920 DR. WE'RE AND THE SECONDARY WAS 2049 01:14:40,920 --> 01:14:42,120 DR. MANLY. 2050 01:14:42,120 --> 01:14:43,080 DR. WE'RE IF YOU COULD SUMMARIZE 2051 01:14:43,080 --> 01:14:44,920 THE DISCUSSION FOR US. 2052 01:14:44,920 --> 01:14:49,000 >>DR. WE'RE: HCAP IS THE 2053 01:14:49,000 --> 01:14:50,600 HARMONIZED COGNITIVE ASSESSMENT 2054 01:14:50,600 --> 01:14:51,560 PROTOCOL THAT JEN JUST 2055 01:14:51,560 --> 01:14:51,840 MENTIONED. 2056 01:14:51,840 --> 01:14:55,160 THAT IS AN ASSESSMENT AIMED AT 2057 01:14:55,160 --> 01:14:57,000 RESEARCH DIAGNOSIS OF DEMENTIA 2058 01:14:57,000 --> 01:14:58,640 AND MILD COGNITIVE IMPAIRMENT 2059 01:14:58,640 --> 01:15:00,360 DEVELOPED WITHIN THE HEALTH 2060 01:15:00,360 --> 01:15:01,720 RETIREMENT STUDY TO ADDRESS THE 2061 01:15:01,720 --> 01:15:04,080 NEED FOR MORE COST EFFECTIVE 2062 01:15:04,080 --> 01:15:06,000 APPROACHES IN LARGE POPULATIONS 2063 01:15:06,000 --> 01:15:06,240 STUDIES. 2064 01:15:06,240 --> 01:15:09,200 IT WAS DONE IN CONSULTATION WITH 2065 01:15:09,200 --> 01:15:11,080 SEVERAL OF THE INTERNATIONAL 2066 01:15:11,080 --> 01:15:13,560 PARTNER STUDIES. 2067 01:15:13,560 --> 01:15:16,920 THE NIA HAS SUPPORTED NOW TWO 2068 01:15:16,920 --> 01:15:21,240 WAVES OF HCAP IN THE HRS WE'LL 2069 01:15:21,240 --> 01:15:21,800 IN MULTIPLE OTHER COUNTRIES 2070 01:15:21,800 --> 01:15:24,920 AROUND THE WORLD SO THERE IS A 2071 01:15:24,920 --> 01:15:27,840 ESTABLISHED AND GROWING BODY OF 2072 01:15:27,840 --> 01:15:29,040 DATA. 2073 01:15:29,040 --> 01:15:34,120 AND THIS CONCEPT AIMS TO 2074 01:15:34,120 --> 01:15:35,040 LEVERAGE THAT INTO REAL 2075 01:15:35,040 --> 01:15:35,680 RESEARCH. 2076 01:15:35,680 --> 01:15:37,040 THOSE STUDIES WERE FUNDED TO 2077 01:15:37,040 --> 01:15:38,960 CREATE THE RESOURCE NOT TO 2078 01:15:38,960 --> 01:15:39,960 REALLY EXPLOIT IT. 2079 01:15:39,960 --> 01:15:43,880 SO THIS IS A TARGETED SET OF 2080 01:15:43,880 --> 01:15:47,560 RO1s THAT WILL USE THE HCAP, 2081 01:15:47,560 --> 01:15:49,160 RESOLVE SOME OF THE CHALLENGES 2082 01:15:49,160 --> 01:15:51,320 TO INTERNATIONAL CULPABILITY AND 2083 01:15:51,320 --> 01:15:55,640 MOVE THE FIELD FORWARD TAKING 2084 01:15:55,640 --> 01:15:56,400 ADVANTAGE OF THE INFORMATION 2085 01:15:56,400 --> 01:15:59,600 ABOUT LIFE EXPERIENCES AND 2086 01:15:59,600 --> 01:16:01,000 ENVIRONMENTAL CONTEXT THAT YOU 2087 01:16:01,000 --> 01:16:04,400 CAN GET FROM INTERNATIONAL 2088 01:16:04,400 --> 01:16:07,000 COMPARISONS FROM ANY ONE 2089 01:16:07,000 --> 01:16:09,000 COUNTRY. 2090 01:16:09,000 --> 01:16:11,280 SO STRONG SUPPORT. 2091 01:16:11,280 --> 01:16:12,440 >>THANK YOU SO MUCH. 2092 01:16:12,440 --> 01:16:15,000 THE NEXT CONCEPT THAT WE 2093 01:16:15,000 --> 01:16:17,560 CONSIDERED IS GRAND CHALLENGE; 2094 01:16:17,560 --> 01:16:21,000 PREDICTING EARLY ALZHEIMER'S 2095 01:16:21,000 --> 01:16:21,560 DEAND RELATED DEMENTIAS. 2096 01:16:21,560 --> 01:16:23,120 DR. MANLY WAS THE PRIMARY 2097 01:16:23,120 --> 01:16:24,120 REVIEWER AND DR. WHITFIELD WAS 2098 01:16:24,120 --> 01:16:25,760 THE SECONDARY. 2099 01:16:25,760 --> 01:16:26,960 DR. MANLY IF YOU COULD SUMMARIZE 2100 01:16:26,960 --> 01:16:36,160 THE DISCUSSION FOR US. 2101 01:16:36,160 --> 01:16:46,640 >>DR. MANLY: SORRY FOLKS, 2102 01:16:47,920 --> 01:16:48,440 TRYING TO SHUFFLE MY DIGITAL 2103 01:16:48,440 --> 01:16:48,840 PAPERS HERE. 2104 01:16:48,840 --> 01:16:50,560 THIS WAS A CONCEPT CLEARANCE WE 2105 01:16:50,560 --> 01:16:54,960 SEEN A YEAR AGO AND THE GOAL OF 2106 01:16:54,960 --> 01:16:56,560 THIS CONCEPT IS TO SUPPORT A 2107 01:16:56,560 --> 01:16:59,600 CONTRACT THAT WOULD PROVIDE THE 2108 01:16:59,600 --> 01:17:01,000 INFRASTRUCTURE FOR DEVELOPMENT, 2109 01:17:01,000 --> 01:17:02,360 COORDINATION AND ADVERTISEMENT 2110 01:17:02,360 --> 01:17:04,800 OF COMPETITIONS THAT ADDRESS THE 2111 01:17:04,800 --> 01:17:06,880 GRAND CHALLENGE OF PREDICTING 2112 01:17:06,880 --> 01:17:09,240 EARLY ALZHEIMER'S DISEASE AND 2113 01:17:09,240 --> 01:17:10,880 RELATED DEMENTIAS. 2114 01:17:10,880 --> 01:17:14,720 SO ESSENTIALLY THIS CONTRACTOR 2115 01:17:14,720 --> 01:17:18,440 WOULD ENGAGE EXPERT ADVISORS AND 2116 01:17:18,440 --> 01:17:19,560 PROVIDE SCIENTIFIC DIRECTION, 2117 01:17:19,560 --> 01:17:21,120 IDENTIFY HIGH-PRIORITY DATA 2118 01:17:21,120 --> 01:17:24,680 SOURCES FOR POTENTIALLY USE FOR 2119 01:17:24,680 --> 01:17:24,880 THIS. 2120 01:17:24,880 --> 01:17:27,000 AI CHALLENGE, WHICH IS TO TAKE A 2121 01:17:27,000 --> 01:17:29,480 BUNCH OF DATA AND PREDICT WHO 2122 01:17:29,480 --> 01:17:36,480 WILL GET ALZHEIMER'S DISEASE, TO 2123 01:17:36,480 --> 01:17:37,000 ESTABLISH CLOUD SPACE FOR 2124 01:17:37,000 --> 01:17:37,600 COMPETITIONS AND TO EVALUATE 2125 01:17:37,600 --> 01:17:40,440 THOSE COMPETITIONS. 2126 01:17:40,440 --> 01:17:45,320 THIS IS ESSENTIALLY A COMMUNITY, 2127 01:17:45,320 --> 01:17:49,160 RESEARCH COMMUNITY BUILDING 2128 01:17:49,160 --> 01:17:49,600 GRANT. 2129 01:17:49,600 --> 01:17:51,280 IT DOESN'T DESCRIBE HOW EXACTLY 2130 01:17:51,280 --> 01:17:53,440 THE CHALLENGE WILL BE MET BUT IT 2131 01:17:53,440 --> 01:17:56,400 IS A CRITICAL INFRASTRUCTURE AND 2132 01:17:56,400 --> 01:18:01,000 HUMAN CAPITAL BUILDING STEP. 2133 01:18:01,000 --> 01:18:04,880 AND THE GOAL IS TO ENGAGE A 2134 01:18:04,880 --> 01:18:06,600 DIVERSE SCIENTIFIC COMMUNITY TO 2135 01:18:06,600 --> 01:18:08,000 BEGIN TO COLLABORATE SO THE 2136 01:18:08,000 --> 01:18:10,600 CHALLENGE CAN BE MET IN THE BEST 2137 01:18:10,600 --> 01:18:11,480 WAY POSSIBLE. 2138 01:18:11,480 --> 01:18:15,160 AND BY DIVERSE, I MEAN AI 2139 01:18:15,160 --> 01:18:18,560 RESEARCHERS AND ENGINEERS, DATE 2140 01:18:18,560 --> 01:18:20,840 SCIENTIFIC, NEUROSCIENTISTS, 2141 01:18:20,840 --> 01:18:23,960 PSYCHOLOGISTS, SOCIOLOGISTS, AND 2142 01:18:23,960 --> 01:18:25,800 CITIZEN SCIENTISTS AND COMMUNITY 2143 01:18:25,800 --> 01:18:28,560 PARTNERS INCLUDING SMALL 2144 01:18:28,560 --> 01:18:29,160 BUSINESS. 2145 01:18:29,160 --> 01:18:32,040 AND THEY WANT TO ENGAGE PEOPLE 2146 01:18:32,040 --> 01:18:33,720 IN THEIR CAREERS ALL THE WAY 2147 01:18:33,720 --> 01:18:36,760 FROM STUDENTS, TRAINEES, EARLY 2148 01:18:36,760 --> 01:18:44,760 INVESTIGATORS, ALL THE WAY TO 2149 01:18:44,760 --> 01:18:45,600 MORE SEASONED INVESTIGATORS. 2150 01:18:45,600 --> 01:18:47,320 THE COUNCIL THOUGHT THIS WAS 2151 01:18:47,320 --> 01:18:48,440 EXTREMELY TIMELY. 2152 01:18:48,440 --> 01:18:52,280 THEY WERE ENTHUSIASTIC ABOUT 2153 01:18:52,280 --> 01:18:55,560 THIS RESOURCE BUILDING CONCEPT 2154 01:18:55,560 --> 01:19:01,600 CLEARANCE AND RECOMMENDED IT. 2155 01:19:01,600 --> 01:19:01,800 S. 2156 01:19:01,800 --> 01:19:02,440 >>THANK YOU VERY MUCH. 2157 01:19:02,440 --> 01:19:04,560 OKAY, THE NEXT ONE THAT WE 2158 01:19:04,560 --> 01:19:07,000 CONSIDERED IS THE CONSORTIUM FOR 2159 01:19:07,000 --> 01:19:07,760 PAYMENT UTILIZATION AND ACCESS 2160 01:19:07,760 --> 01:19:10,160 FOR DEMENTIA CARE. 2161 01:19:10,160 --> 01:19:12,400 THE PRIMARY REVIEWER WAS 2162 01:19:12,400 --> 01:19:14,960 DR. CASE AND THE SECONDARY WAS 2163 01:19:14,960 --> 01:19:15,480 DR. WE'RE. 2164 01:19:15,480 --> 01:19:16,200 DR. CASE IF YOU COULD SUMMARIZE 2165 01:19:16,200 --> 01:19:17,000 FOR US. 2166 01:19:17,000 --> 01:19:20,880 >>DR. CASE: SURE. 2167 01:19:20,880 --> 01:19:21,760 THE CONCEPT MADE A STRONG CASE 2168 01:19:21,760 --> 01:19:23,520 FOR THE NEED FOR RESEARCH IN 2169 01:19:23,520 --> 01:19:24,960 ADDRESSING THE EXTRAORDINARY 2170 01:19:24,960 --> 01:19:27,240 ARRAY OF DECISIONS AND 2171 01:19:27,240 --> 01:19:28,800 DIFFICULTIES FACED IN PROVIDING 2172 01:19:28,800 --> 01:19:31,920 CARE FOR PEOPLE LIVING WITH 2173 01:19:31,920 --> 01:19:32,200 DEMENTIA. 2174 01:19:32,200 --> 01:19:34,840 THE PROPOSAL IS FOR A CONSORTIUM 2175 01:19:34,840 --> 01:19:37,440 WITH A COORDINATING CENTER 2176 01:19:37,440 --> 01:19:41,560 THROUGH A U54 AND SIXER R1s TO 2177 01:19:41,560 --> 01:19:45,800 ADDRESS SPECIFIC AD/ADRD 2178 01:19:45,800 --> 01:19:47,880 MILESTONES SUCH AS HOW FEDERAL 2179 01:19:47,880 --> 01:19:49,040 POLICIES AND PAYMENT MODELS 2180 01:19:49,040 --> 01:19:50,480 EFFECT CARE FOR PEOPLE LIVING 2181 01:19:50,480 --> 01:19:53,280 WITH DEMENTIA, HOW CARE VARIES 2182 01:19:53,280 --> 01:19:55,720 ACROSS INSTITUTIONAL SETTINGS, 2183 01:19:55,720 --> 01:19:58,840 HOW PAYMENT MECHANISMS AFFECT 2184 01:19:58,840 --> 01:20:00,040 UTILIZATIONAL SERVICES, AND 2185 01:20:00,040 --> 01:20:01,320 ACCESS TO CARE. 2186 01:20:01,320 --> 01:20:05,920 SO THE CONCEPT IS TIMELY. 2187 01:20:05,920 --> 01:20:06,760 THE MOTIVATION IS CLEAR. 2188 01:20:06,760 --> 01:20:11,000 THE U54 WILL PLAY A POWERING UP 2189 01:20:11,000 --> 01:20:13,600 COORDINATING ROLE ACROSS THE 2190 01:20:13,600 --> 01:20:16,000 RO1s COORDINATING MEETINGS AND 2191 01:20:16,000 --> 01:20:17,240 STAKEHOLDER ENGAGEMENT, 2192 01:20:17,240 --> 01:20:21,480 IDENTIFYING COMMON DATA 2193 01:20:21,480 --> 01:20:22,960 ELEMENTS, IDENTIFY TRAINING 2194 01:20:22,960 --> 01:20:24,280 PROGRAMS, TRANSLATION AND 2195 01:20:24,280 --> 01:20:28,400 AVAILABILITY OF RESOURCES. 2196 01:20:28,400 --> 01:20:32,880 AND THE COORDINATING CENTER CAN 2197 01:20:32,880 --> 01:20:35,800 ALSO SOLICIT STUDIES TO DIRECTLY 2198 01:20:35,800 --> 01:20:37,080 ADDRESS MILESTONES THAT AREN'T 2199 01:20:37,080 --> 01:20:38,920 ALREADY BEING ADDRESSED BY THE 2200 01:20:38,920 --> 01:20:41,520 FUNDED RL1s. 2201 01:20:41,520 --> 01:20:43,480 SO THERE WAS A GREAT DEAL OF 2202 01:20:43,480 --> 01:20:48,520 ENTHUSIASM FOR THIS CONCEPT 2203 01:20:48,520 --> 01:20:48,760 CLEARANCE. 2204 01:20:48,760 --> 01:20:49,360 >>THANK YOU VERY MUCH. 2205 01:20:49,360 --> 01:20:54,040 THE NEXT CONCEPT DISCUSSED IS 2206 01:20:54,040 --> 01:20:54,480 TITLED DEMENTIA CARE 2207 01:20:54,480 --> 01:20:55,600 COORDINATION RESEARCH CENTER. 2208 01:20:55,600 --> 01:20:57,400 DR. RUBIN WAS THE PRIMARY 2209 01:20:57,400 --> 01:20:59,000 REVIEWER AND DR. WHITFIELD WAS 2210 01:20:59,000 --> 01:21:00,880 THE SECONDARY. 2211 01:21:00,880 --> 01:21:01,800 DR. RUBIN IF YOU COULD SUMMARIZE 2212 01:21:01,800 --> 01:21:06,000 THE DISCUSSION FOR US. 2213 01:21:06,000 --> 01:21:12,120 >>DR. RUBIN: THIS IS A CONCEPT 2214 01:21:12,120 --> 01:21:13,440 THAT STEMMED FROM THE 2020 2215 01:21:13,440 --> 01:21:14,760 DEMENTIA CARE SUMMIT. 2216 01:21:14,760 --> 01:21:17,400 AND THE RATIONAL FOR IT IS THAT 2217 01:21:17,400 --> 01:21:19,600 THERE IS AN URGENT NEED TO 2218 01:21:19,600 --> 01:21:22,240 BETTER UNDERSTAND WHAT WORKS IN 2219 01:21:22,240 --> 01:21:23,120 TERMS OF THE BENEFIT CARE 2220 01:21:23,120 --> 01:21:27,320 COORDINATION AND CARE TRANSITION 2221 01:21:27,320 --> 01:21:28,120 COMMUNITY SETTINGS. 2222 01:21:28,120 --> 01:21:32,560 THIS IS GOING TO BE A U54 2223 01:21:32,560 --> 01:21:37,680 MECHANISM AND IT'S TO SUPPORT 2224 01:21:37,680 --> 01:21:38,240 DEMENTIA CARE INTEGRATION 2225 01:21:38,240 --> 01:21:38,640 RESEARCH NETWORK. 2226 01:21:38,640 --> 01:21:39,920 IT WILL BE A CENTER FOR 2227 01:21:39,920 --> 01:21:41,080 ORGANIZING PARTNERSHIPS WITH 2228 01:21:41,080 --> 01:21:43,960 REGIONAL DATA PROVIDERS AND 2229 01:21:43,960 --> 01:21:44,280 RESEARCHERS. 2230 01:21:44,280 --> 01:21:48,640 AND A DATA HUB FOR DATA SHARING 2231 01:21:48,640 --> 01:21:51,840 THAT WILL INCLUDE PILOTS. 2232 01:21:51,840 --> 01:21:57,400 IT WILL ALSO RECOGNIZE THE 2233 01:21:57,400 --> 01:21:58,000 MULTIPLE STAKEHOLDERS THAT ARE 2234 01:21:58,000 --> 01:21:58,600 INVOLVED, INCLUDING STATES, 2235 01:21:58,600 --> 01:22:00,000 INCLUDING HEALTH CARE 2236 01:22:00,000 --> 01:22:02,400 ORGANIZATIONS, INCLUDING 2237 01:22:02,400 --> 01:22:05,080 COMMUNITY-BASED ORGANIZATIONS, 2238 01:22:05,080 --> 01:22:08,800 INCLUDING INSURERS. 2239 01:22:08,800 --> 01:22:11,280 SO IT IS VERY BROAD, ESPECIALLY 2240 01:22:11,280 --> 01:22:14,320 SET ASIDE IS REQUESTEDS AS WELL 2241 01:22:14,320 --> 01:22:18,000 AS SPECIAL EMPHASIS PANEL. 2242 01:22:18,000 --> 01:22:21,960 AND WITH SOME WORD SMITHING AND 2243 01:22:21,960 --> 01:22:25,840 SOME REVISION, THE CONCEPT WAS 2244 01:22:25,840 --> 01:22:28,280 APPROVED UNAN HUESLY BUT A FINAL 2245 01:22:28,280 --> 01:22:32,080 VERSION WILL BE DISTRIBUTED TO 2246 01:22:32,080 --> 01:22:34,360 COUNCIL FOR FINAL APPROVAL. 2247 01:22:34,360 --> 01:22:34,640 >>GREAT. 2248 01:22:34,640 --> 01:22:36,320 THANK YOU VERY MUCH FOR THE 2249 01:22:36,320 --> 01:22:38,720 SUMMARY. 2250 01:22:38,720 --> 01:22:42,240 THE NEXT CONCEPT THAT WE 2251 01:22:42,240 --> 01:22:42,760 CONSIDERED IS ENTITLEDDED 2252 01:22:42,760 --> 01:22:44,880 LEVERAGING SOCIAL NETWORK TO 2253 01:22:44,880 --> 01:22:45,480 PROMOTE WIDESPREAD INDIVIDUAL 2254 01:22:45,480 --> 01:22:47,080 BEHAVIOR CHANGE. 2255 01:22:47,080 --> 01:22:49,280 DR. RUBIN WAS THE PRIMARY 2256 01:22:49,280 --> 01:22:50,680 REVIEWER AND DR. WHITFIELD WAS 2257 01:22:50,680 --> 01:22:52,520 THE SECONDARY. 2258 01:22:52,520 --> 01:22:53,360 DR. RUBIN IF YOU COULD SUMMARIZE 2259 01:22:53,360 --> 01:22:55,120 THE DISCUSSION FOR US. 2260 01:22:55,120 --> 01:22:58,120 >>DR. RUBIN: THIS WAS A VERY 2261 01:22:58,120 --> 01:23:01,400 INTERESTING AND WELL-RECEIVED 2262 01:23:01,400 --> 01:23:01,920 CONCEPT. 2263 01:23:01,920 --> 01:23:04,520 IT RECOGNIZES THE POTENTIAL OF 2264 01:23:04,520 --> 01:23:06,880 SOCIAL NETWORKS TO PROMOTE 2265 01:23:06,880 --> 01:23:09,480 BEHAVIORAL CHANGE INCLUDING 2266 01:23:09,480 --> 01:23:10,800 TARGETING INITIAL DOCTORS AND AS 2267 01:23:10,800 --> 01:23:13,840 WELL AS MODIFICATION OF NETWORK 2268 01:23:13,840 --> 01:23:15,120 STRUCTURE COMPOSITION. 2269 01:23:15,120 --> 01:23:17,880 AND THIS IS PARTICULARLY TIMELY 2270 01:23:17,880 --> 01:23:19,840 BECAUSE OF THE EXPLOSION OF 2271 01:23:19,840 --> 01:23:21,640 SOCIAL NETWORKING THROUGH THE 2272 01:23:21,640 --> 01:23:24,840 WIDESPREAD ADOPTION OF SOCIAL 2273 01:23:24,840 --> 01:23:26,200 MEDIA, WHICH PRESENTS BOTH 2274 01:23:26,200 --> 01:23:27,320 OPPORTUNITIES AND CHALLENGES IN 2275 01:23:27,320 --> 01:23:31,080 THE MANAGEMENT OF OLDER PERSONS 2276 01:23:31,080 --> 01:23:35,120 WITH RESPECT TO THE BEHAVIORAL 2277 01:23:35,120 --> 01:23:35,360 CHANGES. 2278 01:23:35,360 --> 01:23:40,200 THIS WAS ENTHUSIASTICALLY 2279 01:23:40,200 --> 01:23:42,720 EMBRACED BY COUNCIL AND WE ARE 2280 01:23:42,720 --> 01:23:46,200 EXCITED ABOUT IT. 2281 01:23:46,200 --> 01:23:48,440 IT WILL BE RO1 MECHANISM. 2282 01:23:48,440 --> 01:23:48,720 >>GREAT. 2283 01:23:48,720 --> 01:23:52,480 THANK YOU VERY MUCH FOR THAT 2284 01:23:52,480 --> 01:23:54,000 CONCISE SUMMARY. 2285 01:23:54,000 --> 01:23:56,080 THE NEXT CONCEPT WE CONSIDERED 2286 01:23:56,080 --> 01:23:57,880 IS NETWORKS TO DEVELOP 2287 01:23:57,880 --> 01:23:58,520 BEHAVIORAL AND SOCIAL SCIENCE 2288 01:23:58,520 --> 01:24:01,760 RESEARCH IN AGING AND AD/ADRD. 2289 01:24:01,760 --> 01:24:04,280 PRIMARY REVIEWER WAS 2290 01:24:04,280 --> 01:24:05,160 DR. WHITFIELD AND THE SECONDARY 2291 01:24:05,160 --> 01:24:06,640 WAS DR. CASE. 2292 01:24:06,640 --> 01:24:07,400 DR. WHITFIELD, IF YOU COULD 2293 01:24:07,400 --> 01:24:10,240 SUMMARIZE THE DISCUSSION FOR US. 2294 01:24:10,240 --> 01:24:11,280 >>DR. WHITFIELD: CERTAINLY, 2295 01:24:11,280 --> 01:24:12,800 THIS CONCEPT PROPOSAL WAS 2296 01:24:12,800 --> 01:24:15,240 INTENDED TO OFFER A NIMBLE MEANS 2297 01:24:15,240 --> 01:24:17,000 TO SUPPORT HIGH PRIORITY AREAS 2298 01:24:17,000 --> 01:24:19,040 OF RESEARCH FOR BSR. 2299 01:24:19,040 --> 01:24:21,440 THE CONCEPT WOULD ADDRESS SEVEN 2300 01:24:21,440 --> 01:24:22,160 DIFFERENT OPPORTUNITIES THAT 2301 01:24:22,160 --> 01:24:26,080 WERE RECOMMENDATIONS FROM THE 2302 01:24:26,080 --> 01:24:29,320 2019BSR REVIEW AS WELL AS THE 2303 01:24:29,320 --> 01:24:32,960 NAI,AD/ADRD MILESTONES. 2304 01:24:32,960 --> 01:24:35,880 THIS CONCEPT CLEARANCE WOULD USE 2305 01:24:35,880 --> 01:24:37,040 R24 MECHANISM. 2306 01:24:37,040 --> 01:24:41,680 SO AWARD RESEARCH THROUGH 2307 01:24:41,680 --> 01:24:42,480 SUPPORT NETWORKS THAT WOULD BE 2308 01:24:42,480 --> 01:24:43,480 THE BASIS FOR THE CREATION OF 2309 01:24:43,480 --> 01:24:46,200 THE INNOVATIVE RESEARCH GROUPS 2310 01:24:46,200 --> 01:24:47,480 THAT WOULD LEAD FROM 2311 01:24:47,480 --> 01:24:49,200 DISCOVERING, SUPPORTING, 2312 01:24:49,200 --> 01:24:50,840 IDENTIFYING EMERGING RESEARCH 2313 01:24:50,840 --> 01:24:55,000 AND THINKING ABOUT CONSIDERING 2314 01:24:55,000 --> 01:24:56,560 AND ELUCIDATING OTHER RESEARCH 2315 01:24:56,560 --> 01:24:57,280 RESOURCES. 2316 01:24:57,280 --> 01:25:00,280 THE AREAS OUTLINED FROM THE 2317 01:25:00,280 --> 01:25:01,680 2019BSR REVIEW WILL PROVIDE 2318 01:25:01,680 --> 01:25:03,760 IMPORTANT PLATFORMS FOR 2319 01:25:03,760 --> 01:25:04,800 INTERESTING RESEARCH NETWORKS TO 2320 01:25:04,800 --> 01:25:06,040 BE CREATED. 2321 01:25:06,040 --> 01:25:08,480 THE R24 MECHANISMS EXCELLENT 2322 01:25:08,480 --> 01:25:10,920 MECHANISM FOR FOSTERING 2323 01:25:10,920 --> 01:25:11,720 INTER 2324 01:25:11,720 --> 01:25:14,560 DISCIPLINARY GROUPS OF GROUPS 2325 01:25:14,560 --> 01:25:15,920 SENATOR SCIENTISTS AND TO THINK 2326 01:25:15,920 --> 01:25:17,880 ABOUT IMPORTANT AREAS IN SUPPORT 2327 01:25:17,880 --> 01:25:19,560 OF ADVANCING NEUROSCIENCE. 2328 01:25:19,560 --> 01:25:23,160 THIS CONCEPT AS WE DISCUSSED IT 2329 01:25:23,160 --> 01:25:26,240 IS CLEARLY PROVIDE AN ENTREE AND 2330 01:25:26,240 --> 01:25:29,320 FACILITATE THE ABILITY TO HAVE 2331 01:25:29,320 --> 01:25:30,840 COLLABORATIONS BOTH WITHIN BS R 2332 01:25:30,840 --> 01:25:34,720 AND ACROSS DIVISIONS. 2333 01:25:34,720 --> 01:25:37,160 AND WITH THAT, THE DISCUSSION 2334 01:25:37,160 --> 01:25:38,400 WAS VERY SUPPORTIVE AND WE 2335 01:25:38,400 --> 01:25:45,000 APPROVE THIS CONCEPT. 2336 01:25:45,000 --> 01:25:45,520 >>THANK YOU SO MUCH. 2337 01:25:45,520 --> 01:25:46,160 THE NEXT ONE THAT WE CONSIDERED 2338 01:25:46,160 --> 01:25:47,160 IS MEASURE SYSTEM FINANCIAL 2339 01:25:47,160 --> 01:25:48,920 HARDSHIP AMONG PEOPLE AND 2340 01:25:48,920 --> 01:25:52,160 FAMILIES LIVING WITH AD/ADRD. 2341 01:25:52,160 --> 01:25:54,360 DR. CASE WAS THE PRIMARY 2342 01:25:54,360 --> 01:25:55,840 REVIEWER AND DR. WE'RE WAS 2343 01:25:55,840 --> 01:25:57,360 SECONDARY. 2344 01:25:57,360 --> 01:25:58,640 DR. CASE, IF YOU COULD SUMMARIZE 2345 01:25:58,640 --> 01:26:00,120 THE DISCUSSION FOR US. 2346 01:26:00,120 --> 01:26:02,520 >>DR. CASE: SURE. 2347 01:26:02,520 --> 01:26:05,400 THIS CONCEPT STARTS WITH THE 2348 01:26:05,400 --> 01:26:07,440 OBSERVATION THAT PEOPLE WITH 2349 01:26:07,440 --> 01:26:09,080 AD/ADRD ARE NOT OR EVENTUALLY 2350 01:26:09,080 --> 01:26:12,000 WILL NOT BE IN A POSITION TO 2351 01:26:12,000 --> 01:26:14,960 REPORT THE FULL RANGE OF 2352 01:26:14,960 --> 01:26:18,400 FINANCIAL STRESS AND STRAIN AND 2353 01:26:18,400 --> 01:26:21,320 ASSET COMPLETION AND COSTS THAT 2354 01:26:21,320 --> 01:26:23,960 AD/ADRD BRING WITH IT. 2355 01:26:23,960 --> 01:26:25,800 AND THAT THEY DO NOTE BEAR THE 2356 01:26:25,800 --> 01:26:28,000 ENTIRE COST FOR THE SUPPORT THEY 2357 01:26:28,000 --> 01:26:28,200 RECEIVE. 2358 01:26:28,200 --> 01:26:35,680 AND THAT AS A RESULT, THE 2359 01:26:35,680 --> 01:26:36,240 EXISTING FINANCIAL WELLNESS 2360 01:26:36,240 --> 01:26:40,840 SCREENERS ARE NOT REALLY ABLE TO 2361 01:26:40,840 --> 01:26:42,800 CAPTURE THE COSTS ASSOCIATED 2362 01:26:42,800 --> 01:26:44,080 FULLY CAPTURE THE COSTS 2363 01:26:44,080 --> 01:26:50,200 ASSOCIATED WITH THE DEGREE. 2364 01:26:50,200 --> 01:26:52,160 THE DISCUSSION, THERE WAS SOME 2365 01:26:52,160 --> 01:26:55,640 CONFUSION, PRIMARILY MY OWN, ON 2366 01:26:55,640 --> 01:26:58,600 EXACTLY WHAT THE CONCEPT WAS 2367 01:26:58,600 --> 01:26:59,560 CALLING FOR. 2368 01:26:59,560 --> 01:27:03,360 BUT THE CONCEPT IS FOR A CALL 2369 01:27:03,360 --> 01:27:06,760 FOR RO1 PROPOSALS TO FIND WAYS 2370 01:27:06,760 --> 01:27:11,040 TO CHARACTERIZE THE NETWORK OF 2371 01:27:11,040 --> 01:27:13,480 SUPPORT RECEIVED AND TO FIND 2372 01:27:13,480 --> 01:27:17,040 WAYS TO CAPTURE THE FINANCIAL 2373 01:27:17,040 --> 01:27:19,520 STRESS AND STRAIN AND COSTS BORN 2374 01:27:19,520 --> 01:27:24,320 BY THE NETWORK OF PEOPLE, 2375 01:27:24,320 --> 01:27:25,320 FAMILY, FRIENDS, OTHER SOCIAL 2376 01:27:25,320 --> 01:27:28,520 CONTACTS, THAT SUPPORT A PERSON 2377 01:27:28,520 --> 01:27:32,960 DIAGNOSED AND LIVING WITH 2378 01:27:32,960 --> 01:27:33,600 DEMENTIA. 2379 01:27:33,600 --> 01:27:39,640 SO, THERE WAS ENTHUSIASM ON SE 2380 01:27:39,640 --> 01:27:42,680 SEEING THIS TAKEN FORWARD. 2381 01:27:42,680 --> 01:27:45,480 WITH SOME SUGGESTION ON MAKING 2382 01:27:45,480 --> 01:27:50,480 IT CLEARER, PRECISELY WHAT 2383 01:27:50,480 --> 01:27:52,800 THE -- WHAT IS BEING CALLED FOR 2384 01:27:52,800 --> 01:27:57,480 IN TERMS OF DEVELOPING METHODS 2385 01:27:57,480 --> 01:28:00,880 FOR UNDERSTANDING THE 2386 01:28:00,880 --> 01:28:04,640 ELICITATION OF THE COSTS 2387 01:28:04,640 --> 01:28:07,800 ASSOCIATED WITH PROVIDING CARE 2388 01:28:07,800 --> 01:28:15,120 FOR PEOPLE WITH AD/ADRD. 2389 01:28:15,120 --> 01:28:16,200 >>THANK YOU VERY MUCH. 2390 01:28:16,200 --> 01:28:20,960 THE NEXT ONE THAT WE CONSIDERED 2391 01:28:20,960 --> 01:28:22,360 IS NATIONAL HEALTH AND AGING 2392 01:28:22,360 --> 01:28:23,680 TRENDS, AND NATIONAL STUDY OF 2393 01:28:23,680 --> 01:28:25,480 CARE GIVING. 2394 01:28:25,480 --> 01:28:28,840 THIS CONCEPT WAS REVIEWED BY 2395 01:28:28,840 --> 01:28:30,720 DR. WE'RE AND DR. CASE. 2396 01:28:30,720 --> 01:28:31,200 DR. WE'RE, IF YOU COULD 2397 01:28:31,200 --> 01:28:33,200 SUMMARIZE FOR US. 2398 01:28:33,200 --> 01:28:34,560 >>DR. WE'RE: SURE. 2399 01:28:34,560 --> 01:28:39,600 THIS CONCEPT WAS FOR RENEWAL OF 2400 01:28:39,600 --> 01:28:42,960 THE STUDY AND ITS COMPANION 2401 01:28:42,960 --> 01:28:45,840 STUDY OF CAREGIVERS. 2402 01:28:45,840 --> 01:28:49,840 THE NHATS IS A SUCCESSOR TO THE 2403 01:28:49,840 --> 01:28:52,200 NATIONAL LONG-TERM CARE SURVEY 2404 01:28:52,200 --> 01:28:52,920 WHICH WENT FOR 20-SOMETHING 2405 01:28:52,920 --> 01:28:53,680 YEARS PRIOR TO THAT. 2406 01:28:53,680 --> 01:28:56,680 SO IT CONTINUES A VERY LONG 2407 01:28:56,680 --> 01:28:59,080 TRADITION OF ASSESSMENT OF 2408 01:28:59,080 --> 01:29:00,200 DISABILITY IN THE OLDER 2409 01:29:00,200 --> 01:29:03,480 POPULATION AND THE DEMANDS FOR 2410 01:29:03,480 --> 01:29:03,800 CARE. 2411 01:29:03,800 --> 01:29:08,480 WHAT'S EXCITING ABOUT NEAR 2412 01:29:08,480 --> 01:29:10,400 FUTURE IS THAT NIA HAS 2413 01:29:10,400 --> 01:29:11,400 RESTRUCTURED GOVERNANCE FOR THIS 2414 01:29:11,400 --> 01:29:13,240 STUDY WITH EFFECTIVE DATA 2415 01:29:13,240 --> 01:29:14,920 MONITORING COMMUNITY WHICH HAS 2416 01:29:14,920 --> 01:29:22,200 BROUGHT NEW FOCUS TO ADADRD 2417 01:29:22,200 --> 01:29:22,720 CONCERNS GIVEN TRADITIONAL 2418 01:29:22,720 --> 01:29:24,680 STRENGTHS AND UNDERSTANDING 2419 01:29:24,680 --> 01:29:27,240 DISABILITY AND ADAPTATION TO 2420 01:29:27,240 --> 01:29:31,840 DISABILITY, EXTENDING THIS TO 2421 01:29:31,840 --> 01:29:35,320 THE NEEDS FOR ALZHEIMER'S 2422 01:29:35,320 --> 01:29:35,800 PATIENTS. 2423 01:29:35,800 --> 01:29:40,160 SO LIKE A REAL WINNER FOR NIA. 2424 01:29:40,160 --> 01:29:43,080 SO, WE WERE STRONGLY SUPPORTIVE 2425 01:29:43,080 --> 01:29:45,600 OF CONTINUING. 2426 01:29:45,600 --> 01:29:49,200 >>THANK YOU VERY MUCH FOR THAT 2427 01:29:49,200 --> 01:29:51,280 CONCISE SUMMARY. 2428 01:29:51,280 --> 01:29:54,040 WE'LL CONTINUE WITH THE DCG 2429 01:29:54,040 --> 01:29:55,040 CONCEPT CLEARANCES. 2430 01:29:55,040 --> 01:29:57,640 NEXT IS DEVELOPMENT AND 2431 01:29:57,640 --> 01:29:58,880 VALIDATION OF HARMONIZED 2432 01:29:58,880 --> 01:30:00,720 METHODOLOGIES TO MEASURE NAD 2433 01:30:00,720 --> 01:30:03,960 PLUS AND RELATED LEVELS IN 2434 01:30:03,960 --> 01:30:04,560 CLINICAL TRIALS. 2435 01:30:04,560 --> 01:30:07,120 THE PRIMARY REVIEWER WAS 2436 01:30:07,120 --> 01:30:12,560 DR. VASEEN AND THE SECONDARY WAS 2437 01:30:12,560 --> 01:30:12,880 DR. GREENSPAN. 2438 01:30:12,880 --> 01:30:13,360 DR. BHASIN IF YOU COULD 2439 01:30:13,360 --> 01:30:14,880 SUMMARIZE THE DISCUSSION FOR US. 2440 01:30:14,880 --> 01:30:15,560 THANK YOU. 2441 01:30:15,560 --> 01:30:16,400 >>THANK YOU. 2442 01:30:16,400 --> 01:30:19,880 SO THIS CONCEPT PROPOSAL 2443 01:30:19,880 --> 01:30:21,720 DEVELOPING VALIDATION OF 2444 01:30:21,720 --> 01:30:22,440 HARMONIZED METHODOLOGIES TO 2445 01:30:22,440 --> 01:30:26,080 MEASURE NAD, SEEKS TO SUPPORT 2446 01:30:26,080 --> 01:30:27,720 STUDIES TO DEVELOP AND VALIDATE 2447 01:30:27,720 --> 01:30:29,760 METHODS FOR ACCURATE MEASUREMENT 2448 01:30:29,760 --> 01:30:32,720 OF NAD+ AND RELATED METABOLITES 2449 01:30:32,720 --> 01:30:35,720 IN HUMAN BLOOD AND TISSUES. 2450 01:30:35,720 --> 01:30:38,400 THERE HAS BEEN A LOT OF 2451 01:30:38,400 --> 01:30:40,720 EXCITEMENT ABOUT NAD EVEN THOUGH 2452 01:30:40,720 --> 01:30:43,240 NAD HAS BEEN KNOWN FOR THE ROLE 2453 01:30:43,240 --> 01:30:46,800 IN SYNTHESIS FOR 60-70 YEARS. 2454 01:30:46,800 --> 01:30:49,040 MORE RECENT INVESTIGATIONS OVER 2455 01:30:49,040 --> 01:30:51,960 THE LAST 15 YEARS HAVE REVEALED 2456 01:30:51,960 --> 01:30:56,480 MUCH MORE EXPANSIVE ROLE OF NAD 2457 01:30:56,480 --> 01:30:58,560 IN EMERGING BIOLOGY. 2458 01:30:58,560 --> 01:31:02,480 AND THE NUMBER OF STRATEGIES ARE 2459 01:31:02,480 --> 01:31:05,440 BEING DEVELOPED THROUGH AUGMENT 2460 01:31:05,440 --> 01:31:09,720 NAD AS A -- AS A THERAPEUTIC 2461 01:31:09,720 --> 01:31:10,280 INTERVENTION TO PREVENT AND 2462 01:31:10,280 --> 01:31:12,720 TREAT A NUMBER OF AGE-RELATED 2463 01:31:12,720 --> 01:31:13,440 DISEASES. 2464 01:31:13,440 --> 01:31:15,480 NAD PRECURSORS HAVE BEEN 2465 01:31:15,480 --> 01:31:17,760 INVESTIGATED IN PRE-CLINICAL AS 2466 01:31:17,760 --> 01:31:19,680 WELL AS AT SOME EARLY PHASE 2467 01:31:19,680 --> 01:31:21,640 HUMAN STUDIES AND THE DATA FROM 2468 01:31:21,640 --> 01:31:23,560 THESE EARLY STUDIES ARE 2469 01:31:23,560 --> 01:31:24,720 TANTALIZING AND HAVE SHOWN THE 2470 01:31:24,720 --> 01:31:27,600 PROMISE OF THIS STRATEGY. 2471 01:31:27,600 --> 01:31:33,280 BUT THERE IS ALSO BEEN 2472 01:31:33,280 --> 01:31:33,840 DIFFICULTIES IN THIS DATA 2473 01:31:33,840 --> 01:31:35,600 BECAUSE OF MET LOGIC PROBLEMS IN 2474 01:31:35,600 --> 01:31:38,400 MEASURING NAD AND ITS 2475 01:31:38,400 --> 01:31:39,960 METABOLITES IN THE SERUM AND IN 2476 01:31:39,960 --> 01:31:43,000 OTHER TISSUES, PARTICULARLY IN 2477 01:31:43,000 --> 01:31:43,880 TISSUES. 2478 01:31:43,880 --> 01:31:45,040 THERE ARE THREE TYPES OF 2479 01:31:45,040 --> 01:31:47,400 DIFFICULTIES, HOW TO STABILIZE 2480 01:31:47,400 --> 01:31:47,560 NA. 2481 01:31:47,560 --> 01:31:51,200 AND METABOLITES, PARTICULARLY 2482 01:31:51,200 --> 01:31:53,040 NADA, NADPH AND DOWNSTREAM 2483 01:31:53,040 --> 01:31:55,040 METABOLITES IN THE HUMAN SERUM 2484 01:31:55,040 --> 01:31:57,840 AS WELL AS IN TISSUES PRIOR TO 2485 01:31:57,840 --> 01:31:58,160 MEASUREMENT. 2486 01:31:58,160 --> 01:32:00,760 AND SECOND, HOW TO HARMONIZE THE 2487 01:32:00,760 --> 01:32:02,360 VARIOUS ASSAYS TO MINIMIZE IN 2488 01:32:02,360 --> 01:32:07,680 THE LABORATORY HETEROGENEITY AND 2489 01:32:07,680 --> 01:32:09,640 FINALLY, CAN WE MEASURE NAD AND 2490 01:32:09,640 --> 01:32:13,680 METABOLITES IN SIT YOU USING 2491 01:32:13,680 --> 01:32:15,120 MAGNETIC RESONANCE SPECTROSCOPY? 2492 01:32:15,120 --> 01:32:17,160 AND THEN THERE IS A NEED TO 2493 01:32:17,160 --> 01:32:18,280 HARMONIZE THESE METHODS SO THE 2494 01:32:18,280 --> 01:32:19,720 EVALUATION BEING REPORTED BY 2495 01:32:19,720 --> 01:32:21,800 DIFFERENT LABORATORIES ARE 2496 01:32:21,800 --> 01:32:23,520 COMPARABLE AND ARE BEING 2497 01:32:23,520 --> 01:32:26,440 BENCHMARKED WITH HIGHER ORDER OF 2498 01:32:26,440 --> 01:32:28,040 CALIBRATOR. 2499 01:32:28,040 --> 01:32:29,680 SO THIS PARTICULAR INITIATOR 2500 01:32:29,680 --> 01:32:33,160 THAT HAS BEEN PROPOSED IN THIS 2501 01:32:33,160 --> 01:32:35,600 CONCEPT CLEARANCE AS A UL1 2502 01:32:35,600 --> 01:32:38,200 MECHANISMS IS VERY URGENTLY 2503 01:32:38,200 --> 01:32:41,240 NEEDED TO PROMOTE RESEARCH IN 2504 01:32:41,240 --> 01:32:41,960 THIS SPACE. 2505 01:32:41,960 --> 01:32:46,960 IT WAS A LOT OF ENTHUSIASM FOR 2506 01:32:46,960 --> 01:32:50,440 SUPPORTING THIS CONCEPT. 2507 01:32:50,440 --> 01:32:50,720 >>GREAT. 2508 01:32:50,720 --> 01:32:53,480 >>AND THE NEED FOR SPECIAL 2509 01:32:53,480 --> 01:32:57,040 EMPHASIS ALSO IS WELL JUSTIFIED. 2510 01:32:57,040 --> 01:32:58,600 >>THANK YOU VERY MUCH. 2511 01:32:58,600 --> 01:33:00,560 THE NEXT CONCEPT THAT WE 2512 01:33:00,560 --> 01:33:03,840 CONSIDERED IS CALLED ELUCIDATING 2513 01:33:03,840 --> 01:33:05,040 VARIABILITY OF PHYSIOLOGIC AND 2514 01:33:05,040 --> 01:33:06,400 FUNCTIONAL RESPONSES TO EXERCISE 2515 01:33:06,400 --> 01:33:08,600 TRAINING IN OLDER ADULTS. 2516 01:33:08,600 --> 01:33:10,960 THE PRIMARY REVIEWER IS 2517 01:33:10,960 --> 01:33:11,920 DR. GREENSPAN AND THE SECONDARY 2518 01:33:11,920 --> 01:33:22,160 IS DR. BHASIN. 2519 01:33:24,560 --> 01:33:25,080 DR. GREENSPAN, IF YOU COULD 2520 01:33:25,080 --> 01:33:25,600 RECOUNT THE DECISION FROM 2521 01:33:25,600 --> 01:33:26,000 YESTERDAY, PLEASE. 2522 01:33:26,000 --> 01:33:26,600 >>DR. GREENSPAN: THANK YOU, 2523 01:33:26,600 --> 01:33:26,840 MONICA. 2524 01:33:26,840 --> 01:33:27,440 ALTHOUGH THERE ARE SIGNIFICANT 2525 01:33:27,440 --> 01:33:29,280 EVIDENCE THAT THERE IS BOST 2526 01:33:29,280 --> 01:33:30,520 EXERCISE AND PHYSICAL ACTIVITY 2527 01:33:30,520 --> 01:33:32,680 FOR PREVENTION OF DISEASE IN 2528 01:33:32,680 --> 01:33:34,960 OLDER ADULTS, THERE IS ALSO 2529 01:33:34,960 --> 01:33:38,000 SIGNIFICANT VARIABILITY IN 2530 01:33:38,000 --> 01:33:39,320 INDIVIDUALS RESPONSE TO 2531 01:33:39,320 --> 01:33:39,640 EXERCISE. 2532 01:33:39,640 --> 01:33:42,040 AND THERE HAVE BEEN SEVERAL KEY 2533 01:33:42,040 --> 01:33:43,480 STUDIES THAT HAVE DEMONSTRATED 2534 01:33:43,480 --> 01:33:47,680 THIS VARIABILITY INCLUDING ONE 2535 01:33:47,680 --> 01:33:49,400 VERY LARGE NIA-SUPPORTED STUDY, 2536 01:33:49,400 --> 01:33:51,080 THE LIFE TRIAL, THAT SHOWED A 2537 01:33:51,080 --> 01:33:53,560 REDUCTION IN THE TRANSITION TO 2538 01:33:53,560 --> 01:33:55,480 MOBILITY DISABILITY, BUT 1/3 OF 2539 01:33:55,480 --> 01:33:59,920 THE PARTICIPANTS HAD A DECLINE 2540 01:33:59,920 --> 01:34:01,720 IN GAIT SPEED AND DECLINE IN 2541 01:34:01,720 --> 01:34:02,560 OTHER FUNCTIONAL TESTS. 2542 01:34:02,560 --> 01:34:04,080 THERE WAS AN NIH WORKED SHOP IN 2543 01:34:04,080 --> 01:34:06,920 APRIL OF 2022 THAT HIGHLIGHTED 2544 01:34:06,920 --> 01:34:09,960 THE HETEROGENEITY OF RESPONSE TO 2545 01:34:09,960 --> 01:34:11,960 EXERCISE TRAINING AND FOUND THAT 2546 01:34:11,960 --> 01:34:13,520 THERE WERE KEY GAPS IN 2547 01:34:13,520 --> 01:34:17,400 ELUCIDATING THE RELATIONSHIPS 2548 01:34:17,400 --> 01:34:19,720 BETWEEN EXOGENOUS AND INTRINSIC 2549 01:34:19,720 --> 01:34:22,320 VERSUS EXOGENOUS, EXTRINSIC 2550 01:34:22,320 --> 01:34:23,360 FACTORS UNDERLYING THE 2551 01:34:23,360 --> 01:34:26,440 VARIATIONS IN THIS RESPONSE TO 2552 01:34:26,440 --> 01:34:26,880 EXERCISE. 2553 01:34:26,880 --> 01:34:28,680 FURTHERMORE, THEY NOTED THAT A 2554 01:34:28,680 --> 01:34:33,160 POSITIVE OUTCOME IN ONE DOMAIN 2555 01:34:33,160 --> 01:34:33,680 DID NOT ALWAYS PROVIDE A 2556 01:34:33,680 --> 01:34:35,520 POSITIVE RESPONSE IN ANOTHER 2557 01:34:35,520 --> 01:34:37,760 IMPORTANT OUTCOME OR DOMAIN. 2558 01:34:37,760 --> 01:34:42,560 SO THIS CONCEPT WILL BE AN RFA 2559 01:34:42,560 --> 01:34:44,960 FOR RL1s, SET ASIDE FUNDS TO 2560 01:34:44,960 --> 01:34:48,080 DESIGN CONTROL STUDIES WITH 2561 01:34:48,080 --> 01:34:49,800 MULTIDISCIPLINARY TEAMS 2562 01:34:49,800 --> 01:34:51,440 UTILIZING INNOVATIVE APPROACHES. 2563 01:34:51,440 --> 01:34:53,840 THE CONCEPT WILL SUPPORT NEW 2564 01:34:53,840 --> 01:34:55,840 STUDIES TO UNDERSTAND THE 2565 01:34:55,840 --> 01:34:56,960 MECHANISM UNDERLYING THE 2566 01:34:56,960 --> 01:34:59,080 RESPONSE AND VARIABILITY TO 2567 01:34:59,080 --> 01:35:01,760 EXERCISE TRAINING IN OLDER 2568 01:35:01,760 --> 01:35:02,000 ADULTS. 2569 01:35:02,000 --> 01:35:04,200 IT WAS SUGGESTED THAT 2570 01:35:04,200 --> 01:35:05,720 INVESTIGATORS DESIGN TRIALS THAT 2571 01:35:05,720 --> 01:35:09,400 CONTROL FOR EXERCISE EXPOSURE, 2572 01:35:09,400 --> 01:35:13,320 THE ENVIRONMENT, EXAMINE TEMP 2573 01:35:13,320 --> 01:35:14,240 ASPECTS, EXAMINE THE 2574 01:35:14,240 --> 01:35:15,560 INTERACTIONS OF DRUG AND 2575 01:35:15,560 --> 01:35:17,880 EXERCISE INTERACTIONS, LOOK AT 2576 01:35:17,880 --> 01:35:22,080 THOSE WITH MULTIPLE CHRONIC 2577 01:35:22,080 --> 01:35:23,000 CONDITIONS, HOW THEY RESOLVE THE 2578 01:35:23,000 --> 01:35:25,000 RESULTS AND MECHANISMS OF SEX 2579 01:35:25,000 --> 01:35:27,160 AND AGE DIFFERENCES ALONG WITH 2580 01:35:27,160 --> 01:35:30,240 OTHER CONFOUNDERS AND FACTORS. 2581 01:35:30,240 --> 01:35:32,280 WE FELT THAT THIS WAS A TIMELY 2582 01:35:32,280 --> 01:35:34,120 AND IMPORTANT RFA THAT WILL 2583 01:35:34,120 --> 01:35:36,120 DIRECT INVESTIGATORS TO EXAMINE 2584 01:35:36,120 --> 01:35:38,600 A HOST OF THESE FACTORS THAT 2585 01:35:38,600 --> 01:35:42,520 LEADS TO THIS VARIABILITY IN THE 2586 01:35:42,520 --> 01:35:43,120 EXERCISE RESPONSE. 2587 01:35:43,120 --> 01:35:44,760 THERE WAS A GOOD DISCUSSION AND 2588 01:35:44,760 --> 01:35:48,680 A LOT OF ENTHUSIASM FOR THIS 2589 01:35:48,680 --> 01:35:49,360 CONCEPT. 2590 01:35:49,360 --> 01:35:52,400 >>THANK YOU, SO MUCH. 2591 01:35:52,400 --> 01:35:57,480 THE LAST ONE FROM THE DGCG IS 2592 01:35:57,480 --> 01:35:59,560 CLONAL HEMATOPOIESIS IN AGING 2593 01:35:59,560 --> 01:36:01,560 HUMANS, DETECTION, RISK FACTORS 2594 01:36:01,560 --> 01:36:02,880 AND RELATIONSHIPS TO 2595 01:36:02,880 --> 01:36:04,040 AGING-RELATED PATHOPHYSIOLOGY 2596 01:36:04,040 --> 01:36:05,640 AND CONDITIONS, AND CLINICAL 2597 01:36:05,640 --> 01:36:08,240 UTILITY IN SCREENING AND 2598 01:36:08,240 --> 01:36:09,600 PROGNOSIS. 2599 01:36:09,600 --> 01:36:11,280 DR. BAKER WAS THE PRIMARY 2600 01:36:11,280 --> 01:36:13,760 REVIEWER AND DR. HUANG WAS THE 2601 01:36:13,760 --> 01:36:15,440 SECONDARY. 2602 01:36:15,440 --> 01:36:16,160 DR. BAKER IF YOU COULD SUMMARIZE 2603 01:36:16,160 --> 01:36:19,480 THE DISCUSSION FOR US. 2604 01:36:19,480 --> 01:36:20,040 >>DR. BAKER: ABSOLUTELY. 2605 01:36:20,040 --> 01:36:22,520 SO THIS CONCEPT IS FOR A NEW RFA 2606 01:36:22,520 --> 01:36:23,840 FUNDING MECHANISM THAT IS 2607 01:36:23,840 --> 01:36:26,200 LOOKING TO GET RO1s WITH THE 2608 01:36:26,200 --> 01:36:29,040 3-5 YEAR PERIOD TO INVESTIGATE 2609 01:36:29,040 --> 01:36:35,680 CLONAL HEMATOPOIESIS IN AGING 2610 01:36:35,680 --> 01:36:35,920 HUMANS. 2611 01:36:35,920 --> 01:36:36,520 WITH THE INTENTION TO DETECT, 2612 01:36:36,520 --> 01:36:37,160 IDENTIFY RISK FACTORS, ESTABLISH 2613 01:36:37,160 --> 01:36:37,720 RELATIONSHIPS TO AGE-RELATED 2614 01:36:37,720 --> 01:36:38,360 PATHOPHYSIOLOGY AND CONDITIONS 2615 01:36:38,360 --> 01:36:39,000 AND DAUGHTER-IN-LAW THE CLINICAL 2616 01:36:39,000 --> 01:36:41,600 UTILITY AND SCREENING AND 2617 01:36:41,600 --> 01:36:43,280 PROGRESSINOSIS FOR PATIENTS -- 2618 01:36:43,280 --> 01:36:47,880 DETERMINE -- IT WAS A JOINT 2619 01:36:47,880 --> 01:36:48,120 PROPOSAL. 2620 01:36:48,120 --> 01:36:50,240 FOR A LONG PERIOD, MOST OF THE 2621 01:36:50,240 --> 01:36:52,560 STUDIES HAVE FOCUSED PRIMARILY 2622 01:36:52,560 --> 01:36:54,760 ON PRE CANCEROUS ALTERATION THAT 2623 01:36:54,760 --> 01:36:55,840 IS SUPPORT NEOPLASTIC 2624 01:36:55,840 --> 01:36:57,760 TRANSFORMATION TO BLOOD-TYPE 2625 01:36:57,760 --> 01:36:58,200 CANCERS. 2626 01:36:58,200 --> 01:37:00,160 ABOUT 15-20% OF PEOPLE OVER THE 2627 01:37:00,160 --> 01:37:02,520 AGE OF 70 HAVE BLOOD CELLS WITH 2628 01:37:02,520 --> 01:37:04,040 CANCER ASSOCIATED CHANGES BUT 2629 01:37:04,040 --> 01:37:06,880 THEY DO NOT THEMSELVES DEVELOP 2630 01:37:06,880 --> 01:37:07,120 TUMORS. 2631 01:37:07,120 --> 01:37:08,160 SO WITH ADVANCES IN SEQUENCING 2632 01:37:08,160 --> 01:37:09,560 TECHNOLOGIES AND REDUCTIONS IN 2633 01:37:09,560 --> 01:37:11,240 THE INVESTMENT NEEDED TO ENTER 2634 01:37:11,240 --> 01:37:12,880 INTO THE SPACE, THERE IS AMPLE 2635 01:37:12,880 --> 01:37:13,400 OPPORTUNITY TO FURTHER 2636 01:37:13,400 --> 01:37:15,880 UNDERSTAND HOW THESE VARIATIONS 2637 01:37:15,880 --> 01:37:17,760 THAT OCCUR WITH AGE AND HOW THEY 2638 01:37:17,760 --> 01:37:20,040 ALSO MAYBE ARE OCCURRING IN 2639 01:37:20,040 --> 01:37:21,840 DIVERSE POPULATIONS AND TO THIS 2640 01:37:21,840 --> 01:37:23,360 END, MORE THAN 60,000 2641 01:37:23,360 --> 01:37:26,360 PARTICIPANTS HAVE BEEN 2642 01:37:26,360 --> 01:37:27,720 INVESTIGATED FOR CLONAL 2643 01:37:27,720 --> 01:37:30,080 HEMATOPOIETIC ALTERATIONS OF 2644 01:37:30,080 --> 01:37:31,760 INDETERMINATE POTENTIAL AND 2645 01:37:31,760 --> 01:37:34,080 GENERALLY LONG-LIVED PATIENTS 2646 01:37:34,080 --> 01:37:39,640 TEND TO HAVE FEWER CLONAL 2647 01:37:39,640 --> 01:37:39,840 CHANGES. 2648 01:37:39,840 --> 01:37:41,720 THERE WAS A WORKSHOP TO EXPLORE 2649 01:37:41,720 --> 01:37:43,040 THIS RELATIONSHIP IN 2021. 2650 01:37:43,040 --> 01:37:46,880 A LOT OF EXCITEMENT AROUND THIS. 2651 01:37:46,880 --> 01:37:48,360 LARGELY THIS RFA IS COMING FROM 2652 01:37:48,360 --> 01:37:49,360 THE OUTCOMES FROM THAT 2653 01:37:49,360 --> 01:37:51,240 PARTICULAR WORKSHOP. 2654 01:37:51,240 --> 01:37:52,680 IT SEEMS TO FITTED WELL WITHIN 2655 01:37:52,680 --> 01:37:54,320 THE BEING HIGH PRIORITY WITH THE 2656 01:37:54,320 --> 01:37:55,440 NIA AND THERE WAS NO HESITATION 2657 01:37:55,440 --> 01:37:57,160 WITHIN THE COUNCIL FOR 2658 01:37:57,160 --> 01:37:58,720 SUPPORTING THIS PARTICULAR 2659 01:37:58,720 --> 01:38:02,360 INITIATIVE. 2660 01:38:02,360 --> 01:38:02,680 >>GREAT. 2661 01:38:02,680 --> 01:38:03,120 THANK YOU VERY MUCH. 2662 01:38:03,120 --> 01:38:05,520 WE WILL MOVE ON TO NOW THE 2663 01:38:05,520 --> 01:38:08,200 DIVISION OF NEUROSCIENCE CONCEPT 2664 01:38:08,200 --> 01:38:08,480 CLEARANCES. 2665 01:38:08,480 --> 01:38:10,600 THE FIRST ONE IN THAT GROUP WE 2666 01:38:10,600 --> 01:38:13,280 CONSIDERED WERE NEURONAL AND NON 2667 01:38:13,280 --> 01:38:14,920 NEURONAL MECHANISMS, UNDERLYING 2668 01:38:14,920 --> 01:38:16,440 GAIT AS A PRE-CLINICAL MARKER 2669 01:38:16,440 --> 01:38:18,920 FOR ALZHEIMER'S DISEASE AND 2670 01:38:18,920 --> 01:38:21,480 ALZHEIMER'S DISEASE RELATED 2671 01:38:21,480 --> 01:38:23,280 DEMENTIAS. 2672 01:38:23,280 --> 01:38:25,000 DR. BHASIN WAS PRIMARY REVIEWER 2673 01:38:25,000 --> 01:38:30,080 AND DR. RUBIN WAS SECONDARY. 2674 01:38:30,080 --> 01:38:30,560 DR. BHASIN IF YOU COULD 2675 01:38:30,560 --> 01:38:33,000 SUMMARIZE THE DISCUSSION FOR US. 2676 01:38:33,000 --> 01:38:43,560 >>DR. BHASIN: THANK YOU VERY 2677 01:38:46,040 --> 01:38:46,360 MUCH. 2678 01:38:46,360 --> 01:38:49,560 THIS CONCEPT PROPOSAL SEEKS SET 2679 01:38:49,560 --> 01:38:51,640 ASIDE FUNDS TO ENCOURAGE 2680 01:38:51,640 --> 01:38:53,600 RESEARCH IN ELUCIDATING THE 2681 01:38:53,600 --> 01:38:56,120 NEURAL AS WELL AS NON-NEURAL 2682 01:38:56,120 --> 01:38:59,960 MECHANISMS THAT UNDERLIE THE 2683 01:38:59,960 --> 01:39:03,720 ASSOCIATION BETWEEN MOBILITY AND 2684 01:39:03,720 --> 01:39:08,480 COGNITION IN AGING AND ADRD. 2685 01:39:08,480 --> 01:39:10,520 THERE IS WIDE AGREEMENT THAT 2686 01:39:10,520 --> 01:39:13,840 IMPAIRED MOBILITY PRECEDES AND 2687 01:39:13,840 --> 01:39:16,520 PREDICTS IMPAIRED COGNITION AND 2688 01:39:16,520 --> 01:39:18,360 ALSO PREDICTS AN INCREASE RISK 2689 01:39:18,360 --> 01:39:21,840 OF DEVELOPING ALZHEIMER'S 2690 01:39:21,840 --> 01:39:22,040 DISEASE. 2691 01:39:22,040 --> 01:39:23,400 THE PREDICTIVE ABILITY OF GAIT 2692 01:39:23,400 --> 01:39:24,360 SPEED IS MARKER OF HEALTH AND 2693 01:39:24,360 --> 01:39:26,880 PHYSICAL DISABILITY, COGNITIVE 2694 01:39:26,880 --> 01:39:28,800 DECLINE AND ALZHEIMER'S AND 2695 01:39:28,800 --> 01:39:30,840 MORTALITY IS WIDELY RECOGNIZED. 2696 01:39:30,840 --> 01:39:32,520 EVEN THOUGH THE NEURAL AS WELL 2697 01:39:32,520 --> 01:39:35,200 AS NON-NEURAL MECHANISMS THAT 2698 01:39:35,200 --> 01:39:38,440 LINK WALKING AND OTHER MOTOR 2699 01:39:38,440 --> 01:39:42,960 FUNCTIONS WITH COGNITION AND 2700 01:39:42,960 --> 01:39:43,560 SUBSEQUENT DECLINE IN COGNITION 2701 01:39:43,560 --> 01:39:44,960 AND DEVELOPMENT OF ALZHEIMER'S 2702 01:39:44,960 --> 01:39:47,320 DISEASE ARE INCOMPLETELY 2703 01:39:47,320 --> 01:39:47,600 UNDERSTOOD. 2704 01:39:47,600 --> 01:39:48,280 THAT IS WHAT IS BEING ENCOURAGED 2705 01:39:48,280 --> 01:39:50,440 IN THIS PARTICULAR CONCEPT 2706 01:39:50,440 --> 01:39:50,720 PROPOSAL. 2707 01:39:50,720 --> 01:39:54,880 SO THE PROPOSAL SEEKS TO SET 2708 01:39:54,880 --> 01:39:56,440 ASIDE FUNDS AND SPECIAL EMPHASIS 2709 01:39:56,440 --> 01:40:00,600 PANEL TO REVIEW THE RESULTING 2710 01:40:00,600 --> 01:40:02,480 GRANT APPLICATIONS. 2711 01:40:02,480 --> 01:40:04,440 THERE WAS GENERAL ENTHUSIASM 2712 01:40:04,440 --> 01:40:05,760 THAT THIS IS A VERY IMPORTANT 2713 01:40:05,760 --> 01:40:07,440 AREA FOR INVESTIGATION THAT 2714 01:40:07,440 --> 01:40:12,480 NEEDS TO BE SUPPORTED AND THIS 2715 01:40:12,480 --> 01:40:15,040 MECHANISM SEEMS APPROPRIATE. 2716 01:40:15,040 --> 01:40:17,480 THERE WAS LIVELY DISCUSSION 2717 01:40:17,480 --> 01:40:21,200 AROUND THIS AND SOME SUGGESTION 2718 01:40:21,200 --> 01:40:23,760 WERE MADE TO NEURODOWN THE FOCUS 2719 01:40:23,760 --> 01:40:25,120 OF THE INITIATIVE AND FOCUS ON 2720 01:40:25,120 --> 01:40:28,680 THE NEURAL MECHANISMS. 2721 01:40:28,680 --> 01:40:31,200 BUT THERE WAS WIDE SUPPORT AND 2722 01:40:31,200 --> 01:40:34,880 ENTHUSIASM FOR THIS CONCEPT 2723 01:40:34,880 --> 01:40:36,880 PROPOSAL. 2724 01:40:36,880 --> 01:40:37,360 >>THANK YOU SO MUCH. 2725 01:40:37,360 --> 01:40:39,320 THE NEXT ONE THAT WE CONSIDERED 2726 01:40:39,320 --> 01:40:41,400 IS ANALYTICAL AND CLINICAL 2727 01:40:41,400 --> 01:40:43,280 VALIDATION OF BIOMARKERS FOR 2728 01:40:43,280 --> 01:40:45,240 ALZHEIMER'S DISEASE AND RELATED 2729 01:40:45,240 --> 01:40:46,160 DIMENS YALS. 2730 01:40:46,160 --> 01:40:47,680 PRIMARY REVIEWER WAS DR. SNYDER 2731 01:40:47,680 --> 01:40:50,920 AND THE SECONDARY WAS 2732 01:40:50,920 --> 01:40:51,240 DR. VANELEDIC. 2733 01:40:51,240 --> 01:40:52,600 DR. SNYDER, IF YOU COULD REVIEW 2734 01:40:52,600 --> 01:40:54,280 THE DISCUSSION FOR US. 2735 01:40:54,280 --> 01:40:54,440 ED. 2736 01:40:54,440 --> 01:40:57,520 >>DR. SNYDER: SO THIS IS 2737 01:40:57,520 --> 01:40:59,120 CONCEPT CLEARANCE -- 2738 01:40:59,120 --> 01:41:09,360 [ LOW AUDIO ] 2739 01:41:09,880 --> 01:41:20,080 [ INAUDIBLE ] 2740 01:41:34,920 --> 01:41:36,280 FOCUSES ON HIGH QUALITY, COST 2741 01:41:36,280 --> 01:41:37,720 EFFECTIVENESS AND UNDER 2742 01:41:37,720 --> 01:41:38,280 REPRESENTED COMMUNITIES AND 2743 01:41:38,280 --> 01:41:42,680 WHILE IT'S NOT RESTRICTED TO LOW 2744 01:41:42,680 --> 01:41:44,160 BIOMARKERS, THERE IS SPECIFIC -- 2745 01:41:44,160 --> 01:41:47,800 OF PROMISE OF BIOMARKERS -- NEED 2746 01:41:47,800 --> 01:41:51,400 FOR CLINICAL UTILITY STUDY. 2747 01:41:51,400 --> 01:41:53,920 ALSO BIOMARKERS -- FRAMEWORK 2748 01:41:53,920 --> 01:41:56,200 INCLUDES THE FRAMEWORK AND 2749 01:41:56,200 --> 01:41:58,400 BIOMARKERS FOR TOOLS FROM 2750 01:41:58,400 --> 01:42:00,200 MEDICAL DEVICE DEVELOPMENT -- SO 2751 01:42:00,200 --> 01:42:03,600 PRETTY WIDE OPEN INCLUDING 2752 01:42:03,600 --> 01:42:06,080 FLUID, PLASMA, IMAGING AND 2753 01:42:06,080 --> 01:42:08,280 REALLY FOCUS ON THE ANALYTICAL 2754 01:42:08,280 --> 01:42:10,680 AND CLINICAL VALIDITY. 2755 01:42:10,680 --> 01:42:13,560 UL1 MECHANISM WHICH WE THOUGHT 2756 01:42:13,560 --> 01:42:15,880 WAS APPROPRIATE MECHANISM THAT 2757 01:42:15,880 --> 01:42:21,000 ALLOWS COOPERATIVE AGREEMENT AND 2758 01:42:21,000 --> 01:42:25,280 WITH NIA MILESTONES AND INPUT, 2759 01:42:25,280 --> 01:42:35,800 THE TYPE -- REALLY IMPORTANT 2760 01:42:52,280 --> 01:42:53,720 BECAUSE REALLY THE ULTIMATE BUT 2761 01:42:53,720 --> 01:42:55,280 NOT REQUIRED GOAL IS TO APPLY 2762 01:42:55,280 --> 01:43:05,320 FOR FDA BIOMARKER -- PROGRAM. 2763 01:43:05,320 --> 01:43:15,800 SO VERY -- RESPONSIVE TO THE 2764 01:43:20,920 --> 01:43:21,720 STRATEGIC PLAN. 2765 01:43:21,720 --> 01:43:23,680 OVERALL WE THOUGHT IT WAS TIMELY 2766 01:43:23,680 --> 01:43:30,760 AND MUCH-NEEDED INITIATIVE 2767 01:43:30,760 --> 01:43:33,760 STANDARDS REQUIRED VIA FDA. 2768 01:43:33,760 --> 01:43:36,320 WE LIKED IT BECAUSE BIOMARKERS 2769 01:43:36,320 --> 01:43:46,800 AND REALLY ACROSS -- WE WERE 2770 01:43:50,240 --> 01:43:50,440 SUPPORTIVE. 2771 01:43:50,440 --> 01:43:52,680 THERE WERE A FEW QUESTIONS 2772 01:43:52,680 --> 01:43:53,680 EASILY ANSWERED BY PROGRAM AND 2773 01:43:53,680 --> 01:43:59,720 WE ARE EXCITED. 2774 01:43:59,720 --> 01:44:00,240 >>THANK YOU. 2775 01:44:00,240 --> 01:44:06,600 THE NEXT APPLICATION IS ENTIT 2776 01:44:06,600 --> 01:44:09,160 ENTITLED -- CHIMERIC ANTIGEN 2777 01:44:09,160 --> 01:44:09,560 RECEPTOR APPROACHES. 2778 01:44:09,560 --> 01:44:11,880 THE PRIMARY REVIEWER WAS 2779 01:44:11,880 --> 01:44:15,920 DR. HUANG AND THE SECONDARY WAS 2780 01:44:15,920 --> 01:44:18,000 DR. BAKER. 2781 01:44:18,000 --> 01:44:18,800 DR. HUAN GOVERNMENT IS 2782 01:44:18,800 --> 01:44:19,760 STRUGGLING WITH LOSING HIS VOICE 2783 01:44:19,760 --> 01:44:24,800 SO DR. BAKER TOOK ON THE VERGEAL 2784 01:44:24,800 --> 01:44:26,880 PRESENTATION. 2785 01:44:26,880 --> 01:44:29,880 AND I THINK THAT -- NOT SURE WHO 2786 01:44:29,880 --> 01:44:31,880 WILL TELL US ABOUT TODAY -- 2787 01:44:31,880 --> 01:44:34,040 >>I CAN TAKE IT. 2788 01:44:34,040 --> 01:44:36,280 SO YES, BASICALLY WE WERE VERY 2789 01:44:36,280 --> 01:44:41,560 MUCH IN AGREEMENT ON THIS WORN. 2790 01:44:41,560 --> 01:44:42,040 >>[ INDISCERNIBLE ] 2791 01:44:42,040 --> 01:44:42,520 >>CAN YOU HEAR ME? 2792 01:44:42,520 --> 01:44:44,800 THIS CONCEPT CLEARANCE IS FOR A 2793 01:44:44,800 --> 01:44:50,880 NEW R61R33 MECHANISMS FOR 2794 01:44:50,880 --> 01:44:53,800 CHIMERIC ANTIGEN RECEPTOR 2795 01:44:53,800 --> 01:44:54,480 APPROACHES. 2796 01:44:54,480 --> 01:44:56,880 WE ARE AVAILABLE WITH CAR AND MA 2797 01:44:56,880 --> 01:44:57,520 SLUG CEASE SO IN THIS CASE WHAT 2798 01:44:57,520 --> 01:44:59,640 THEY ARE TRYING TO DO IS GO 2799 01:44:59,640 --> 01:45:01,000 AFTER MORE PROOF OF PRINCIPLE 2800 01:45:01,000 --> 01:45:04,160 THAT IS SIMILAR APPROACH 2801 01:45:04,160 --> 01:45:05,560 COUPLING CHIMERIC ANTIGEN 2802 01:45:05,560 --> 01:45:06,280 RECEPTORS AGAINST THINGS THAT 2803 01:45:06,280 --> 01:45:08,480 ARE RELEVANT FOR ALZHEIMER'S 2804 01:45:08,480 --> 01:45:11,400 DISEASE AND ALZHEIMER'S 2805 01:45:11,400 --> 01:45:12,120 DISEASE-RELATED PATHOLOGIES TO 2806 01:45:12,120 --> 01:45:13,400 BE POTENTIALLY USEFUL. 2807 01:45:13,400 --> 01:45:15,000 SO IN ESSENCE, THAT WAS THE MAIN 2808 01:45:15,000 --> 01:45:16,760 THING IT'S GOING TO BE EXISTING 2809 01:45:16,760 --> 01:45:18,520 IN TWO STAGES. 2810 01:45:18,520 --> 01:45:21,200 R61 IS DURING THE FIRST TWO 2811 01:45:21,200 --> 01:45:23,200 YEARS OF THE FUNDING CYCLE WHERE 2812 01:45:23,200 --> 01:45:24,440 THERE ARE MILESTONES PEOPLE WILL 2813 01:45:24,440 --> 01:45:26,320 NEED TO MEET AND THEN 2814 01:45:26,320 --> 01:45:27,520 SUBSEQUENTLY LEADING INTO R33 2815 01:45:27,520 --> 01:45:28,320 MECHANISMS FOR THE REMAINING 2816 01:45:28,320 --> 01:45:32,600 THREE YEARS OF FUNDING FOR THIS. 2817 01:45:32,600 --> 01:45:33,200 OVERALL, THERE WAS THIS FEELS 2818 01:45:33,200 --> 01:45:36,280 LIKE IT FIDDLE A VERY IMPORTANT 2819 01:45:36,280 --> 01:45:37,600 PRIORITY AND TO DEVELOP NEW 2820 01:45:37,600 --> 01:45:42,280 ANIMAL MODELS THAT MAY HAVE HIGH 2821 01:45:42,280 --> 01:45:42,920 PREDICTIVE VALUE FOR THINGS THAT 2822 01:45:42,920 --> 01:45:44,760 COULD BE USEFUL FOR DRUG 2823 01:45:44,760 --> 01:45:47,960 DEVELOPMENT FOR TRANSLATIONALLY 2824 01:45:47,960 --> 01:45:48,600 RELEVANT TREATMENT OPPORTUNITIES 2825 01:45:48,600 --> 01:45:49,320 FOR PEOPLE. 2826 01:45:49,320 --> 01:45:50,480 NO HESITATIONS WITH SUPPORT OF 2827 01:45:50,480 --> 01:45:51,080 THIS. 2828 01:45:51,080 --> 01:45:54,800 AGAIN A VERY WELL WRITTEN RFA 2829 01:45:54,800 --> 01:45:57,400 REQUEST. 2830 01:45:57,400 --> 01:45:58,200 >>GREAT. 2831 01:45:58,200 --> 01:46:04,200 THANK YOU VERY MUCH. 2832 01:46:04,200 --> 01:46:07,160 THE NEXT CONCEPT WAS BUILDING 2833 01:46:07,160 --> 01:46:07,880 NEUROSCIENCE RESEARCH 2834 01:46:07,880 --> 01:46:10,400 INFRASTRUCTURE FOR ALZHEIMER'S 2835 01:46:10,400 --> 01:46:13,720 DISEASE AND RELATED DEMENTIAS IN 2836 01:46:13,720 --> 01:46:15,240 AFRICA. 2837 01:46:15,240 --> 01:46:15,880 DR. WE'RE, IF YOU COULD 2838 01:46:15,880 --> 01:46:20,520 SUMMARIZE THE DISCUSSION FOR US. 2839 01:46:20,520 --> 01:46:20,760 >>SURE. 2840 01:46:20,760 --> 01:46:25,000 WE FELT THIS WAS A DYNAMIC AND 2841 01:46:25,000 --> 01:46:28,200 TIMELY INITIATIVE T REPRESENTS A 2842 01:46:28,200 --> 01:46:28,800 COOPERATION BETWEEN DN AND THE 2843 01:46:28,800 --> 01:46:32,200 SPONSOR AND DBSR. 2844 01:46:32,200 --> 01:46:35,320 THE FOCUS IS ON SUB-SAHARAN 2845 01:46:35,320 --> 01:46:38,400 AFRICA WHICH IS A REGION THAT IS 2846 01:46:38,400 --> 01:46:41,000 GREATLY UNDERSTUDIED AND IS A 2847 01:46:41,000 --> 01:46:42,400 POTENTIALLY GREAT VALUE TO 2848 01:46:42,400 --> 01:46:45,160 GENETIC RELEVANCE AND DIVERSITY, 2849 01:46:45,160 --> 01:46:51,320 DUE TO THE UNIQUE DISEASE AND 2850 01:46:51,320 --> 01:46:53,040 ENVIRONMENTAL EXPOSURES IN THAT 2851 01:46:53,040 --> 01:46:54,320 PART OF THE WORLD. 2852 01:46:54,320 --> 01:46:55,840 SO WE FELT THAT FOCUS WAS WELL 2853 01:46:55,840 --> 01:46:58,200 JUSTIFIED IT'S TIMELY IN THAT 2854 01:46:58,200 --> 01:46:59,800 THERE HAS BEEN NOW STUDIES IN 2855 01:46:59,800 --> 01:47:06,440 SOUTH AFRICA AND IN KENYA 2856 01:47:06,440 --> 01:47:07,520 COLLABORATING WITH THE NETWORKS 2857 01:47:07,520 --> 01:47:12,280 TO BUILD COMPARABLE DIAGNOSTIC 2858 01:47:12,280 --> 01:47:12,800 TOOLS. 2859 01:47:12,800 --> 01:47:15,680 THERE WAS MEETING SPONSORED IN 2860 01:47:15,680 --> 01:47:17,000 NAIROBI WELL ATTENDED BY 2861 01:47:17,000 --> 01:47:19,760 SCIENTISTS FROM THE U.S. AND 2862 01:47:19,760 --> 01:47:20,000 AFRICA. 2863 01:47:20,000 --> 01:47:21,720 SO THE POTENTIAL REALLY DOES 2864 01:47:21,720 --> 01:47:24,720 SEEM TO BE THERE NOW FOR THINGS 2865 01:47:24,720 --> 01:47:25,120 TO START HAPPENING. 2866 01:47:25,120 --> 01:47:29,720 THE MECHANISM IS STAGE UG3UH3 IN 2867 01:47:29,720 --> 01:47:33,400 WHICH THERE WILL BE MILESTONES 2868 01:47:33,400 --> 01:47:35,440 IN THE START UP PHASE AND ONLY 2869 01:47:35,440 --> 01:47:37,280 SUCCESSFUL PROJECTS WILL GO 2870 01:47:37,280 --> 01:47:37,640 FORWARD. 2871 01:47:37,640 --> 01:47:41,560 AND THE MAIN CRITERION WHICH 2872 01:47:41,560 --> 01:47:42,960 SUCCESS WILL BE EVALUATED IS THE 2873 01:47:42,960 --> 01:47:44,840 BUILDING OF CAPACITY IN AFRICA. 2874 01:47:44,840 --> 01:47:49,760 SO THIS IS NOT TO FINANCE DRIVE 2875 01:47:49,760 --> 01:47:51,240 BY STUDIES FROM U.S. 2876 01:47:51,240 --> 01:47:51,720 INVESTIGATORS. 2877 01:47:51,720 --> 01:47:53,880 IT'S REALLY TO PARTNER AND 2878 01:47:53,880 --> 01:47:56,840 DEVELOP CAPACITY ON A MORE 2879 01:47:56,840 --> 01:47:59,440 PERMANENT BASIS IN AFRICA. 2880 01:47:59,440 --> 01:48:04,280 SO WE HAVE GREAT ENTHUSIASM FOR 2881 01:48:04,280 --> 01:48:05,880 THIS PROJECT. 2882 01:48:05,880 --> 01:48:06,400 >>THANK YOU SO MUCH. 2883 01:48:06,400 --> 01:48:06,600 GREAT. 2884 01:48:06,600 --> 01:48:09,000 THE NEXT CONCEPT THAT WE 2885 01:48:09,000 --> 01:48:10,000 CONSIDERED IS ARTIFICIAL 2886 01:48:10,000 --> 01:48:11,240 INTELLIGENCE IN PRE-CLINICAL 2887 01:48:11,240 --> 01:48:15,400 DRUG DEVELOPMENT FOR AD/ADRD. 2888 01:48:15,400 --> 01:48:17,800 DR. LONGO WAS THE PRIMARY 2889 01:48:17,800 --> 01:48:22,240 REVIEWER AND DR. H. 2890 01:48:22,240 --> 01:48:22,640 ANG WAS SECONDARY. 2891 01:48:22,640 --> 01:48:23,160 DR. LONG OH, IF YOU COULD 2892 01:48:23,160 --> 01:48:25,960 SUMMARIZE THE DISCUSSION FOR US. 2893 01:48:25,960 --> 01:48:27,280 >>DR. LONGO: SURE. 2894 01:48:27,280 --> 01:48:32,720 THIS IS A UH2/UH3 MODEL TO 2895 01:48:32,720 --> 01:48:35,400 DEVELOP AI APPROACHES FOR 2896 01:48:35,400 --> 01:48:36,600 PRE-CLINICAL DRUG DEVELOPMENT. 2897 01:48:36,600 --> 01:48:38,760 SO WHAT THIS TECHNOLOGY ALLOWS 2898 01:48:38,760 --> 01:48:41,280 ONE TO DO IS DESIGN SMALL 2899 01:48:41,280 --> 01:48:45,560 MOLECULES OR OTHER ENTITIES IN A 2900 01:48:45,560 --> 01:48:47,760 MORE EFFICIENT WAY LIKELY 2901 01:48:47,760 --> 01:48:50,040 EFFECTIVE WAY, TO DESIGN THEM TO 2902 01:48:50,040 --> 01:48:52,360 INTERACT WITH GIVEN TARGET THAT 2903 01:48:52,360 --> 01:48:54,760 MIGHT BENEFIT ALZHEIMER'S AND 2904 01:48:54,760 --> 01:48:55,920 RELATED AREAS. 2905 01:48:55,920 --> 01:48:57,640 SO, THIS IS A VERY TIMELY 2906 01:48:57,640 --> 01:49:02,160 PROPOSAL FOR TWO REASONS, ONE IS 2907 01:49:02,160 --> 01:49:04,320 THE CAPABILITIES IN AI FOR DRUG 2908 01:49:04,320 --> 01:49:05,960 AND THERAPEUTIC DESIGN 2909 01:49:05,960 --> 01:49:07,280 CONTINUING TO ACCELERATE AND 2910 01:49:07,280 --> 01:49:10,200 BECOME MORE AND MORE EFFECTIVE 2911 01:49:10,200 --> 01:49:11,080 AND CRITICAL TOOLS IN THE FIELD 2912 01:49:11,080 --> 01:49:13,840 AT THIS POINT. 2913 01:49:13,840 --> 01:49:15,400 NUMBER 2, OTHER NIA PROGRAMS, 2914 01:49:15,400 --> 01:49:17,000 INCLUDINGASM AD, TREAT AD, ARE 2915 01:49:17,000 --> 01:49:21,120 BEING SUCCESSFUL IN FINDING 2916 01:49:21,120 --> 01:49:25,640 NOVEL TARGETS, NOVEL NON AMYLOID 2917 01:49:25,640 --> 01:49:26,680 TARGETS THAT MIGHT BE OF 2918 01:49:26,680 --> 01:49:27,320 BENEFIT. 2919 01:49:27,320 --> 01:49:29,240 AND SO THIS APPROACH WILL ALLOW 2920 01:49:29,240 --> 01:49:32,840 THESE TARGETS TO BE MORE QUICKLY 2921 01:49:32,840 --> 01:49:34,520 EFFICIENTLY EFFECTIVELY 2922 01:49:34,520 --> 01:49:35,280 ADDRESSED. 2923 01:49:35,280 --> 01:49:36,640 IT'S APPROPRIATELY STAGE 2924 01:49:36,640 --> 01:49:39,200 PROGRAMS WHERE THE APPROACHES 2925 01:49:39,200 --> 01:49:41,160 ARE DEVELOPED IN THE UH2 AND 2926 01:49:41,160 --> 01:49:44,760 THEN APPLIED EITHER CONCEPTUALLY 2927 01:49:44,760 --> 01:49:47,400 OR WITH EXPERIMENTS IN THE UH3. 2928 01:49:47,400 --> 01:49:50,440 SO I THINK WE THOUGHT THAT THIS 2929 01:49:50,440 --> 01:49:53,200 WOULD DEVELOP INTO ENHANCING THE 2930 01:49:53,200 --> 01:49:57,680 DEVELOPMENT OF THERAPEUTICS. 2931 01:49:57,680 --> 01:49:58,440 >>GREAT. 2932 01:49:58,440 --> 01:50:01,680 THANK YOU VERY MUCH. 2933 01:50:01,680 --> 01:50:06,320 THE NEXT CONCEPT THAT WE 2934 01:50:06,320 --> 01:50:07,200 CONSIDERED WAS SMALL RESEARCH 2935 01:50:07,200 --> 01:50:07,760 GRANT PROGRAM FOR THE NEXT 2936 01:50:07,760 --> 01:50:10,520 GENERATION OF RESEARCHERS IN 2937 01:50:10,520 --> 01:50:11,960 AD/ADRD RESEARCH. 2938 01:50:11,960 --> 01:50:13,160 DR. SNYDER WAS THE PRIMARY 2939 01:50:13,160 --> 01:50:15,800 REVIEWER AND DR. MANLY WAS THE 2940 01:50:15,800 --> 01:50:17,040 SECONDARY. 2941 01:50:17,040 --> 01:50:18,040 DR. SNYDER IF YOU COULD 2942 01:50:18,040 --> 01:50:20,000 SUMMARIZE THE DISCUSSION FOR US. 2943 01:50:20,000 --> 01:50:25,000 >>DR. SNYDER: THANK YOU MONICA 2944 01:50:25,000 --> 01:50:26,200 AND LET ME KNOW IF YOU CAN'T 2945 01:50:26,200 --> 01:50:26,720 HEAR ME. 2946 01:50:26,720 --> 01:50:27,280 >>YOU SOUND PERFECT NOW. 2947 01:50:27,280 --> 01:50:27,560 THANK YOU. 2948 01:50:27,560 --> 01:50:27,840 >>GOOD. 2949 01:50:27,840 --> 01:50:28,720 I CHANGED MY MICROPHONE. 2950 01:50:28,720 --> 01:50:31,440 SO THE CONCEPT PROPOSED HERE IS 2951 01:50:31,440 --> 01:50:34,280 A RE-ISSUANCE OF THE NEXT 2952 01:50:34,280 --> 01:50:35,440 GENERATION PROGRAM. 2953 01:50:35,440 --> 01:50:38,880 THE OVERALL GOAL OF THIS FOA IS 2954 01:50:38,880 --> 01:50:41,520 RESEARCH IN VARIOUS MEETING FOR 2955 01:50:41,520 --> 01:50:42,160 SCIENTIFIC INVESTIGATIONS 2956 01:50:42,160 --> 01:50:43,440 FOCUSING ON PREVENTION, 2957 01:50:43,440 --> 01:50:45,160 DIAGNOSIS AND TREATMENT. 2958 01:50:45,160 --> 01:50:48,560 SO BROAD RANGE OF TOPICS. 2959 01:50:48,560 --> 01:50:51,840 THE MAIN THEME IS TO ENCOURAGE 2960 01:50:51,840 --> 01:50:53,800 THE NEXT GENERATION AS IN THE 2961 01:50:53,800 --> 01:50:55,320 TITLE,FUL RESEARCHERS THEIR 2962 01:50:55,320 --> 01:50:58,840 RESEARCH ACADEMIC CAREERS IN 2963 01:50:58,840 --> 01:50:59,200 ADADRD. 2964 01:50:59,200 --> 01:51:02,000 ANOTHER AIM IS LIKE NOVEL 2965 01:51:02,000 --> 01:51:05,080 RESEARCH IDEAS IN OTHER FIELDS. 2966 01:51:05,080 --> 01:51:05,840 SO THIS IS A RE-ISSUANCE BUT 2967 01:51:05,840 --> 01:51:06,200 IT'S CHANGED. 2968 01:51:06,200 --> 01:51:09,320 INSTEAD OF BEING MULTIPLE 2969 01:51:09,320 --> 01:51:11,680 DIFFERENT MECHANISMS, SMALL 2970 01:51:11,680 --> 01:51:14,120 GRANTER OPPORTUNITIES, IT'S ALL 2971 01:51:14,120 --> 01:51:15,720 WITHIN NOW RFA AND THE GOAL IS 2972 01:51:15,720 --> 01:51:22,680 TO GET -- ALSO CHANGED THAT IT 2973 01:51:22,680 --> 01:51:23,120 IS REALLY TO GET NEW 2974 01:51:23,120 --> 01:51:23,440 INVESTIGATORS. 2975 01:51:23,440 --> 01:51:24,040 OR INVESTIGATORS WHO HAVE NOT 2976 01:51:24,040 --> 01:51:28,320 HAD RO1 FUNDING. 2977 01:51:28,320 --> 01:51:30,320 SO THAT'S A TAKE FROM THE 2978 01:51:30,320 --> 01:51:30,600 ORIGINAL. 2979 01:51:30,600 --> 01:51:34,920 THE ORIGINAL WAS VERY PRODUCTIVE 2980 01:51:34,920 --> 01:51:37,240 AND DID QUITE WELL, HOWEVER, 2981 01:51:37,240 --> 01:51:39,640 THEY DID WANT TO KIND OF REFOCUS 2982 01:51:39,640 --> 01:51:42,120 ON THIS NEW NEXT GENERATION 2983 01:51:42,120 --> 01:51:44,080 BECAUSE SOME OF THESE PEOPLE 2984 01:51:44,080 --> 01:51:44,800 WERE MORE SENIOR. 2985 01:51:44,800 --> 01:51:47,400 SO THEY ARE EXPECTING NOW THAT 2986 01:51:47,400 --> 01:51:50,640 ABOUT HALF WILL BE EARLY-STAGE 2987 01:51:50,640 --> 01:51:52,600 INVESTIGATORS TO ACHIEVE THE 2988 01:51:52,600 --> 01:51:55,160 GOAL OF FOSTERING NEW 2989 01:51:55,160 --> 01:51:55,680 DEVELOPMENT. 2990 01:51:55,680 --> 01:51:59,320 AGAIN SUCH THAT THEY CAN'T HAVE 2991 01:51:59,320 --> 01:52:00,280 A SEPARATE STUDY SECTION BUT 2992 01:52:00,280 --> 01:52:03,120 THEY WILL HAVE SET ASIDE FUNDS 2993 01:52:03,120 --> 01:52:04,520 FOR THESE RESEARCH GRANTS. 2994 01:52:04,520 --> 01:52:08,760 SO WE'RE REALLY ENTHUSIASTIC 2995 01:52:08,760 --> 01:52:09,040 ABOUT THIS. 2996 01:52:09,040 --> 01:52:10,400 ENTRY OF PROMISING NEW 2997 01:52:10,400 --> 01:52:12,040 INVESTIGATORS IN THE AGING 2998 01:52:12,040 --> 01:52:14,360 RESEARCH, ENCOURAGE THE 2999 01:52:14,360 --> 01:52:14,960 ESTABLISHED INVESTIGATORS TO 3000 01:52:14,960 --> 01:52:19,040 ENTER NEW AREAS OF AGING 3001 01:52:19,040 --> 01:52:20,480 RESEARCH AND GOING TO BE USED AS 3002 01:52:20,480 --> 01:52:22,120 PILOTS THAT HOPEFULLY WILL LEAD 3003 01:52:22,120 --> 01:52:25,400 TO RO1s FOCUSED ON AGING AND 3004 01:52:25,400 --> 01:52:26,800 SIGNIFICANT AGING RESEARCH. 3005 01:52:26,800 --> 01:52:30,960 SO WE WERE HIGHLY SUPPORTIVE OF 3006 01:52:30,960 --> 01:52:31,160 THIS. 3007 01:52:31,160 --> 01:52:32,000 >>THANK YOU VERY MUCH. 3008 01:52:32,000 --> 01:52:34,320 SO THE NEXT ONE THAT WE 3009 01:52:34,320 --> 01:52:35,960 CONSIDERED IS SEAMLESS EARLY 3010 01:52:35,960 --> 01:52:38,680 STAGE CLINICAL DRUG DEVELOPMENT 3011 01:52:38,680 --> 01:52:41,440 FOR NOVEL THERAPEUTIC AGENTS FOR 3012 01:52:41,440 --> 01:52:44,480 THE SPECTRUM OF ALZHEIMER'S AND 3013 01:52:44,480 --> 01:52:45,080 ALZHEIMER'S-RELATED DEMENTIAS. 3014 01:52:45,080 --> 01:52:49,280 THE PRIMARY REVIEWER WAS 3015 01:52:49,280 --> 01:52:50,080 DR. VANELEDIC AND THE SECONDARY 3016 01:52:50,080 --> 01:52:51,120 WAS DR. LONGO. 3017 01:52:51,120 --> 01:52:52,440 IF YOU COULD SUMMARIZE THE 3018 01:52:52,440 --> 01:52:53,840 DISCUSSION FOR US. 3019 01:52:53,840 --> 01:52:55,240 >>YES, THANK YOU. 3020 01:52:55,240 --> 01:53:00,880 SO THIS CONCEPT PROPOSES A NEW 3021 01:53:00,880 --> 01:53:02,720 UG3/UH3 PHASED AWARD INITIATIVE 3022 01:53:02,720 --> 01:53:04,520 AIMED AT STREAMLINING EARLY 3023 01:53:04,520 --> 01:53:08,880 STAGE EVALUATION OF PROMISING 3024 01:53:08,880 --> 01:53:10,360 NOVEL PHARMACOLOGICAL 3025 01:53:10,360 --> 01:53:10,680 INTERVENTIONS. 3026 01:53:10,680 --> 01:53:11,600 AND THE WAY THEY ARE GOING TO DO 3027 01:53:11,600 --> 01:53:15,040 THIS IS TO FUND PHASE I CLINICAL 3028 01:53:15,040 --> 01:53:17,240 TRIALS FIRST AND THEN SEAMLESSLY 3029 01:53:17,240 --> 01:53:21,120 MOVE TO PHASE I B2A TRIALS BASED 3030 01:53:21,120 --> 01:53:23,000 ON PRE-SPECIFIED GO-NO-GO SAFETY 3031 01:53:23,000 --> 01:53:25,040 AND TOLERABILITY CRITERIA IN 3032 01:53:25,040 --> 01:53:26,480 PHASE I. 3033 01:53:26,480 --> 01:53:30,400 THE THERAPEUTIC CANDIDATES MUST 3034 01:53:30,400 --> 01:53:33,360 TARGET NON AMYLOID AND CAN BE 3035 01:53:33,360 --> 01:53:34,680 TESTED IN INDIVIDUALS ACROSS ANY 3036 01:53:34,680 --> 01:53:36,880 STAGE OF DISEASE PROGRESSION. 3037 01:53:36,880 --> 01:53:38,400 AND THERE ARE ALSO REQUIREMENTS 3038 01:53:38,400 --> 01:53:39,880 FOR DIVERSITY WITHIN THE TRIAL 3039 01:53:39,880 --> 01:53:42,760 COHORTS AND DATA AND BIOSAMPLE 3040 01:53:42,760 --> 01:53:43,080 SHARING. 3041 01:53:43,080 --> 01:53:45,000 WE THOUGHT THIS WAS A VERY 3042 01:53:45,000 --> 01:53:46,200 IMPORTANT INITIATIVE BECAUSE IT 3043 01:53:46,200 --> 01:53:48,960 WILL ALLOW TIMELY TESTING AND 3044 01:53:48,960 --> 01:53:51,560 PRIORITIZATION OF PROMISING 3045 01:53:51,560 --> 01:53:53,920 INTERVENTIONS WITHOUT THE USUAL 3046 01:53:53,920 --> 01:53:54,480 SIGNIFICANT FUNDING DELAY 3047 01:53:54,480 --> 01:53:56,200 BETWEEN CONCLUSION OF PHASE I A 3048 01:53:56,200 --> 01:53:58,640 TRIALS AND THE START OF PHASE 3049 01:53:58,640 --> 01:54:02,760 1B2A STUDIES. 3050 01:54:02,760 --> 01:54:03,400 THE REQUIREMENT FOR NON AMYLOID 3051 01:54:03,400 --> 01:54:04,600 NON TAU INTERVENTIONS WAS GOOD 3052 01:54:04,600 --> 01:54:06,200 BECAUSE THERE IS ALREADY 3053 01:54:06,200 --> 01:54:07,520 SIGNIFICANT EFFORT BY PHARMA AND 3054 01:54:07,520 --> 01:54:09,000 BIOTECH TO TARGET AMYLOID AND 3055 01:54:09,000 --> 01:54:11,480 TAU AND THERE ARE SO MANY OTHER 3056 01:54:11,480 --> 01:54:12,560 POTENTIAL DISEASE MECHANISMS 3057 01:54:12,560 --> 01:54:15,200 THAT NEED TO BE EXAMINED AND 3058 01:54:15,200 --> 01:54:19,880 PRIORITIZED EITHER MOVED FORWARD 3059 01:54:19,880 --> 01:54:21,000 OR MOVED OFF. 3060 01:54:21,000 --> 01:54:21,600 ALSO, FINALLY THE REQUIREMENTS 3061 01:54:21,600 --> 01:54:23,160 FOR COHORT DIVERSITY AND DATA 3062 01:54:23,160 --> 01:54:25,880 SAMPLE SHARING ARE CRITICAL TO 3063 01:54:25,880 --> 01:54:27,680 ENSURE BROAD APPLICABILITY AT 3064 01:54:27,680 --> 01:54:28,240 THE RESULTS. 3065 01:54:28,240 --> 01:54:30,520 SO WE WERE VERY HIGHLY 3066 01:54:30,520 --> 01:54:33,120 SUPPORTIVE OF THIS CONCEPT. 3067 01:54:33,120 --> 01:54:37,000 >>THANK YOU VERY MUCH FOR THAT 3068 01:54:37,000 --> 01:54:40,880 SUMMARY. 3069 01:54:40,880 --> 01:54:41,920 WE WILL MOVE ON TO THE DIVISION 3070 01:54:41,920 --> 01:54:44,040 OF EXTRAMURAL ACTIVITY AND 3071 01:54:44,040 --> 01:54:48,320 OFFICE OF COMMUNICATIONS AND 3072 01:54:48,320 --> 01:54:49,000 PUBLIC LIASON. 3073 01:54:49,000 --> 01:54:56,600 WHO PRESENTED TWO CONCEPTS, 3074 01:54:56,600 --> 01:54:58,240 NATIONAL IN INSTITUTE ON THE 3075 01:54:58,240 --> 01:55:00,240 AGING CLINICAL SUPPORT SERVICES. 3076 01:55:00,240 --> 01:55:04,440 PRIMARY REVIEWER WAS 3077 01:55:04,440 --> 01:55:04,760 DR. GREENSPAN. 3078 01:55:04,760 --> 01:55:06,640 IF YOU COULD SUMMARIZE FOR US. 3079 01:55:06,640 --> 01:55:09,960 >>THANK YOU, MONICA. 3080 01:55:09,960 --> 01:55:12,920 SO THE NIA HAS A RESPONSIBILITY 3081 01:55:12,920 --> 01:55:14,800 TO MANAGE CLINICAL RESEARCH 3082 01:55:14,800 --> 01:55:15,960 GRANTS AND THE RESPONSIBILITY 3083 01:55:15,960 --> 01:55:18,040 HAS BEEN INCREASING 3084 01:55:18,040 --> 01:55:18,560 EXPONENTIALLY. 3085 01:55:18,560 --> 01:55:22,120 AND A REPORT IN 2021 FOUND THERE 3086 01:55:22,120 --> 01:55:25,120 WAS BROAD SUPPORT FOR SOME KIND 3087 01:55:25,120 --> 01:55:26,600 OF CENTRALIZED CLINICAL RESEARCH 3088 01:55:26,600 --> 01:55:32,240 MANAGEMENT ACROSS THE INSTITUTE. 3089 01:55:32,240 --> 01:55:34,080 THE PROPOSAL WILL PROVIDE 3090 01:55:34,080 --> 01:55:35,640 CONTRACT TO EXPAND, CENTRALIZE 3091 01:55:35,640 --> 01:55:37,840 AND INTEGRATE ADMINISTRATIVE 3092 01:55:37,840 --> 01:55:41,000 REGULATORY, STATISTICAL SUPPORT 3093 01:55:41,000 --> 01:55:43,320 TO MANAGE NIA CLINICAL RESEARCH 3094 01:55:43,320 --> 01:55:43,560 STUDIES. 3095 01:55:43,560 --> 01:55:46,400 THIS WILL STREAMLINE THE SERVICE 3096 01:55:46,400 --> 01:55:48,880 AND ENSURE CONSISTENCY ACROSS 3097 01:55:48,880 --> 01:55:50,160 THE INSTITUTE AND MOREOVER, IT 3098 01:55:50,160 --> 01:55:54,120 WILL REDUCE THE BURDEN ON BOTH 3099 01:55:54,120 --> 01:55:57,280 THE STAFF AND ON INVESTIGATORS. 3100 01:55:57,280 --> 01:55:59,800 SO THE SPECIFIC TASKS WILL 3101 01:55:59,800 --> 01:56:04,560 INCLUDE REGULATORY OVERSIGHT AND 3102 01:56:04,560 --> 01:56:05,800 SUPPORT, FOR EXAMPLE HELP WITH 3103 01:56:05,800 --> 01:56:08,000 IDENTIFYING A DATEY SAFETY 3104 01:56:08,000 --> 01:56:09,560 MONITORING BOARD, RISK 3105 01:56:09,560 --> 01:56:11,520 ASSESSMENT, TRACKING COMPLIANCE, 3106 01:56:11,520 --> 01:56:14,160 TRACKING TRAINING FOR GOOD 3107 01:56:14,160 --> 01:56:15,800 CLINICAL PRACTICE, MAKING SURE 3108 01:56:15,800 --> 01:56:17,520 THAT THEY ARE MAINTAINING A 3109 01:56:17,520 --> 01:56:20,200 DATABASE, HELPING WITH 3110 01:56:20,200 --> 01:56:21,600 RECRUITMENT AND RETENTION, 3111 01:56:21,600 --> 01:56:23,160 REALLY TO HELP IDENTIFY BEST 3112 01:56:23,160 --> 01:56:25,160 PRACTICES AND PARTICULARLY 3113 01:56:25,160 --> 01:56:28,160 MAKING SURE THAT THEY ARE 3114 01:56:28,160 --> 01:56:30,920 ENROLLING UNDER REPRESENTED 3115 01:56:30,920 --> 01:56:32,960 POPULATIONS. 3116 01:56:32,960 --> 01:56:34,520 ASSURING A QUALITY ASSURANCE FOR 3117 01:56:34,520 --> 01:56:36,960 CLINICAL RESEARCH OPERATIONS. 3118 01:56:36,960 --> 01:56:38,240 PROVIDING STATISTICAL AND 3119 01:56:38,240 --> 01:56:41,320 METHODOLOGICAL CONSULTATIONS, 3120 01:56:41,320 --> 01:56:43,120 MAINLY FOR PROGRAM AND TRAINING 3121 01:56:43,120 --> 01:56:46,480 THE STAFF IN CLINICAL REACH 3122 01:56:46,480 --> 01:56:46,760 PROCEDURES. 3123 01:56:46,760 --> 01:56:48,840 THERE WAS A LOT OF ENTHUSIASM 3124 01:56:48,840 --> 01:56:49,120 FOR THIS. 3125 01:56:49,120 --> 01:56:52,360 THERE WAS A NEED FOR NIA TO 3126 01:56:52,360 --> 01:56:55,440 OVERSEE A WIDE RANGE OF CLINICAL 3127 01:56:55,440 --> 01:56:57,240 TRIALS THAT INCLUDE MANY 3128 01:56:57,240 --> 01:56:58,760 COMPLICATION AND -- COMPLICATED 3129 01:56:58,760 --> 01:57:00,240 AND DIVERSE POPULATIONS. 3130 01:57:00,240 --> 01:57:02,400 AND THIS IS EXPANDED WITH THE 3131 01:57:02,400 --> 01:57:06,760 INCREASE IN AD AND ADRD RESEARCH 3132 01:57:06,760 --> 01:57:07,120 CLINICAL TRIALS. 3133 01:57:07,120 --> 01:57:09,320 WE FELT THAT THIS WOULD BE A 3134 01:57:09,320 --> 01:57:13,440 GREAT BENEFIT FOR BOTH NIA AND 3135 01:57:13,440 --> 01:57:15,920 INVESTIGATORS TO SUPPORT THE 3136 01:57:15,920 --> 01:57:16,280 OVERALL PROGRAM. 3137 01:57:16,280 --> 01:57:21,000 SO THERE WAS A LOT OF ENTHUSIASM 3138 01:57:21,000 --> 01:57:21,560 FOR THIS. 3139 01:57:21,560 --> 01:57:21,880 >>GREAT. 3140 01:57:21,880 --> 01:57:23,520 THANK YOU VERY MUCH. 3141 01:57:23,520 --> 01:57:28,120 AND OUR FINAL IS NIA INFORMATION 3142 01:57:28,120 --> 01:57:29,040 RESOURCE CENTERS. 3143 01:57:29,040 --> 01:57:32,680 DR. SNYDER WAS THE PRIMARY 3144 01:57:32,680 --> 01:57:33,480 REVIEWER AND DR. HUMBLE WAS THE 3145 01:57:33,480 --> 01:57:36,000 SECONDARY REVIEWER. 3146 01:57:36,000 --> 01:57:37,320 D. SNYDER IF YOU COULD SUMMARIZE 3147 01:57:37,320 --> 01:57:41,000 THE DISCUSSION FOR US. 3148 01:57:41,000 --> 01:57:45,040 >>DR. SNYDER: THIS IS FOR THE 3149 01:57:45,040 --> 01:57:47,680 RENEWAL OF A CONTRACT WHICH IS 3150 01:57:47,680 --> 01:57:52,000 ONGOING SINCE 1990. 3151 01:57:52,000 --> 01:57:53,760 BROADLY TO THE PUBLIC, HEALTH 3152 01:57:53,760 --> 01:57:54,600 CARE PROFESSIONALS AND 3153 01:57:54,600 --> 01:57:56,120 SCIENTIFIC COMMUNITY. 3154 01:57:56,120 --> 01:57:57,840 IT PROVIDES COMMUNICATION 3155 01:57:57,840 --> 01:58:00,920 SUPPORT TO ADVANCE NIA'S 3156 01:58:00,920 --> 01:58:03,760 DISSEMINATION OF INFORMATION. 3157 01:58:03,760 --> 01:58:06,200 IT'S A SMALL ACCIDENT SET 3158 01:58:06,200 --> 01:58:07,600 ASIDE -- SMALL BUSINESS SET 3159 01:58:07,600 --> 01:58:09,920 ASIDE AND TWO INFORMATION 3160 01:58:09,920 --> 01:58:10,400 RESOURCE CENTERS. 3161 01:58:10,400 --> 01:58:15,240 THERE IS THE CONGRESSIONALLY 3162 01:58:15,240 --> 01:58:16,640 MANDATED -- WHICH IS RELATED TO 3163 01:58:16,640 --> 01:58:18,320 EDUCATIONAL REFERRALS AND THE 3164 01:58:18,320 --> 01:58:20,480 NIA INFORMATION RESOURCE CENTER. 3165 01:58:20,480 --> 01:58:22,720 SO THE CONTRACT PROVIDES PUBLIC 3166 01:58:22,720 --> 01:58:25,600 INQUIRY RESPONSE, WEBSITE 3167 01:58:25,600 --> 01:58:27,160 DESIGN, PUBLIC DEVELOPMENT -- 3168 01:58:27,160 --> 01:58:29,000 PUBLICATION DEVELOPMENT OF 3169 01:58:29,000 --> 01:58:30,720 PRINTING, WAREHOUSING EDITORIAL 3170 01:58:30,720 --> 01:58:34,520 SCIENCE WRITING, DATABASE 3171 01:58:34,520 --> 01:58:36,560 DEVELOPMENT, COMMUNICATION 3172 01:58:36,560 --> 01:58:36,800 RESEARCH. 3173 01:58:36,800 --> 01:58:39,560 SO ALSO CONFERENCE SUPPORT AND 3174 01:58:39,560 --> 01:58:40,720 OTHER COMMUNICATION SUPPORT 3175 01:58:40,720 --> 01:58:41,480 SERVICES. 3176 01:58:41,480 --> 01:58:44,480 SO IT DOES QUITE A BIT. 3177 01:58:44,480 --> 01:58:49,000 WE WERE VERY ENTHUSIASTIC ABOUT 3178 01:58:49,000 --> 01:58:52,200 RENEWING THIS CONTRACT BOTH 3179 01:58:52,200 --> 01:58:53,440 DR. HUMBLE AND MYSELF HAD A FEW 3180 01:58:53,440 --> 01:58:53,720 QUESTIONS. 3181 01:58:53,720 --> 01:58:58,880 I THINK DR. HUMBLE POSED GREAT 3182 01:58:58,880 --> 01:58:59,680 QUOS REGARDING UTILIZATION AND 3183 01:58:59,680 --> 01:59:03,280 THEY WERE ABLE TO COME BACK WITH 3184 01:59:03,280 --> 01:59:05,560 REALLY THE GREAT JOB THAT THEY 3185 01:59:05,560 --> 01:59:08,440 ARE DOING WITH REACHING OUT TO 3186 01:59:08,440 --> 01:59:10,760 PEOPLE AND MAKING THEM AWARE OF 3187 01:59:10,760 --> 01:59:13,960 WHAT IS HAPPENING IN THE 3188 01:59:13,960 --> 01:59:15,400 ALZHEIMER'S FIELD. 3189 01:59:15,400 --> 01:59:16,480 AND JUST GREAT PROGRESS WITH 3190 01:59:16,480 --> 01:59:18,120 REACHING OUT NOT ONLY TO THE 3191 01:59:18,120 --> 01:59:25,000 PUBLIC BUT ALSO TO PHYSICIANS. 3192 01:59:25,000 --> 01:59:28,800 SO, IT APPEARS THAT THAT THERE 3193 01:59:28,800 --> 01:59:30,080 REALLY ARE ON TRACK TO CONTINUE 3194 01:59:30,080 --> 01:59:33,480 GREAT WORK AND REALLY HIGHLY 3195 01:59:33,480 --> 01:59:35,720 SUPPORTIVE OF CONTINUING THE 3196 01:59:35,720 --> 01:59:37,520 SUPPORT INITIATIVE. 3197 01:59:37,520 --> 01:59:37,800 >>GREAT. 3198 01:59:37,800 --> 01:59:40,800 THANK YOU VERY MUCH VERY, VERY 3199 01:59:40,800 --> 01:59:41,000 MUCH. 3200 01:59:41,000 --> 01:59:43,880 SO, THAT CONCLUDES THE SUMMARY 3201 01:59:43,880 --> 01:59:47,600 OF THE CONCEPTS THAT WE 3202 01:59:47,600 --> 01:59:48,400 CONSIDERED YESTERDAY. 3203 01:59:48,400 --> 01:59:51,560 AT THIS POINT, I'LL ASK FOR 3204 01:59:51,560 --> 01:59:54,040 MOTION TO VOTE UNBLOCK FOR 3205 01:59:54,040 --> 01:59:55,440 APPROVAL OF THE RECOMMENDED 3206 01:59:55,440 --> 01:59:58,480 CONCEPTS WITH A VERY TINY 3207 01:59:58,480 --> 02:00:00,040 ASTERISK TO REMIND YOU THAT WE 3208 02:00:00,040 --> 02:00:03,600 ASK FOR A TRANSIENT DEFERRAL FOR 3209 02:00:03,600 --> 02:00:06,760 THE DEMENTIA CARE COORDINATION 3210 02:00:06,760 --> 02:00:08,600 PROPOSAL PENDING ADDITION OF A 3211 02:00:08,600 --> 02:00:13,280 LITTLE BIT MORE INFORMATION AND 3212 02:00:13,280 --> 02:00:13,560 REFINEMENT. 3213 02:00:13,560 --> 02:00:16,320 BUT THAT WAS THE SUMMARY OF THE 3214 02:00:16,320 --> 02:00:17,440 RECOMMENDATION THAT I WOULD LIKE 3215 02:00:17,440 --> 02:00:21,400 SOMEONE TO GO FOR THAT MOTION. 3216 02:00:21,400 --> 02:00:22,840 >>SO MOVED. 3217 02:00:22,840 --> 02:00:25,760 >>AND SO SECOND? 3218 02:00:25,760 --> 02:00:26,040 >>SECOND. 3219 02:00:26,040 --> 02:00:26,680 >>OKAY. 3220 02:00:26,680 --> 02:00:29,960 ANY -- ALL THOSE IN FAVOR? 3221 02:00:29,960 --> 02:00:30,320 >>AYE. 3222 02:00:30,320 --> 02:00:34,440 >>ANY OPPOSED? 3223 02:00:34,440 --> 02:00:37,240 NOT SEEING ANY. 3224 02:00:37,240 --> 02:00:39,880 THE COUNCIL ENTHUSIASTICALLY 3225 02:00:39,880 --> 02:00:42,920 VOTES TO MOVE THESE CONCEPTS 3226 02:00:42,920 --> 02:00:44,480 FORWARD AND THANKS PROGRAM FOR 3227 02:00:44,480 --> 02:00:45,520 ALL THEIR HARD WORK. 3228 02:00:45,520 --> 02:00:48,320 AND I THANK ALL THE MEMBERS OF 3229 02:00:48,320 --> 02:00:52,000 COUNCIL FOR THEIR VERY NICE 3230 02:00:52,000 --> 02:00:52,640 CONCISE SUMMARIES YESTERDAY AND 3231 02:00:52,640 --> 02:00:54,000 TODAY AND GREAT DISCUSSION. 3232 02:00:54,000 --> 02:00:59,000 SO THANK YOU. 3233 02:00:59,000 --> 02:01:01,040 >>THANK YOU VERY MUCH, MONICA. 3234 02:01:01,040 --> 02:01:02,840 JUST ALSO WANT TO REITERATE AND 3235 02:01:02,840 --> 02:01:03,840 SEND MY THANKS TO ALL OUR 3236 02:01:03,840 --> 02:01:09,400 COUNCIL MEMBERS FOR THEIR 3237 02:01:09,400 --> 02:01:10,640 CONCEPTS AND THE PROGRAM PEOPLE 3238 02:01:10,640 --> 02:01:12,480 FOR ALL THEIR HARD WORK PUTTING 3239 02:01:12,480 --> 02:01:13,320 INTO THESE CONCEPTS. 3240 02:01:13,320 --> 02:01:17,720 JUST TO REMIND THE PUBLIC, THESE 3241 02:01:17,720 --> 02:01:20,720 CONCEPTS WILL BE POSTED ON OUR 3242 02:01:20,720 --> 02:01:26,880 WEB PAGE AS OUTLINED AND BY 3243 02:01:26,880 --> 02:01:27,320 DR. HOEDINGS SLIDE. 3244 02:01:27,320 --> 02:01:28,960 THERE IS A LINK FOR THESE 3245 02:01:28,960 --> 02:01:30,680 CONCEPTS AND PROBABLY WITHIN THE 3246 02:01:30,680 --> 02:01:32,280 WEEK, THESE WILL BE ALL LISTED 3247 02:01:32,280 --> 02:01:40,240 ON OUR WEBSITE. 3248 02:01:40,240 --> 02:01:41,480 SO TAKE ADVANTAGE OF THE AFFECT 3249 02:01:41,480 --> 02:01:43,400 THAT THESE ARE POTENTIAL FUNDING 3250 02:01:43,400 --> 02:01:44,080 OPPORTUNITIES IN THE NEAR FUTURE 3251 02:01:44,080 --> 02:01:45,480 AND START THINKING ABOUT 3252 02:01:45,480 --> 02:01:46,480 APPLICATIONS. 3253 02:01:46,480 --> 02:01:49,040 I WANT TO THANK DR. MONICA 3254 02:01:49,040 --> 02:01:51,840 DRISCOL FOR BEING THE CHAIR OVER 3255 02:01:51,840 --> 02:01:52,960 THE PAST YEARS OF OUR WORKING 3256 02:01:52,960 --> 02:01:53,600 GROUP. 3257 02:01:53,600 --> 02:01:55,840 MONICA WAS REALLY A PLEASURE 3258 02:01:55,840 --> 02:01:58,040 WORKING WITH YOU ALL THESE 3259 02:01:58,040 --> 02:02:02,680 YEARS, ESPECIALLY THROUGH OUR 3260 02:02:02,680 --> 02:02:04,040 COVID YEARS AND BEING ON LINE 3261 02:02:04,040 --> 02:02:06,400 INSTEAD OF IN PERSON ALL THIS 3262 02:02:06,400 --> 02:02:07,240 TIME. 3263 02:02:07,240 --> 02:02:08,040 SO WE THANK YOU VERY MUCH. 3264 02:02:08,040 --> 02:02:10,480 AND WE ALSO WELCOME 3265 02:02:10,480 --> 02:02:11,080 DR. GREENSPAN AS OUR NEW CHAIR 3266 02:02:11,080 --> 02:02:14,400 OF THE WORKING GROUP. 3267 02:02:14,400 --> 02:02:15,880 >>AND THANK YOU ALL SO MUCH. 3268 02:02:15,880 --> 02:02:17,360 A COMPLETE HONOR AND PRIVILEGE 3269 02:02:17,360 --> 02:02:19,760 TO BE ABLE TO MEET ALL OF YOU 3270 02:02:19,760 --> 02:02:22,920 AND HEAR ALL OF THIS EXCITING -- 3271 02:02:22,920 --> 02:02:24,800 ALL THESE EXCITING THINGS COMING 3272 02:02:24,800 --> 02:02:26,000 UP FOR NIA. 3273 02:02:26,000 --> 02:02:28,760 IT'S FANTASTIC. 3274 02:02:28,760 --> 02:02:31,600 SO THANK YOU. 3275 02:02:31,600 --> 02:02:38,640 >>KEN, SORRY, CAN I JUST ASK -- 3276 02:02:38,640 --> 02:02:41,040 I KNOW THAT THE -- THIS 3277 02:02:41,040 --> 02:02:42,360 ATTENDANCE OF THIS MEETING WAS 3278 02:02:42,360 --> 02:02:46,720 PUT ON AN AGENDA FOR THE 3279 02:02:46,720 --> 02:02:47,760 DIRECTORS YESTERDAY. 3280 02:02:47,760 --> 02:02:49,840 AND HOPEFULLY THEY PASSED IT ON 3281 02:02:49,840 --> 02:02:53,080 TO SOME OF THEIR GRANTEES. 3282 02:02:53,080 --> 02:02:54,920 AND WHAT I GET ASKED A LOT IS, 3283 02:02:54,920 --> 02:02:56,880 SO YOU DID THESE CONCEPT 3284 02:02:56,880 --> 02:03:00,240 CLEARANCES, NOW WHAT? 3285 02:03:00,240 --> 02:03:01,360 WONDERING IF -- I KNOW YOU JUST 3286 02:03:01,360 --> 02:03:03,040 SAID THAT THESE ARE GOING TO BE 3287 02:03:03,040 --> 02:03:04,960 PUT ON THE WEBSITE AND YOU GAVE 3288 02:03:04,960 --> 02:03:07,080 THE DIRECTIONS HOW TO DO THAT. 3289 02:03:07,080 --> 02:03:10,800 AND YOU SAID, THIS IS SORT OF A 3290 02:03:10,800 --> 02:03:12,960 NOTICE TO THE RESEARCH COMMUNITY 3291 02:03:12,960 --> 02:03:14,600 ABOUT WHAT MIGHT BE OUT THERE. 3292 02:03:14,600 --> 02:03:16,200 AND SO PEOPLE MIGHT WANT TO 3293 02:03:16,200 --> 02:03:17,840 START THINKING ABOUT IT. 3294 02:03:17,840 --> 02:03:19,280 BUT, I'M WONDERING IF YOU COULD 3295 02:03:19,280 --> 02:03:25,520 GIVE A LITTLE MORE DETAIL. 3296 02:03:25,520 --> 02:03:28,440 SHOULD RESEARCHERS POTENTIALLY 3297 02:03:28,440 --> 02:03:30,440 TALK WITH PROGRAM OFFICERS ABOUT 3298 02:03:30,440 --> 02:03:30,680 IT? 3299 02:03:30,680 --> 02:03:32,600 LIKE MAYBE YOU CAN EXPAND A 3300 02:03:32,600 --> 02:03:36,440 LITTLE BIT ON WHAT IT MEANS FOR 3301 02:03:36,440 --> 02:03:37,720 CONCEPT CLEARANCE TO BE OUT 3302 02:03:37,720 --> 02:03:39,040 THERE AND WHAT RESEARCHERS MIGHT 3303 02:03:39,040 --> 02:03:42,880 DO TO PREPARE. 3304 02:03:42,880 --> 02:03:43,160 >>OKAY. 3305 02:03:43,160 --> 02:03:43,600 GREAT QUESTION, JEN. 3306 02:03:43,600 --> 02:03:46,800 HAPPY TO ADDRESS THAT. 3307 02:03:46,800 --> 02:03:49,080 SO NOW THAT THESE CONCEPTS HAVE 3308 02:03:49,080 --> 02:03:51,240 BEEN APPROVED, THEY ARE IN THE 3309 02:03:51,240 --> 02:03:54,880 PUBLIC DOMAIN TOO, AND WE 3310 02:03:54,880 --> 02:03:56,720 ENCOURAGE EVERYONE TO START 3311 02:03:56,720 --> 02:03:58,280 DISSEMINATING THIS INFORMATION 3312 02:03:58,280 --> 02:04:00,400 TO EVERYONE AND START THINKING 3313 02:04:00,400 --> 02:04:03,240 ABOUT POTENTIAL PROJECTS AND 3314 02:04:03,240 --> 02:04:05,320 BUILDING TEAMS, ET CETERA. 3315 02:04:05,320 --> 02:04:07,240 BUT YES, PLEASE ON THE WEBSITE, 3316 02:04:07,240 --> 02:04:11,160 EACH OF THESE CONCEPTS WILL HAVE 3317 02:04:11,160 --> 02:04:12,120 THE PROGRAM OFFICER WHO IS IN 3318 02:04:12,120 --> 02:04:15,760 CHARGE OF EACH OF THESE CONCEPTS 3319 02:04:15,760 --> 02:04:19,000 LINKED TO EACH OF THE CONCEPTS. 3320 02:04:19,000 --> 02:04:20,120 SO YOU ABSOLUTELY CAN GET IN 3321 02:04:20,120 --> 02:04:21,800 TOUCH WITH THEM, START 3322 02:04:21,800 --> 02:04:27,400 DISCUSSING YOUR IDEAS, ET CET 3323 02:04:27,400 --> 02:04:27,920 ET CETERA. 3324 02:04:27,920 --> 02:04:29,400 HOWEVER, ONE OF THE CAVEATS IS, 3325 02:04:29,400 --> 02:04:31,280 THERE IS REALLY NO GUARANTEE 3326 02:04:31,280 --> 02:04:34,400 THAT A FUNDING OPPORTUNITY WILL 3327 02:04:34,400 --> 02:04:36,520 BE GENERATED FROM THESE 3328 02:04:36,520 --> 02:04:37,000 CONCEPTS. 3329 02:04:37,000 --> 02:04:42,000 IT REALLY DOES DEPEND ON OUR 3330 02:04:42,000 --> 02:04:45,240 FISCAL SITUATION THROUGHOUT THE 3331 02:04:45,240 --> 02:04:46,000 YEAR. 3332 02:04:46,000 --> 02:04:47,480 WE NEVER KNOW. 3333 02:04:47,480 --> 02:04:48,560 DIFFERENT PRIORITIES MAYBE COME 3334 02:04:48,560 --> 02:04:48,720 IN. 3335 02:04:48,720 --> 02:04:50,600 WE MIGHT HAVE TO SHIFT FOCUSES, 3336 02:04:50,600 --> 02:04:51,000 ET CETERA. 3337 02:04:51,000 --> 02:04:53,200 SO THERE ARE POTENTIALS. 3338 02:04:53,200 --> 02:04:55,520 BUT, YOU KNOW, THERE IS A VERY 3339 02:04:55,520 --> 02:04:58,440 HIGH LIKELIHOOD THAT THESE WILL 3340 02:04:58,440 --> 02:05:00,560 BE TURNED INTO FUNDING 3341 02:05:00,560 --> 02:05:02,640 OPPORTUNITIES AS WITH HISTORICAL 3342 02:05:02,640 --> 02:05:05,520 KNOWLEDGE OF OUR PAST PRACTICES, 3343 02:05:05,520 --> 02:05:07,440 ALL THE CONCEPTS HAVE BEEN IN 3344 02:05:07,440 --> 02:05:10,200 THE PAST TURNED INTO FUNDING 3345 02:05:10,200 --> 02:05:10,720 OPPORTUNITY ANNOUNCEMENTS. 3346 02:05:10,720 --> 02:05:12,000 UNLESS THERE HAVE BEEN ISSUES 3347 02:05:12,000 --> 02:05:13,680 WITH COUNCIL AND WE DECIDED NOT 3348 02:05:13,680 --> 02:05:16,760 TO MOVE THEM FORWARD. 3349 02:05:16,760 --> 02:05:18,720 SO, YES, PLEASE GET IN CONTACT 3350 02:05:18,720 --> 02:05:21,160 WITH THE PROGRAM OFFICERS. 3351 02:05:21,160 --> 02:05:25,400 YES, DEFINITELY START THINKING 3352 02:05:25,400 --> 02:05:28,400 ABOUT THE POTENTIAL IDEAS FOR 3353 02:05:28,400 --> 02:05:29,680 APPLICATIONS IN THE FUTURE AND 3354 02:05:29,680 --> 02:05:37,560 KEEP THAT CONVERSATION GOING. 3355 02:05:37,560 --> 02:05:37,840 ALL RIGHT. 3356 02:05:37,840 --> 02:05:40,000 WE HAD TWO SPEAKERS COMING UP 3357 02:05:40,000 --> 02:05:40,920 NEXT. 3358 02:05:40,920 --> 02:05:42,920 BUT I WOULD LIKE TO GIVE OUR 3359 02:05:42,920 --> 02:05:45,840 COUNCIL, EVERYONE A 5-MINUTE 3360 02:05:45,840 --> 02:05:48,800 BREAK AT THIS POINT, TO JUST TO 3361 02:05:48,800 --> 02:05:51,600 HAVE A SHORT BREAK BEFORE WE 3362 02:05:51,600 --> 02:05:53,960 START OUR TWO SPEAKERS. 3363 02:05:53,960 --> 02:05:56,080 SO IF EVERYONE COULD JUST MUTE 3364 02:05:56,080 --> 02:05:58,120 AND STOP THEIR VIDEO, WE'LL TAKE 3365 02:05:58,120 --> 02:06:01,760 A 5-MINUTE BREAK AND BE BACK TO 3366 02:06:01,760 --> 02:06:02,200 HEAR OUR FIRST SPEAKER WHO IS 3367 02:06:02,200 --> 02:06:16,360 DR. ERIC ORWOLL. 3368 02:06:16,360 --> 02:06:18,080 >>GOOD AFTERNOON, EVERYONE. 3369 02:06:18,080 --> 02:06:19,680 IT'S MY GREAT PLEASURE TO 3370 02:06:19,680 --> 02:06:22,880 INTRODUCE DR. ERIC ORWOLL, HE IS 3371 02:06:22,880 --> 02:06:23,960 PROFESSOR OF MEDICINE IN THE 3372 02:06:23,960 --> 02:06:26,520 DIVISION OF ENDOCRINOLOGY 3373 02:06:26,520 --> 02:06:28,360 DIABETES AND CLINICAL NUTRITION 3374 02:06:28,360 --> 02:06:30,360 AT OREGON HEALTH AND SCIENCE 3375 02:06:30,360 --> 02:06:30,760 UNIVERSITY. 3376 02:06:30,760 --> 02:06:32,640 HE IS AN INTERNATIONALLY 3377 02:06:32,640 --> 02:06:35,800 RECOGNIZED EXPERT IN THE AREA OF 3378 02:06:35,800 --> 02:06:38,080 AGE-RELATED CHANGES AND 3379 02:06:38,080 --> 02:06:39,480 MUSCULOSKELETAL HEALTH INCLUDING 3380 02:06:39,480 --> 02:06:41,200 SARKO PENIA. 3381 02:06:41,200 --> 02:06:42,600 DR. ERIC ORWOLL HAS BEEN THE PI 3382 02:06:42,600 --> 02:06:44,120 OF MANY NIH-SUPPORTED STUDIES 3383 02:06:44,120 --> 02:06:45,960 AND SO TODAY, WE ARE GOING TO 3384 02:06:45,960 --> 02:06:48,800 HEAR ABOUT THE WIDE RANGING 3385 02:06:48,800 --> 02:06:52,320 IMPACT OF THE STUDY OF 3386 02:06:52,320 --> 02:06:54,160 OSTEOPRIORITYIC FRACTURES IN MEN 3387 02:06:54,160 --> 02:06:56,520 STUDY OR Mr. OS ON AGING 3388 02:06:56,520 --> 02:06:57,320 RESEARCH. 3389 02:06:57,320 --> 02:06:59,520 INITIATED IN 1999 AND LED BY 3390 02:06:59,520 --> 02:07:03,080 DR. ERIC ORWOLL, Mr. OS WAS 3391 02:07:03,080 --> 02:07:04,400 ONE OF THE FIRST PROSPECTIVE 3392 02:07:04,400 --> 02:07:07,120 STUDY OF RISK FACTORS IN OLDER 3393 02:07:07,120 --> 02:07:09,840 MEN AND AS THE COHORT 3394 02:07:09,840 --> 02:07:14,920 TRANSITIONED TO OLDER AGES, ITS 3395 02:07:14,920 --> 02:07:15,720 AIMS EXPANDED TO ADDRESS 3396 02:07:15,720 --> 02:07:16,320 IMPORTANT GERIATRIC OUTCOMES 3397 02:07:16,320 --> 02:07:18,200 SUCH AS SLEEP, FALLS, PHYSICAL 3398 02:07:18,200 --> 02:07:20,720 PERFORMANCE AND FUNCTIONAL 3399 02:07:20,720 --> 02:07:20,960 DECLINE. 3400 02:07:20,960 --> 02:07:23,920 MORE RECENTLY, THE WEALTH OF 3401 02:07:23,920 --> 02:07:26,080 EXISTING LONGITUDINAL TYPIC DATA 3402 02:07:26,080 --> 02:07:29,400 FROM THE COHORT, THE GWAS DATA 3403 02:07:29,400 --> 02:07:30,920 AND BIOSPECIMEN COLLECTION HAVE 3404 02:07:30,920 --> 02:07:34,160 BEEN LEVERAGED FOR STUDIES OF 3405 02:07:34,160 --> 02:07:36,320 EXCEPTIONAL LONGEVITY AND HEALTH 3406 02:07:36,320 --> 02:07:36,640 SPAN. 3407 02:07:36,640 --> 02:07:38,440 I'D LIKE TO THANK DR. ERIC 3408 02:07:38,440 --> 02:07:41,840 ORWOLL FOR JOINING US TODAY AND 3409 02:07:41,840 --> 02:07:43,760 THE TITLE OF HIS TALK IS 3410 02:07:43,760 --> 02:07:45,720 Mr. OS, A 20+ YEAR STUDY OF 3411 02:07:45,720 --> 02:07:48,760 AGING IN OLDER MEN. 3412 02:07:48,760 --> 02:07:48,960 ERIC? 3413 02:07:48,960 --> 02:07:49,920 >>ERIC ORWOLL: THANK YOU VERY 3414 02:07:49,920 --> 02:07:50,440 MUCH. 3415 02:07:50,440 --> 02:07:54,520 LET ME SEE IF I CAN SHARE MY 3416 02:07:54,520 --> 02:08:04,680 SCREEN. 3417 02:08:14,760 --> 02:08:17,240 SO PROGRAM ASKED THAT I REVIEW 3418 02:08:17,240 --> 02:08:19,080 SOME OF THE PROGRESS MADE WITH 3419 02:08:19,080 --> 02:08:22,560 Mr. OS, WHICH IS A 3420 02:08:22,560 --> 02:08:23,960 LONGITUDINAL STUDY OF AGING IN 3421 02:08:23,960 --> 02:08:25,240 OLDER MEN. 3422 02:08:25,240 --> 02:08:27,120 I'D START WITH THE BASIC STUDY 3423 02:08:27,120 --> 02:08:28,040 DESIGN, HIGHLIGHT SOME OF THE 3424 02:08:28,040 --> 02:08:30,280 PROGRESS MADE OVER THE COURSE OF 3425 02:08:30,280 --> 02:08:33,520 THE STUDY AND FINISH WITH SOME 3426 02:08:33,520 --> 02:08:35,360 RECENT FINDINGS IN SEVERAL 3427 02:08:35,360 --> 02:08:38,680 AREAS, INCLUDING SARK PENIA AND 3428 02:08:38,680 --> 02:08:41,760 PROTEOMICS AND BIKE ROW BIOME. 3429 02:08:41,760 --> 02:08:43,960 Mr. OS WAS DESIGNED PRIMARILY 3430 02:08:43,960 --> 02:08:47,480 TO UNDERSTAND MUSCULOSKELETAL 3431 02:08:47,480 --> 02:08:48,840 AGING, OSTEOPOROSIS AND FRACTURE 3432 02:08:48,840 --> 02:08:51,280 BUT COVERED BROAD AREAS OF AGING 3433 02:08:51,280 --> 02:08:51,960 AS WELL. 3434 02:08:51,960 --> 02:08:54,400 IT STARTED WITH THE RECRUITMENT 3435 02:08:54,400 --> 02:08:58,240 OF ABOUT 6000 MEN OVER THE AGE 3436 02:08:58,240 --> 02:08:59,880 OF 65 AT SIX CLINICAL SITES 3437 02:08:59,880 --> 02:09:01,000 ACROSS THE U.S. 3438 02:09:01,000 --> 02:09:03,600 THE MEAN AGE AT BASELINE WAS 74 3439 02:09:03,600 --> 02:09:06,000 YEARS WITH A WIDE RANGE. 3440 02:09:06,000 --> 02:09:08,080 THERE WERE FEW EXCLUSION 3441 02:09:08,080 --> 02:09:11,600 CRITERIA SO THE COHORT IS FAIRLY 3442 02:09:11,600 --> 02:09:12,200 REPRESENTATIVE OF MEN AT THAT 3443 02:09:12,200 --> 02:09:13,680 AGE, ALTHOUGH SOMEWHAT MORE 3444 02:09:13,680 --> 02:09:17,080 HEALTHY THAN RANDOMLY SELECTED 3445 02:09:17,080 --> 02:09:19,280 COHORTS LIKE NHANES. 3446 02:09:19,280 --> 02:09:23,560 AT BASELINE, MEN WERE PHENOTYPED 3447 02:09:23,560 --> 02:09:27,000 WITH EMPHASIS ON MUSCULOSKELETAL 3448 02:09:27,000 --> 02:09:30,880 TRAITS AND SERUM, URINE, DNA AND 3449 02:09:30,880 --> 02:09:34,680 IMAGE LIBRARY. 3450 02:09:34,680 --> 02:09:36,320 PARTICIPANTS HAVE BEEN FOLLOWED 3451 02:09:36,320 --> 02:09:39,160 REGULARLY WITH QUESTIONNAIRES 3452 02:09:39,160 --> 02:09:41,720 EVERY FOUR MONTHS AND REGULAR 3453 02:09:41,720 --> 02:09:43,840 IN-CLINIC EVALUATIONS WHERE 3454 02:09:43,840 --> 02:09:48,080 ADDITIONAL PHENOTYPING AND 3455 02:09:48,080 --> 02:09:50,760 SPECIMEN COLLECTION. 3456 02:09:50,760 --> 02:09:54,280 RETENTION HAS BEEN OUTSTANDING 3457 02:09:54,280 --> 02:09:55,840 WITH CONTENT MAINTAINED WITH 3458 02:09:55,840 --> 02:09:58,000 GREATER THAN 95% OF SURVIVORS 3459 02:09:58,000 --> 02:10:03,160 AND Mr. OS WAS EXPANDED EARLY 3460 02:10:03,160 --> 02:10:07,600 ON TO INCLUDE 3000 MEN IN SWEDEN 3461 02:10:07,600 --> 02:10:10,880 AND 2000 MEN IN HONG KONG. 3462 02:10:10,880 --> 02:10:14,800 OVER THE YEARS, Mr. OS HAS 3463 02:10:14,800 --> 02:10:15,280 BEEN VERY PRODUCTIVE. 3464 02:10:15,280 --> 02:10:17,320 MANY, MANY INVESTIGATORS HAVE 3465 02:10:17,320 --> 02:10:18,120 BEEN INVOLVED. 3466 02:10:18,120 --> 02:10:22,040 MORE THAN 1000 ANALYSIS PLANS 3467 02:10:22,040 --> 02:10:22,440 HAVE BEEN ENACTED. 3468 02:10:22,440 --> 02:10:23,840 500 PEER-REVIEWED PUP 3469 02:10:23,840 --> 02:10:26,440 INDICATIONS HAVE RESULTED AND AT 3470 02:10:26,440 --> 02:10:29,200 PRESENT, THERE HAVE BEEN 89 3471 02:10:29,200 --> 02:10:30,560 INDEPENDENTLY-FUNDED ANCILLARY 3472 02:10:30,560 --> 02:10:33,000 STUDIES IN ADDITION TO THE NIH 3473 02:10:33,000 --> 02:10:35,720 SUPPORT FOR THE PARENT STUDY. 3474 02:10:35,720 --> 02:10:38,080 OF COURSE THE COHORT HAS AGED 3475 02:10:38,080 --> 02:10:40,880 OVER THE 20 YEARS OF FOLLOW-UP 3476 02:10:40,880 --> 02:10:42,920 SO THE MEAN AGE OF SURVIVORS ON 3477 02:10:42,920 --> 02:10:45,960 THE LEFT IS NOW MORE THAN 90 AND 3478 02:10:45,960 --> 02:10:47,920 ON THE RIGHT, MORE THAN 80% OF 3479 02:10:47,920 --> 02:10:50,880 THE PARTICIPANTS HAVE DIED THUS 3480 02:10:50,880 --> 02:10:53,800 Mr. OS NOW IS A COHORT OF A 3481 02:10:53,800 --> 02:10:56,120 BIT LESS THAN 1000 VERY ELDERLY 3482 02:10:56,120 --> 02:11:00,280 MEN, WHICH CONTINUES TO OFFER 3483 02:11:00,280 --> 02:11:00,920 UNIQUE ONGOING RESEARCH 3484 02:11:00,920 --> 02:11:01,240 OPPORTUNITIES. 3485 02:11:01,240 --> 02:11:02,520 WE ARE JUST IN THE MIDDLE OF THE 3486 02:11:02,520 --> 02:11:07,840 LATEST CYCLE OF NIA FUNDING. 3487 02:11:07,840 --> 02:11:09,640 Mr. OS CONTRIBUTED TO A 3488 02:11:09,640 --> 02:11:12,120 VARIETY OF ISSUES RELATED TO 3489 02:11:12,120 --> 02:11:12,600 AGING. 3490 02:11:12,600 --> 02:11:14,040 IT'S BEEN A MAJOR SOURCE OF 3491 02:11:14,040 --> 02:11:16,720 KNOWLEDGE ABOUT MUSCULOSKELETAL 3492 02:11:16,720 --> 02:11:20,880 AGING LIKE OST YORE PROSIS AND 3493 02:11:20,880 --> 02:11:21,160 SARCOPENIA. 3494 02:11:21,160 --> 02:11:24,920 BUT ALSO ACTIVE IN A NUMBER OF 3495 02:11:24,920 --> 02:11:26,760 OTHER AREAS AS ARE LISTED. 3496 02:11:26,760 --> 02:11:28,880 ON THE RIGHT ARE SHOWING SOME OF 3497 02:11:28,880 --> 02:11:32,040 THE PARADIGM CHANGING WORK WHICH 3498 02:11:32,040 --> 02:11:34,960 Mr. OS HAS BEEN A MAJOR 3499 02:11:34,960 --> 02:11:36,960 FACTOR. 3500 02:11:36,960 --> 02:11:38,400 A UNIQUE CONTRIBUTION OF 3501 02:11:38,400 --> 02:11:39,200 Mr. OS IS THE COLLABORATION 3502 02:11:39,200 --> 02:11:43,400 WITH THE STUDY OF OSTEOFRACTURES 3503 02:11:43,400 --> 02:11:46,400 WHICH IS A SIMILAR NIA-FUNDED 3504 02:11:46,400 --> 02:11:50,000 STUDY OF ABOUT 9000 WOMEN OF THE 3505 02:11:50,000 --> 02:11:53,520 SAME AGE RANGE AS Mr. OS. 3506 02:11:53,520 --> 02:11:54,640 INTENTION ALLEY, Mr. OS WAS 3507 02:11:54,640 --> 02:11:57,040 DESIGNED TO INCLUDE PHENOTYPIC 3508 02:11:57,040 --> 02:11:59,800 MEASURES THAT WERE IN MOST CASES 3509 02:11:59,800 --> 02:12:03,600 IDENTICAL TO THOSE IN THE SOF, 3510 02:12:03,600 --> 02:12:05,960 ENABLING A VARIETY OF SEX 3511 02:12:05,960 --> 02:12:06,240 COMPARISONS. 3512 02:12:06,240 --> 02:12:09,240 FOR INSTANCE HERE ON THE LEFT, 3513 02:12:09,240 --> 02:12:12,240 COMBINED ANALYSIS OF Mr. OS 3514 02:12:12,240 --> 02:12:14,160 AND SOF REVEALED THAT BOTH LOW 3515 02:12:14,160 --> 02:12:16,600 TRAUMA AND HIGH TRAUMA FRACTURES 3516 02:12:16,600 --> 02:12:17,560 HAVE THE SAME RELATIONSHIP TO 3517 02:12:17,560 --> 02:12:19,960 LOW BONE MINERAL DENSITY. 3518 02:12:19,960 --> 02:12:22,480 FINDING THAT SOME FUNDAMENTALLY 3519 02:12:22,480 --> 02:12:25,000 CHANGED HOW WE CONSIDER 3520 02:12:25,000 --> 02:12:27,320 FRACTURES IN OLDER PEOPLE BOTH 3521 02:12:27,320 --> 02:12:29,560 CLINICALLY AND IN RESEARCH 3522 02:12:29,560 --> 02:12:29,840 SETTINGS. 3523 02:12:29,840 --> 02:12:33,000 ON THE RIGHT, A SIMILAR ANALYSIS 3524 02:12:33,000 --> 02:12:33,320 IN SO. 3525 02:12:33,320 --> 02:12:36,200 AND Mr. OS SHOWS THAT 3526 02:12:36,200 --> 02:12:37,320 FRACTURES IN OLDER MEN ARE MUCH 3527 02:12:37,320 --> 02:12:39,480 MORE LIKELY TO BE RELATED TO 3528 02:12:39,480 --> 02:12:42,600 HIGH ACTIVITY AND TRAUMA 3529 02:12:42,600 --> 02:12:45,760 COMPARED TO WOMEN, FINDING WHICH 3530 02:12:45,760 --> 02:12:46,680 INFLUENCES IMPORTANT PUBLIC 3531 02:12:46,680 --> 02:12:51,400 HEALTH PREVENTIVE STRATEGIES. 3532 02:12:51,400 --> 02:12:54,720 Mr. OS HAS BEEN THE PLATFORM 3533 02:12:54,720 --> 02:12:55,400 FOR THE DEVELOPMENT OF IMPORTANT 3534 02:12:55,400 --> 02:12:58,320 NEW METHODS FOR EVALUATING 3535 02:12:58,320 --> 02:12:59,480 MUSCULOSKELETAL HEALTH. 3536 02:12:59,480 --> 02:13:01,880 ONE EXAMPLE IS THE USE OF 3537 02:13:01,880 --> 02:13:04,960 CENTRAL QCT IN FINITE ELEMENT 3538 02:13:04,960 --> 02:13:07,920 ANALYSIS OF BIOMECHANICAL BONE 3539 02:13:07,920 --> 02:13:10,760 STRENGTH AS AN ASSESSMENT OF 3540 02:13:10,760 --> 02:13:12,280 FRACTURE RISK. 3541 02:13:12,280 --> 02:13:14,520 ANOTHER MORE RECENT DEVELOPMENT 3542 02:13:14,520 --> 02:13:19,600 IS NOVEL WAY TO MEASURE MUSCLE 3543 02:13:19,600 --> 02:13:20,240 MASS. 3544 02:13:20,240 --> 02:13:22,640 THE SUMMARY OF THOSE RESULTS ARE 3545 02:13:22,640 --> 02:13:24,600 SHOWN HERE. 3546 02:13:24,600 --> 02:13:26,520 BASICALLY, MUSCLE MASS MOST 3547 02:13:26,520 --> 02:13:29,760 OFTEN HAVE BEEN ESTIMATED BY 3548 02:13:29,760 --> 02:13:32,000 USING DEXABASED MEASURES OF LIEN 3549 02:13:32,000 --> 02:13:35,720 MASS, AN APPROACH THAT IS 3550 02:13:35,720 --> 02:13:37,400 FUNDAMENTALLY FLAWED BECAUSE 3551 02:13:37,400 --> 02:13:38,960 LIEN MASS IS MADE UP OF A 3552 02:13:38,960 --> 02:13:42,600 VARIETY OF TISSUES OTHER THAN 3553 02:13:42,600 --> 02:13:42,840 MUSCLE. 3554 02:13:42,840 --> 02:13:46,120 TO REMEDY THIS, BILL EVANS AND 3555 02:13:46,120 --> 02:13:47,440 MARK HELLERSTEIN AT BERKLEY TOOK 3556 02:13:47,440 --> 02:13:51,480 ADVANTAGE OF THE FACT THAT 3557 02:13:51,480 --> 02:13:53,080 CREATINE IS VIRTUALLY ENTIRELY 3558 02:13:53,080 --> 02:13:55,080 LOCALIZED IN CONTRACT ON MUSCLE 3559 02:13:55,080 --> 02:13:58,760 AND DEVELOPED AN APPROACH THAT 3560 02:13:58,760 --> 02:14:02,200 USES D3 CREATINE TO MEASURE THE 3561 02:14:02,200 --> 02:14:05,080 CREATINE POOL AND ENHANCE 3562 02:14:05,080 --> 02:14:09,200 ACCURATE LEMUSEL MASS IN-VIVO. 3563 02:14:09,200 --> 02:14:11,120 AND THIS TECHNIQUE WAS APPLIED 3564 02:14:11,120 --> 02:14:14,160 INITIALLY ON A LARGE-SCALE IN 3565 02:14:14,160 --> 02:14:15,960 Mr. OS AND WE USED IT TO 3566 02:14:15,960 --> 02:14:17,160 INVESTIGATE A VARIETY OF 3567 02:14:17,160 --> 02:14:17,680 QUESTIONS. 3568 02:14:17,680 --> 02:14:20,880 AND THE UPPER MIDDLE PANEL, I 3569 02:14:20,880 --> 02:14:25,400 HAVE ILLUSTRATED HOW D3 CREATINE 3570 02:14:25,400 --> 02:14:28,640 MUSCLE MASS AND DEXAMEASURES 3571 02:14:28,640 --> 02:14:32,920 COMPARE AS A PERCENT OF BODY 3572 02:14:32,920 --> 02:14:35,600 WEIGHT IN ABOUT 1400 Mr. OS 3573 02:14:35,600 --> 02:14:35,960 MEN. 3574 02:14:35,960 --> 02:14:41,880 MUSCLE MASS BY D3 CREATINE IS IN 3575 02:14:41,880 --> 02:14:44,280 DARK BLUE WITH MEN ARRAYED 3576 02:14:44,280 --> 02:14:45,560 ACROSS THE AXIS HERE, HIGH 3577 02:14:45,560 --> 02:14:48,240 MUSCLE MASS ON THE LEFT, LOWER 3578 02:14:48,240 --> 02:14:52,400 MUSCLE MASS ON THE RIGHT. 3579 02:14:52,400 --> 02:14:54,120 DEXAMESS BASED MEASURES ARE 3580 02:14:54,120 --> 02:14:56,440 SHOWN, INCLUDING BONE MASS IN 3581 02:14:56,440 --> 02:14:59,320 BLACK AT THE TOP, FAT MASS AND 3582 02:14:59,320 --> 02:15:02,200 TOTAL LEAN MASS. 3583 02:15:02,200 --> 02:15:04,720 OBVIOUSLY D3 CREATINE MUSCLE 3584 02:15:04,720 --> 02:15:06,200 MASS IS VERY DIFFERENT THAN 3585 02:15:06,200 --> 02:15:08,920 TOTAL LEAN MASS AND POORLY 3586 02:15:08,920 --> 02:15:11,240 CORRELATED WITH IT. 3587 02:15:11,240 --> 02:15:14,280 AND SHOWN IN THE YELLOW DOTS AND 3588 02:15:14,280 --> 02:15:16,800 IN THE SCATTER PLOT IN THE UPPER 3589 02:15:16,800 --> 02:15:20,680 RIGHT, IS SHOWN THAT D3 CREATINE 3590 02:15:20,680 --> 02:15:23,600 MUSCLE MASS IN LEAN MASS ARE NOT 3591 02:15:23,600 --> 02:15:23,920 CORRELATED. 3592 02:15:23,920 --> 02:15:25,360 BASICALLY THEY ARE QUITE 3593 02:15:25,360 --> 02:15:26,400 DIFFERENT MEASURES. 3594 02:15:26,400 --> 02:15:29,800 IN THE BOTTOM GRAPHS, ARE THE 3595 02:15:29,800 --> 02:15:31,880 RELATIONSHIP OF WALKING SPEED 3596 02:15:31,880 --> 02:15:36,280 AND LOWER EXTREMITY POWER TO 3597 02:15:36,280 --> 02:15:37,840 QUARTILES OF D3 CREATINE MUSCLE 3598 02:15:37,840 --> 02:15:41,480 MASS IN THE OPEN BARS. 3599 02:15:41,480 --> 02:15:43,360 AND QUARTILES OF LEAN MASS IN 3600 02:15:43,360 --> 02:15:46,320 THE GRAY BARS. 3601 02:15:46,320 --> 02:15:47,520 CLEARLY A MEASURE -- THESE 3602 02:15:47,520 --> 02:15:48,720 MEASURES OF PHYSICAL FUNCTION 3603 02:15:48,720 --> 02:15:52,040 ARE MUCH MORE RELATED TO D3 3604 02:15:52,040 --> 02:15:54,480 CREATINE MUSCLE MASS THANG TO 3605 02:15:54,480 --> 02:15:54,760 LEAN MASS. 3606 02:15:54,760 --> 02:15:56,560 WE HAVE SHOWN THERE IS SIMILAR 3607 02:15:56,560 --> 02:15:59,240 RELATIONSHIPS THAT D3 CREATINE 3608 02:15:59,240 --> 02:16:02,800 MUSCLE MASS WITH FRACTURES, 3609 02:16:02,800 --> 02:16:05,000 DISABILITY, FRAILTY AND 3610 02:16:05,000 --> 02:16:05,320 MORTALITY ED. 3611 02:16:05,320 --> 02:16:06,240 BASICALLY THESE MEASURES OF 3612 02:16:06,240 --> 02:16:08,120 MUSCLE MASS HAVE VERY MUCH 3613 02:16:08,120 --> 02:16:13,040 CHANGED THE FIELD OF SARCOPENIA 3614 02:16:13,040 --> 02:16:14,600 RESEARCH. 3615 02:16:14,600 --> 02:16:15,760 D3 CREATINE MEASURES HAVE ALSO 3616 02:16:15,760 --> 02:16:18,280 ALLOWED US TO RECONSIDER THE 3617 02:16:18,280 --> 02:16:20,720 CONCEPT OF MUSCLE QUALITY. 3618 02:16:20,720 --> 02:16:22,840 IT'S LONG BEEN KNOWN THAT MUSCLE 3619 02:16:22,840 --> 02:16:25,640 PERFORMANCE DECLINES WITH AGE. 3620 02:16:25,640 --> 02:16:26,960 IN THE ABSENCE OF MAJOR CHANGES 3621 02:16:26,960 --> 02:16:28,960 IN LEAN MASS, A FINDING THAT HAS 3622 02:16:28,960 --> 02:16:30,640 BEEN INTERPRETED AS EVIDENCE 3623 02:16:30,640 --> 02:16:34,400 THAT MUSCLE QUALITY DECLINES 3624 02:16:34,400 --> 02:16:37,320 INDEPENDENT OF MUSCLE MASS. 3625 02:16:37,320 --> 02:16:39,800 HOWEVER, WHEREAS MEASURES OF 3626 02:16:39,800 --> 02:16:41,240 LEAN MASS CHANGE LITTLE OVER 3627 02:16:41,240 --> 02:16:43,640 TIME IN Mr. OS, AS IS SHOWN BY 3628 02:16:43,640 --> 02:16:49,400 THE LEFT HAND BARS ON THE GRAPH, 3629 02:16:49,400 --> 02:16:51,080 D3 CREATINE MUSCLE MASS IN THE 3630 02:16:51,080 --> 02:16:53,600 MIDDLE BARS DECLINES QUICKLY AND 3631 02:16:53,600 --> 02:16:56,560 IN PROPORTION TO THE DECLINES IN 3632 02:16:56,560 --> 02:17:00,200 PERFORMANCE MEASURES, WALKING 3633 02:17:00,200 --> 02:17:03,720 SPEED IN THE RIGHT BARS. 3634 02:17:03,720 --> 02:17:04,240 THUS CONTRARY TO PREVIOUS 3635 02:17:04,240 --> 02:17:05,920 BELIEF, THIS FINDING SUGGESTS 3636 02:17:05,920 --> 02:17:07,480 THE PRIMARY IMPORTANCE OF CHANGE 3637 02:17:07,480 --> 02:17:09,600 IN MUSCLE MASS IN DETERMINING 3638 02:17:09,600 --> 02:17:11,280 THE DECLINE IN PHYSICAL 3639 02:17:11,280 --> 02:17:14,120 PERFORMANCE WITH AGE. 3640 02:17:14,120 --> 02:17:15,880 THIS DOESN'T MEAN THAT MUSCLE 3641 02:17:15,880 --> 02:17:16,800 QUALITY ISN'T IMPORTANT. 3642 02:17:16,800 --> 02:17:19,840 AND THE AVAILABILITY OF ACCURATE 3643 02:17:19,840 --> 02:17:23,280 MUSCLE MASS MEASUREMENTS WITH D3 3644 02:17:23,280 --> 02:17:24,640 CREATINE ALLOWS US TO MORE 3645 02:17:24,640 --> 02:17:26,120 EFFECTIVELY CALIBRATE THE 3646 02:17:26,120 --> 02:17:28,320 CONTRIBUTIONS OF MUSCLE MASS 3647 02:17:28,320 --> 02:17:28,800 VERSUS QUALITY. 3648 02:17:28,800 --> 02:17:30,520 FOR INSTANCE, ON THE RIGHT, IS 3649 02:17:30,520 --> 02:17:33,360 SHOWN THE PERCENT OF Mr. OS 3650 02:17:33,360 --> 02:17:36,560 MEN WITH ABNORMAL WALKING SPEED 3651 02:17:36,560 --> 02:17:38,200 ON THE Y AXIS. 3652 02:17:38,200 --> 02:17:41,560 AS A FUNCTION OF QUARTILES OF 3653 02:17:41,560 --> 02:17:44,200 BOTH D3, CREATINE MUSSEL MASS ON 3654 02:17:44,200 --> 02:17:46,400 THE RIGHT. 3655 02:17:46,400 --> 02:17:49,960 AND TO THE MUSCLE DENSITY BY CT 3656 02:17:49,960 --> 02:17:53,520 ON THE BOTTOM. 3657 02:17:53,520 --> 02:17:59,160 LOW MUSCLE DENSITY BY QCT IS A 3658 02:17:59,160 --> 02:18:02,320 REFLECTION OF MUSCLE FAT 3659 02:18:02,320 --> 02:18:04,520 ACCUMULATION WHICH IS IT LINKED 3660 02:18:04,520 --> 02:18:06,240 TO MUSCLE QUALITY AND 3661 02:18:06,240 --> 02:18:06,600 PERFORMANCE. 3662 02:18:06,600 --> 02:18:08,440 HERE, ITS CLEAR THAT THE MEN 3663 02:18:08,440 --> 02:18:13,680 WITH THE LOWEST MUSCLE MASS AND 3664 02:18:13,680 --> 02:18:14,360 THE LOWEST US MUSCLE DENSITY 3665 02:18:14,360 --> 02:18:16,040 HAVE THE WORST WALKING SPEED. 3666 02:18:16,040 --> 02:18:17,880 AND THAT BOTH MEASURES 3667 02:18:17,880 --> 02:18:20,000 CONTRIBUTE INDEPENDENTLY TO 3668 02:18:20,000 --> 02:18:21,840 WALKING SPEED. 3669 02:18:21,840 --> 02:18:24,120 WALKING SPEED IS SHOWN HERE BUT 3670 02:18:24,120 --> 02:18:24,800 WE FOUND SIMILAR RELATIONSHIPS 3671 02:18:24,800 --> 02:18:28,080 WITH OTHER MEASURES OF 3672 02:18:28,080 --> 02:18:28,760 PERFORMANCE AS WELL AS 3673 02:18:28,760 --> 02:18:31,920 DISABILITY AND MORTALITY. 3674 02:18:31,920 --> 02:18:34,480 THIS IS ANOTHER EXAMPLE OF HOW 3675 02:18:34,480 --> 02:18:38,160 Mr. OS RECONFIGURING 3676 02:18:38,160 --> 02:18:39,880 SARCOPENIA RESEARCH. 3677 02:18:39,880 --> 02:18:43,080 THE ABILITY OF THE Mr. OS 3678 02:18:43,080 --> 02:18:46,160 BIOBANK WITH LONGITUDINAL 3679 02:18:46,160 --> 02:18:47,440 PHENOTYPING MAKES POSSIBLE 3680 02:18:47,440 --> 02:18:48,640 UNIQUE OPPORTUNITIES TO EXAMINE 3681 02:18:48,640 --> 02:18:53,120 THE BIOLOGICAL UNDERPINNINGS OF 3682 02:18:53,120 --> 02:18:53,320 AGING. 3683 02:18:53,320 --> 02:18:56,240 ONE DIRECTION WE HAVE TAKEN IS 3684 02:18:56,240 --> 02:18:59,640 TO USE LARGE-SCALE PROTEOMICS. 3685 02:18:59,640 --> 02:19:04,000 IN ABOUT 2015, WE UNDERTOOK WHAT 3686 02:19:04,000 --> 02:19:07,120 WAS AT THAT POINT THE LARGEST 3687 02:19:07,120 --> 02:19:10,400 POPULATION BASED PROTEOMICS 3688 02:19:10,400 --> 02:19:10,720 EXPERIMENT. 3689 02:19:10,720 --> 02:19:14,320 WE USED A NOVEL HIGH-THROUGHPUT 3690 02:19:14,320 --> 02:19:15,720 MASS SPEC BASED PROTEOMICS 3691 02:19:15,720 --> 02:19:17,880 APPROACH DEVELOPED AT SPECIFIC 3692 02:19:17,880 --> 02:19:19,240 NORTHWEST NATIONAL LABS TO 3693 02:19:19,240 --> 02:19:21,920 MEASURE THE ABUNDANCE OF SERUM 3694 02:19:21,920 --> 02:19:25,040 PROTEINS IN ABOUT 2500 MEN AT 3695 02:19:25,040 --> 02:19:26,920 BASELINE AND EXAMINED THEIR 3696 02:19:26,920 --> 02:19:29,080 ASSOCIATIONS WITH INCIDENT 3697 02:19:29,080 --> 02:19:30,080 LONGEVITY, DEFINED THOSE 3698 02:19:30,080 --> 02:19:32,840 REACHING AT LEAST THE 90th 3699 02:19:32,840 --> 02:19:35,160 PERCENTILE OF SURVIVAL DURING 15 3700 02:19:35,160 --> 02:19:37,480 YEARS OF FOLLOW-UP FOLLOWING 3701 02:19:37,480 --> 02:19:38,760 BASELINE. 3702 02:19:38,760 --> 02:19:39,880 WE IDENTIFIED A GROUP OF 3703 02:19:39,880 --> 02:19:41,240 PROTEINS ASSOCIATED WITH 3704 02:19:41,240 --> 02:19:43,240 LONGEVITY SHOWN IN THE VOLCANO 3705 02:19:43,240 --> 02:19:43,440 PLOT. 3706 02:19:43,440 --> 02:19:45,680 MOST OF THESE PROTEINS WERE 3707 02:19:45,680 --> 02:19:48,280 LOWER ABUNDANCE IN THE 3708 02:19:48,280 --> 02:19:50,520 LONG-LIVED MEN, COMPARED TO MEN 3709 02:19:50,520 --> 02:19:53,560 WHO DIED EARLIER. 3710 02:19:53,560 --> 02:19:55,680 WE MAPPED THESE PROTEINS TO 3711 02:19:55,680 --> 02:19:58,880 BIOLOGICAL PATHWAYS AND MANY 3712 02:19:58,880 --> 02:20:04,440 WERE RELATED TO INFLAMMATION. 3713 02:20:04,440 --> 02:20:05,440 AS SHOWN IN THE TABLE ON THE 3714 02:20:05,440 --> 02:20:09,160 RIGHT, THESE PROTEINS WERE ALSO 3715 02:20:09,160 --> 02:20:11,880 ASSOCIATED WITH BETTER STATUS IN 3716 02:20:11,880 --> 02:20:15,880 ADDITION TO LONGEVITY. 3717 02:20:15,880 --> 02:20:18,680 IN A DIFFERENT TO LONGEVITY, WE 3718 02:20:18,680 --> 02:20:20,840 EXAMINED ASSOCIATIONS OF SERUM 3719 02:20:20,840 --> 02:20:23,360 PROTEINS WHERE OTHER PHENOTYPES, 3720 02:20:23,360 --> 02:20:24,680 INCLUDING MORTALITY WITHIN FIVE 3721 02:20:24,680 --> 02:20:28,120 YEARS OF BASELINE AND BONE LOSS 3722 02:20:28,120 --> 02:20:30,560 FOLLOWING BASELINE. 3723 02:20:30,560 --> 02:20:32,000 INTERESTINGLY, THERE WERE 3724 02:20:32,000 --> 02:20:34,200 CONSIDERABLE OVERLAP IN THE 3725 02:20:34,200 --> 02:20:35,640 PROTEINS ASSOCIATED WITH THE 3726 02:20:35,640 --> 02:20:38,680 THREE PHENOTYPES AS IS SHOWN. 3727 02:20:38,680 --> 02:20:40,760 AND PERHAPS NOT UNEXPECTEDLY, AS 3728 02:20:40,760 --> 02:20:42,680 SHOWN IN THE HEAT MAP, THE 3729 02:20:42,680 --> 02:20:44,680 ASSOCIATIONS WITH MORTALITY AND 3730 02:20:44,680 --> 02:20:47,680 BONE LOSS WERE IN THE OPPOSITE 3731 02:20:47,680 --> 02:20:50,720 DIRECTION FROM THOSE WITH 3732 02:20:50,720 --> 02:20:53,960 LONGEVITY. 3733 02:20:53,960 --> 02:20:55,360 ADDITIONAL FINDINGS WAS THAT AS 3734 02:20:55,360 --> 02:20:58,440 DEATH APPROACHED, THE ABUNDANCE 3735 02:20:58,440 --> 02:20:59,440 OF THOSE PROTEINS ASSOCIATED 3736 02:20:59,440 --> 02:21:04,000 WITH LONGEVITY, TENDED TO 3737 02:21:04,000 --> 02:21:05,200 INCREASE ON THE LEFT AND TO 3738 02:21:05,200 --> 02:21:10,080 REVERT TO LEVELS SEEN IN CONTROL 3739 02:21:10,080 --> 02:21:10,440 MEN. 3740 02:21:10,440 --> 02:21:12,800 THE PROTEINS NOT SOCIALED WITH 3741 02:21:12,800 --> 02:21:13,880 LONGEVITY DID NOT CHANGE. 3742 02:21:13,880 --> 02:21:17,080 THIS FINDING IF REPLICATED HAS 3743 02:21:17,080 --> 02:21:20,000 OBVIOUS IMPLICATIONS FOR THE 3744 02:21:20,000 --> 02:21:20,640 UNDERSTANDING OF THE BIOLOGY OF 3745 02:21:20,640 --> 02:21:22,880 LONGEVITY AND MORTALITY. 3746 02:21:22,880 --> 02:21:27,360 BUT ALSO THE UNDERSTANDING OF 3747 02:21:27,360 --> 02:21:30,440 HOW PROTEOME CHANGES WILL 3748 02:21:30,440 --> 02:21:32,520 IMPLEMENTS WE IDENTIFY 3749 02:21:32,520 --> 02:21:35,440 BIOMARKERS OF IMPORTANT 3750 02:21:35,440 --> 02:21:38,280 AGE-RELATED OUTCOMES. 3751 02:21:38,280 --> 02:21:40,920 THESE PROTEOMICS CHANGES IN 3752 02:21:40,920 --> 02:21:42,240 Mr. OS WERE AN IMPORTANT PART 3753 02:21:42,240 --> 02:21:44,240 OF THE DESIGN OF THE CURRENT 3754 02:21:44,240 --> 02:21:46,560 CYCLE OF THE LONGEVITY 3755 02:21:46,560 --> 02:21:47,200 CONSORTIUM. 3756 02:21:47,200 --> 02:21:49,120 THE LONGEVITY CONSORTIUM IS A 3757 02:21:49,120 --> 02:21:51,840 LARGE NIA-FUNDED UNDERTAKING 3758 02:21:51,840 --> 02:21:56,040 THAT HAS ANIMAL COHORT BASE AND 3759 02:21:56,040 --> 02:21:57,720 COMPUTATIONAL PROJECTS. 3760 02:21:57,720 --> 02:21:59,840 THERE ARE ALL UNDERSTANDING THE 3761 02:21:59,840 --> 02:22:02,240 BIOLOGY OF LONGEVITY AND 3762 02:22:02,240 --> 02:22:03,240 IDENTIFYING POSSIBLE 3763 02:22:03,240 --> 02:22:07,440 INTERVENTION TO INCREASE HEALTH 3764 02:22:07,440 --> 02:22:08,080 PROTEOMICS IS A IMPORTANT PART 3765 02:22:08,080 --> 02:22:11,440 OF THE WORK AND MASS SPEC 3766 02:22:11,440 --> 02:22:13,240 PROTEOMICS IS BEING DONE ON 3767 02:22:13,240 --> 02:22:14,360 SERUM OBTAINED FROM FOUR 3768 02:22:14,360 --> 02:22:17,720 COHORTS, Mr. O16789, SOF, 3769 02:22:17,720 --> 02:22:22,280 HEALTH AB R AND CHS -- Mr. OS. 3770 02:22:22,280 --> 02:22:24,240 TO COMPARE LONG-LIVED 3771 02:22:24,240 --> 02:22:25,920 INDIVIDUALS TO CONTROLS. 3772 02:22:25,920 --> 02:22:27,840 METABOLOMICS IS ALSO BEING DONE 3773 02:22:27,840 --> 02:22:30,360 AND SYSTEMS APPROACHES ARE BEING 3774 02:22:30,360 --> 02:22:37,600 USED TO ANALYZE THE COMBINED 3775 02:22:37,600 --> 02:22:38,840 DATA PRELIMINARY ANALYSIS OF THE 3776 02:22:38,840 --> 02:22:40,480 PROTEOMICS FINDINGS LOOKS LIKE 3777 02:22:40,480 --> 02:22:44,320 TWO-THIRDS OF THE PROTEINS THAT 3778 02:22:44,320 --> 02:22:45,240 WE PREVIOUSLY FOUND TO BE 3779 02:22:45,240 --> 02:22:49,720 ASSOCIATED WITH LONGEVITY IN 3780 02:22:49,720 --> 02:22:50,320 Mr. OS ARE ALSO ASSOCIATED IN 3781 02:22:50,320 --> 02:22:51,640 COMBINED COHORTS AND WE ARE ONCE 3782 02:22:51,640 --> 02:22:53,120 AGAIN SEEING THE 3783 02:22:53,120 --> 02:22:55,720 PREVIOUSLY-NOTED CHANGES 3784 02:22:55,720 --> 02:22:58,720 ASSOCIATED WITH IMPENDING DEATH. 3785 02:22:58,720 --> 02:23:00,600 WE HOPE THESE STUDIES WILL 3786 02:23:00,600 --> 02:23:01,640 CONSIDERABLY INCREASE OUR 3787 02:23:01,640 --> 02:23:04,720 UNDERSTANDING OF THE BIOLOGY OF 3788 02:23:04,720 --> 02:23:10,960 LONGEVITY INCREASE BIOMARKER 3789 02:23:10,960 --> 02:23:13,960 DISCOVERY AND DESIGN 3790 02:23:13,960 --> 02:23:14,320 INTERVENTIONS. 3791 02:23:14,320 --> 02:23:16,800 FINALLY, THE IMPORTANCE OF A 3792 02:23:16,800 --> 02:23:18,520 MICROBIOME TO HUMAN HEALTH HAS 3793 02:23:18,520 --> 02:23:20,120 BECOME OBVIOUS BUT THERE IS 3794 02:23:20,120 --> 02:23:24,600 LIMITED UNDERSTANDING OF HOW THE 3795 02:23:24,600 --> 02:23:25,080 GUT MICROBIOME CHANGES 3796 02:23:25,080 --> 02:23:25,880 THROUGHOUT ADULTHOOD. 3797 02:23:25,880 --> 02:23:28,920 AND HOW THOSE CHANGES INFLUENCE 3798 02:23:28,920 --> 02:23:30,280 HOST PHYSIOLOGY. 3799 02:23:30,280 --> 02:23:35,520 ALMOST 10 YEARS AGO WE COLLECTED 3800 02:23:35,520 --> 02:23:36,600 STOOL SAMPLES FROM ABOUT 1000 3801 02:23:36,600 --> 02:23:40,480 MEN IN Mr. OS AND UNDERTOOK 16 3802 02:23:40,480 --> 02:23:40,760 GENOTYPING. 3803 02:23:40,760 --> 02:23:42,600 A NUMBER OF ANALYSIS HAVE BEEN 3804 02:23:42,600 --> 02:23:44,720 PUBLISHED, INCLUDING THE 3805 02:23:44,720 --> 02:23:48,800 ASSOCIATIONS OF THE MICROBIOME 3806 02:23:48,800 --> 02:23:49,440 WITH THE MEASURES ON THE RIGHT. 3807 02:23:49,440 --> 02:23:51,280 I'LL SPECIFICALLY MENTION ONE 3808 02:23:51,280 --> 02:23:52,440 COLLABORATION WITH THE GROUP AT 3809 02:23:52,440 --> 02:23:54,680 THE INSTITUTE FOR SYSTEMS 3810 02:23:54,680 --> 02:23:56,920 BIOLOGY IN SEATTLE IN WHICH WE 3811 02:23:56,920 --> 02:24:02,080 EXAMINED THE MICROBIOME AND AG 3812 02:24:02,080 --> 02:24:02,280 AGING. 3813 02:24:02,280 --> 02:24:04,120 THE CURRENT CONCEPT OF HOW THE 3814 02:24:04,120 --> 02:24:08,320 GUT MICROBIOME REALITIES TO 3815 02:24:08,320 --> 02:24:08,920 AGING AND HEALTH IS SHOWN THE 3816 02:24:08,920 --> 02:24:09,120 LEFT. 3817 02:24:09,120 --> 02:24:10,960 ESSENTIALLY AS AGING INCREASES, 3818 02:24:10,960 --> 02:24:13,680 THOSE WHO AGE WELL PRESUMABLY 3819 02:24:13,680 --> 02:24:16,920 HAS A LESSER ACCUMULATION OF 3820 02:24:16,920 --> 02:24:21,240 DETRIMENTAL BACTERIAL SPECIES OR 3821 02:24:21,240 --> 02:24:21,760 PATHOBIOMES. 3822 02:24:21,760 --> 02:24:22,960 ACQUIRE MORE PROTECTEDDIVE 3823 02:24:22,960 --> 02:24:25,880 SPECIES AND AS A RESULT, HAVE 3824 02:24:25,880 --> 02:24:34,560 LESS INFLAMMATION AS ONE MAJOR 3825 02:24:34,560 --> 02:24:34,800 RESULT. 3826 02:24:34,800 --> 02:24:36,800 WE EXAMINED THIS ISSUE IN 3827 02:24:36,800 --> 02:24:39,960 CONCERT WITH THE COHORT FROM 3828 02:24:39,960 --> 02:24:43,240 SEATTLE, ABOUT 3600 ADULTS 3829 02:24:43,240 --> 02:24:44,920 HEAVILY PHENOTYPED AND OF A 3830 02:24:44,920 --> 02:24:45,920 BROAD AGE RANGE AND DATA FROM 3831 02:24:45,920 --> 02:24:48,480 THE AMERICAN GUT PROJECT, ABOUT 3832 02:24:48,480 --> 02:24:51,680 1600 ADULTS WITH A BROAD AGE 3833 02:24:51,680 --> 02:24:53,280 RANGE AS WELL. 3834 02:24:53,280 --> 02:24:56,720 THE MAJOR FINDINGS OF OUR 3835 02:24:56,720 --> 02:24:57,720 ANALYSIS WERE FIRST THAT 3836 02:24:57,720 --> 02:25:00,920 INDIVIDUAL GUT MICROBIOMES 3837 02:25:00,920 --> 02:25:05,080 BECAME INCREASING MORE UNIQUE TO 3838 02:25:05,080 --> 02:25:06,840 EACH INDIVIDUAL WITH AGE 3839 02:25:06,840 --> 02:25:09,040 STARTING IN MID TO LATE 3840 02:25:09,040 --> 02:25:11,680 ADULTHOOD AS SHOWN ON THE LEFT. 3841 02:25:11,680 --> 02:25:13,360 THE GRAY CURVE IS UNIQUENESS 3842 02:25:13,360 --> 02:25:17,560 SCORE INCREASED WITH AGE AT THE 3843 02:25:17,560 --> 02:25:21,040 BOTTOM AND IN THE HUMAN GUT 3844 02:25:21,040 --> 02:25:23,240 PROJECT, ABOVE. 3845 02:25:23,240 --> 02:25:24,720 THIS UNIQUENESS WAS POSITIVELY 3846 02:25:24,720 --> 02:25:27,520 ASSOCIATED WITH MICROBIAL 3847 02:25:27,520 --> 02:25:31,360 METABOLIC MARKERS PREVIOUSLY 3848 02:25:31,360 --> 02:25:32,880 IMPLICATED IN IMMUNE REGULATION, 3849 02:25:32,880 --> 02:25:35,640 INFLAMMATION, AGING AND 3850 02:25:35,640 --> 02:25:36,840 LONGEVITY. 3851 02:25:36,840 --> 02:25:41,280 INCLUDING A NUMBER OF END GOALS. 3852 02:25:41,280 --> 02:25:43,960 SECOND UNIQUENESS WAS ASSOCIATED 3853 02:25:43,960 --> 02:25:45,960 WITH MORE HEALTHY AGING. 3854 02:25:45,960 --> 02:25:48,760 IN THE UPPER RIGHT GRAPH, THE 3855 02:25:48,760 --> 02:25:52,120 RELATIVE ABUNDANCE OF ONE OF THE 3856 02:25:52,120 --> 02:25:54,800 CORE TAX DECREASE WITH AGE IS 3857 02:25:54,800 --> 02:25:59,560 PLOTTED WITH AGE IN Mr. OS. 3858 02:25:59,560 --> 02:26:00,720 HEALTHY INDIVIDUALS ON THE LEFT 3859 02:26:00,720 --> 02:26:02,000 SHOW A DECLINE IN THIS WHEREAS 3860 02:26:02,000 --> 02:26:06,720 THIS PATTERN WAS ABSENT IN THOSE 3861 02:26:06,720 --> 02:26:07,920 WHERE WORSE HEALTH. 3862 02:26:07,920 --> 02:26:10,800 FINALLY IN THE OLDEST Mr. OS 3863 02:26:10,800 --> 02:26:14,920 MEN RETENTIONFUL HIGH RELATIVE 3864 02:26:14,920 --> 02:26:17,600 ABUNDANCES AND LOW GUT 3865 02:26:17,600 --> 02:26:18,480 MICROBIOME UNIQUENESS. 3866 02:26:18,480 --> 02:26:20,760 BOTH ASSOCIATED WITH 3867 02:26:20,760 --> 02:26:22,160 SIGNIFICANTLY DECREASED SURVIVAL 3868 02:26:22,160 --> 02:26:25,320 IN THE COURSE OF A FOUR-YEAR 3869 02:26:25,320 --> 02:26:25,560 FOLLOW-UP. 3870 02:26:25,560 --> 02:26:29,600 THE ASSOCIATION WITH UNIQUENESS 3871 02:26:29,600 --> 02:26:30,680 TO MORTALITY IS SHOWN IN THE 3872 02:26:30,680 --> 02:26:31,600 LOWER RIGHT. 3873 02:26:31,600 --> 02:26:34,360 THE HYPOTHESES WE FORMED FROM 3874 02:26:34,360 --> 02:26:37,160 THIS WORK ARE SHOWN HERE WITH 3875 02:26:37,160 --> 02:26:38,920 HEALTHY AGING BEING ASSOCIATED 3876 02:26:38,920 --> 02:26:41,600 WITH REDUCTIONS AND CORPS TAXA 3877 02:26:41,600 --> 02:26:44,440 AND THE ACCUMULATION OF UNIQUE 3878 02:26:44,440 --> 02:26:47,240 TAXA WITH ASSOCIATED METABOLIC 3879 02:26:47,240 --> 02:26:50,000 CHANGES WHILE LESS HEALTHY AGING 3880 02:26:50,000 --> 02:26:50,880 IS NOT. 3881 02:26:50,880 --> 02:26:55,520 THIS IS OBVIOUSLY STILL A VERY 3882 02:26:55,520 --> 02:26:57,640 INVESTIGATION SO THE STORY 3883 02:26:57,640 --> 02:26:58,640 CONTINUES TO UNFOLD. 3884 02:26:58,640 --> 02:27:01,840 THE MICROBIOME WORK IN Mr. OS 3885 02:27:01,840 --> 02:27:05,080 HAD A MULTIPLIER EFFECT. 3886 02:27:05,080 --> 02:27:06,400 Mr. OS ANALYSIS OF THE GUT 3887 02:27:06,400 --> 02:27:07,680 MICROBIOME ASSOCIATIONS WITH 3888 02:27:07,680 --> 02:27:10,080 BONE MASS AND STRUCTURE LED TO A 3889 02:27:10,080 --> 02:27:13,720 FOLLOW ON RO1 IN A COLLABORATION 3890 02:27:13,720 --> 02:27:16,440 BETWEEN Mr. OS AND FRAMINGHAM 3891 02:27:16,440 --> 02:27:19,000 WHERE THERE ARE SHARED BONE 3892 02:27:19,000 --> 02:27:21,320 PHENOTYPES AND AVAILABLE STOOL 3893 02:27:21,320 --> 02:27:21,680 SPECIMENS. 3894 02:27:21,680 --> 02:27:24,840 AS PART OF THAT COLLABORATION WE 3895 02:27:24,840 --> 02:27:26,280 ARE LEVERAGING MORE IN-DEPTH 3896 02:27:26,280 --> 02:27:28,360 MEHTA GENOME SEQUENCING AT THE 3897 02:27:28,360 --> 02:27:31,480 BRODE TO DIG DEEPER INTO THE 3898 02:27:31,480 --> 02:27:32,920 MICROBIOME BONE RELATIONSHIPS. 3899 02:27:32,920 --> 02:27:36,240 AS WELL WITH THAT SHARED MEHTA 3900 02:27:36,240 --> 02:27:39,240 GENOME DATA, RESEARCHING A 3901 02:27:39,240 --> 02:27:40,000 NUMBER OF AREAS RELEVANT TO 3902 02:27:40,000 --> 02:27:45,520 AGING SHOWN HERE ON THE RIGHT 3903 02:27:45,520 --> 02:27:46,120 HAVE BEEN CATALYZED. 3904 02:27:46,120 --> 02:27:48,480 FOR INSTANCE, THE AVAILABILITY 3905 02:27:48,480 --> 02:27:51,000 OF THE ACCURATE D3 CREATINE 3906 02:27:51,000 --> 02:27:53,920 MUSCLE MASS MEASURES MAKE 3907 02:27:53,920 --> 02:27:56,400 MICROBIOME MUSCLE MASS 3908 02:27:56,400 --> 02:27:58,040 ASSOCIATIONS A PARTICULARLY 3909 02:27:58,040 --> 02:28:08,360 INTERESTING TARGET. 3910 02:28:11,320 --> 02:28:13,120 ON THE LAST SLIDE I WANT TO 3911 02:28:13,120 --> 02:28:16,480 ACKNOWLEDGE THE AMAZING 3912 02:28:16,480 --> 02:28:17,720 CONTRIBUTIONS OF OUR 3913 02:28:17,720 --> 02:28:18,120 PARTICIPANTS. 3914 02:28:18,120 --> 02:28:21,240 MANY INVESTIGATORS HAVE 3915 02:28:21,240 --> 02:28:23,040 CONTRIBUTED, PARTICULARLY THE 3916 02:28:23,040 --> 02:28:24,840 CURRENT CO-PIs AND THE PIs 3917 02:28:24,840 --> 02:28:26,920 OF THE CONTRIBUTING CENTERS AS 3918 02:28:26,920 --> 02:28:28,880 WELL AS THE FUNDING FROM THE NIH 3919 02:28:28,880 --> 02:28:31,920 THAT HAVE MADE ALL OF THIS 3920 02:28:31,920 --> 02:28:32,200 POSSIBLE. 3921 02:28:32,200 --> 02:28:35,320 THANK YOU VERY MUCH. 3922 02:28:35,320 --> 02:28:35,640 >>TERRIFIC! 3923 02:28:35,640 --> 02:28:40,920 THANK YOU DR. ERIC ORWOLL. 3924 02:28:40,920 --> 02:28:41,680 GREAT PRESENTATION AND OVERVIEW 3925 02:28:41,680 --> 02:28:44,240 IN EXPLAINING HOW THE VAST 3926 02:28:44,240 --> 02:28:47,520 AMOUNT OF RESEARCH THAT WAS DONE 3927 02:28:47,520 --> 02:28:49,320 IN THE Mr. OS COHORT. 3928 02:28:49,320 --> 02:28:51,880 I'LL OPEN IT UP FOR QUESTIONS 3929 02:28:51,880 --> 02:28:54,600 FROM OUR PANEL. 3930 02:28:54,600 --> 02:28:57,680 SHELLY? 3931 02:28:57,680 --> 02:28:58,280 >>HARRY, CONTHE GRATES. 3932 02:28:58,280 --> 02:29:03,600 WHAT A TOUR DE FORCE AND WHAT A 3933 02:29:03,600 --> 02:29:05,200 PRODUCTIVE COHORT THAT HAS MADE 3934 02:29:05,200 --> 02:29:06,840 SUCH IMPORTANT DISCOVERIES. 3935 02:29:06,840 --> 02:29:08,960 THE QUESTION I HAD RELATES TO 3936 02:29:08,960 --> 02:29:11,160 THE APPLICATION OF D3 CREATINE 3937 02:29:11,160 --> 02:29:18,520 IN AGING STUDIES. 3938 02:29:18,520 --> 02:29:19,160 THE CREATINE CLEARANCE WOULD BE 3939 02:29:19,160 --> 02:29:20,400 EXPECTED TO DECREASE WITH 3940 02:29:20,400 --> 02:29:23,760 ADVANCING AGE AND DUE TO OTHER 3941 02:29:23,760 --> 02:29:24,920 INCREASING PREVALENCE OF KIDNEY 3942 02:29:24,920 --> 02:29:27,680 DISEASE WITH ADVANCING AGE. 3943 02:29:27,680 --> 02:29:32,040 HOW MIGHT THAT EFFECT CREATINE 3944 02:29:32,040 --> 02:29:33,240 CLEARANCE AND THE ESTIMATES OF 3945 02:29:33,240 --> 02:29:37,400 SKELETAL MUSCLE MASS BASED ON D3 3946 02:29:37,400 --> 02:29:37,880 CREATINE DIPOLLUTION? 3947 02:29:37,880 --> 02:29:38,440 >>GREAT QUESTION. 3948 02:29:38,440 --> 02:29:41,520 OBVIOUSLY THERE ARE A NUMBER OF 3949 02:29:41,520 --> 02:29:42,520 ELEMENTS OF CREATINE BIOLOGY 3950 02:29:42,520 --> 02:29:44,960 THAT HAVE TO BE TAKEN INTO 3951 02:29:44,960 --> 02:29:48,600 ACCOUNT HERE. 3952 02:29:48,600 --> 02:29:50,360 ONE BEING RENAL FUNCTION. 3953 02:29:50,360 --> 02:29:53,000 AND WE HAVE LOOKED THAT PRETTY 3954 02:29:53,000 --> 02:29:56,600 CAREFULLY AND IT TURNS OUT THAT 3955 02:29:56,600 --> 02:29:57,760 CHANGES IN RENAL FUNCTION DON'T 3956 02:29:57,760 --> 02:29:59,160 MAKE MUCH DIFFERENCE PRIMARILY 3957 02:29:59,160 --> 02:30:01,520 BECAUSE WHAT YOU'RE LOOKING AT 3958 02:30:01,520 --> 02:30:07,960 HERE, THE ENDPOINT IS CREATINE 3959 02:30:07,960 --> 02:30:11,840 RATIO TO UNLABELED CREATINE. 3960 02:30:11,840 --> 02:30:13,880 SO THE CREATININE FUNCTION 3961 02:30:13,880 --> 02:30:15,240 REALLY DOESN'T PLAY A PART SINCE 3962 02:30:15,240 --> 02:30:18,600 YOU'RE LOOKING AT THE RATIO. 3963 02:30:18,600 --> 02:30:21,600 AND THE LABELED CREATINE AND THE 3964 02:30:21,600 --> 02:30:23,200 UNLABELED CREATINE ARE HANDLED 3965 02:30:23,200 --> 02:30:25,080 BASICALLY THE SAME BY THE 3966 02:30:25,080 --> 02:30:25,320 KIDNEY. 3967 02:30:25,320 --> 02:30:28,080 AT ANY RATE, RENAL FUNCTION 3968 02:30:28,080 --> 02:30:35,760 DOESN'T SEEM TO PLAY MUCH OF A 3969 02:30:35,760 --> 02:30:36,280 PART. 3970 02:30:36,280 --> 02:30:39,160 >>THANK YOU FOR THAT: I ALSO 3971 02:30:39,160 --> 02:30:41,080 WAS GOING TO ASK -- 3972 02:30:41,080 --> 02:30:51,320 [ INAUDIBLE ] 3973 02:31:16,520 --> 02:31:19,240 >>ALSO IMPORTANT QUESTIONS. 3974 02:31:19,240 --> 02:31:21,520 SO HAVEN'T BEEN COMPLETELY 3975 02:31:21,520 --> 02:31:23,120 EXPLORED, OUR EXPERIENCE WITH 3976 02:31:23,120 --> 02:31:24,960 Mr. OS IS OF COURSE WITH 3977 02:31:24,960 --> 02:31:27,520 AMBULATORY COMMUNITY DWELLING 3978 02:31:27,520 --> 02:31:31,760 MEN, RATHER THAN THE KIND OF ILL 3979 02:31:31,760 --> 02:31:34,000 CONDITIONS THAT YOU ALLUDED TO. 3980 02:31:34,000 --> 02:31:37,400 THOSE STUDIES ARE ONGOING. 3981 02:31:37,400 --> 02:31:40,800 AND I THINK THOSE ANSWERS WILL 3982 02:31:40,800 --> 02:31:46,600 COME IN THE FUTURE. 3983 02:31:46,600 --> 02:31:48,640 >>FOLLOW-UP -- 3984 02:31:48,640 --> 02:31:58,880 [ INAUDIBLE ] 3985 02:32:06,840 --> 02:32:09,120 WE END UP WITH A LOT OF 3986 02:32:09,120 --> 02:32:10,440 WOMEN -- IT WOULD BE WONDERFUL 3987 02:32:10,440 --> 02:32:14,800 TO BE ABLE TO DO COGNITIVE 3988 02:32:14,800 --> 02:32:15,880 FUNCTIONS -- 3989 02:32:15,880 --> 02:32:20,480 [ INAUDIBLE ] 3990 02:32:20,480 --> 02:32:23,040 >>SO COGNITION WITH SOME BROAD 3991 02:32:23,040 --> 02:32:27,200 MEASURES AT LEAST, LIKE TRAILS 3992 02:32:27,200 --> 02:32:27,880 BEE AND GENERAL STUFF, HAVE BEEN 3993 02:32:27,880 --> 02:32:29,160 PART OF THE Mr. OS PHENOTYPING 3994 02:32:29,160 --> 02:32:30,600 FROM THE BEGINNING. 3995 02:32:30,600 --> 02:32:32,920 SO, WE HAVE SOME ESTIMATES OF 3996 02:32:32,920 --> 02:32:36,360 COGNITION OVER THE 20-YEAR SPAN. 3997 02:32:36,360 --> 02:32:37,840 AND THAT'S BEEN THE SOURCE OF A 3998 02:32:37,840 --> 02:32:40,080 NUMBER OF PUBLICATIONS. 3999 02:32:40,080 --> 02:32:42,400 I THINK GOING FORWARD COGNITION 4000 02:32:42,400 --> 02:32:45,440 MIGHT BE A REALLY INTERESTING 4001 02:32:45,440 --> 02:32:47,560 THING TO INCLUDE. 4002 02:32:47,560 --> 02:32:49,000 WE THOUGHT ABOUT BRAIN 4003 02:32:49,000 --> 02:32:49,440 DONATIONS. 4004 02:32:49,440 --> 02:32:51,640 HAVEN'T DONE ANYTHING ABOUT IT. 4005 02:32:51,640 --> 02:32:55,680 I GUESS THIS IS A GOOD TIME TO 4006 02:32:55,680 --> 02:32:56,880 ENCOURAGE PEOPLE WHO WANT TO 4007 02:32:56,880 --> 02:32:59,880 JUMP IN TO TAKE ADVANTAGE OF THE 4008 02:32:59,880 --> 02:33:02,280 Mr. OS COHORT TO DO SO WITH 4009 02:33:02,280 --> 02:33:03,920 ANCILLARY STUDIES. 4010 02:33:03,920 --> 02:33:09,840 SO, COME AT US. 4011 02:33:09,840 --> 02:33:11,400 >>THANK YOU. 4012 02:33:11,400 --> 02:33:12,160 >>THANK YOU. 4013 02:33:12,160 --> 02:33:13,320 REALLY GREAT TALK. 4014 02:33:13,320 --> 02:33:15,960 AND I GUESS IN THESE KINDS OF 4015 02:33:15,960 --> 02:33:17,200 LONGITUDINAL STUDIES IN THE 4016 02:33:17,200 --> 02:33:18,640 CONTEXT OF AGING ON AN 4017 02:33:18,640 --> 02:33:21,920 INDIVIDUAL BASIS, YOU CAN GET 4018 02:33:21,920 --> 02:33:24,760 ENTRAPPANCY OF CHRONOLOGICAL AGE 4019 02:33:24,760 --> 02:33:26,240 VERSUS THE PATTERNS THAT YOU'RE 4020 02:33:26,240 --> 02:33:30,760 SEEING IN YOUR DATA OR SOME -- 4021 02:33:30,760 --> 02:33:33,320 INDIVIDUALS ARE CHRONOLOGICALLY 4022 02:33:33,320 --> 02:33:35,240 OLDER OR THE OTHER WAY AROUND? 4023 02:33:35,240 --> 02:33:37,480 IS THAT IN THIS CONTEXT, DID 4024 02:33:37,480 --> 02:33:39,760 Mr. OS GIVE YOU INSIGHTS INTO 4025 02:33:39,760 --> 02:33:40,520 AGING MECHANISMS? 4026 02:33:40,520 --> 02:33:42,320 IS THAT ONE OF YOUR APPROACHES? 4027 02:33:42,320 --> 02:33:45,480 >>YOU MEAN SORT OF BIOLOGICAL 4028 02:33:45,480 --> 02:33:45,840 CLOCKS? 4029 02:33:45,840 --> 02:33:49,240 THAT KIND OF THING? 4030 02:33:49,240 --> 02:33:53,200 >>WE HAVE THOUGHT ABOUT 4031 02:33:53,200 --> 02:33:54,200 TRANSFORMING PROTEOMICS DATA AND 4032 02:33:54,200 --> 02:33:57,880 WE ARE ADDITIONALLY GAINING SOME 4033 02:33:57,880 --> 02:34:00,600 EXPERIENCE WITH METABOLOMICS AND 4034 02:34:00,600 --> 02:34:04,760 OTHER OMICS INTO AN AGING CLOCK 4035 02:34:04,760 --> 02:34:05,600 OR BIOLOGICAL CLOCK. 4036 02:34:05,600 --> 02:34:06,120 VIOLENT DONE THAT SO FAR. 4037 02:34:06,120 --> 02:34:07,800 I THINK THERE ARE SOME 4038 02:34:07,800 --> 02:34:10,480 OPPORTUNITIES TO DO SO BUT RIGHT 4039 02:34:10,480 --> 02:34:14,680 NOW, WE DON'T HAVE PROTEOMICS 4040 02:34:14,680 --> 02:34:16,160 MEASURES OTHER THAN AT BASELINE. 4041 02:34:16,160 --> 02:34:17,880 OBVIOUSLY WHAT WOULD BE IDEAL IS 4042 02:34:17,880 --> 02:34:21,000 TO HAVE LONGITUDINAL MEASURES OF 4043 02:34:21,000 --> 02:34:22,800 PROTEOMICS, METABOLOMICS AND 4044 02:34:22,800 --> 02:34:24,200 OTHER THINGS TO INCORPORATE. 4045 02:34:24,200 --> 02:34:25,080 THAT'S ONE OF THE THINGS THAT I 4046 02:34:25,080 --> 02:34:28,280 THINK WOULD REALLY BENEFIT THE 4047 02:34:28,280 --> 02:34:31,640 BIOLOGICAL CLOCK DEVELOPMENT AND 4048 02:34:31,640 --> 02:34:31,920 HYPOTHESIS. 4049 02:34:31,920 --> 02:34:33,840 SO, IT'S A GREAT DIRECTION. 4050 02:34:33,840 --> 02:34:35,720 HAVEN'T PROCEEDED WITH IT YET. 4051 02:34:35,720 --> 02:34:38,120 >>THE LONGITUDINAL WOULD BE 4052 02:34:38,120 --> 02:34:38,480 GREAT. 4053 02:34:38,480 --> 02:34:40,080 SOUNDS LIKE IT WOULD BE GREAT TO 4054 02:34:40,080 --> 02:34:42,360 HAVE EXTRA FUNDING TO DO THAT. 4055 02:34:42,360 --> 02:34:45,280 >>YES, IT WOULD, INDEED. 4056 02:34:45,280 --> 02:34:45,520 [ LAUGHS ] 4057 02:34:45,520 --> 02:34:46,480 >>AND RELATED TO THAT, I GUESS 4058 02:34:46,480 --> 02:34:48,320 IT WOULD BE MORE OF A 4059 02:34:48,320 --> 02:34:48,800 LONGITUDINAL QUESTION. 4060 02:34:48,800 --> 02:34:50,640 WHEN YOU SEE THESE CHANGES, YOU 4061 02:34:50,640 --> 02:34:54,920 ALWAYS ASK ARE THEY CAUSAL OR 4062 02:34:54,920 --> 02:34:55,240 COMPENSATORY? 4063 02:34:55,240 --> 02:34:57,600 I THINKFUL INFLAMMATORY STUFF AS 4064 02:34:57,600 --> 02:34:58,800 BAD BUT I GUESS YOUR DATA 4065 02:34:58,800 --> 02:35:00,760 ANALYSIS WILL GET INTO THAT AS 4066 02:35:00,760 --> 02:35:00,960 WELL? 4067 02:35:00,960 --> 02:35:01,400 >>YES, EXACTLY. 4068 02:35:01,400 --> 02:35:04,200 THESE ARE OBSERVATIONAL STUDIES. 4069 02:35:04,200 --> 02:35:09,120 ALTHOUGH WE CAN INFER COGNITION, 4070 02:35:09,120 --> 02:35:13,080 WE CAN'T DEMONSTRATE IT. 4071 02:35:13,080 --> 02:35:15,280 SO, FOR INSTANCE, THE LONGEVITY 4072 02:35:15,280 --> 02:35:17,880 CONSORTIUM IS LOOKING NOT ONLY 4073 02:35:17,880 --> 02:35:19,280 AT THESE SORTS OF OBSERVATIONAL 4074 02:35:19,280 --> 02:35:20,840 STUDIES BUT ALSO HOPING TO 4075 02:35:20,840 --> 02:35:22,720 DEVELOP INTERVENTIONS THAT CAN 4076 02:35:22,720 --> 02:35:23,560 BE TESTED. 4077 02:35:23,560 --> 02:35:27,160 BOTH IN ANIMAL MODELS AND IN 4078 02:35:27,160 --> 02:35:31,400 HUMAN MODELS TO GET MORE 4079 02:35:31,400 --> 02:35:31,800 CAUSATION. 4080 02:35:31,800 --> 02:35:34,800 >>THANK YOU. 4081 02:35:34,800 --> 02:35:35,240 >>MONICA? 4082 02:35:35,240 --> 02:35:37,080 >>YES, SO, THAT WAS A FANTASTIC 4083 02:35:37,080 --> 02:35:37,280 TALK. 4084 02:35:37,280 --> 02:35:40,960 I REALLY ENJOYED IT AND SORRY TO 4085 02:35:40,960 --> 02:35:45,120 BRING THE WOMAN PERSPECTIVE IN 4086 02:35:45,120 --> 02:35:48,240 HERE BUT A LOT OF WOMEN ARE 4087 02:35:48,240 --> 02:35:53,680 TAKING DRUGS, ANTI-PROSIS DRUGS, 4088 02:35:53,680 --> 02:35:54,280 FOUR EXTENDED PERIODS OF TIME. 4089 02:35:54,280 --> 02:35:56,200 AND I'M CURIOUS IF ANY -- IF 4090 02:35:56,200 --> 02:35:57,960 THESE INTERVENTIONS ARE GIVEN TO 4091 02:35:57,960 --> 02:36:00,600 MEN AND IF THERE IS ANYTHING 4092 02:36:00,600 --> 02:36:02,920 UNDERSTOOD ABOUT THEIR IMPACT -- 4093 02:36:02,920 --> 02:36:05,200 OBVIOUSLY IN BONE -- BUT MUSCLE 4094 02:36:05,200 --> 02:36:05,800 HEALTH, ESPECIALLY USING SOME OF 4095 02:36:05,800 --> 02:36:10,960 THE NEW TECHNOLOGIES? 4096 02:36:10,960 --> 02:36:14,400 >>YES, IT'S A GREAT QUESTION. 4097 02:36:14,400 --> 02:36:17,080 IT TURNS OUT THAT -- OBVIOUSLY 4098 02:36:17,080 --> 02:36:18,600 OSTEOPOROSIS HAPPENS IN MEN AS 4099 02:36:18,600 --> 02:36:21,040 WELL. 4100 02:36:21,040 --> 02:36:21,440 NOT INFREQUENTLY. 4101 02:36:21,440 --> 02:36:24,600 AND THAT OSTEOPOROSIS THERAPY IN 4102 02:36:24,600 --> 02:36:28,240 MEN IS UNDERTAKEN 4103 02:36:28,240 --> 02:36:29,480 PROPORTIONATELY MUCH LESS THAN 4104 02:36:29,480 --> 02:36:30,680 IN WOMEN. 4105 02:36:30,680 --> 02:36:33,240 THERE ARE SOME MEN IN Mr. OS, 4106 02:36:33,240 --> 02:36:36,920 A SMALL PROPORTION, THAT USE 4107 02:36:36,920 --> 02:36:37,680 OSTEOPOROSIS THERAPIES. 4108 02:36:37,680 --> 02:36:43,440 AND WE THOUGHT ABOUT HOW WE 4109 02:36:43,440 --> 02:36:44,600 COULD LEVERAGE THE TREATMENTS TO 4110 02:36:44,600 --> 02:36:46,680 TRY AND UNDERSTAND THEIR 4111 02:36:46,680 --> 02:36:47,120 INFLUENCE. 4112 02:36:47,120 --> 02:36:50,080 WE HAVEN'T UNDERTAKEN THOSE 4113 02:36:50,080 --> 02:36:50,280 STUDIES. 4114 02:36:50,280 --> 02:36:51,680 THERE ARE STUDS OUTSIDE Mr. OS 4115 02:36:51,680 --> 02:36:55,440 THAT DO SUGGEST THAT WHAT YOU 4116 02:36:55,440 --> 02:36:57,160 PAUSE IT MAY BE TRUE. 4117 02:36:57,160 --> 02:37:00,960 THAT INTERVENTIONS DIRECTED AT 4118 02:37:00,960 --> 02:37:05,360 BONE MAY HAVE INFLUENCERS ON 4119 02:37:05,360 --> 02:37:05,560 MUSCLE. 4120 02:37:05,560 --> 02:37:06,200 AGAIN, NOTHING VERY DEFINITIVE 4121 02:37:06,200 --> 02:37:08,600 AS OF YET BUT THE RELATIONSHIP 4122 02:37:08,600 --> 02:37:12,040 BETWEEN MUSCLE AND BONE IS 4123 02:37:12,040 --> 02:37:13,400 INTIMATE AND YOU WOULD EXPECT 4124 02:37:13,400 --> 02:37:18,360 THAT SOME INTERVENTION THREAT 4125 02:37:18,360 --> 02:37:22,000 WOULD INFLUENCE MUSCLE. 4126 02:37:22,000 --> 02:37:23,080 CAN'T CONCLUDE VERY MUCH FROM 4127 02:37:23,080 --> 02:37:25,920 THOSE STUDIES YET. 4128 02:37:25,920 --> 02:37:26,720 SORRY ABOUT THE NOISE. 4129 02:37:26,720 --> 02:37:28,040 I'M IN CALIFORNIA AND THEY ARE 4130 02:37:28,040 --> 02:37:29,520 CUTTING DOWN A TREE OUTSIDE OF 4131 02:37:29,520 --> 02:37:32,600 MY WINDOW. 4132 02:37:32,600 --> 02:37:35,240 >>ALMOST AS BAD AS JEN'S 4133 02:37:35,240 --> 02:37:39,680 JACKHAMMERS YESTERDAY. 4134 02:37:39,680 --> 02:37:39,960 >>YES. 4135 02:37:39,960 --> 02:37:41,720 >>THANK YOU FOR A GREAT 4136 02:37:41,720 --> 02:37:42,200 PRESENTATION. 4137 02:37:42,200 --> 02:37:44,680 JUST A FOLLOW-UP TO DR. SNYDER'S 4138 02:37:44,680 --> 02:37:45,560 COMMENT. 4139 02:37:45,560 --> 02:37:47,000 I WONDER IF IN ADDITION TO 4140 02:37:47,000 --> 02:37:49,240 COGNITION YOU MIGHT THINK OF 4141 02:37:49,240 --> 02:37:51,240 COLLECTING SOME ULTIMATE 4142 02:37:51,240 --> 02:37:53,240 BIOMARKERS AND IMAGING DATA. 4143 02:37:53,240 --> 02:37:55,120 THE REASON I SAY THIS IS BECAUSE 4144 02:37:55,120 --> 02:37:57,600 SO MUCH IMPRESSED IN ASSESSING 4145 02:37:57,600 --> 02:38:00,640 THE RELATIONSHIP BETWEEN 4146 02:38:00,640 --> 02:38:01,920 PRE-CLINICAL ALZHEIMER'S AND 4147 02:38:01,920 --> 02:38:02,960 GAIT CHANGES AND EVENTUALLY 4148 02:38:02,960 --> 02:38:03,880 MOBILITY CHANGES. 4149 02:38:03,880 --> 02:38:06,280 YOUR COHORT IS VERY WELL PLACED 4150 02:38:06,280 --> 02:38:07,520 GIVEN YOU HAVE BEEN FOLLOWING UP 4151 02:38:07,520 --> 02:38:10,520 FOR SUCH A LONG TIME. 4152 02:38:10,520 --> 02:38:11,600 TO START COLLECTING SOME 4153 02:38:11,600 --> 02:38:13,600 BIOMARKERS DATA ON THE 4154 02:38:13,600 --> 02:38:14,240 ALZHEIMER'S SIDE AND THAT COULD 4155 02:38:14,240 --> 02:38:16,560 BE DONE AS AN INDEPENDENT RO1 OR 4156 02:38:16,560 --> 02:38:17,720 ANCILLARY STUDY. 4157 02:38:17,720 --> 02:38:18,960 BUT I WONDER IF YOU THOUGHT 4158 02:38:18,960 --> 02:38:20,560 ABOUT THAT AS WELL. 4159 02:38:20,560 --> 02:38:23,000 >>WE HAVE THOUGHT ABOUT IT. 4160 02:38:23,000 --> 02:38:25,360 AGAIN, WE ARE A BUNCH OF 4161 02:38:25,360 --> 02:38:29,040 PRIMARILY A BUNCH OF 4162 02:38:29,040 --> 02:38:29,640 MUSCULOSKELETAL TYPES RATHER 4163 02:38:29,640 --> 02:38:31,280 THAN COGNITION AND ALZHEIMER'S 4164 02:38:31,280 --> 02:38:31,480 TYPES. 4165 02:38:31,480 --> 02:38:34,560 BUT I AGREE THE STUDY IS VERY 4166 02:38:34,560 --> 02:38:37,600 WELL POSITIONED TO LOOK AT 4167 02:38:37,600 --> 02:38:41,120 BIOMARKERS FOR COGNITION. 4168 02:38:41,120 --> 02:38:41,440 OVER 20 YEARS. 4169 02:38:41,440 --> 02:38:45,240 SO AGAIN, THIS IS A PERFECT KIND 4170 02:38:45,240 --> 02:38:51,000 OF ANCILLARY STUDY THAT I THINK 4171 02:38:51,000 --> 02:38:51,680 SHOULD BE ENTERTAINED BY PEOPLE 4172 02:38:51,680 --> 02:38:53,240 IN COGNITION. 4173 02:38:53,240 --> 02:38:56,840 SO AGAIN, BRING IT ON. 4174 02:38:56,840 --> 02:38:57,200 >>THANK YOU. 4175 02:38:57,200 --> 02:38:59,240 >>ALL RIGHT, I THINK WE HAVE 4176 02:38:59,240 --> 02:39:09,360 TIME FOR THE LAST TWO QUESTIONS. 4177 02:39:09,360 --> 02:39:12,240 >>WHAT PROPORTION OF THE COHORT 4178 02:39:12,240 --> 02:39:13,320 WAS MINORITIES AND 4179 02:39:13,320 --> 02:39:13,720 NATIVE-AMERICANS? 4180 02:39:13,720 --> 02:39:14,840 I'M CONCERNED ABOUT -- THE 4181 02:39:14,840 --> 02:39:18,240 REASON I SAY THAT IS, WORKING 4182 02:39:18,240 --> 02:39:19,560 WITH CHEROKEES FOR SO LONG, A 4183 02:39:19,560 --> 02:39:24,000 LONG TIME AGO I WAS TOLD THAT 4184 02:39:24,000 --> 02:39:25,400 THEY ARE LACTOSE INTOLERANT AND 4185 02:39:25,400 --> 02:39:27,960 I THINK IT'S A COMMON TRAIT 4186 02:39:27,960 --> 02:39:30,120 AMONG A LOT OF NATIVE-AMERICANS. 4187 02:39:30,120 --> 02:39:33,360 AND THAT MAY ACCOUNT FOR LODI 4188 02:39:33,360 --> 02:39:40,880 TERRY CALCIUM INTAKE -- ACCOUNT 4189 02:39:40,880 --> 02:39:50,240 FOR LOW DIAGNOSIS OF CALCIUM IN 4190 02:39:50,240 --> 02:39:53,760 TAKE. 4191 02:39:53,760 --> 02:39:57,240 LODI TERRY. 4192 02:39:57,240 --> 02:39:58,840 >>LESS THAN WE HOPED DESPITE 4193 02:39:58,840 --> 02:40:01,240 ACTIVE ATTEMPTS TO ENCOURAGE IT. 4194 02:40:01,240 --> 02:40:06,200 ABOUT 10% WAS OVERALL COHORT. 4195 02:40:06,200 --> 02:40:16,720 WE CONSIDERED TO BE MINORITY. 4196 02:40:17,960 --> 02:40:19,200 A VAR SMALL PERCENTAGE WERE 4197 02:40:19,200 --> 02:40:19,720 NATIVE. 4198 02:40:19,720 --> 02:40:21,080 WE THOUGHT ON NUMEROUS OCCASIONS 4199 02:40:21,080 --> 02:40:24,320 HOW TO LEVERAGE EVEN THAT SMALL 4200 02:40:24,320 --> 02:40:26,280 PROPORTION OF MINORITIES AND 4201 02:40:26,280 --> 02:40:29,240 JUST HAVEN'T THOUGHT WE HAD THE 4202 02:40:29,240 --> 02:40:32,040 POWER TO DO ANYTHING VERY 4203 02:40:32,040 --> 02:40:35,440 EFFECTIVE IN THAT REGARD. 4204 02:40:35,440 --> 02:40:37,240 OBVIOUSLY WE WOULD BE OPEN TO 4205 02:40:37,240 --> 02:40:39,160 ANY NOVEL APPROACH THAT IS MIGHT 4206 02:40:39,160 --> 02:40:43,440 ALLOW US TO TAKE ADVANTAGE OF 4207 02:40:43,440 --> 02:40:44,480 THE SMALL PROPORTION OF 4208 02:40:44,480 --> 02:40:46,920 MINORITIES THAT WE HAVE. 4209 02:40:46,920 --> 02:40:51,680 >>AND SUSAN? 4210 02:40:51,680 --> 02:40:53,320 >>ERIC, THAT WAS REALLY, REALLY 4211 02:40:53,320 --> 02:40:54,520 TERRIFIC. 4212 02:40:54,520 --> 02:40:56,680 AMAZING WORK THAT YOU HAVE DONE. 4213 02:40:56,680 --> 02:40:57,040 >>THANK YOU. 4214 02:40:57,040 --> 02:40:57,880 >>REALLY IMPRESSIVE. 4215 02:40:57,880 --> 02:40:59,840 A QUESTION FOR YOU. 4216 02:40:59,840 --> 02:41:04,160 SO, AS YOU KNOW, THERE IS SORT 4217 02:41:04,160 --> 02:41:05,760 OFOG GOING DEBATE IN THE BONE 4218 02:41:05,760 --> 02:41:06,600 WORLD WHETHER OR NOT WE SHOULD 4219 02:41:06,600 --> 02:41:08,760 REALLY USE FRAC OR NOT BECAUSE 4220 02:41:08,760 --> 02:41:10,040 IT'S MISSING IMPORTANT THINGS 4221 02:41:10,040 --> 02:41:14,560 SUCH AS FALLS AND I KNOW YOU SEE 4222 02:41:14,560 --> 02:41:15,480 THESE PEOPLE EVERY FOUR MONTHS. 4223 02:41:15,480 --> 02:41:17,600 SO THE QUESTION IS, HAVE YOU 4224 02:41:17,600 --> 02:41:19,360 THOUGHT ABOUT, OR DO YOU HAVE 4225 02:41:19,360 --> 02:41:21,680 FALLS DATA AND HAVE YOU THOUGHT 4226 02:41:21,680 --> 02:41:26,680 ABOUT RE-THINKING FRACS OR SOME 4227 02:41:26,680 --> 02:41:28,120 TYPE OF RISK PREDICTION WHICH 4228 02:41:28,120 --> 02:41:31,560 WOULD INCLUDE FALLS IN THIS MALE 4229 02:41:31,560 --> 02:41:32,280 POPULATION? 4230 02:41:32,280 --> 02:41:35,360 BECAUSE THAT WOULD JUST BE SO 4231 02:41:35,360 --> 02:41:35,960 VALUABLE TO BE ABLE TO GET A 4232 02:41:35,960 --> 02:41:37,080 BETTER RISK PREDICTION. 4233 02:41:37,080 --> 02:41:40,440 AND ALSO RATHER THAN 10 YEARS 4234 02:41:40,440 --> 02:41:41,880 OUT TO DO SOMETHING SHORTER THAT 4235 02:41:41,880 --> 02:41:45,120 WOULD BE CLINICALLY RELEVANT 4236 02:41:45,120 --> 02:41:45,920 LIKE FIVE YEARS OUT. 4237 02:41:45,920 --> 02:41:47,360 >>BOTH OF THOSE THINGS ARE 4238 02:41:47,360 --> 02:41:50,480 REALLY INTERESTING TO ME. 4239 02:41:50,480 --> 02:41:53,040 WE HAVE LOOKED AT FRAC. 4240 02:41:53,040 --> 02:41:56,160 AND Mr. OS IN COMPARISON AND 4241 02:41:56,160 --> 02:41:57,880 TOGETHER IN NUMEROUS 4242 02:41:57,880 --> 02:41:58,200 PUBLICATIONS. 4243 02:41:58,200 --> 02:42:03,200 MOST RECENTLY, NICK HARTLEY FROM 4244 02:42:03,200 --> 02:42:05,120 THE GROUP, HAS LOOKED AT THE 4245 02:42:05,120 --> 02:42:06,840 Mr. OS DATA TO EXAMINE EXACTLY 4246 02:42:06,840 --> 02:42:08,560 THOSE ISSUES. 4247 02:42:08,560 --> 02:42:10,520 THE INFLUENCE OF FALLS AND MOST 4248 02:42:10,520 --> 02:42:13,440 RECENTLY, THE INFLUENCE OF 4249 02:42:13,440 --> 02:42:15,800 MUSCLE AND MUSCLE DENSITY. 4250 02:42:15,800 --> 02:42:18,640 SO YOU MIGHT LOOK AT A COUPLE OF 4251 02:42:18,640 --> 02:42:19,160 HIS RECENTLY PUBLICATIONS. 4252 02:42:19,160 --> 02:42:22,280 IT LOOKS FROM THE Mr. OS 4253 02:42:22,280 --> 02:42:25,520 ANALYSIS THAT YOU MIGHT EXPECT A 4254 02:42:25,520 --> 02:42:28,480 CHANGE IN FRACS IN THE NEAR 4255 02:42:28,480 --> 02:42:31,440 FUTURE AND INCORPORATE QUESTIONS 4256 02:42:31,440 --> 02:42:35,240 ABOUT FALLS AND INCORPORATE 4257 02:42:35,240 --> 02:42:37,960 QUESTIONS ABOUT MUSCLE. 4258 02:42:37,960 --> 02:42:42,760 SO, IT'S BEEN VERY ACTIVE AS A 4259 02:42:42,760 --> 02:42:43,960 Mr. OSFRACS COLLABORATION. 4260 02:42:43,960 --> 02:42:46,600 LOOK FOR NICK HARVEY AND HIS 4261 02:42:46,600 --> 02:42:46,960 PUBLICATIONS. 4262 02:42:46,960 --> 02:42:49,800 >>THANKS. 4263 02:42:49,800 --> 02:42:50,000 OF. 4264 02:42:50,000 --> 02:42:53,800 >>THANK YOU AGAIN, ERIC FOR A 4265 02:42:53,800 --> 02:42:54,240 REALLY TERRIFIC TALK. 4266 02:42:54,240 --> 02:42:55,640 WE APPRECIATE YOU TAKING THE 4267 02:42:55,640 --> 02:42:57,880 TIME OUT SPEAKING WITH US AND 4268 02:42:57,880 --> 02:43:00,480 ANSWERING MANY QUESTIONS AND 4269 02:43:00,480 --> 02:43:01,880 PERHAPS YOU MAY BE CONTACTED IN 4270 02:43:01,880 --> 02:43:05,080 THE FUTURE WITH SOME NEW 4271 02:43:05,080 --> 02:43:05,920 COLLABORATIONS T SOUNDS LIKE. 4272 02:43:05,920 --> 02:43:07,520 >>I THINK THAT WOULD BE 4273 02:43:07,520 --> 02:43:07,800 FABULOUS. 4274 02:43:07,800 --> 02:43:10,640 THANK YOU VERY MUCH. 4275 02:43:10,640 --> 02:43:11,640 >>THANK YOU VERY MUCH. 4276 02:43:11,640 --> 02:43:16,600 ALL RIGHT, NEXT WE HAVE OUR NEXT 4277 02:43:16,600 --> 02:43:18,960 SPEAKER. 4278 02:43:18,960 --> 02:43:20,600 SO DR. RICHARD HODES WOULD YOU 4279 02:43:20,600 --> 02:43:22,680 LIKE TO INTRODUCE OUR NEXT 4280 02:43:22,680 --> 02:43:24,640 SPEAKER? 4281 02:43:24,640 --> 02:43:28,080 >>IT'S MY PRIVILEGE TO 4282 02:43:28,080 --> 02:43:28,640 INTRODUCE DR. SUSAN WHO WAS 4283 02:43:28,640 --> 02:43:31,280 APOINTED AS THE FOUNDING DEPUTY 4284 02:43:31,280 --> 02:43:34,960 DIRECTOR OF ARPH, AN AGENCY 4285 02:43:34,960 --> 02:43:36,720 WHICH NIH LOOKS AT WITH GREAT 4286 02:43:36,720 --> 02:43:40,320 INTEREST AS A PARTNER AND 4287 02:43:40,320 --> 02:43:40,720 COLLABORATIONS. 4288 02:43:40,720 --> 02:43:41,520 SUSAN HAS HAD A DISTINGUISHED 4289 02:43:41,520 --> 02:43:44,360 CAREER WHICH PROVIDES HER WITH A 4290 02:43:44,360 --> 02:43:45,400 STRONG BACKGROUND FOR 4291 02:43:45,400 --> 02:43:46,560 APPOINTMENT AS AN OUTSTANDING 4292 02:43:46,560 --> 02:43:47,600 FOUNDING DIRECTOR. 4293 02:43:47,600 --> 02:43:50,040 SHE PREVIOUSLY LED STRATEGY 4294 02:43:50,040 --> 02:43:54,000 ANALYSIS AND RISK MANAGEMENT FOR 4295 02:43:54,000 --> 02:43:55,080 ARPAH AND ACTING DEPUTY DIRECTOR 4296 02:43:55,080 --> 02:43:56,840 FOR A BIT OF TIME PRIOR TO THAT. 4297 02:43:56,840 --> 02:43:58,520 SHE WAS AT HRSA PRIOR TO THAT 4298 02:43:58,520 --> 02:44:00,520 WHERE SHE WAS THE FOUNDING 4299 02:44:00,520 --> 02:44:01,080 DIRECTOR FOR THE CENTER FOR 4300 02:44:01,080 --> 02:44:02,520 INNOVATION AND HEALTH RESOURCES 4301 02:44:02,520 --> 02:44:04,200 AND SERVED IN THE WHITE HOUSE 4302 02:44:04,200 --> 02:44:05,160 AND ASSISTANT DIRECTOR FOR 4303 02:44:05,160 --> 02:44:07,680 NATIONAL HEALTH SECURITY, 4304 02:44:07,680 --> 02:44:08,280 INTERNATIONAL AFFAIRS IN THE 4305 02:44:08,280 --> 02:44:09,880 OFFICE OF SCIENCE AND 4306 02:44:09,880 --> 02:44:11,800 TECHNOLOGY, OSDP. 4307 02:44:11,800 --> 02:44:14,320 OUR ACADEMIC BACKGROUND INCLUDED 4308 02:44:14,320 --> 02:44:17,000 FASFA DEGREE AND DOCTORATES FROM 4309 02:44:17,000 --> 02:44:20,480 YY OF WISCONSIN MAD SONG AND 4310 02:44:20,480 --> 02:44:22,640 MICROBIOLOGY AND IMMUNOLOGY AND 4311 02:44:22,640 --> 02:44:27,480 FELLOWSHIP IN AAAS AT STANFORD. 4312 02:44:27,480 --> 02:44:29,120 SO CAREER IN PUBLIC SERVICE AND 4313 02:44:29,120 --> 02:44:31,600 ACADEMICS THAT MAKE HER A STRONG 4314 02:44:31,600 --> 02:44:34,960 AND OPTIMAL CANDIDATE AND NOW 4315 02:44:34,960 --> 02:44:35,960 SELECTEE FOR THE POSITION OF 4316 02:44:35,960 --> 02:44:37,760 DEPUTY DIRECTOR OF ARPAH. 4317 02:44:37,760 --> 02:44:40,680 I THINK MANY OF US AT NIH AND 4318 02:44:40,680 --> 02:44:41,680 NIA AND IN THE COUNCIL LOOK 4319 02:44:41,680 --> 02:44:43,160 FORWARD TO HEARING FROM YOU. 4320 02:44:43,160 --> 02:44:45,120 SO ONE OF THE EARLIEST 4321 02:44:45,120 --> 02:44:46,160 OPPORTUNITIES WE INTERACT. 4322 02:44:46,160 --> 02:44:49,360 SO WELCOME, PLEASE TAKE IT AWAY. 4323 02:44:49,360 --> 02:44:49,720 >>THANK YOU! 4324 02:44:49,720 --> 02:44:51,920 I WAS ABLE TO JOIN FOR A LITTLE 4325 02:44:51,920 --> 02:44:54,280 BIT OF THE SCALE OF THAT 4326 02:44:54,280 --> 02:44:54,920 PRESENTATION AND I KEPT THINKING 4327 02:44:54,920 --> 02:44:55,760 TO MYSELF, A YEAR FROM NOW, I 4328 02:44:55,760 --> 02:44:57,400 WANT TO BE ABLE TO TELL A GREAT 4329 02:44:57,400 --> 02:44:59,800 STORY ABOUT THE RESEARCH WE HAVE 4330 02:44:59,800 --> 02:45:00,800 FUNDED AND THE POTENTIAL FOR IT 4331 02:45:00,800 --> 02:45:04,400 TO TRANSFORM SOME PART OF THE 4332 02:45:04,400 --> 02:45:04,640 ECOSYSTEM. 4333 02:45:04,640 --> 02:45:06,400 SO THANK YOU FOR LETTING ME JOIN 4334 02:45:06,400 --> 02:45:07,120 YOUR GROUP TODAY. 4335 02:45:07,120 --> 02:45:08,240 I'M HAPPY TO WALK YOU THROUGH 4336 02:45:08,240 --> 02:45:10,880 WHERE WE ARE, WHERE WE ARE GOING 4337 02:45:10,880 --> 02:45:12,640 AND THEN WELCOME QUESTIONS. 4338 02:45:12,640 --> 02:45:13,840 I KNOW WE ARE RUNNING A LITTLE 4339 02:45:13,840 --> 02:45:15,000 BIT OVER ON TIME BUT I BLOCKED 4340 02:45:15,000 --> 02:45:16,360 MY AFTERNOON OFF FOR THIS. 4341 02:45:16,360 --> 02:45:18,640 SO I CAN TAKE QUESTIONS IF YOU 4342 02:45:18,640 --> 02:45:20,920 ALL HAVE THE TIME TO DO THAT. 4343 02:45:20,920 --> 02:45:22,640 SO WHY DON'T I JUST JUMP IN. 4344 02:45:22,640 --> 02:45:24,760 AR APPROXIMATE. 4345 02:45:24,760 --> 02:45:30,600 AH, ADVANCED HEALTH RESEARCH 4346 02:45:30,600 --> 02:45:32,040 AGENCY ADVANCED PROJECTS 4347 02:45:32,040 --> 02:45:33,480 RESEARCH AGENCY FOR HEALTH 4348 02:45:33,480 --> 02:45:33,880 MODELS ADD DARPA. 4349 02:45:33,880 --> 02:45:36,040 OUR GOAL IS REALLY TO MAKE SURE 4350 02:45:36,040 --> 02:45:38,680 THAT WE ARE ACCELERATING BETTER 4351 02:45:38,680 --> 02:45:39,840 OUTCOMES FOR EVERYONE. 4352 02:45:39,840 --> 02:45:41,720 SIMILAR TO HOW DARPA REALLY 4353 02:45:41,720 --> 02:45:43,720 WORKED TO DISRUPT AND INNOVATE 4354 02:45:43,720 --> 02:45:45,280 WITHIN THE DEFENSE ARENA. 4355 02:45:45,280 --> 02:45:48,200 SO THEIR MISSION WAS VERY MUCH 4356 02:45:48,200 --> 02:45:48,480 STREAMLINED. 4357 02:45:48,480 --> 02:45:50,480 OF COURSE TO THE DEFENSE 4358 02:45:50,480 --> 02:45:50,760 ECOSYSTEMS. 4359 02:45:50,760 --> 02:45:53,240 OUR IS EVERYONE, THE AMERICAN 4360 02:45:53,240 --> 02:45:54,520 PUBLIC AND REALLY TRYING TO OPEN 4361 02:45:54,520 --> 02:45:57,400 UP EVERYTHING WE DO TO REALLY 4362 02:45:57,400 --> 02:45:59,360 FUND THOSE TRANSFORMATIONAL 4363 02:45:59,360 --> 02:46:00,880 ACTIVITIES WHERE 3-5 YEARS FROM 4364 02:46:00,880 --> 02:46:02,640 NOW OR 10 YEARS FROM NOW, WE SAY 4365 02:46:02,640 --> 02:46:04,960 TO OURSELVES, OH, MY GOSH, WE 4366 02:46:04,960 --> 02:46:08,120 NEVER THOUGHT WE WOULD GET HERE. 4367 02:46:08,120 --> 02:46:10,880 NEVER THOUGHT WE WOULD DO 4368 02:46:10,880 --> 02:46:11,880 SOMETHING TO SUPPORT SLOWING 4369 02:46:11,880 --> 02:46:14,400 DOWN OR REDUCING AGING. 4370 02:46:14,400 --> 02:46:16,360 WE WERE JUST HEARING ABOUT. 4371 02:46:16,360 --> 02:46:18,320 SOMETHING JUST SLIGHTLY 4372 02:46:18,320 --> 02:46:18,800 TRANSFORMATIONAL. 4373 02:46:18,800 --> 02:46:21,040 THAT'S OUR MISSION AND WHAT 4374 02:46:21,040 --> 02:46:22,360 DRIVES US EVERY DAY. 4375 02:46:22,360 --> 02:46:22,680 NEXT SLIDE. 4376 02:46:22,680 --> 02:46:25,200 WE ARE VERY FORTUNATE TO HAVE 4377 02:46:25,200 --> 02:46:27,400 SUCH GREAT SUPPORT FOR THIS 4378 02:46:27,400 --> 02:46:27,760 ADMINISTRATION. 4379 02:46:27,760 --> 02:46:28,600 SO PRESIDENT BIDEN WHO IS A 4380 02:46:28,600 --> 02:46:30,080 STRONG SUPPORTER FOR HEALTH AND 4381 02:46:30,080 --> 02:46:32,960 SCIENCE BOTH AT THIS TIME AND AS 4382 02:46:32,960 --> 02:46:35,000 VICE PRESIDENT, WAS REALLY 4383 02:46:35,000 --> 02:46:37,080 TRANSNORIMATIONAL IN SAYING WE 4384 02:46:37,080 --> 02:46:40,360 NEED AN AGENCY LIKE ARPAH, AN 4385 02:46:40,360 --> 02:46:41,440 ORGANIZATION THAT IS CONNECTED 4386 02:46:41,440 --> 02:46:44,080 TO WORLD CLASS RESEARCH 4387 02:46:44,080 --> 02:46:45,040 SCIENTISTS LIKE THOSE AT NIH BUT 4388 02:46:45,040 --> 02:46:49,400 WHO CAN TAKE ON THESE HIGH RISK, 4389 02:46:49,400 --> 02:46:50,080 HIGHER REWARD TASTES NO ONE ELSE 4390 02:46:50,080 --> 02:46:50,320 CAN TAKE. 4391 02:46:50,320 --> 02:46:52,200 WE UNDERSTAND THAT FAILURE IS 4392 02:46:52,200 --> 02:46:53,520 PART OF WHAT WE GOING TO BE 4393 02:46:53,520 --> 02:46:54,440 WORKING TOWARDS. 4394 02:46:54,440 --> 02:46:56,600 BUT WE TELL OURSELVES IT'S NOT 4395 02:46:56,600 --> 02:46:57,800 FAILURE IF YOU LEARN SOMETHING. 4396 02:46:57,800 --> 02:46:59,440 IF WE SHARED THAT LEARNING WITH 4397 02:46:59,440 --> 02:46:59,680 OTHERS. 4398 02:46:59,680 --> 02:47:01,480 THAT'S WHERE WE ARE PLACED AND 4399 02:47:01,480 --> 02:47:04,000 WE WANT TO MAKE SURE THAT WE ARE 4400 02:47:04,000 --> 02:47:06,600 JUST BREAKING THE MOLD ON HOW WE 4401 02:47:06,600 --> 02:47:08,520 SUPPORT FUNDAMENTAL RESEARCH AND 4402 02:47:08,520 --> 02:47:11,600 THE DEVELOPMENT OF COMMERCIAL 4403 02:47:11,600 --> 02:47:12,200 PRODUCTS THAT ARE AVAILABLE TO 4404 02:47:12,200 --> 02:47:15,840 EVERYONE IN THE HEALTH 4405 02:47:15,840 --> 02:47:16,120 ECOSYSTEM. 4406 02:47:16,120 --> 02:47:17,960 NEXT SLIDE. 4407 02:47:17,960 --> 02:47:18,880 WE TALK A LOT RIGHT NOW AS WE 4408 02:47:18,880 --> 02:47:20,760 ARE BUILDING THE AGENCY ABOUT 4409 02:47:20,760 --> 02:47:22,880 WHAT IS IT THAT IS DRIVING US? 4410 02:47:22,880 --> 02:47:25,240 AND WE ANCHOR OURSELVES IN THE 4411 02:47:25,240 --> 02:47:27,880 CONCEPT OF THE SLOW SPUTNIK 4412 02:47:27,880 --> 02:47:28,080 MOMENTS. 4413 02:47:28,080 --> 02:47:28,880 WE THINK ABOUT WHEAT ARE IN AN 4414 02:47:28,880 --> 02:47:31,880 ERA OF COMPLEX TECHNOLOGY WITH 4415 02:47:31,880 --> 02:47:34,320 MASSIVE ECONOMIC AND SOCIAL 4416 02:47:34,320 --> 02:47:34,640 DISRUPTIONS. 4417 02:47:34,640 --> 02:47:35,800 POWERFUL BIOLOGICAL FACTORS 4418 02:47:35,800 --> 02:47:36,760 INCLUDING WHAT WE LIVED THROUGH, 4419 02:47:36,760 --> 02:47:39,760 THE PANDEMIC, BUT ALSO KNOWING 4420 02:47:39,760 --> 02:47:41,560 EMERGING BIOTECHNOLOGIES ARE 4421 02:47:41,560 --> 02:47:44,200 CHANGING ALMOST DAILY, WEEKLY, 4422 02:47:44,200 --> 02:47:47,000 MONTHLY AND THERE IS SO MUCH 4423 02:47:47,000 --> 02:47:49,480 POTENTIAL TO LEVERAGE THESE 4424 02:47:49,480 --> 02:47:51,040 TECHNOLOGIES TO BE 4425 02:47:51,040 --> 02:47:51,440 TRANSFORMATIONAL. 4426 02:47:51,440 --> 02:47:53,240 OUR PROMISE IS OUR PROGRAM 4427 02:47:53,240 --> 02:47:54,400 MANAGERS WHICH WE WILL TALK 4428 02:47:54,400 --> 02:47:55,760 ABOUT, THEY ARE THE ENGINE THAT 4429 02:47:55,760 --> 02:47:57,280 DRIVES US, THEY WILL DESIGN, 4430 02:47:57,280 --> 02:47:58,560 BUILD AND LAUNCH THESE SOLUTIONS 4431 02:47:58,560 --> 02:48:00,160 TO CREATE THE BEST VERSIONS OF 4432 02:48:00,160 --> 02:48:03,880 OUR HEALTH FUTURE. 4433 02:48:03,880 --> 02:48:05,480 NEXT SLIDE. 4434 02:48:05,480 --> 02:48:07,160 SO MUCH LIKE KNOWING WHAT 4435 02:48:07,160 --> 02:48:09,200 ANCHORS US IS THERE IS A SPUTNIK 4436 02:48:09,200 --> 02:48:11,800 MOMENT, A NEED FOR 4437 02:48:11,800 --> 02:48:12,440 TRANSFORMATIONAL APPROACHES TO 4438 02:48:12,440 --> 02:48:13,760 DISRUPTION AND INNOVATION IN THE 4439 02:48:13,760 --> 02:48:14,440 HEALTH ECOSYSTEM. 4440 02:48:14,440 --> 02:48:15,840 WE ALWAYS ARE CHALLENGING 4441 02:48:15,840 --> 02:48:20,320 OURSELVES WITH THESE MANAGE IF 4442 02:48:20,320 --> 02:48:20,600 STATEMENT. 4443 02:48:20,600 --> 02:48:21,600 IMAGINE IF YOU COULD TRANSFORM 4444 02:48:21,600 --> 02:48:22,200 THE ECOSYSTEM. 4445 02:48:22,200 --> 02:48:23,040 A FEW EXAMPLES HERE. 4446 02:48:23,040 --> 02:48:26,880 WHAT IF WE HAD CELL THERAPY THAT 4447 02:48:26,880 --> 02:48:29,440 COULD BE BUILT AND ASSEMBLED ON 4448 02:48:29,440 --> 02:48:30,520 DEMAND? 4449 02:48:30,520 --> 02:48:32,280 AND READILY PROGRAMMED FOR EACH 4450 02:48:32,280 --> 02:48:33,880 NOW DISEASE TARGET? 4451 02:48:33,880 --> 02:48:35,960 WHAT IF MRIs COULD BE 4452 02:48:35,960 --> 02:48:38,080 DELIVERED IN YOUR HOME? 4453 02:48:38,080 --> 02:48:40,160 WHAT ABOUT A PERSONALIZED CANCER 4454 02:48:40,160 --> 02:48:42,640 VACCINE COST THE SAME AS A CUP 4455 02:48:42,640 --> 02:48:43,680 OF COFFEE? 4456 02:48:43,680 --> 02:48:45,120 IF WE ARE ABLE TO ACHIEVE THIS 4457 02:48:45,120 --> 02:48:47,720 WITHIN THE HEALTH ECOSYSTEM, WE 4458 02:48:47,720 --> 02:48:48,760 COULD ALL REALIZE A BETTER 4459 02:48:48,760 --> 02:48:49,080 HEALTH FUTURE. 4460 02:48:49,080 --> 02:48:51,400 NEXT SLIDE. 4461 02:48:51,400 --> 02:48:53,440 SO, WHERE WE ARE PLACED, WE SORT 4462 02:48:53,440 --> 02:48:57,240 OF LOOK AT IT AS HAVING THE BEST 4463 02:48:57,240 --> 02:48:57,960 OF BOTH WORDS WORLDS. 4464 02:48:57,960 --> 02:49:00,840 ON THE ONE HAND, WE HAVE DIRECT 4465 02:49:00,840 --> 02:49:01,320 AUTHORITY AND DIRECT 4466 02:49:01,320 --> 02:49:02,880 RELATIONSHIP WITH HHS SECRETARY. 4467 02:49:02,880 --> 02:49:07,280 SO WE HAVE THE ABILITY TO GO AND 4468 02:49:07,280 --> 02:49:09,400 DIRECTLY SORT OF SEEK GUIDANCE 4469 02:49:09,400 --> 02:49:10,880 AND OFFER SOLUTIONS AND HAVE 4470 02:49:10,880 --> 02:49:11,880 THAT RELATIONSHIP BUT WE ARE 4471 02:49:11,880 --> 02:49:13,840 ALSO DIRECTLY CONNECTED TO OUR 4472 02:49:13,840 --> 02:49:15,040 COLLEAGUES AT NIH. 4473 02:49:15,040 --> 02:49:16,560 SO WE ARE A DOTTED LINE TO THE 4474 02:49:16,560 --> 02:49:17,440 NIH DIRECTOR AND WHAT WE ARE 4475 02:49:17,440 --> 02:49:20,160 HOPING TO DO IS BUILD OUT THE 4476 02:49:20,160 --> 02:49:22,600 NIH AND ICs AS PARTNERS. 4477 02:49:22,600 --> 02:49:24,560 KEY PARTNERS, INDIVIDUALS WHO 4478 02:49:24,560 --> 02:49:26,120 HAVE SUCH DEPTH AND BREATH OF 4479 02:49:26,120 --> 02:49:27,920 EXPERIENCE IT WILL ONLY ALLOW US 4480 02:49:27,920 --> 02:49:30,240 TO BECOME BETTER AS WE DEVELOP 4481 02:49:30,240 --> 02:49:35,320 OUR PROGRAMS AND HIRE OUR 4482 02:49:35,320 --> 02:49:35,920 PROGRAM MANAGER BY BEING THIS 4483 02:49:35,920 --> 02:49:36,760 CONNECTION TO OUR NIH 4484 02:49:36,760 --> 02:49:37,320 COLLEAGUES. 4485 02:49:37,320 --> 02:49:38,440 WE GENERALLY HAVE TWO BIG SIDES 4486 02:49:38,440 --> 02:49:39,880 OF THE ORGANIZATION. 4487 02:49:39,880 --> 02:49:41,880 WE HAVE OUR PROGRAM MANAGERS AND 4488 02:49:41,880 --> 02:49:42,640 WE'LL TALK ABOUT THOSE. 4489 02:49:42,640 --> 02:49:44,520 THOSE ARE THE ONES THAT ARE 4490 02:49:44,520 --> 02:49:46,160 REALLY GOING TO DRIVE WHAT WE DO 4491 02:49:46,160 --> 02:49:46,520 AS AN AGENCY. 4492 02:49:46,520 --> 02:49:48,560 AND THEN WE HAVE BUSINESS TEAM 4493 02:49:48,560 --> 02:49:48,800 MEMBERS. 4494 02:49:48,800 --> 02:49:49,480 SO THOSE ARE THE ONES THAT KEEP 4495 02:49:49,480 --> 02:49:50,560 THE LIGHTS ON AND MAKE SURE THAT 4496 02:49:50,560 --> 02:49:53,560 FOLKS GET PAID AND WE HAVE SEATS 4497 02:49:53,560 --> 02:49:55,000 TO SIT IN AND CONTRACTS TO BE 4498 02:49:55,000 --> 02:49:58,600 LET AND SO IT'S THOSE TWO LARGE 4499 02:49:58,600 --> 02:49:58,840 DIVISIONS. 4500 02:49:58,840 --> 02:50:03,240 AND AT A GLANCE, WE RECEIVE 1-- 4501 02:50:03,240 --> 02:50:03,760 ONE BILLION DOLLARS IN. 4502 02:50:03,760 --> 02:50:07,120 IF YOU Y22 AND ANOTHER WORN.5 IN 4503 02:50:07,120 --> 02:50:09,240 FY23 -- 1.5 -- WE HAVE 2 1/2 4504 02:50:09,240 --> 02:50:10,480 BILLION DOLLARS WE ARE LOOKING 4505 02:50:10,480 --> 02:50:14,240 TO EXPEND OVER THE NEXT COW OF 4506 02:50:14,240 --> 02:50:14,440 YEARS. 4507 02:50:14,440 --> 02:50:16,880 EVERYTHING WE DO IS EXTRAMURAL. 4508 02:50:16,880 --> 02:50:18,640 IT'S GOING TO BE DISEASE 4509 02:50:18,640 --> 02:50:19,560 AGNOSTIC AND THE MONEY GOES OUT. 4510 02:50:19,560 --> 02:50:23,120 WE DON'T HAVE BRICKS AND MORTAR 4511 02:50:23,120 --> 02:50:23,360 OR LABS. 4512 02:50:23,360 --> 02:50:24,680 THE PROGRAM MANAGERS ARE THE 4513 02:50:24,680 --> 02:50:25,000 ENGINE. 4514 02:50:25,000 --> 02:50:26,960 THEY DRIVE THE IDEAS AND THEY 4515 02:50:26,960 --> 02:50:28,800 DRIVE THE DECISION-MAKING. 4516 02:50:28,800 --> 02:50:30,880 OUR GOAL IS TOW REMAIN LEAN AND 4517 02:50:30,880 --> 02:50:31,120 NIMBLE. 4518 02:50:31,120 --> 02:50:34,080 WHEN YOU LOOK AT HOW BIG OF AN 4519 02:50:34,080 --> 02:50:34,720 ORGANIZATION WE WILL BE, WE HOPE 4520 02:50:34,720 --> 02:50:36,440 TO HAVE A VERY BALANCED APPROACH 4521 02:50:36,440 --> 02:50:37,840 BETWEEN THE PROGRAM MANAGERS AND 4522 02:50:37,840 --> 02:50:39,720 THE BUSINESS TEAM MANAGERS BUT 4523 02:50:39,720 --> 02:50:41,840 THE TOTAL FOOTPRINT OF 4524 02:50:41,840 --> 02:50:43,640 POTENTIALLY 100 OR SO PROGRAM 4525 02:50:43,640 --> 02:50:44,800 MANAGERS DEPENDING ON THE BUDGET 4526 02:50:44,800 --> 02:50:45,840 AND THEN THE BUSINESS SIDE WE'LL 4527 02:50:45,840 --> 02:50:49,720 HAVE 100 OR SO BUSINESS MEMBERS. 4528 02:50:49,720 --> 02:50:51,720 AND THE GOAL IS TO FUND THIS 4529 02:50:51,720 --> 02:50:54,520 HIGH UNCERTAINTY, HIGH 4530 02:50:54,520 --> 02:50:55,000 CONSEQUENCE RESEARCH. 4531 02:50:55,000 --> 02:50:57,320 SO THINGS THAT ARE ON THE CUSP 4532 02:50:57,320 --> 02:50:58,240 OF RISK THAT NO ONE ELSE CAN 4533 02:50:58,240 --> 02:50:58,800 TAKE ON. 4534 02:50:58,800 --> 02:51:00,120 AND WE ARE WILL BE TO ACCEPT 4535 02:51:00,120 --> 02:51:01,720 THAT RISK TO TRANSFORM THE 4536 02:51:01,720 --> 02:51:02,480 HEALTH ECOSYSTEM. 4537 02:51:02,480 --> 02:51:06,320 NEXT SLIDE. 4538 02:51:06,320 --> 02:51:07,800 SO, THIS IS THE GENERAL WAY WE 4539 02:51:07,800 --> 02:51:09,040 THINK ABOUT PROGRAM FOUNDATION. 4540 02:51:09,040 --> 02:51:12,240 SO THE FIRST IS, IT'S PROGRAM 4541 02:51:12,240 --> 02:51:13,080 MANAGERCENTRIC. 4542 02:51:13,080 --> 02:51:15,800 SO MUCH LIKE DARPA, WE WILL NOT 4543 02:51:15,800 --> 02:51:16,440 FUND PROGRAMS UNLESS WE HAVE A 4544 02:51:16,440 --> 02:51:18,880 PROGRAM MANAGER WHO COMES IN 4545 02:51:18,880 --> 02:51:20,120 WITH AN IDEA OF SOMETHING 4546 02:51:20,120 --> 02:51:23,280 RELATED TO THAT PROGRAM THAT IS 4547 02:51:23,280 --> 02:51:26,120 NEW AND NOVEL AND BASED ON THE 4548 02:51:26,120 --> 02:51:29,160 QUESTIONS THAT IS SOMETHING THAT 4549 02:51:29,160 --> 02:51:31,160 REALLY ARE THIS FRAMEWORK THAT 4550 02:51:31,160 --> 02:51:34,760 ALLOWS US TO CONSIDER THE 4551 02:51:34,760 --> 02:51:36,400 UNIQUENESS OF THE PROGRAM AND 4552 02:51:36,400 --> 02:51:39,960 THE WAY THE PROGRAM MANAGER 4553 02:51:39,960 --> 02:51:40,880 SEEKS TO ACTUALLY FIELD THAT 4554 02:51:40,880 --> 02:51:41,120 PROGRAM. 4555 02:51:41,120 --> 02:51:42,760 SO LOOKING AT THE PROGRAM 4556 02:51:42,760 --> 02:51:44,800 MANAGER IDENTIFYING DIFFICULT 4557 02:51:44,800 --> 02:51:46,920 HEALTH RELATED CHALLENGES THAT 4558 02:51:46,920 --> 02:51:48,680 IS RIGHT FOR SOLVING. 4559 02:51:48,680 --> 02:51:50,080 SO, THE CHALLENGES THAT WE WANT 4560 02:51:50,080 --> 02:51:52,360 TO TAKE - ARE THOSE THAT SHOULD 4561 02:51:52,360 --> 02:51:53,920 NOT BE EASILY SOLVABLE THROUGH 4562 02:51:53,920 --> 02:51:55,880 TRADITIONAL ACTIVITY. 4563 02:51:55,880 --> 02:51:58,440 SO IT'S SOMETHING THAT OUR 4564 02:51:58,440 --> 02:51:59,920 COLLEAGUES AT NIH THROUGH THEIR 4565 02:51:59,920 --> 02:52:01,720 PROCESSES, THEIR INNOVATING AND 4566 02:52:01,720 --> 02:52:02,600 PUSHING AT THE CUTTING-EDGE OF 4567 02:52:02,600 --> 02:52:05,120 RESEARCH AND TECHNOLOGY AND THIS 4568 02:52:05,120 --> 02:52:06,480 WOULD BE ONE STEP FURTHER DOWN 4569 02:52:06,480 --> 02:52:07,880 THE PIKE WHERE JUST WOULDN'T BE 4570 02:52:07,880 --> 02:52:09,800 APPROPRIATE FOR THE WAY THAT 4571 02:52:09,800 --> 02:52:11,320 THEIR FUNDING ACTIVITIES NOW. 4572 02:52:11,320 --> 02:52:12,880 BUT WE ALSO LOOK FOR 4573 02:52:12,880 --> 02:52:13,200 PARTNERSHIPS. 4574 02:52:13,200 --> 02:52:14,240 WHEN WE ARE GOING TO TAKE ON 4575 02:52:14,240 --> 02:52:15,280 THIS RESPONSIBILITY OF FUNDING 4576 02:52:15,280 --> 02:52:16,920 IT, WE HAVE OUR COLLEAGUES AT 4577 02:52:16,920 --> 02:52:20,080 NIH TO HELP WITH THE GUIDING THE 4578 02:52:20,080 --> 02:52:20,360 PROGRAMS. 4579 02:52:20,360 --> 02:52:21,520 ONCE WE HAVE IDENTIFIED THE 4580 02:52:21,520 --> 02:52:24,360 CHALLENGE, WE HAVE OUR PROGRAM 4581 02:52:24,360 --> 02:52:24,960 MANAGERS ONBOARD, WE GO TO THE 4582 02:52:24,960 --> 02:52:26,400 NEXT STEP WHICH IS THE LAUNCH. 4583 02:52:26,400 --> 02:52:30,240 SO THE PROGRAM MANAGER WILL 4584 02:52:30,240 --> 02:52:31,000 OVERSEE SEVERAL GROUPS OF 4585 02:52:31,000 --> 02:52:32,120 PERFORMERS AIMED AT SOLVING 4586 02:52:32,120 --> 02:52:32,360 PROBLEMS. 4587 02:52:32,360 --> 02:52:36,360 SO THIS IS ALL CONTRACTOR OR 4588 02:52:36,360 --> 02:52:38,640 COOPERATIVE AGREEMENT FUNDING. 4589 02:52:38,640 --> 02:52:39,440 NOT GRANTEES. 4590 02:52:39,440 --> 02:52:40,840 WE MAKE SURE THAT THE PROGRAM OR 4591 02:52:40,840 --> 02:52:42,600 PERFORMERS ARE ABLE TO COMPETE 4592 02:52:42,600 --> 02:52:44,440 TO CARRY OUT THE POTENTIAL 4593 02:52:44,440 --> 02:52:46,400 INNOVATIVE SOLUTIONS TO THE 4594 02:52:46,400 --> 02:52:46,640 CHALLENGE. 4595 02:52:46,640 --> 02:52:47,680 SO IT'S A LITTLE BIT DIFFERENT 4596 02:52:47,680 --> 02:52:49,320 THAN THE GRANT-BASED MODEL WHERE 4597 02:52:49,320 --> 02:52:51,720 THERE IS ACTUALLY CONTRACT OR 4598 02:52:51,720 --> 02:52:52,800 COOPERATIVE AGREEMENT BASED. 4599 02:52:52,800 --> 02:52:56,600 NEXT SLIDE. 4600 02:52:56,600 --> 02:53:00,400 BECAUSE WE HAVE THE ABILITY TO 4601 02:53:00,400 --> 02:53:01,360 SUPPORT CONTRACTS, WE WANT TO 4602 02:53:01,360 --> 02:53:03,920 REALLY MAKE SURE WE HAVE A 4603 02:53:03,920 --> 02:53:05,720 ROBUST EVALUATION PROCESS IN 4604 02:53:05,720 --> 02:53:06,120 PLACE. 4605 02:53:06,120 --> 02:53:08,520 SO WE WILL FUND MULTIPLE 4606 02:53:08,520 --> 02:53:09,120 PERFORMERS FOR ANY PARTICULAR 4607 02:53:09,120 --> 02:53:10,680 PROGRAM AND REALLY HELPING THAT 4608 02:53:10,680 --> 02:53:13,400 THE BEST PERFORMER WAS ABLE TOL 4609 02:53:13,400 --> 02:53:14,640 CONTRIBUTE THE SOLUTIONS THAT WE 4610 02:53:14,640 --> 02:53:15,360 NEED. 4611 02:53:15,360 --> 02:53:16,320 AND SO FOR EXAMPLE WE HAVE 4612 02:53:16,320 --> 02:53:21,040 PEOPLE WORKING ON A PARTICULAR 4613 02:53:21,040 --> 02:53:22,800 PROGRAM AREA. 4614 02:53:22,800 --> 02:53:23,560 WE'LL DESIGN A SERIES OF PHASE 4615 02:53:23,560 --> 02:53:24,800 GATES AND MILESTONES FOR US TO 4616 02:53:24,800 --> 02:53:27,160 BE ABLE TO EVALUATE, ARE THESE 4617 02:53:27,160 --> 02:53:30,000 PERFORMERS MEETING THOSE 4618 02:53:30,000 --> 02:53:31,440 STRUCTURED CRITERIA? 4619 02:53:31,440 --> 02:53:34,280 AND IF THEY ARE NOT, OUR GOAL IS 4620 02:53:34,280 --> 02:53:35,920 TO BE ABLE TO TAKE THOSE 4621 02:53:35,920 --> 02:53:37,440 RESOURCES THAT HAVE BEEN APPLIED 4622 02:53:37,440 --> 02:53:39,120 TO THE PERFORMERS THAT ARE 4623 02:53:39,120 --> 02:53:41,120 WORKING IN THIS SPACE THAT ARE 4624 02:53:41,120 --> 02:53:42,560 FAILING AND THEN REAPPLY THEM 4625 02:53:42,560 --> 02:53:44,760 EITHER TO THE PERFORMER THAT IS 4626 02:53:44,760 --> 02:53:47,160 WORKING OR TO OTHER AREAS WITHIN 4627 02:53:47,160 --> 02:53:48,160 THE ORGANIZATION. 4628 02:53:48,160 --> 02:53:49,440 AND BY DOING THIS APPROACH, WHAT 4629 02:53:49,440 --> 02:53:54,560 WE ARE HOPING IS THAT OF THE 4630 02:53:54,560 --> 02:53:55,120 PERFORMERS, ONE OR MORE THAT 4631 02:53:55,120 --> 02:53:57,720 REACHES THROUGH ALL THE VARIOUS 4632 02:53:57,720 --> 02:54:00,360 MILESTONES ANDISTS TO REACH THE 4633 02:54:00,360 --> 02:54:00,960 FINAL STATE OF THE PROGRAM OR 4634 02:54:00,960 --> 02:54:03,880 ACTIVITY THAT WE WERE HOPING TO 4635 02:54:03,880 --> 02:54:07,160 SEE FROM WITHIN THAT PERFORMER 4636 02:54:07,160 --> 02:54:09,360 COHORT. 4637 02:54:09,360 --> 02:54:09,880 NEXT SLIDE. 4638 02:54:09,880 --> 02:54:11,400 WE ARE NOT DONE THERE. 4639 02:54:11,400 --> 02:54:14,680 SO OUR BIG GOAL WITH OR PROGRAMS 4640 02:54:14,680 --> 02:54:16,600 IS TRANSITION. 4641 02:54:16,600 --> 02:54:18,840 SO, GIVING THE PROGRAM MANAGERS 4642 02:54:18,840 --> 02:54:19,360 AND THE PERFORMERS ALL THE 4643 02:54:19,360 --> 02:54:20,560 RESOURCES NECESSARY TO REACH 4644 02:54:20,560 --> 02:54:22,200 SUCCESS AND THEN TAKING WHATEVER 4645 02:54:22,200 --> 02:54:23,920 SUCCESS LOOKS LIKE, WHATEVER 4646 02:54:23,920 --> 02:54:27,200 THAT PRODUCT IS AND WORKING WITH 4647 02:54:27,200 --> 02:54:28,880 OUR TRANSITION PARTNERS SO THAT 4648 02:54:28,880 --> 02:54:31,360 WHEN THE CHALLENGE, PER SE IS 4649 02:54:31,360 --> 02:54:33,120 SOLVED, THE PROJECT CAN THEN 4650 02:54:33,120 --> 02:54:34,040 TRANSFER TO OTHER PARTNERS WHO 4651 02:54:34,040 --> 02:54:35,360 HAVE BEEN INVOLVED IN THE START 4652 02:54:35,360 --> 02:54:38,440 AND CAN SCALE THE SOLUTION TO 4653 02:54:38,440 --> 02:54:40,960 THE COMMUNITY THAT WOULD BE -- 4654 02:54:40,960 --> 02:54:43,040 THAT WOULD BENEFIT FROM HAVING 4655 02:54:43,040 --> 02:54:45,080 THAT SOLUTION IN THEIR 4656 02:54:45,080 --> 02:54:45,680 ECOSYSTEM. 4657 02:54:45,680 --> 02:54:48,120 SO, THE GOAL IS TO TAKE 4658 02:54:48,120 --> 02:54:49,400 EVERYTHING THAT WE DO, STOP AT 4659 02:54:49,400 --> 02:54:51,160 SOME POINT AND TRANSITION IT TO 4660 02:54:51,160 --> 02:54:53,480 OTHERS WHO CAN TAKE IT ON TO 4661 02:54:53,480 --> 02:54:55,600 WHATEVER THE NEXT STEPS ARE IN 4662 02:54:55,600 --> 02:54:58,400 THAT PRODUCT DEVELOPMENT 4663 02:54:58,400 --> 02:54:59,880 PATHWAY. 4664 02:54:59,880 --> 02:55:01,600 >>NEXT SLIDE. 4665 02:55:01,600 --> 02:55:04,440 THE PROGRAM MANAGERS ARE THE 4666 02:55:04,440 --> 02:55:05,000 CENTER OF THEUBE VERSE. 4667 02:55:05,000 --> 02:55:07,720 WE BRING THEM ON FOR 3-6 YEARS 4668 02:55:07,720 --> 02:55:10,280 SO THERE IS AN URGENCY THEY ALL 4669 02:55:10,280 --> 02:55:11,000 HAVE TO BE ABLE TO MAKE SURE 4670 02:55:11,000 --> 02:55:12,320 THEY ARE COMING IN WITH WELL 4671 02:55:12,320 --> 02:55:14,280 DEFINED CHALLENGES. 4672 02:55:14,280 --> 02:55:17,240 WE SUPPORT THEM WITH ESSENTIALLY 4673 02:55:17,240 --> 02:55:19,160 WRAP AROUND SERVICES FROM 4674 02:55:19,160 --> 02:55:19,960 EVERYTHING HOW TO WORK IN THE 4675 02:55:19,960 --> 02:55:22,120 FEDERAL GOVERNMENT, HOW TO DO 4676 02:55:22,120 --> 02:55:22,960 CONTRACTING, HOW TO LEAD TEAMS, 4677 02:55:22,960 --> 02:55:25,840 HOW TO MAKE SURE THAT YOU'RE 4678 02:55:25,840 --> 02:55:27,200 WORKING WELL WITH TRANSITION 4679 02:55:27,200 --> 02:55:30,840 PARTNERS FROM THE BEGINNING OF 4680 02:55:30,840 --> 02:55:33,000 YOUR TENURE. 4681 02:55:33,000 --> 02:55:35,280 AND THEN MOVE THEIR PROGRAMS 4682 02:55:35,280 --> 02:55:37,760 TOWARDS SOLUTIONS. 4683 02:55:37,760 --> 02:55:39,440 SO THEY HAVE THROUGH-6 YEARS 4684 02:55:39,440 --> 02:55:42,240 WITH US AND -- 3-6 YEARS AND AND 4685 02:55:42,240 --> 02:55:45,080 THEN THE PROGRAMS WILL LAST 2-4 4686 02:55:45,080 --> 02:55:45,520 YEARS. 4687 02:55:45,520 --> 02:55:48,560 AND THEY WILL BE HANDOFFS ON 4688 02:55:48,560 --> 02:55:49,280 OCCASION BETWEEN PROGRAM 4689 02:55:49,280 --> 02:55:50,480 MANAGERS THAT ARE OUTGOING AS 4690 02:55:50,480 --> 02:55:53,320 THEIR 6 YEARS COMES TO AN END 4691 02:55:53,320 --> 02:55:55,480 AND IN COMING WHEN THEY ARE JUST 4692 02:55:55,480 --> 02:55:56,320 STARTING AND THEY WILL HAND OVER 4693 02:55:56,320 --> 02:55:58,160 OR TAKE ON SOME PROGRAMS THAT 4694 02:55:58,160 --> 02:56:01,360 WERE ALREADY IN THE PIPELINE. 4695 02:56:01,360 --> 02:56:02,120 NEXT SLIDE. 4696 02:56:02,120 --> 02:56:04,080 WE FULLY RECOGNIZE THAT A 4697 02:56:04,080 --> 02:56:06,000 HEALTHY ECOSYSTEM IS VERY 4698 02:56:06,000 --> 02:56:06,560 COMPLEX. 4699 02:56:06,560 --> 02:56:10,400 MUCH MORE COMPLEX THAN YOU WOULD 4700 02:56:10,400 --> 02:56:11,720 SEE WITH DARPA OR ANYWHERE ELSE. 4701 02:56:11,720 --> 02:56:14,640 SOME OF THE OTHER ARPAs IN THE 4702 02:56:14,640 --> 02:56:15,040 FEDERAL GOVERNMENT. 4703 02:56:15,040 --> 02:56:17,280 AND WE WANT TO MAKE SURE WE ARE 4704 02:56:17,280 --> 02:56:18,560 EMBRACING THIS COMPLEXITY BY 4705 02:56:18,560 --> 02:56:20,040 PARTNERING WITH OUR COLLEAGUES 4706 02:56:20,040 --> 02:56:24,320 WITHIN HHS, FEDERAL GOVERNMENT, 4707 02:56:24,320 --> 02:56:24,920 INDUSTRY, ACADEMIA, PATIENT 4708 02:56:24,920 --> 02:56:26,720 GROUPS, HEALTH CARE PROVIDERS 4709 02:56:26,720 --> 02:56:28,400 AND THE AMERICAN PUBLIC BOTH ON 4710 02:56:28,400 --> 02:56:30,200 THE WHAT IS THE MOST URGENT AND 4711 02:56:30,200 --> 02:56:31,800 PRESSING NEEDS WITHIN THE 4712 02:56:31,800 --> 02:56:32,960 HEALTHY ECOSYSTEM AND ALSO AS WE 4713 02:56:32,960 --> 02:56:36,240 ARE DEVELOPING THESE 4714 02:56:36,240 --> 02:56:39,200 CAPABILITIES, WHAT DOES SUCCESS 4715 02:56:39,200 --> 02:56:39,800 LOOK LIKE FOR TRANSITION MAKING 4716 02:56:39,800 --> 02:56:41,800 SURE THEY ARE SUPPORTING THE 4717 02:56:41,800 --> 02:56:43,800 BROADEST SET OF CONSTITUENCIES 4718 02:56:43,800 --> 02:56:47,040 WITHIN THE HEALTHY ECOSYSTEM. 4719 02:56:47,040 --> 02:56:48,440 NEXT SLIDE. 4720 02:56:48,440 --> 02:56:49,840 SEE JUST TO TALK ABOUT WHAT WE 4721 02:56:49,840 --> 02:56:51,880 HAVE DONE AT NIH. 4722 02:56:51,880 --> 02:56:53,200 I CAN'T EMPHASIZE ENOUGH HOW 4723 02:56:53,200 --> 02:56:54,280 MUCH WE WANT TO MAKE SURE THAT 4724 02:56:54,280 --> 02:56:57,480 WE ARE PARTNERING WITH OUR 4725 02:56:57,480 --> 02:56:59,320 AMAZING COLLEAGUES AT NIH. 4726 02:56:59,320 --> 02:57:02,280 SO WE HAVE ALREADY HAD SEVERAL 4727 02:57:02,280 --> 02:57:04,360 OPPORTUNITIES TO WORK TOGETHER 4728 02:57:04,360 --> 02:57:05,000 MOSTLY NOW IT'S JUST TALKING AND 4729 02:57:05,000 --> 02:57:07,560 WE ARE HOPING THAT AT SOME POINT 4730 02:57:07,560 --> 02:57:09,520 IT'S ACTUALLY DOING MORE OF THE 4731 02:57:09,520 --> 02:57:13,240 TALKING, EXCHANGING TECHNICAL 4732 02:57:13,240 --> 02:57:14,040 INFORMATION, POTENTIALLY 4733 02:57:14,040 --> 02:57:15,120 COFUNDING VARIOUS ACTIVITIES. 4734 02:57:15,120 --> 02:57:18,640 REALLY MAKING SURE THAT WE ARE 4735 02:57:18,640 --> 02:57:20,040 OPTIMALLY LEVERAGING OUR 4736 02:57:20,040 --> 02:57:21,000 RELATIONSHIP WITHIN NIH. 4737 02:57:21,000 --> 02:57:23,720 SO WE HAVE DONE SEVERAL. 4738 02:57:23,720 --> 02:57:27,960 WE DID THE KICKOFF EVENT AT 4739 02:57:27,960 --> 02:57:29,600 HOWARD, A NUMBER OF DIFFERENT 4740 02:57:29,600 --> 02:57:34,920 SPEAKING ENGAGEMENTS THAT THE 4741 02:57:34,920 --> 02:57:36,600 DIRECTOR OF ARPAH ENGAGED IN 4742 02:57:36,600 --> 02:57:37,880 FROM -- YOU CAN READ THOSE. 4743 02:57:37,880 --> 02:57:41,000 SO JUST REALLY MAKING SURE THAT 4744 02:57:41,000 --> 02:57:43,640 WE ARE OPEN AND TRANSPARENT AND 4745 02:57:43,640 --> 02:57:46,160 REALLY MAKING SURE THAT WE ARE 4746 02:57:46,160 --> 02:57:48,320 REACHING ACROSS THE CAMPUS IT 4747 02:57:48,320 --> 02:57:50,240 OUR NIH COLLEAGUES SO WE CAN 4748 02:57:50,240 --> 02:57:50,760 BUILD THOSE PARTNERSHIPS. 4749 02:57:50,760 --> 02:57:52,040 AND WE HAVE SEVERAL THINGS WE 4750 02:57:52,040 --> 02:57:52,840 ARE GOING AT OR ABOUT DOING IN 4751 02:57:52,840 --> 02:57:53,440 THE FUTURE. 4752 02:57:53,440 --> 02:57:54,640 AND ALL OF WHICH WE ARE VERY, 4753 02:57:54,640 --> 02:57:58,280 VERY EXCITED ABOUT. 4754 02:57:58,280 --> 02:57:59,560 NEXT SLIDE. 4755 02:57:59,560 --> 02:58:02,640 I TALK A LITTLE BIT ABOUT THE 4756 02:58:02,640 --> 02:58:03,880 PROGRAM MANAGER, PROGRAM LIFE 4757 02:58:03,880 --> 02:58:04,080 CYCLE. 4758 02:58:04,080 --> 02:58:07,120 THIS GIVES A LITTLE BIT MORE OF 4759 02:58:07,120 --> 02:58:08,680 THE -- A LITTLE MORE OF THE 4760 02:58:08,680 --> 02:58:09,040 DETAILS. 4761 02:58:09,040 --> 02:58:12,600 I'M NOT GOING TO GO INTO ALL OF 4762 02:58:12,600 --> 02:58:13,320 THE SPECIFIC ELEMENTS. 4763 02:58:13,320 --> 02:58:14,960 YOU HAVE THE SLIDES. 4764 02:58:14,960 --> 02:58:15,960 REALLY THE GOAL IS TO MAKE SURE 4765 02:58:15,960 --> 02:58:18,600 THAT WE HAVE A CONSISTENT 4766 02:58:18,600 --> 02:58:20,600 SUCCESSFUL APPROACH FOR ALL THE 4767 02:58:20,600 --> 02:58:22,480 PROGRAM MANAGERS THAT COME ON 4768 02:58:22,480 --> 02:58:27,160 THAT WE HAVE WELL DEFINED 4769 02:58:27,160 --> 02:58:27,480 PROBLEMS. 4770 02:58:27,480 --> 02:58:28,960 THE PROGRAMS ARE DESIGNED TO 4771 02:58:28,960 --> 02:58:30,800 ADDRESS THOSE PROBLEMS AND THAT 4772 02:58:30,800 --> 02:58:32,560 AT THE END OF THE TENURE OF THE 4773 02:58:32,560 --> 02:58:34,360 PROGRAM MANAGER OR THE PROGRAM, 4774 02:58:34,360 --> 02:58:36,640 THAT WE CAN SUCCESSFULLY 4775 02:58:36,640 --> 02:58:38,320 COMMERCIALIZE OR TRANSITION AS 4776 02:58:38,320 --> 02:58:42,640 APPROPRIATE THE VARIOUS PRODU 4777 02:58:42,640 --> 02:58:42,920 PRODUCTS. 4778 02:58:42,920 --> 02:58:43,640 NEXT SLIDE. 4779 02:58:43,640 --> 02:58:45,360 SO THIS IS WHERE WE ARE STARTING 4780 02:58:45,360 --> 02:58:48,760 FROM OUR TECHNICAL STRATEGY. 4781 02:58:48,760 --> 02:58:50,600 SO WITHIN THE FIRST MONTH OR SO 4782 02:58:50,600 --> 02:58:53,200 OF COMING ONBOARD WAS THINKING 4783 02:58:53,200 --> 02:58:55,160 ABOUT HOW TO STRUCTURE OUR 4784 02:58:55,160 --> 02:58:55,800 PORTFOLIOS. 4785 02:58:55,800 --> 02:58:57,840 SO WE COVER THE BREATH OF THE 4786 02:58:57,840 --> 02:58:59,560 HEALTHY ECOSYSTEM BUT PUSHING 4787 02:58:59,560 --> 02:59:00,840 PUSHING TOWARDS THOSE AREAS THAT 4788 02:59:00,840 --> 02:59:03,200 ARE PARTICULARLY IN NEED OF 4789 02:59:03,200 --> 02:59:04,000 INNOVATION. 4790 02:59:04,000 --> 02:59:06,080 SO, WE SETTLED ON THESE FOUR 4791 02:59:06,080 --> 02:59:08,320 DIFFERENT LARGE DOMAINS THAT 4792 02:59:08,320 --> 02:59:09,600 WE'LL BE SUPPORTING PROGRAMS IN. 4793 02:59:09,600 --> 02:59:10,760 THE FIRST IS HEALTH SCIENCE 4794 02:59:10,760 --> 02:59:11,000 FUTURES. 4795 02:59:11,000 --> 02:59:13,000 AND THAT IS REALLY THINKING 4796 02:59:13,000 --> 02:59:14,800 ABOUT PLATFORMS THAT CAN APPLY 4797 02:59:14,800 --> 02:59:16,880 TO A BROAD RANGE OF DISEASES. 4798 02:59:16,880 --> 02:59:20,480 SO RATHER THAN GO ON THE DISEASE 4799 02:59:20,480 --> 02:59:22,800 BY DISEASE SPECIFIC PURSUIT OF 4800 02:59:22,800 --> 02:59:24,920 VARIOUS THERAPEUTICS AND 4801 02:59:24,920 --> 02:59:25,720 INTERVENTIONS, THIS IS SAYING 4802 02:59:25,720 --> 02:59:27,480 WHAT CAN WE DO FROM A PLATFORM 4803 02:59:27,480 --> 02:59:30,320 PERSPECTIVE THAT WOULD ALLOW US 4804 02:59:30,320 --> 02:59:31,880 TO ADDRESS AS MANY OF THESE 4805 02:59:31,880 --> 02:59:34,240 CHALLENGES AS POSSIBLE WITH A 4806 02:59:34,240 --> 02:59:36,560 SINGLE TOOL OR A SINGLE 4807 02:59:36,560 --> 02:59:38,680 PLATFORM. 4808 02:59:38,680 --> 02:59:40,680 SCALABLE SOLUTIONS IS REALLY 4809 02:59:40,680 --> 02:59:41,880 THINKING ABOUT HOW TO WE MAKE 4810 02:59:41,880 --> 02:59:43,760 SURE THAT THE SOLUTIONS THAT ARE 4811 02:59:43,760 --> 02:59:45,360 BEING DEVELOPED, AND THERE ARE 4812 02:59:45,360 --> 02:59:48,160 SOME SOLUTIONS THAT WORK AT A 4813 02:59:48,160 --> 02:59:49,880 SMALL SCALE FOR A SMALL 4814 02:59:49,880 --> 02:59:55,400 POPULATION, BUT REALLY NEED SOME 4815 02:59:55,400 --> 02:59:57,520 INNOVATION TO REACH EVERYONE AND 4816 02:59:57,520 --> 02:59:59,440 REACH EVERYONE WHO NEEDS THE 4817 02:59:59,440 --> 03:00:01,520 INTERVENTION AND THE THERAPY 4818 03:00:01,520 --> 03:00:02,200 VACCINE, WHATEVER IT HAPPENS TO 4819 03:00:02,200 --> 03:00:02,560 BE. 4820 03:00:02,560 --> 03:00:04,320 AND TO DO SO QUICKLY. 4821 03:00:04,320 --> 03:00:07,240 SO LOOKING AT BOTH GEOGRAPHY, 4822 03:00:07,240 --> 03:00:10,920 MANUFACTURING, DATA INFORMATION, 4823 03:00:10,920 --> 03:00:11,360 ECONOMIES OF SCALE. 4824 03:00:11,360 --> 03:00:14,480 SO TAKING EXISTING PRODUCTS AND 4825 03:00:14,480 --> 03:00:15,080 EXISTING 50s SAYING, HOW CAN 4826 03:00:15,080 --> 03:00:18,760 WE HELP SCALE THESE SOY THAT 4827 03:00:18,760 --> 03:00:19,920 EVERYONE CAN BENEFIT? 4828 03:00:19,920 --> 03:00:21,960 PROACTIVE HEALTH IS THINKING 4829 03:00:21,960 --> 03:00:23,760 ABOUT KEEPING PEOPLE FROM BEING 4830 03:00:23,760 --> 03:00:25,120 PATIENTS IN THE FIRST PLACE. 4831 03:00:25,120 --> 03:00:27,240 SO LOOKING AT PREVENTIVE 4832 03:00:27,240 --> 03:00:30,280 PROGRAMS IN DIFFERENT WAYS THAT 4833 03:00:30,280 --> 03:00:31,800 THINKING ABOUT CHARACTERIZING 4834 03:00:31,800 --> 03:00:35,440 DISEASE RISK AND PROMOTING 4835 03:00:35,440 --> 03:00:36,040 TREATMENTS AND BEHAVIORS THAT 4836 03:00:36,040 --> 03:00:40,560 AMOUNT THOSE THREATS SO WE CAN 4837 03:00:40,560 --> 03:00:44,280 MITIGATE THE POTENTIAL TO HEALTH 4838 03:00:44,280 --> 03:00:46,920 IMPACTS BY UP STREAMING BY BEING 4839 03:00:46,920 --> 03:00:49,000 PROACTIVE ABOUT THE 4840 03:00:49,000 --> 03:00:50,200 INTERVENTIONS THAT WILL BE 4841 03:00:50,200 --> 03:00:50,920 PURSUING AND THEN RESILIENT 4842 03:00:50,920 --> 03:00:52,560 SYSTEM SYSTEM. 4843 03:00:52,560 --> 03:00:56,200 THIS IS ABOUT HOW DO WE CREATE A 4844 03:00:56,200 --> 03:00:57,520 BETTER HEALTH CARE SYSTEM? 4845 03:00:57,520 --> 03:01:00,600 SO LOOKING AT CAPABILITIES, 4846 03:01:00,600 --> 03:01:02,960 BUSINESS MODELS, INTEGRATION 4847 03:01:02,960 --> 03:01:04,080 THAT ALLOWS US TO WEATHER CRISIS 4848 03:01:04,080 --> 03:01:06,600 SUCH AS PANDEMICS, SOCIAL 4849 03:01:06,600 --> 03:01:07,200 DISRUPTIONS, CLIMATE CHANGE, 4850 03:01:07,200 --> 03:01:09,200 ECONOMIC INSTABILITY. 4851 03:01:09,200 --> 03:01:11,560 SYSTEMS THAT ARE SUSTAINED 4852 03:01:11,560 --> 03:01:13,680 BETWEEN CRISIS FROM THE 4853 03:01:13,680 --> 03:01:14,240 MOLECULAR TO THE SOCIETAL. 4854 03:01:14,240 --> 03:01:15,800 AND I THINK WE HAVE SEEN THIS. 4855 03:01:15,800 --> 03:01:17,280 I HAVE BEEN IN GOVERNMENT FOR 4856 03:01:17,280 --> 03:01:19,200 QUITE SOMETIME AND IN LEADERSHIP 4857 03:01:19,200 --> 03:01:20,840 POSITIONS IN THE HEALTH 4858 03:01:20,840 --> 03:01:21,560 INNOVATION FOR QUITE SOMETIME 4859 03:01:21,560 --> 03:01:22,680 AND THERE IS NOTHING MORE 4860 03:01:22,680 --> 03:01:25,720 FRUSTRATING WHEN YOU HAVE ANG 4861 03:01:25,720 --> 03:01:26,320 EMERGENT CRISIS AND EVERYTHING 4862 03:01:26,320 --> 03:01:29,960 RUSHES TO FIND A SOLUTION AND 4863 03:01:29,960 --> 03:01:32,280 THERE IS NEVER TIME TO ACTUALLY 4864 03:01:32,280 --> 03:01:34,560 GET FROM SOLUTION IDEATION TO 4865 03:01:34,560 --> 03:01:35,760 DEPLOYMENT OF SOMETHING THAT IS 4866 03:01:35,760 --> 03:01:36,960 SUSTAINABLE BEFORE THAT CRISIS 4867 03:01:36,960 --> 03:01:39,440 ENDS UP PASSING AND ATTENTION 4868 03:01:39,440 --> 03:01:41,920 GETS DILUTED IN OTHER CRISIS 4869 03:01:41,920 --> 03:01:42,440 COME ON. 4870 03:01:42,440 --> 03:01:45,840 AND THEN YOU FIND YOURSELF IN 4871 03:01:45,840 --> 03:01:47,280 THAT SAME SITUATION TWO, 5, 10 4872 03:01:47,280 --> 03:01:49,440 YEARS LATER AND IT'S ALMOST 4873 03:01:49,440 --> 03:01:50,880 LIKE, GROUNDHOG DAY WHERE YOU'RE 4874 03:01:50,880 --> 03:01:53,520 SAYING, WE WERE JUST HERE AND WE 4875 03:01:53,520 --> 03:01:55,360 DIDN'T ACTUALLY DEVELOP 4876 03:01:55,360 --> 03:01:59,840 SOMETHING THAT WAS READY TO BE 4877 03:01:59,840 --> 03:02:02,120 PUT IN PLACE RAPIDLY TO MITIGATE 4878 03:02:02,120 --> 03:02:03,000 THE CIRCUMSTANCES OF THE 4879 03:02:03,000 --> 03:02:03,480 EMERGING ISSUE. 4880 03:02:03,480 --> 03:02:06,600 SO THINKING ABOUT WHAT RESILIENT 4881 03:02:06,600 --> 03:02:07,880 SYSTEMS AND HEALTH CARE LOOKS 4882 03:02:07,880 --> 03:02:09,520 LIKE. 4883 03:02:09,520 --> 03:02:12,480 NEXT SLIDE. 4884 03:02:12,480 --> 03:02:13,600 OY TALKED A LOT ABOUT THE 4885 03:02:13,600 --> 03:02:14,080 PROGRAM MOTHER-IN-LAW. 4886 03:02:14,080 --> 03:02:16,400 THIS IS WHERE WE CAN USE YOUR 4887 03:02:16,400 --> 03:02:16,600 HELP. 4888 03:02:16,600 --> 03:02:16,880 -- MANAGER. 4889 03:02:16,880 --> 03:02:18,040 WE ARE LOOKING FOR INDIVIDUALS 4890 03:02:18,040 --> 03:02:21,480 WHO WILL COME ON TO CHAMPION THE 4891 03:02:21,480 --> 03:02:23,880 VARIOUS PORTFOLIO AREAS WITH 4892 03:02:23,880 --> 03:02:26,280 PROGRAMS THAT WE ALL KNOW ARE SO 4893 03:02:26,280 --> 03:02:26,760 CRUCIAL AND IMPORTANT. 4894 03:02:26,760 --> 03:02:29,080 AGING IS ONE OF THOSE HOW DO WE 4895 03:02:29,080 --> 03:02:30,520 AGE MORE HEALTHY? 4896 03:02:30,520 --> 03:02:37,480 HOW DO WE ACTUALLY THINK ABOUT 4897 03:02:37,480 --> 03:02:40,200 THE -- WHETHER OR NOT THERE ARE 4898 03:02:40,200 --> 03:02:42,560 BEHAVIORAL HEALTH OR CLINICAL 4899 03:02:42,560 --> 03:02:45,240 CARE, INTERVENTIONS THAT WOULD 4900 03:02:45,240 --> 03:02:49,640 ALLOW US TO AGE BETTER TO REDUCE 4901 03:02:49,640 --> 03:02:53,040 THE POTENTIAL DISEASES THAT COME 4902 03:02:53,040 --> 03:02:53,640 ON WITH AGING. 4903 03:02:53,640 --> 03:02:57,080 SO REALLY THINKING ABOUT THAT AS 4904 03:02:57,080 --> 03:02:58,720 AN OPPORTUNITY TO IDENTIFY 4905 03:02:58,720 --> 03:03:00,240 PROGRAM MANAGERS WHO ARE 4906 03:03:00,240 --> 03:03:01,960 PASSIONATED ABOUT THIS SECTOR 4907 03:03:01,960 --> 03:03:03,200 AND THEY ARE WILLING TO COME ON 4908 03:03:03,200 --> 03:03:06,280 FOR 3-6 YEARS, TAKE ON REALLY 4909 03:03:06,280 --> 03:03:07,720 HARD PROBLEMS AND BE GIVEN ALL 4910 03:03:07,720 --> 03:03:12,160 THE RESOURCES NECESSARY TO BE 4911 03:03:12,160 --> 03:03:12,600 SUCCESSFUL. 4912 03:03:12,600 --> 03:03:14,080 AND IT IS FULLY SUPPORTIVE. 4913 03:03:14,080 --> 03:03:16,760 WE HAVE BUSINESS AND TECHNICAL 4914 03:03:16,760 --> 03:03:19,760 TEAMS THAT WILL ALLOW SOMEONE 4915 03:03:19,760 --> 03:03:20,840 WHO MAYBE NEVER WORKED IN 4916 03:03:20,840 --> 03:03:21,680 GOVERNMENT, NO THE TO HAVE TO 4917 03:03:21,680 --> 03:03:24,280 WORRY ABOUT HOW DOES THAT WORK. 4918 03:03:24,280 --> 03:03:26,280 BECAUSE WE'LL SUPPORT OR FILL IN 4919 03:03:26,280 --> 03:03:27,840 THE GAPS ASSOCIATED WITH THAT 4920 03:03:27,840 --> 03:03:30,760 WITH OUR TEAM. 4921 03:03:30,760 --> 03:03:32,360 AND THEN THE RESPONSIBILITY ONCE 4922 03:03:32,360 --> 03:03:34,480 THEY ARE IN THE DOOR, AND THEY 4923 03:03:34,480 --> 03:03:35,160 HAVE IDENTIFIED THE PROBLEMS, IS 4924 03:03:35,160 --> 03:03:36,680 TO ASSEMBLE A TEAM FROM 4925 03:03:36,680 --> 03:03:37,560 INDUSTRY, ACADEMIA AND 4926 03:03:37,560 --> 03:03:40,560 GOVERNMENT AND GO OUT AND SOLVE 4927 03:03:40,560 --> 03:03:43,120 THE PROBLEMS. 4928 03:03:43,120 --> 03:03:45,160 NEXT SLIDE. 4929 03:03:45,160 --> 03:03:48,960 PEOPLE ASK US, WHAT ARE THE 4930 03:03:48,960 --> 03:03:49,920 CRITERIA FOR OUR PROGRAM 4931 03:03:49,920 --> 03:03:50,240 MANAGER? 4932 03:03:50,240 --> 03:03:54,000 AND THE ANSWER IS, WE DON'T HAVE 4933 03:03:54,000 --> 03:03:56,800 ANY SET CRITERIA THAT ONE NEEDS 4934 03:03:56,800 --> 03:03:59,520 TO HAVE GONE THROUGH THE PHASE 4935 03:03:59,520 --> 03:04:00,280 GATES ASSOCIATED WITH IT. 4936 03:04:00,280 --> 03:04:02,040 WE ARE LOOKING FOR UNCOMMON 4937 03:04:02,040 --> 03:04:03,080 PEOPLE WITH UNCOMMON TRAITS. 4938 03:04:03,080 --> 03:04:05,400 SO PEOPLE WHO HAVE EXPERTISE 4939 03:04:05,400 --> 03:04:08,000 THAT ARE JUST INIZATIONABLY 4940 03:04:08,000 --> 03:04:08,240 CURIOUS. 4941 03:04:08,240 --> 03:04:08,960 HOW COME THIS? 4942 03:04:08,960 --> 03:04:10,520 HOW DOES THIS WORK THIS WAY? 4943 03:04:10,520 --> 03:04:13,440 IT'S HELPFUL TO HAVE AN 4944 03:04:13,440 --> 03:04:14,240 INTERDISCIPLINARY TRACK RECORD. 4945 03:04:14,240 --> 03:04:17,160 SO THEY WORKED IN ACADEMIA, 4946 03:04:17,160 --> 03:04:18,840 GOVERNMENT, PRIVATE SECTOR AND 4947 03:04:18,840 --> 03:04:22,000 MORE THAN ONE PORTFOLIO AREA. 4948 03:04:22,000 --> 03:04:23,000 IT'S NOT A -- IF YOU DON'T HAVE 4949 03:04:23,000 --> 03:04:25,200 THAT, YOU CAN'T BE HIRED. 4950 03:04:25,200 --> 03:04:26,960 IT'S JUST THAT IT WOULD BE 4951 03:04:26,960 --> 03:04:29,080 HELPFUL TO YOU AND THEM AS THEY 4952 03:04:29,080 --> 03:04:31,840 ARE WORKING WITHIN THE 4953 03:04:31,840 --> 03:04:32,160 GOVERNMENT. 4954 03:04:32,160 --> 03:04:34,640 SERIOUSLY SO YOU ONLY HAVE 3-6 4955 03:04:34,640 --> 03:04:34,840 YEARS. 4956 03:04:34,840 --> 03:04:36,160 WE NEED PEOPLE WHO WAKE UP EVERY 4957 03:04:36,160 --> 03:04:39,200 DAY WHO ARE READY TO JUST KEEP 4958 03:04:39,200 --> 03:04:42,600 PUSHING ALONG AND IT IS INTENSE 4959 03:04:42,600 --> 03:04:46,520 TRYING TO MAKE SURE THAT YOU CAN 4960 03:04:46,520 --> 03:04:47,520 CONTRIBUTE SOMETHING OF 4961 03:04:47,520 --> 03:04:52,280 SIGNIFICANCE COMING OUT OF HERE 4962 03:04:52,280 --> 03:04:53,080 IN YOUR LIMITED TENURE HERE. 4963 03:04:53,080 --> 03:04:54,400 AND NO FEAR OF FAILURE. 4964 03:04:54,400 --> 03:04:57,120 SO FAILURE TO US IS NOT THAT THE 4965 03:04:57,120 --> 03:04:57,800 PROGRAM DIDN'T WORK. 4966 03:04:57,800 --> 03:04:59,600 THE FAILURE IS IF TWEE DIDN'T 4967 03:04:59,600 --> 03:05:01,080 LEARN ANYTHING. 4968 03:05:01,080 --> 03:05:05,200 AND IF WE DIDN'T TAKE THOSE 4969 03:05:05,200 --> 03:05:06,400 FINDINGS OF IF SOMETHING FAILED 4970 03:05:06,400 --> 03:05:09,080 AND SHARE IT SO NOT ONLY ARE WE 4971 03:05:09,080 --> 03:05:10,320 LEARNING WITHIN THE ORGANIZATION 4972 03:05:10,320 --> 03:05:12,040 WHY SOMETHING DIDN'T WORK BUT WE 4973 03:05:12,040 --> 03:05:13,440 GIVE THAT KNOWLEDGE OUT TO 4974 03:05:13,440 --> 03:05:14,640 EVERYONE ELSE WHO MAY BE 4975 03:05:14,640 --> 03:05:15,720 THINKING ABOUT THE SAME TYPE OF 4976 03:05:15,720 --> 03:05:17,600 ACTIVITY OR PORTFOLIO. 4977 03:05:17,600 --> 03:05:19,320 IN WHICH CASE, THEN IT'S NOT A 4978 03:05:19,320 --> 03:05:21,880 FAILURE, IT'S AN INCREDIBLE 4979 03:05:21,880 --> 03:05:23,000 VALUE TO THE RESEARCH THAT IS 4980 03:05:23,000 --> 03:05:23,600 GOING ON. 4981 03:05:23,600 --> 03:05:25,160 AND THEN TECHNICAL HONESTY. 4982 03:05:25,160 --> 03:05:27,520 OUR GOAL IS TO BE ABLE TO 4983 03:05:27,520 --> 03:05:29,200 TRANSITION PRODUCTS THAT CAN GO 4984 03:05:29,200 --> 03:05:31,200 OUT AND BE EFFECTIVE IN THE 4985 03:05:31,200 --> 03:05:32,080 HEALTHY ECOSYSTEM. 4986 03:05:32,080 --> 03:05:34,400 SO ALL ALONG THE WAY WE HAVE TO 4987 03:05:34,400 --> 03:05:35,000 MAKE SURE THAT THEY HAVE THE 4988 03:05:35,000 --> 03:05:36,520 HIGHEST LEVEL OF INTEGRITY TO 4989 03:05:36,520 --> 03:05:37,880 MAKE SURE THAT WE ARE BUILDING 4990 03:05:37,880 --> 03:05:39,920 SOMETHING THAT WILL WORK AND IS 4991 03:05:39,920 --> 03:05:40,400 SUSTAINABLE. 4992 03:05:40,400 --> 03:05:42,200 AND THEN THERE ARE DIFFERENT 4993 03:05:42,200 --> 03:05:43,640 APPROACHES TO THE CAREER STAGE, 4994 03:05:43,640 --> 03:05:44,200 I'M NOT GOING IN THERE. 4995 03:05:44,200 --> 03:05:44,880 YOU CAN READ THOSE. 4996 03:05:44,880 --> 03:05:47,640 BUT REALLY THAT IDEA IS THAT 4997 03:05:47,640 --> 03:05:49,840 THERE IS NO ONE TYPE OF 4998 03:05:49,840 --> 03:05:52,360 INDIVIDUAL THAT WE ARE LOOKING 4999 03:05:52,360 --> 03:05:53,120 FOR IN THE PROGRAM MANAGER. 5000 03:05:53,120 --> 03:05:55,120 WE ARE LOOKING FOR EVERYONE WHO 5001 03:05:55,120 --> 03:05:57,120 SORT OF HAS SOME COMPOSITION OF 5002 03:05:57,120 --> 03:05:59,720 IDEAS OF THESE CRITERIA AND IS 5003 03:05:59,720 --> 03:06:01,080 REALLY EXCITED ABOUT COMING TO 5004 03:06:01,080 --> 03:06:01,840 JOIN US. 5005 03:06:01,840 --> 03:06:04,680 NEXT SLIDE. 5006 03:06:04,680 --> 03:06:05,760 THESE ARE THE QUESTIONS. 5007 03:06:05,760 --> 03:06:09,240 SO THIS IS HOW WE THINK ABOUT 5008 03:06:09,240 --> 03:06:11,160 WHETHER OR NOT A PROGRAM MANAGER 5009 03:06:11,160 --> 03:06:15,040 HAS CONCEPTUALIZED THE CHALLENGE 5010 03:06:15,040 --> 03:06:17,120 AND THE SOLUTION IN A WAY THAT 5011 03:06:17,120 --> 03:06:20,080 WE CAN UNDERSTAND AND ASSESS HOW 5012 03:06:20,080 --> 03:06:21,680 UNIQUE IT IS AND WHETHER OR NOT 5013 03:06:21,680 --> 03:06:24,840 IT IS GOING TO HAVE A 5014 03:06:24,840 --> 03:06:25,480 TRANSFORMATIONAL IMPACT. 5015 03:06:25,480 --> 03:06:28,720 SO THESE ARE DERIVED FROM THE 5016 03:06:28,720 --> 03:06:31,800 DARPA QUESTIONS AND THEY ARE 5017 03:06:31,800 --> 03:06:34,280 VERY SIMPLE TO WRITE. 5018 03:06:34,280 --> 03:06:36,360 THEY ARE MISLEADINGLY HARD TO 5019 03:06:36,360 --> 03:06:36,640 ADDRESS. 5020 03:06:36,640 --> 03:06:38,240 ESPECIALLY WE HAVE A REALLY 5021 03:06:38,240 --> 03:06:41,200 STRONG TECHNICAL TEAM THAT IS 5022 03:06:41,200 --> 03:06:42,560 EVALUATING EVERY SUBMISSION AND 5023 03:06:42,560 --> 03:06:44,080 REALLY TOO IING TO MAKE SURE 5024 03:06:44,080 --> 03:06:46,440 THAT THE BEST ANSWERS ARE COMING 5025 03:06:46,440 --> 03:06:47,840 THROUGH FROM THE POTENTIAL 5026 03:06:47,840 --> 03:06:48,840 PROGRAM MANAGERS. 5027 03:06:48,840 --> 03:06:52,000 WE DID ADD TWO CRITERIA. 5028 03:06:52,000 --> 03:06:54,480 SO FIRST 8 COME FROM TARP A THE 5029 03:06:54,480 --> 03:06:55,040 LAST TWO ARE ONES WE ADDED 5030 03:06:55,040 --> 03:06:59,720 BECAUSE THEY ARE SO IMPORTANT 5031 03:06:59,720 --> 03:07:00,680 FOR OUR HEALTH ASPECT OF BEING 5032 03:07:00,680 --> 03:07:01,560 IN OUR BOAT. 5033 03:07:01,560 --> 03:07:02,680 THE FIRST IS WE WANT TO MAKE 5034 03:07:02,680 --> 03:07:06,360 SURE THAT THERE IS EQUITABLE 5035 03:07:06,360 --> 03:07:08,200 ACCESS FOR ALL PEOPLE. 5036 03:07:08,200 --> 03:07:09,720 SO, ENSURING THAT COST, 5037 03:07:09,720 --> 03:07:10,560 ACCESSIBILITY AND USER 5038 03:07:10,560 --> 03:07:11,920 EXPERIENCE WILL ALL BE ADDRESSED 5039 03:07:11,920 --> 03:07:15,200 IN TERMS OF THE PROGRAM. 5040 03:07:15,200 --> 03:07:16,120 AND THEN THE LAST ONE IS 5041 03:07:16,120 --> 03:07:17,160 MISPERCEPTION OR MISUSE. 5042 03:07:17,160 --> 03:07:18,840 WE KNOW THAT THERE ARE 5043 03:07:18,840 --> 03:07:20,640 CHALLENGES IN SCIENCE 5044 03:07:20,640 --> 03:07:21,280 COMMUNICATION AND ASSEMBLY FROM 5045 03:07:21,280 --> 03:07:22,640 THE BROADER PUBLIC AND SO MAKING 5046 03:07:22,640 --> 03:07:25,360 SURE THAT IF WE ARE DESIGNING A 5047 03:07:25,360 --> 03:07:27,960 PROGRAM OR A PARTICULAR SOLUTION 5048 03:07:27,960 --> 03:07:30,160 FROM WITHIN THE PROGRAM AREA, 5049 03:07:30,160 --> 03:07:31,480 THINKING REALLY CRITICALLY, LIKE 5050 03:07:31,480 --> 03:07:33,800 HOW COULD THIS POTENTIALLY BE 5051 03:07:33,800 --> 03:07:35,520 MISPERCEIVED OR MISUSED? 5052 03:07:35,520 --> 03:07:36,360 AND THEN HOW WOULD WE MITIGATE 5053 03:07:36,360 --> 03:07:37,800 THAT AND MAKE SURE THAT IS BUILT 5054 03:07:37,800 --> 03:07:38,960 IN FROM THE PROGRAM DESIGN IN 5055 03:07:38,960 --> 03:07:40,120 THE FIRST PLACE? 5056 03:07:40,120 --> 03:07:44,800 NEXT SLIDE. 5057 03:07:44,800 --> 03:07:48,000 SO, HOW DO WE THINK ABOUT 5058 03:07:48,000 --> 03:07:48,880 SUCCESS? 5059 03:07:48,880 --> 03:07:51,560 WE TALKED ABOUT THE WELL DEFINED 5060 03:07:51,560 --> 03:07:51,880 PROBLEMS. 5061 03:07:51,880 --> 03:07:54,240 WE TALKED ABOUT THE PROGRAM LIFE 5062 03:07:54,240 --> 03:07:54,440 CYCLE. 5063 03:07:54,440 --> 03:07:56,880 THE GOAL IS, THESE PRODUCTS OR 5064 03:07:56,880 --> 03:08:02,200 ACTIVITIES WE ENGAGE IN, THEY 5065 03:08:02,200 --> 03:08:04,560 CAN MEANINGFULLY HELP REAL 5066 03:08:04,560 --> 03:08:08,280 PEOPLE WHO WANT THEM AND WILL 5067 03:08:08,280 --> 03:08:08,600 ADOPT THEM. 5068 03:08:08,600 --> 03:08:10,960 WE TALK ABOUT SEPARATING THE 5069 03:08:10,960 --> 03:08:14,560 IMPROBABLE FROM IMPOSSIBLE. 5070 03:08:14,560 --> 03:08:15,160 OCCASIONALLY YOU SAY YOU WANT TO 5071 03:08:15,160 --> 03:08:16,640 DO THIS THING AND YOU GET A 5072 03:08:16,640 --> 03:08:17,880 CONSTITUENCY THAT SAYS, THAT IS 5073 03:08:17,880 --> 03:08:18,680 IMPOSSIBLE. 5074 03:08:18,680 --> 03:08:19,840 WE DON'T THINK ANYTHING IS 5075 03:08:19,840 --> 03:08:20,160 IMPOSSIBLE. 5076 03:08:20,160 --> 03:08:21,000 WE THINK WITH THE RIGHT THINKING 5077 03:08:21,000 --> 03:08:22,960 WE CAN TAKE IT TO IMPROBABLE AND 5078 03:08:22,960 --> 03:08:26,960 THAT IS REALLY WHERE WE WANT TO 5079 03:08:26,960 --> 03:08:29,200 EXIST IS THOSE THINGS THAT 5080 03:08:29,200 --> 03:08:30,080 SEEMINGLY ARE IMPOSSIBLE, WHAT 5081 03:08:30,080 --> 03:08:34,760 CAN WE DO TO DESIGN A PROGRAM TO 5082 03:08:34,760 --> 03:08:36,480 MAKE THEM MEASURE IN THE 5083 03:08:36,480 --> 03:08:38,360 IMPROBABLE SIDE AND THEN WE'LL 5084 03:08:38,360 --> 03:08:40,240 TAKE ON THAT RISK AND WITH THE 5085 03:08:40,240 --> 03:08:41,320 RIGHT PROGRAM MANAGERS AND THE 5086 03:08:41,320 --> 03:08:43,000 RIGHT FUNDING, WE'LL SEE IF WE 5087 03:08:43,000 --> 03:08:44,120 CAN ADDRESS IT. 5088 03:08:44,120 --> 03:08:46,480 AND THEN AGAIN, DELIVER A BETTER 5089 03:08:46,480 --> 03:08:48,560 HEALTH RESULTS TO EVERYONE. 5090 03:08:48,560 --> 03:08:50,160 SO, WE, IT'S WIDE OPEN THE WAY 5091 03:08:50,160 --> 03:08:53,080 WE ARE THINKING ABOUT HOW WE 5092 03:08:53,080 --> 03:08:54,400 PRIORITIZE WITHIN THE HEALTHY 5093 03:08:54,400 --> 03:08:57,000 ECOSYSTEM AND SO LOOKING FOR THE 5094 03:08:57,000 --> 03:08:58,800 PROGRAM MANAGERS TO HELP DRIVE 5095 03:08:58,800 --> 03:08:59,000 THAT. 5096 03:08:59,000 --> 03:09:02,880 AND OUR FUNDING WILL BE VERY 5097 03:09:02,880 --> 03:09:03,720 FLEXIBLE, CONTRACTS AND 5098 03:09:03,720 --> 03:09:05,080 COOPERATIVE AGREEMENTS, OTHER 5099 03:09:05,080 --> 03:09:06,520 TRANSACTIONAL AUTHORITY IS IT'S 5100 03:09:06,520 --> 03:09:09,440 NOT GRANTS BASED WHICH IS AGAIN 5101 03:09:09,440 --> 03:09:13,360 A UNIQUE CAPABILITY WE HAVE 5102 03:09:13,360 --> 03:09:15,360 WITHIN THE NIH ECOSYSTEM. 5103 03:09:15,360 --> 03:09:15,680 NEXT SLIDE. 5104 03:09:15,680 --> 03:09:17,320 THE LAST THING I WANT TO TALK 5105 03:09:17,320 --> 03:09:18,560 ABOUT AND I'LL STOP AND OPEN UP 5106 03:09:18,560 --> 03:09:20,240 FOR QUESTIONS, THE WAY WE ARE 5107 03:09:20,240 --> 03:09:22,080 THINKERRING ABOUT ENSURING THAT 5108 03:09:22,080 --> 03:09:25,680 WE CAN TAKE A PRODUCT AND REALLY 5109 03:09:25,680 --> 03:09:28,800 TRANSITION IT TO THE CURRENT 5110 03:09:28,800 --> 03:09:30,320 SECTOR OR CURRENT MARKET. 5111 03:09:30,320 --> 03:09:31,440 WHICH IS CRITICALLY IMPORTANT 5112 03:09:31,440 --> 03:09:33,400 FOR THE VAST MAJORITY OF WHAT WE 5113 03:09:33,400 --> 03:09:33,560 DO. 5114 03:09:33,560 --> 03:09:36,720 WE ARE BUILDING IN, DEVELOPED AN 5115 03:09:36,720 --> 03:09:40,840 ENTIRELY NYE OFFICE DIFFERENT 5116 03:09:40,840 --> 03:09:42,560 THAN DARPA AND THE OTHERS AND IT 5117 03:09:42,560 --> 03:09:45,680 SPECIFICALLY IS DEDICATED TO 5118 03:09:45,680 --> 03:09:46,240 TRANSITION OF PATIENTS. 5119 03:09:46,240 --> 03:09:49,520 SO WE HAVE A SUPPORT PROGRAM. 5120 03:09:49,520 --> 03:09:51,120 WHEN A PROGRAM MANAGER IS 5121 03:09:51,120 --> 03:09:52,480 DESIGNING THAT PROGRAM, WE WILL 5122 03:09:52,480 --> 03:09:54,080 DO A NUMBER OF DIFFERENT 5123 03:09:54,080 --> 03:09:56,160 ACTIVITIES INCLUDING MARKET 5124 03:09:56,160 --> 03:09:57,640 ACCESSMENT AND HUMAN SUBJECT 5125 03:09:57,640 --> 03:09:59,560 DESIGN TO SUPPORT OMIZEDING THAT 5126 03:09:59,560 --> 03:10:00,360 PROGRAM. 5127 03:10:00,360 --> 03:10:03,480 MAKING SURE THAT DURING BAA 5128 03:10:03,480 --> 03:10:05,560 DEVELOPMENT, THE WE THINK WHO 5129 03:10:05,560 --> 03:10:09,200 ARE THE PERFORMERS AND HOW CAN 5130 03:10:09,200 --> 03:10:10,680 WE LEVERAGE INNOVATION HUBS TO 5131 03:10:10,680 --> 03:10:14,480 BE ABLE TO SUPPORT THE PROGRAM 5132 03:10:14,480 --> 03:10:14,760 DEVELOPMENT. 5133 03:10:14,760 --> 03:10:17,120 WE'LL DO VENTURE CAPITAL STYLE 5134 03:10:17,120 --> 03:10:20,280 DUE DILIGENCE MAKING SURE THE 5135 03:10:20,280 --> 03:10:23,000 PERFORMERS CAN BE TRUSTED WITH 5136 03:10:23,000 --> 03:10:26,040 THE RESOURCES THAT WE ARE 5137 03:10:26,040 --> 03:10:26,680 AFFORDING THEM, THE TIME WE ARE 5138 03:10:26,680 --> 03:10:27,040 AFFORDING THEM. 5139 03:10:27,040 --> 03:10:28,960 AND VALIDATE THE TRANSITION 5140 03:10:28,960 --> 03:10:29,240 POTENTIAL. 5141 03:10:29,240 --> 03:10:33,000 LOOK AT A LOT OF EARLY PROGRAM 5142 03:10:33,000 --> 03:10:33,240 PERFORMS. 5143 03:10:33,240 --> 03:10:34,600 I TALKED ABOUT THAT. 5144 03:10:34,600 --> 03:10:37,320 BRINGING FROM INVESTORS, TRYING 5145 03:10:37,320 --> 03:10:39,160 TO MAKE SHUSH THAT WE IDENTIFY 5146 03:10:39,160 --> 03:10:39,960 MITIGATING RISK. 5147 03:10:39,960 --> 03:10:42,280 THE REGULATORY PROCESS IS HUGELY 5148 03:10:42,280 --> 03:10:44,200 COMPLEX MAKING SURE THAT ANY OF 5149 03:10:44,200 --> 03:10:45,640 THE PERFORMERS AND THE PROGRAM 5150 03:10:45,640 --> 03:10:47,080 MANAGERS UNDERSTAND THAT. 5151 03:10:47,080 --> 03:10:50,040 AND MAKING SURE THAT WE PROTECT 5152 03:10:50,040 --> 03:10:50,640 IT, HELP COMPANY FORMATION. 5153 03:10:50,640 --> 03:10:53,960 SO IF A PRODUCT CAN GO OFF AND 5154 03:10:53,960 --> 03:10:54,920 BECOME A COMPANY, MAKING SURE 5155 03:10:54,920 --> 03:10:56,680 THAT IT IS DONE IN A SUSTAINABLE 5156 03:10:56,680 --> 03:10:58,320 WAY, HELPING WITH LEGAL AND 5157 03:10:58,320 --> 03:10:59,640 MARKETING SERVICES AND THEN 5158 03:10:59,640 --> 03:11:01,120 ULTIMATELY TRANSITIONING THE 5159 03:11:01,120 --> 03:11:03,480 OUTPUTS AS WE SAY TO SURVIVE IN 5160 03:11:03,480 --> 03:11:06,560 THE WILD SO THEY CAN TRANSITION 5161 03:11:06,560 --> 03:11:07,160 TO THE THIRD PARTY INVESTMENTS 5162 03:11:07,160 --> 03:11:08,400 AND THEN CONTINUE WITH 5163 03:11:08,400 --> 03:11:11,320 MENTORSHIP AND ACCESS TO KEY 5164 03:11:11,320 --> 03:11:15,120 CUSTOMERS AND INVESTORS. 5165 03:11:15,120 --> 03:11:18,280 I THINK -- NEXT SLIDE. 5166 03:11:18,280 --> 03:11:20,640 SO THESIS ARULE JUST -- WHERE WE 5167 03:11:20,640 --> 03:11:21,360 ARE NOW. 5168 03:11:21,360 --> 03:11:23,720 SO WE ARE STANDING UP AND 5169 03:11:23,720 --> 03:11:28,760 ACHIEVING A LOT OF EXTERNAL 5170 03:11:28,760 --> 03:11:29,520 ENGAGEMENT, POTENTIAL 5171 03:11:29,520 --> 03:11:31,160 COOPERATIVE PARTNERS TO REALLY 5172 03:11:31,160 --> 03:11:34,360 MAKE SURE THAT WE ARE SETTING 5173 03:11:34,360 --> 03:11:36,560 OUR AGENCY UP FOR SUCCESSFUL 5174 03:11:36,560 --> 03:11:38,320 NEXT SLIDE. 5175 03:11:38,320 --> 03:11:39,680 THAT'S IT. 5176 03:11:39,680 --> 03:11:41,800 SO, OUR CALL TO ACTION IS, IF 5177 03:11:41,800 --> 03:11:44,640 YOU KNOW OF ANY PROGRAM MANAGERS 5178 03:11:44,640 --> 03:11:47,040 THAT REALLY EMBODY THAT 5179 03:11:47,040 --> 03:11:48,360 INNOVATIVE SPIRIT AND THAT RISK 5180 03:11:48,360 --> 03:11:51,280 TAKING, WE ARE ACTIVELY LOOKING 5181 03:11:51,280 --> 03:11:53,480 FOR PROGRAM MANAGER APPLICANTS 5182 03:11:53,480 --> 03:11:53,760 RIGHT NOW. 5183 03:11:53,760 --> 03:11:55,400 OUR GOAL IS TO HIRE 10-20 THIS 5184 03:11:55,400 --> 03:11:55,680 YEAR. 5185 03:11:55,680 --> 03:11:57,520 WE HAVE NONE. 5186 03:11:57,520 --> 03:11:59,960 AND OUR GOAL IS TO SCALE THAT TO 5187 03:11:59,960 --> 03:12:01,720 POTENTIALLY UP TO 30 BY THE END 5188 03:12:01,720 --> 03:12:02,720 OF NEXT FISCAL YEAR. 5189 03:12:02,720 --> 03:12:05,480 SO WE ARE IN THE RAPID GROWTH 5190 03:12:05,480 --> 03:12:07,160 PHASE WHICH MEANS THAT IF YOU 5191 03:12:07,160 --> 03:12:09,560 HAVE A PROGRAM MANAGER WITH A 5192 03:12:09,560 --> 03:12:11,040 GREAT IDEA IN AN AREA YOU'RE 5193 03:12:11,040 --> 03:12:11,880 PARTICULARLY PASSIONATE ABOUT, 5194 03:12:11,880 --> 03:12:14,640 THEY STAND A BETTER CHANCE RIGHT 5195 03:12:14,640 --> 03:12:16,520 NOW OF MAKING IT THROUGH THE 5196 03:12:16,520 --> 03:12:17,800 PIPELINE QUICKLY WHILE WE ARE 5197 03:12:17,800 --> 03:12:19,400 STILL IN THIS PHASE. 5198 03:12:19,400 --> 03:12:21,240 I WILL STOP THERE AND HAPPY TO 5199 03:12:21,240 --> 03:12:23,160 TAKE ANY QUESTIONS THAT YOU MAY 5200 03:12:23,160 --> 03:12:25,720 HAVE. 5201 03:12:25,720 --> 03:12:26,160 >>THAT WAS GREAT. 5202 03:12:26,160 --> 03:12:27,000 I HAVE SO MANY QUESTIONS. 5203 03:12:27,000 --> 03:12:28,880 LET ME TAKE THE LIBERTY OF 5204 03:12:28,880 --> 03:12:30,280 ASKING A COUPLE OF MANY AND I'LL 5205 03:12:30,280 --> 03:12:31,920 TRY TO MAKE THEM GENERAL. 5206 03:12:31,920 --> 03:12:34,560 FIRST UNDERSTANDING THE 5207 03:12:34,560 --> 03:12:36,880 IMPORTANCE OF THE PROGRAM 5208 03:12:36,880 --> 03:12:37,120 OFFICER. 5209 03:12:37,120 --> 03:12:41,240 DO THE IDEAS AND PROPOSALS COME 5210 03:12:41,240 --> 03:12:43,960 FROM THE PROGRAM MANAGER TO 5211 03:12:43,960 --> 03:12:46,880 ARPAH OR DO YOU IN ANY WAY REACH 5212 03:12:46,880 --> 03:12:48,480 OUT SOLICITING INTEREST IN 5213 03:12:48,480 --> 03:12:51,400 CERTAIN AREAS CENTRALLY? 5214 03:12:51,400 --> 03:12:53,240 SO IS IT DETERMINING OR DO YOU 5215 03:12:53,240 --> 03:12:54,440 DEPEND ON THE PROGRAM OFFICER? 5216 03:12:54,440 --> 03:12:55,600 AND THEN THE SECOND PART AND 5217 03:12:55,600 --> 03:12:56,640 IT'S RELATED. 5218 03:12:56,640 --> 03:13:02,080 MANY OF US, NIH PARTICULAR ARE 5219 03:13:02,080 --> 03:13:05,280 SENSITIVE TO THE IMPORTANT BUT 5220 03:13:05,280 --> 03:13:05,720 AT TIMES CONTROVERSIAL 5221 03:13:05,720 --> 03:13:07,120 RELATIONSHIP BETWEEN NIH AND 5222 03:13:07,120 --> 03:13:08,240 ARPAH. 5223 03:13:08,240 --> 03:13:11,920 WHAT DO YOU SEE AS THE 5224 03:13:11,920 --> 03:13:12,440 NON-CONTROVERSIAL, PURELY 5225 03:13:12,440 --> 03:13:16,560 PRODUCTIVE WAYS THAT WE CAN 5226 03:13:16,560 --> 03:13:17,560 INTERACT WITH ARPH WITHOUT 5227 03:13:17,560 --> 03:13:20,800 RAISING CONCERNS ABOUT THE NEED 5228 03:13:20,800 --> 03:13:24,640 FOR THESE TO BE THROUGH THESE 5229 03:13:24,640 --> 03:13:29,560 DISTINCT AGENCY? 5230 03:13:29,560 --> 03:13:31,360 >>IT'S BOTH. 5231 03:13:31,360 --> 03:13:33,160 RIGHT NOW WE HAVE A OPEN 5232 03:13:33,160 --> 03:13:34,000 SOLICITATION FOR PROGRAM 5233 03:13:34,000 --> 03:13:35,480 MANAGERS COMING IN AND BRINGING 5234 03:13:35,480 --> 03:13:37,120 WITH THEM THEIR PROBLEMS. 5235 03:13:37,120 --> 03:13:39,320 SO IT'S VERY MUCH A PUSH 5236 03:13:39,320 --> 03:13:39,600 FUNCTION. 5237 03:13:39,600 --> 03:13:42,800 YOU NEED TO DO MORE IN WHATEVER 5238 03:13:42,800 --> 03:13:44,360 PARTICULAR HEALTHY ECOSYSTEM 5239 03:13:44,360 --> 03:13:45,720 DOMAIN OR BIOTECH DOMAIN. 5240 03:13:45,720 --> 03:13:47,760 BUT WE ARE ALSO DOING THE EVENTS 5241 03:13:47,760 --> 03:13:49,840 LIKE THIS WHERE WE KNOW WE WANT 5242 03:13:49,840 --> 03:13:50,800 TO FUND RESEARCH. 5243 03:13:50,800 --> 03:13:53,000 WE WANT TO FUND SOMETHING IN 5244 03:13:53,000 --> 03:13:53,760 THIS SPACE. 5245 03:13:53,760 --> 03:13:56,000 AND SO, PROACTIVELY REACHING OUT 5246 03:13:56,000 --> 03:13:59,040 TO YOUR COMMUNITY OR OTHER 5247 03:13:59,040 --> 03:14:00,040 COMMUNITIES WHERE WE ARE HOPING 5248 03:14:00,040 --> 03:14:01,840 THAT BY OUR PARTICIPATION IN 5249 03:14:01,840 --> 03:14:06,000 YOUR EVENTS, WE ACTUALLY CAN GET 5250 03:14:06,000 --> 03:14:06,360 PROGRAM MANAGER. 5251 03:14:06,360 --> 03:14:08,480 SOMEONE ON THIS CALL OR SOMEONE 5252 03:14:08,480 --> 03:14:11,280 YOU KNOW WHO IS LIKE, I LOVE TO 5253 03:14:11,280 --> 03:14:13,120 DO THAT. 5254 03:14:13,120 --> 03:14:17,320 LIKED YOUR CONSTITUENCY AND YOUR 5255 03:14:17,320 --> 03:14:17,600 COLLEAGUES. 5256 03:14:17,600 --> 03:14:18,200 AND THEN THAT WAY, TRYING TO 5257 03:14:18,200 --> 03:14:19,440 BALANCE THE PUSH AND PULL 5258 03:14:19,440 --> 03:14:21,560 FUNCTION SO WE GET A REALLY 5259 03:14:21,560 --> 03:14:23,440 ROBUST, BROAD SET OF ACTIVITIES 5260 03:14:23,440 --> 03:14:25,560 THAT CROSS OUR PORTFOLIO AREAS. 5261 03:14:25,560 --> 03:14:28,000 IN TERMS OF PRODUCTIVE 5262 03:14:28,000 --> 03:14:30,600 ENGAGEMENT WITH OUR NIH 5263 03:14:30,600 --> 03:14:31,320 COLLEAGUES, THAT FOR ME IS ONE 5264 03:14:31,320 --> 03:14:32,480 OF MY PRIORITIES. 5265 03:14:32,480 --> 03:14:35,880 I HAVE HAD THE OPPORTUNITY TO 5266 03:14:35,880 --> 03:14:38,480 WORK NEAR NIH -- THIS IS MY 5267 03:14:38,480 --> 03:14:40,000 FIRST OPPORTUNITY TO WORK AT 5268 03:14:40,000 --> 03:14:40,240 NIH. 5269 03:14:40,240 --> 03:14:42,680 I'M SUPER EXCITED ABOUT IT AND I 5270 03:14:42,680 --> 03:14:43,280 HAVE SUCH TREMENDOUS RESPECT FOR 5271 03:14:43,280 --> 03:14:45,320 THE COLLEAGUES AND EVERYTHING 5272 03:14:45,320 --> 03:14:45,800 YOU DO WITHIN YOUR ICs. 5273 03:14:45,800 --> 03:14:47,520 SO TRYING TO FIGURE OUT WHAT IS 5274 03:14:47,520 --> 03:14:49,280 THE ROUTINE ENGAGEMENT THAT WE 5275 03:14:49,280 --> 03:14:50,760 HAVE WITH YOU SUCH THAT YOU KNOW 5276 03:14:50,760 --> 03:14:52,400 WHAT WE ARE DOING, WE CAN 5277 03:14:52,400 --> 03:14:55,040 BENEFIT FROM KNOWING WHAT YOU'RE 5278 03:14:55,040 --> 03:14:55,240 DOING. 5279 03:14:55,240 --> 03:14:56,640 WE DON'T DUPLICATE ACTIVITIES. 5280 03:14:56,640 --> 03:14:59,400 WE DON'T COMPETE FOR THE 5281 03:14:59,400 --> 03:15:00,560 POTENTIAL PARTNERS TO DO THE 5282 03:15:00,560 --> 03:15:01,840 WORK WE NEED TO DO. 5283 03:15:01,840 --> 03:15:04,000 UNLESS WE ARE ACTUALLY IN A 5284 03:15:04,000 --> 03:15:07,440 PLACE WHERE WE CAN DO SORT OF -- 5285 03:15:07,440 --> 03:15:09,360 I DON'T KNOW WE CAN DO 5286 03:15:09,360 --> 03:15:09,640 CO-FUNDING. 5287 03:15:09,640 --> 03:15:11,320 I WOULD HAVE TO ASK OUR BUDGET 5288 03:15:11,320 --> 03:15:11,800 FOLKS. 5289 03:15:11,800 --> 03:15:13,880 BUT CAN WE WORK IN PARALLEL WITH 5290 03:15:13,880 --> 03:15:15,920 ON THE SAME TYPE OF PROBLEM? 5291 03:15:15,920 --> 03:15:17,240 WE'LL TAKE SOME OF THE RISKIER 5292 03:15:17,240 --> 03:15:17,840 ASPECT, YOU TAKE SOME OF THE 5293 03:15:17,840 --> 03:15:21,720 WORK THAT YOU KNOW YOU CAN DO 5294 03:15:21,720 --> 03:15:23,520 WITHIN YOUR -- WHATEVER THE 5295 03:15:23,520 --> 03:15:25,760 STRUCTURES ARE WITHIN YOUR IC, 5296 03:15:25,760 --> 03:15:28,200 BUT WE COME TOGETHER TO HAVE 5297 03:15:28,200 --> 03:15:29,480 THESE VERY PRODUCTIVE 5298 03:15:29,480 --> 03:15:29,800 RELATIONSHIPS. 5299 03:15:29,800 --> 03:15:32,200 AND I THINK ONE OF MY GOALS AS 5300 03:15:32,200 --> 03:15:34,760 WE GET PROGRAM MANAGERS ON, AND 5301 03:15:34,760 --> 03:15:35,240 THE PROGRAM MANAGERS ARE 5302 03:15:35,240 --> 03:15:36,280 INTERESTED IN DOING SOMETHING 5303 03:15:36,280 --> 03:15:40,120 THAT WE KNOW IS ALREADY THE 5304 03:15:40,120 --> 03:15:40,880 TOPICALLY ONGOING AT NIH, NOT 5305 03:15:40,880 --> 03:15:41,880 BEING SHY. 5306 03:15:41,880 --> 03:15:45,040 LIKE NOT LIKE LET'S NOT HUDDLE 5307 03:15:45,040 --> 03:15:45,680 AND JUST PRETEND NO ONE ELSE IS 5308 03:15:45,680 --> 03:15:46,480 DOING IT. 5309 03:15:46,480 --> 03:15:48,240 LET'S TALK ABOUT WHAT WE THINK 5310 03:15:48,240 --> 03:15:49,760 WE ARE GOING TO DO AND GET 5311 03:15:49,760 --> 03:15:50,040 FEEDBACK. 5312 03:15:50,040 --> 03:15:51,360 THERE IS A LIKELIHOOD AND I SAY 5313 03:15:51,360 --> 03:15:54,680 THIS ALL THE TIME. 5314 03:15:54,680 --> 03:15:56,920 WITHIN THE ICs YOU'RE THE 5315 03:15:56,920 --> 03:15:59,280 LEADING EDGE TECHNICAL EXPERTS 5316 03:15:59,280 --> 03:16:00,040 WITHIN THOSE AREAS. 5317 03:16:00,040 --> 03:16:02,960 AND SO FOR US, THE HUBRIS 5318 03:16:02,960 --> 03:16:04,320 THINKING WE ARE THE FIRST PEOPLE 5319 03:16:04,320 --> 03:16:06,200 TO THINK OF IT, PROBABLY WON'T 5320 03:16:06,200 --> 03:16:06,800 WORK OUT SO WELL. 5321 03:16:06,800 --> 03:16:08,200 SO WE THINK OF SOMETHING LIKE, 5322 03:16:08,200 --> 03:16:10,400 WE HAVE TO DO THIS, GOING OVER 5323 03:16:10,400 --> 03:16:17,560 TO THE IC AND HAVING A 5324 03:16:17,560 --> 03:16:18,160 CONVERSATION AND HAVING THE IC 5325 03:16:18,160 --> 03:16:18,880 SAY TO US, WELL, WE TRIED THAT 5326 03:16:18,880 --> 03:16:19,520 THREE YEARS AGO AND HERE IS WHY 5327 03:16:19,520 --> 03:16:20,160 IT DIDN'T WORK. 5328 03:16:20,160 --> 03:16:20,960 OR WE ALREADY HAVE THREE 5329 03:16:20,960 --> 03:16:22,600 PROGRAMS THAT ARE WORKING IN 5330 03:16:22,600 --> 03:16:24,840 THAT SPACE AND ALLOWING US TO 5331 03:16:24,840 --> 03:16:26,840 TAILOR OUR PROGRAM TO OCCUPY 5332 03:16:26,840 --> 03:16:29,600 UNIQUE SPACES. 5333 03:16:29,600 --> 03:16:30,960 SO I SEE GREAT POSITIVE 5334 03:16:30,960 --> 03:16:32,560 POTENTIAL TO WORK WITH 5335 03:16:32,560 --> 03:16:36,160 COLLEAGUES AT NIH AND I'M 5336 03:16:36,160 --> 03:16:44,400 HOPEFUL IT'S A BIDIRECTIONAL 5337 03:16:44,400 --> 03:16:45,440 RELATIONSHIP. 5338 03:16:45,440 --> 03:16:47,320 IF WE CAN'T TAKE THAT RISK, PASS 5339 03:16:47,320 --> 03:16:48,880 IT TO US SO WE MIGHT BE ABLE TO 5340 03:16:48,880 --> 03:16:51,720 THINK ABOUT IT IF WE HAVE THE 5341 03:16:51,720 --> 03:16:52,360 RIGHT PROGRAM MANAGER IN PLACE. 5342 03:16:52,360 --> 03:16:54,680 I HOPE TO HAVE IT. 5343 03:16:54,680 --> 03:16:57,280 >>GREAT EXCITING ANSWER. 5344 03:16:57,280 --> 03:16:59,480 SHALL WE TAKE QUESTIONS FROM 5345 03:16:59,480 --> 03:17:06,680 SOME OF OUR MEMBERS? 5346 03:17:06,680 --> 03:17:08,000 SHELLY? 5347 03:17:08,000 --> 03:17:08,800 >>THANK YOU VERY MUCH FOR YOUR 5348 03:17:08,800 --> 03:17:10,320 VERY INSPIRATIONAL TALK. 5349 03:17:10,320 --> 03:17:13,400 I WAS VERY ENERGIZED BY YOUR 5350 03:17:13,400 --> 03:17:16,040 BOLD WISH AND EXPEDITING 5351 03:17:16,040 --> 03:17:16,360 INNOVATION. 5352 03:17:16,360 --> 03:17:18,720 THE QUESTION I HAD IS A 5353 03:17:18,720 --> 03:17:20,280 CLARIFYING ONE. 5354 03:17:20,280 --> 03:17:24,680 DO YOU ENVISION THAT THE 5355 03:17:24,680 --> 03:17:25,280 PRODUCTS AND THE PROJECTS WILL 5356 03:17:25,280 --> 03:17:27,520 BE INITIATED BY THE PROGRAM 5357 03:17:27,520 --> 03:17:27,760 STAFF? 5358 03:17:27,760 --> 03:17:30,960 OR DO YOU SEE A PROCESS FOR 5359 03:17:30,960 --> 03:17:32,280 INVESTIGATOR INITIATIVE PROPOSAL 5360 03:17:32,280 --> 03:17:35,240 TO BE REVIEWED AND THEN COULD 5361 03:17:35,240 --> 03:17:39,320 THOSE LEAD TO FUNDING? 5362 03:17:39,320 --> 03:17:40,280 >>IT'S A REALLY GOOD QUESTION. 5363 03:17:40,280 --> 03:17:41,360 SO, THE VAST MAJORITY ARE GOING 5364 03:17:41,360 --> 03:17:43,760 TO COME IN AS PROGRAM MANAGER 5365 03:17:43,760 --> 03:17:45,160 DESIGNED PROGRAMS SO THEY COME 5366 03:17:45,160 --> 03:17:45,960 IN WITH THE PROBLEMS THAT THEY 5367 03:17:45,960 --> 03:17:49,520 COME UP WITH THE PROGRAM DESIGN 5368 03:17:49,520 --> 03:17:51,760 AND THEN WE FUND PERFORMERS THAT 5369 03:17:51,760 --> 03:17:54,200 ARE ALIGNED THE ASPECTS OF THEIR 5370 03:17:54,200 --> 03:17:54,840 PROGRAM DESIGN. 5371 03:17:54,840 --> 03:17:57,800 BUT WE ARE GOING TO HAVE AN OPEN 5372 03:17:57,800 --> 03:17:59,520 VAA AND WHAT THAT MEANS IS THAT 5373 03:17:59,520 --> 03:18:00,680 IT'S SORT OF GOING TO LAY OUT 5374 03:18:00,680 --> 03:18:02,760 SOME FOUNDATIONAL PRINCIPLES 5375 03:18:02,760 --> 03:18:04,840 ABOUT WHAT ARE WE LOOKING FOR IN 5376 03:18:04,840 --> 03:18:06,320 INNOVATION ACROSS THE HEALTHY 5377 03:18:06,320 --> 03:18:06,960 ECOSYSTEM? 5378 03:18:06,960 --> 03:18:07,720 SO IT'S NOT DEFINED TO A 5379 03:18:07,720 --> 03:18:09,960 SPECIFIC DISEASE OR A SPECIFIC 5380 03:18:09,960 --> 03:18:13,160 SOLUTION SET BUT IT'S RATHER 5381 03:18:13,160 --> 03:18:15,920 MORE OPEN AND IT SAYS, 5382 03:18:15,920 --> 03:18:17,240 PARAPHRASING, WHAT IS IS IT WE 5383 03:18:17,240 --> 03:18:18,800 ARE NOT DOING? 5384 03:18:18,800 --> 03:18:20,000 WHAT IS IT NOT BEING FUNDED THAT 5385 03:18:20,000 --> 03:18:21,000 IS PARTICULARLY INNOVATIVE THAT 5386 03:18:21,000 --> 03:18:23,400 WE WOULD REALLY WANT TO -- THAT 5387 03:18:23,400 --> 03:18:26,040 LIKE AN INVESTIGATOR SAYS, YOU 5388 03:18:26,040 --> 03:18:28,480 KNOW, ARPAH YOU NEED TO FUND 5389 03:18:28,480 --> 03:18:34,600 THIS TYPE OF RESEARCH PORTFOLIO. 5390 03:18:34,600 --> 03:18:35,640 AND I DON'T WANT TO OVER PROMISE 5391 03:18:35,640 --> 03:18:36,880 BUT REALLY GOOD IDEAS COME 5392 03:18:36,880 --> 03:18:38,840 THROUGH THAT TYPE OF AN OPEN 5393 03:18:38,840 --> 03:18:39,160 VAA. 5394 03:18:39,160 --> 03:18:40,800 AND THAT WOULD ALLOW US TO SAY, 5395 03:18:40,800 --> 03:18:43,880 OH, MY GOSH, WE HAVE NOT -- WE 5396 03:18:43,880 --> 03:18:45,800 DON'T HAVE A PORTFOLIO OR A 5397 03:18:45,800 --> 03:18:46,760 PROGRAM MANAGER AND THEN BEFORE 5398 03:18:46,760 --> 03:18:49,320 WE FUND IT OF COURSE, WE WOULD 5399 03:18:49,320 --> 03:18:49,920 HAVE TO FIND A PROGRAM MANAGER 5400 03:18:49,920 --> 03:18:53,680 THAT COULD RUN THAT PARTICULAR 5401 03:18:53,680 --> 03:18:54,640 ACTIVITY. 5402 03:18:54,640 --> 03:18:56,480 IN AN IDEAL WORLD YOU'D HAVE AN 5403 03:18:56,480 --> 03:18:57,320 INVESTIGATOR WHO PUTS IN 5404 03:18:57,320 --> 03:18:59,160 SOMETHING IN THE OPEN VAA THAT 5405 03:18:59,160 --> 03:18:59,760 SAYS YOU MUST FUND THIS. 5406 03:18:59,760 --> 03:19:02,240 AND THEN RAISES THEIR HAND AND 5407 03:19:02,240 --> 03:19:05,280 SAYS, I WILL BECOME YOUR PROGRAM 5408 03:19:05,280 --> 03:19:05,480 MANAGER. 5409 03:19:05,480 --> 03:19:06,640 AND IF IT WORKS OUT WE HAVE THE 5410 03:19:06,640 --> 03:19:07,280 IDEA AND THE PROGRAM MANAGER AT 5411 03:19:07,280 --> 03:19:08,720 THE SAME TIME. 5412 03:19:08,720 --> 03:19:11,040 SO, THERE IS AN OPPORTUNITY 5413 03:19:11,040 --> 03:19:11,960 OUTSIDE OF THE PROGRAM MANAGERS 5414 03:19:11,960 --> 03:19:14,200 THROUGH THESE OPEN VAAs THAT 5415 03:19:14,200 --> 03:19:15,680 WE'LL PUT OUT THERE. 5416 03:19:15,680 --> 03:19:18,240 WE'RE HOPING TO BE ABLE TO GET 5417 03:19:18,240 --> 03:19:20,000 OUR OPEN VAA OUT. 5418 03:19:20,000 --> 03:19:22,640 WE ARE BRAND NEW AND VERY 5419 03:19:22,640 --> 03:19:23,480 EXCITED. 5420 03:19:23,480 --> 03:19:26,240 WITHIN THE NEXT SIX MONTHS 5421 03:19:26,240 --> 03:19:26,840 HOPING TO GET A OPEN VAA OUT 5422 03:19:26,840 --> 03:19:30,640 THERE TO START TO GENERATE THESE 5423 03:19:30,640 --> 03:19:34,760 INVESTIGATOR OF-INITIATED IDEAS. 5424 03:19:34,760 --> 03:19:36,640 >>ABC ANNOUNCEMENTS AND I THINK 5425 03:19:36,640 --> 03:19:37,560 NIH HAS THE AUTHORITY AND HAS 5426 03:19:37,560 --> 03:19:41,280 USED IT INFREQUENTLY, CORRECT? 5427 03:19:41,280 --> 03:19:42,480 >>YES, ABSOLUTELY. 5428 03:19:42,480 --> 03:19:44,160 I GUESS IT'S THE CLOSEST THING 5429 03:19:44,160 --> 03:19:53,240 IN THE CONTRACT WORLD TO A 5430 03:19:53,240 --> 03:19:53,800 UNSOLICITED GRANT MECHANISM, 5431 03:19:53,800 --> 03:19:55,760 REALLY. 5432 03:19:55,760 --> 03:19:58,240 >>THAT'S RIGHT. 5433 03:19:58,240 --> 03:19:59,240 ANN: THANK YOU VERY MUCH. 5434 03:19:59,240 --> 03:20:01,840 THIS WAS REALLY EXCITING. 5435 03:20:01,840 --> 03:20:04,720 I HAVE A KIND OF -- I'M AN 5436 03:20:04,720 --> 03:20:06,880 ECONOMIST BY TRAINING AND I HAVE 5437 03:20:06,880 --> 03:20:10,080 A QUESTION ABOUT, SO WE PAY FOR 5438 03:20:10,080 --> 03:20:14,600 THE HIGH-UNCERTAINTY HIGH 5439 03:20:14,600 --> 03:20:16,120 CONSEQUENCE RESEARCH AND THEN 5440 03:20:16,120 --> 03:20:18,560 WHAT STOPS THAT FROM IN 5 YEARS 5441 03:20:18,560 --> 03:20:20,200 TIME BEING A DRUG THAT APPEARS 5442 03:20:20,200 --> 03:20:23,040 ON THE MARKET WITH A PRICE TAG 5443 03:20:23,040 --> 03:20:24,680 OF 36,000? 5444 03:20:24,680 --> 03:20:26,600 I MEAN, I ASSUME THAT WAS UNDER 5445 03:20:26,600 --> 03:20:30,280 PART 9 OF YOUR 10 QUESTIONS BUT 5446 03:20:30,280 --> 03:20:34,880 IT IS ONE THAT I THINK CERTAINLY 5447 03:20:34,880 --> 03:20:37,880 HAS BIG CONSEQUENCES FOR US ALL 5448 03:20:37,880 --> 03:20:41,400 BEING ABLE TO BENEFIT FROM THIS. 5449 03:20:41,400 --> 03:20:41,760 >>ABSOLUTELY. 5450 03:20:41,760 --> 03:20:43,680 IT IS PART OF -- BUILT INTO PART 5451 03:20:43,680 --> 03:20:45,480 9 ENSURING EQUITABLE ACCESS. 5452 03:20:45,480 --> 03:20:47,200 IT WILL BE A VERY PROACTIVE PART 5453 03:20:47,200 --> 03:20:49,280 OF WHAT WE ARE THINKING ABOUT SO 5454 03:20:49,280 --> 03:20:50,400 YOU HAVE YOUR PROBLEM. 5455 03:20:50,400 --> 03:20:52,000 HERE IS HOW YOU'RE DESIGNING 5456 03:20:52,000 --> 03:20:54,160 YOUR PROGRAM. 5457 03:20:54,160 --> 03:20:54,760 HERE IS WHAT YOU ARE THINK THE 5458 03:20:54,760 --> 03:20:55,720 SOLUTION S HOW IS THAT GOING TO 5459 03:20:55,720 --> 03:20:56,600 BE EQUITABLE? 5460 03:20:56,600 --> 03:21:01,240 AND REALLY MAKING SURE, WE'LL 5461 03:21:01,240 --> 03:21:03,240 CALL IT PROWELL CONDUCT 5462 03:21:03,240 --> 03:21:03,520 PROFILES. 5463 03:21:03,520 --> 03:21:05,520 SO IF YOU'RE GOING TO CREATE A 5464 03:21:05,520 --> 03:21:06,440 PRODUCT, PART OF YOUR TARGET 5465 03:21:06,440 --> 03:21:08,040 PRODUCT PROFILE HAS TO BE COST 5466 03:21:08,040 --> 03:21:08,600 EFFECTIVE. 5467 03:21:08,600 --> 03:21:11,560 AND SO, WHAT DOES YOUR PRODUCT 5468 03:21:11,560 --> 03:21:14,520 HAVE TO LOOK LIKE TO ACHIEVE 5469 03:21:14,520 --> 03:21:15,040 COST EFFECTIVE NATURE? 5470 03:21:15,040 --> 03:21:18,960 SO WE TALKED ABOUT THE CANCER 5471 03:21:18,960 --> 03:21:20,760 VACCINE FOR THE PRICE OF A CUP 5472 03:21:20,760 --> 03:21:21,880 OF COFFEE. 5473 03:21:21,880 --> 03:21:24,560 SO IT'S ON OUR MIND AND IT WILL 5474 03:21:24,560 --> 03:21:26,480 BE A CONSTRAINT FOR SOME OF OUR 5475 03:21:26,480 --> 03:21:27,480 PROGRAMS WHERE WE SAY, IF IT'S 5476 03:21:27,480 --> 03:21:29,120 GOING TO COST US 36,000 DOLLARS 5477 03:21:29,120 --> 03:21:30,200 A TREATMENT DOSE AND THAT'S THE 5478 03:21:30,200 --> 03:21:33,760 OUT OF REACH FOR SO MANY PEOPLE 5479 03:21:33,760 --> 03:21:36,400 WHO MAY HAVE THAT CONDITION, 5480 03:21:36,400 --> 03:21:38,440 THEN IT'S NOT FOR US. 5481 03:21:38,440 --> 03:21:39,360 UNLESS THERE IS A WAY WE CAN 5482 03:21:39,360 --> 03:21:41,240 TAKE IT FROM 36,000 DOLLARS AND 5483 03:21:41,240 --> 03:21:43,400 WE CAN SCALE IT SO THAT IT 5484 03:21:43,400 --> 03:21:46,240 BECOMES 3.60 OR SOMETHING LIKE 5485 03:21:46,240 --> 03:21:46,440 THAT. 5486 03:21:46,440 --> 03:21:48,400 WE ARE ALSO PUTTING IN PLACE, 5487 03:21:48,400 --> 03:21:51,000 AND THIS -- MANY ARE FAMILIAR 5488 03:21:51,000 --> 03:21:54,320 WITH IT, IT IS AN LC PROGRAM SO 5489 03:21:54,320 --> 03:21:56,080 THE ETHICS LEGAL AND SOCIETAL 5490 03:21:56,080 --> 03:21:57,680 IMPLICATIONS ABOUT MAKING SURE 5491 03:21:57,680 --> 03:21:59,800 WE HAVE A MATURE WAY TO THINK 5492 03:21:59,800 --> 03:22:02,080 ABOUT OUR PORTFOLIO AND PROGRAMS 5493 03:22:02,080 --> 03:22:02,400 SPECIFICALLY. 5494 03:22:02,400 --> 03:22:05,560 AND PART OF WHAT THEY ARE TASKED 5495 03:22:05,560 --> 03:22:08,520 WITH IS THIS EVALUATION COST 5496 03:22:08,520 --> 03:22:11,040 BENEFIT AND IMPACT TO SOCIETY. 5497 03:22:11,040 --> 03:22:12,920 SO, WE ARE BAKING IT IN IN A 5498 03:22:12,920 --> 03:22:15,400 NUMBER OF DIFFERENT WAYS BECAUSE 5499 03:22:15,400 --> 03:22:17,240 YOU'RE RIGHT. 5500 03:22:17,240 --> 03:22:18,600 THERE IS BOST DEVELOPING 5501 03:22:18,600 --> 03:22:20,320 SOMETHING THAT MAYBE IS SO 5502 03:22:20,320 --> 03:22:22,960 UNIQUE THAT ONE COULD SAY, WELL, 5503 03:22:22,960 --> 03:22:23,840 WE SHOULD CHARGE 36,000 DOLLARS 5504 03:22:23,840 --> 03:22:25,880 A YEAR. 5505 03:22:25,880 --> 03:22:26,480 BUT IT'S NOT IN LINE WITH WHAT 5506 03:22:26,480 --> 03:22:31,080 OUR GOALS ARE AS AN AGENCY. 5507 03:22:31,080 --> 03:22:32,720 >>THANK YOU. 5508 03:22:32,720 --> 03:22:33,520 >>SUSAN? 5509 03:22:33,520 --> 03:22:34,760 >>SUSAN: THIS WAS REALLY, 5510 03:22:34,760 --> 03:22:35,440 REALLY EXCITING. 5511 03:22:35,440 --> 03:22:38,880 SO I HAVE A QUESTION SORT OF 5512 03:22:38,880 --> 03:22:40,640 ABOUT TRYING TO GET MY HEAD 5513 03:22:40,640 --> 03:22:43,360 AROUND THIS IN TERMS OF, CAN YOU 5514 03:22:43,360 --> 03:22:46,480 GIVE US AN EXAMPLE OF -- I WAS 5515 03:22:46,480 --> 03:22:48,560 NOT CLEAR ON HOW SPECIFIC THIS 5516 03:22:48,560 --> 03:22:53,640 WOULD BE VERSUS HOW BROAD 5517 03:22:53,640 --> 03:22:54,200 FINDINGS COULD BE OR PROGRAM 5518 03:22:54,200 --> 03:22:54,880 MANAGER INDIVIDUAL AN IDEA TO DO 5519 03:22:54,880 --> 03:22:56,840 SOMETHING REALLY BROAD, REALLY 5520 03:22:56,840 --> 03:22:59,160 FOCUSED AND MAYBE AN EXAMPLE OF 5521 03:22:59,160 --> 03:23:00,200 SOMETHING THAT WAS A SUCCESS 5522 03:23:00,200 --> 03:23:02,560 VERSUS SOMETHING THAT WAS A 5523 03:23:02,560 --> 03:23:04,160 FAILURE AND WHY. 5524 03:23:04,160 --> 03:23:06,360 JUST TO GET A BETTER GRASP. 5525 03:23:06,360 --> 03:23:07,680 >>THE GOOD NEWS IS WE HAVEN'T 5526 03:23:07,680 --> 03:23:09,520 HAD ANY SUCCESS SYSTEM OR 5527 03:23:09,520 --> 03:23:10,960 FAILURES YET BECAUSE WE HAVEN'T 5528 03:23:10,960 --> 03:23:11,680 SPENT ANY MONEY. 5529 03:23:11,680 --> 03:23:13,080 BUT GIVE US TIME. 5530 03:23:13,080 --> 03:23:15,600 I CAN GIVE YOU A COUPLE OF IDEAS 5531 03:23:15,600 --> 03:23:16,680 THAT HAVE COME THROUGH. 5532 03:23:16,680 --> 03:23:18,680 SO AS WE INTERVIEWED THESE 5533 03:23:18,680 --> 03:23:19,600 PROGRAM MANAGERS AND THEY ARE 5534 03:23:19,600 --> 03:23:21,560 TELLING US OR GIVING US THEIR 5535 03:23:21,560 --> 03:23:22,800 PITCH FOR WHAT THEY WOULD WANT 5536 03:23:22,800 --> 03:23:24,200 TO WORK ON. 5537 03:23:24,200 --> 03:23:26,920 SO SOMETHING AS SMALL AS LIVING 5538 03:23:26,920 --> 03:23:29,160 CELLS THAT COULD IMPLANTED AND 5539 03:23:29,160 --> 03:23:32,480 SECRETE SMALL BIOMOLECULES TO 5540 03:23:32,480 --> 03:23:35,080 TARGET CERTAIN DISEASE STATES OR 5541 03:23:35,080 --> 03:23:36,080 CERTAIN THERAPEUTIC 5542 03:23:36,080 --> 03:23:36,560 INTERVENTION. 5543 03:23:36,560 --> 03:23:38,800 AND IT WOULD NEED TO BE 5544 03:23:38,800 --> 03:23:40,320 NECESSARILY TAILORED TO THE 5545 03:23:40,320 --> 03:23:41,120 PHYSIOLOGY OF THE INDIVIDUAL TA 5546 03:23:41,120 --> 03:23:43,800 IS RECEIVING THE LIVE 5547 03:23:43,800 --> 03:23:45,200 REPLICATING CELLS THAT ARE 5548 03:23:45,200 --> 03:23:45,880 PRODUCING THE SMALL MOLECULES. 5549 03:23:45,880 --> 03:23:47,080 SO SOMETHING ON THAT SCALE. 5550 03:23:47,080 --> 03:23:49,160 AND THEN ALL THE WAY ON THE 5551 03:23:49,160 --> 03:23:51,760 SCALE WHERE WE ARE LOOKING AT 5552 03:23:51,760 --> 03:23:56,800 USING AIML TO HELP FILL IN THE 5553 03:23:56,800 --> 03:23:59,080 GAPS FOR BEHAVIORAL HEALTH 5554 03:23:59,080 --> 03:23:59,400 CHALLENGES. 5555 03:23:59,400 --> 03:24:01,960 SO INDIVIDUALS WHO ARE POTENTIAL 5556 03:24:01,960 --> 03:24:04,840 RISK OF ABUSING OPIOIDS OR GOING 5557 03:24:04,840 --> 03:24:07,760 THROUGH RECOVERY AND TRYING TO 5558 03:24:07,760 --> 03:24:09,680 CREATE AT SCALE SORT OF 5559 03:24:09,680 --> 03:24:13,280 COMPANION TO ALLOW US, AN AI 5560 03:24:13,280 --> 03:24:17,600 COMPANION ALLOWING 24-7 INTIMATE 5561 03:24:17,600 --> 03:24:19,840 CULTURALLY APPROPRIATE AND 5562 03:24:19,840 --> 03:24:22,080 TAILORED CARE FOR THE 5563 03:24:22,080 --> 03:24:23,160 INDIVIDUALS KNOWING THAT THAT IS 5564 03:24:23,160 --> 03:24:25,000 GOING TO BE AN INCREDIBLY -- 5565 03:24:25,000 --> 03:24:26,520 LIKE THAT ON RISK, WHEN YOU TALK 5566 03:24:26,520 --> 03:24:28,240 ABOUT RISK, THAT ONE IS GOING TO 5567 03:24:28,240 --> 03:24:29,880 BE SUPER HIGH RISK AND THERE IS 5568 03:24:29,880 --> 03:24:31,840 SO MUCH CHALLENGES ASSOCIATED 5569 03:24:31,840 --> 03:24:32,560 WITH IT. 5570 03:24:32,560 --> 03:24:34,320 SO THINKING ABOUT THAT. 5571 03:24:34,320 --> 03:24:37,520 WE HAD OTHER PEOPLE PROPOSE 5572 03:24:37,520 --> 03:24:39,200 CHANGES TO CITY DESIGN TO CREATE 5573 03:24:39,200 --> 03:24:42,680 A HEALTH AND WELLNESS 5574 03:24:42,680 --> 03:24:42,960 ENVIRONMENT. 5575 03:24:42,960 --> 03:24:45,360 WE HAD PEOPLE TALK ABOUT HEALTHY 5576 03:24:45,360 --> 03:24:46,120 BUILDINGS. 5577 03:24:46,120 --> 03:24:47,920 I MEAN JUST A NUMBER OF 5578 03:24:47,920 --> 03:24:50,520 DIFFERENT ASPECTS OF THE HEALTHY 5579 03:24:50,520 --> 03:24:52,000 ECOSYSTEM WHICH GETS US SUPER 5580 03:24:52,000 --> 03:24:53,720 EXCITED AND THAT'S EXACTLY WHERE 5581 03:24:53,720 --> 03:24:55,320 WE WANT TO BE IS NOT JUST A 5582 03:24:55,320 --> 03:24:55,960 BIOTECH COMPANY. 5583 03:24:55,960 --> 03:24:59,160 WE WANT TO BE AN ORGANIZATION 5584 03:24:59,160 --> 03:25:00,640 THAT CAN SUPPORT INNOVATION 5585 03:25:00,640 --> 03:25:02,000 ACROSS THE HEALTH ECOSYSTEM. 5586 03:25:02,000 --> 03:25:05,040 ASK ME IN A YEAR AND I'LL GIVE 5587 03:25:05,040 --> 03:25:06,120 YOU A MORE BIG ANSWER ABOUT WHAT 5588 03:25:06,120 --> 03:25:07,920 WORKED AND WHAT HAS NOT WORKED. 5589 03:25:07,920 --> 03:25:10,480 >>THANK YOU. 5590 03:25:10,480 --> 03:25:12,440 >>I THINK WE JUST HAVE TIME FOR 5591 03:25:12,440 --> 03:25:13,960 MAYBE ONE MORE QUESTION. 5592 03:25:13,960 --> 03:25:15,080 SO SHARON DO YOU WANT TO ASK 5593 03:25:15,080 --> 03:25:17,280 YOUR QUESTION? 5594 03:25:17,280 --> 03:25:19,080 >>THANK YOU. 5595 03:25:19,080 --> 03:25:21,080 IT WAS A WONDERFUL TALK. 5596 03:25:21,080 --> 03:25:21,920 I REALLY AM VERY EXCITED. 5597 03:25:21,920 --> 03:25:26,320 I REALLY APPRECIATED IT. 5598 03:25:26,320 --> 03:25:29,120 HAVING BEEN INVOLVED IN ANOTHER 5599 03:25:29,120 --> 03:25:31,120 KIND OF GRAND CHALLENGE LIKE 5600 03:25:31,120 --> 03:25:36,640 THIS, AND KNOWING THAT 5601 03:25:36,640 --> 03:25:37,400 COMMERCIALIZATION IS ONE OF 5602 03:25:37,400 --> 03:25:47,480 THOSE THINGS ON YOUR LAST SLIDE 5603 03:25:47,480 --> 03:25:49,000 IT SOUNDS LIKE IT'S NOT ONLY 5604 03:25:49,000 --> 03:25:49,280 FINANCIAL. 5605 03:25:49,280 --> 03:25:50,800 YOU'RE GOING TO LOOK AT THE 5606 03:25:50,800 --> 03:25:54,040 GREATER GOOD AND SOCIETAL 5607 03:25:54,040 --> 03:25:55,800 IMPACTS BECAUSE WE CAN ALL, I'M 5608 03:25:55,800 --> 03:25:59,000 SURE, THINK OF SO MANY EXAMPLES 5609 03:25:59,000 --> 03:26:01,080 OF MAJOR PUBLIC HEALTH 5610 03:26:01,080 --> 03:26:04,160 INNOVATIONS OR CLIMATE CHANGE 5611 03:26:04,160 --> 03:26:07,000 INNOVATIONS THAT MAY NOT BRING 5612 03:26:07,000 --> 03:26:10,840 IN THE DOLLARS IMMEDIATELY BUT 5613 03:26:10,840 --> 03:26:13,440 WOULD BE SO ESSENTIAL TO ADVANCE 5614 03:26:13,440 --> 03:26:14,840 THE GREATER GOOD. 5615 03:26:14,840 --> 03:26:17,960 SO, I JUST WANT TO MAKE SURE 5616 03:26:17,960 --> 03:26:20,280 EXPLICITLY THAT WILL BE FACTORED 5617 03:26:20,280 --> 03:26:20,480 IN? 5618 03:26:20,480 --> 03:26:22,920 >>IT REALLY IS. 5619 03:26:22,920 --> 03:26:25,000 OUR CHALLENGE IS, WE HAVE LIMIT 5620 03:26:25,000 --> 03:26:27,200 DOLLARSS AND WE DON'T HAVE 5621 03:26:27,200 --> 03:26:28,520 DOLLARS FOR SUSSTATEMENT. 5622 03:26:28,520 --> 03:26:33,040 SO IF BEE DEVELOP SOMETHING THAT 5623 03:26:33,040 --> 03:26:34,440 HAS THAT IMPACT FOR THE GREATER 5624 03:26:34,440 --> 03:26:37,000 GOOD, WHICH I HOPE WE DO. 5625 03:26:37,000 --> 03:26:39,200 ONE OF THE THINGS I DID IN MY 5626 03:26:39,200 --> 03:26:41,160 PREVIOUS WORK AT THE HEALTH 5627 03:26:41,160 --> 03:26:41,600 RESOURCES AND SERVICES 5628 03:26:41,600 --> 03:26:43,560 ADMINISTRATION IS TO THINK MORE 5629 03:26:43,560 --> 03:26:45,520 POPULATION LEVEL IMPROVEMENTS. 5630 03:26:45,520 --> 03:26:48,680 THAT'S WHERE I SORT OF WORKED ON 5631 03:26:48,680 --> 03:26:49,920 MY REN ORIVATION TO THINK ABOUT 5632 03:26:49,920 --> 03:26:51,400 HOW DO WE CHANGE THE WHOLE 5633 03:26:51,400 --> 03:26:53,280 SYSTEM? 5634 03:26:53,280 --> 03:26:54,200 HOW DO WE BENEFIT WHOLE 5635 03:26:54,200 --> 03:26:54,720 POPULATIONS? 5636 03:26:54,720 --> 03:26:56,520 THE CHALLENGE IS, AND YOU CAN 5637 03:26:56,520 --> 03:26:59,240 APPRECIATE THIS, YOU CAN COME UP 5638 03:26:59,240 --> 03:27:01,120 WITH AN INCREDIBLY SMART DESIGN 5639 03:27:01,120 --> 03:27:02,520 OR CAPABILITY OR WHATEVER IT 5640 03:27:02,520 --> 03:27:05,240 HAPPENS TO BE, POLICY AND 5641 03:27:05,240 --> 03:27:05,920 PROCEDURES AND TECHNOLOGY, BUT 5642 03:27:05,920 --> 03:27:07,880 IF YOU DON'T HAVE A SUSTAINMENT 5643 03:27:07,880 --> 03:27:09,880 PARTNER AND IF THERE IS JUST A 5644 03:27:09,880 --> 03:27:11,560 RELIANCE ON THE GOVERNMENT FOR 5645 03:27:11,560 --> 03:27:13,360 SUSTAINMENT, IT STARTS TO 5646 03:27:13,360 --> 03:27:16,160 CONSTRAIN WHAT YOU CAN 5647 03:27:16,160 --> 03:27:17,240 MEANINGFULLY DEVELOP AND THEN 5648 03:27:17,240 --> 03:27:17,760 TRANSITION. 5649 03:27:17,760 --> 03:27:20,040 SO WE HAVE TO KEEP THAT IN MIND 5650 03:27:20,040 --> 03:27:23,040 THAT DOESN'T MEAN WE CAN'T 5651 03:27:23,040 --> 03:27:26,120 DEVELOP NOVEL PARTNERSHIPS FOR 5652 03:27:26,120 --> 03:27:26,760 SUSSTATEMENT AND THERE IS A LOT 5653 03:27:26,760 --> 03:27:30,240 OF ORGANIZATIONS THAT WE CAN 5654 03:27:30,240 --> 03:27:33,600 POTENTIALLY TRY TO PARTNER WITH 5655 03:27:33,600 --> 03:27:35,720 FOR NON-BIOTECH INNOVATIONS. 5656 03:27:35,720 --> 03:27:36,920 AND THAT IS SOMETHING WE'LL LOOK 5657 03:27:36,920 --> 03:27:37,080 AT. 5658 03:27:37,080 --> 03:27:45,400 BUT I DO HOPE WE CAN INNOVATE ON 5659 03:27:45,400 --> 03:27:47,560 A LEVEL OF IMPACT. 5660 03:27:47,560 --> 03:27:52,280 >>SUSAN, THANK YOU VERY MUCH 5661 03:27:52,280 --> 03:27:54,160 FOR YOUR TALK WE REALLY 5662 03:27:54,160 --> 03:27:54,840 APPRECIATE THIS OVERVIEW AND 5663 03:27:54,840 --> 03:27:56,280 WISH YOU ALL THE BEST. 5664 03:27:56,280 --> 03:27:58,840 WE ARE DRINKING FROM THE FIRE 5665 03:27:58,840 --> 03:27:59,880 HYDRANT AND SETTING UP A NEW 5666 03:27:59,880 --> 03:28:01,120 AGENCY LIKE THIS. 5667 03:28:01,120 --> 03:28:04,120 WE DO LOOK FORWARD TO 5668 03:28:04,120 --> 03:28:04,760 COLLABORATIONS AND PLEASE REACH 5669 03:28:04,760 --> 03:28:07,520 OUT TO US AT ANY TIME. 5670 03:28:07,520 --> 03:28:09,640 BECAUSE WE HAVE A LOT OF 5671 03:28:09,640 --> 03:28:12,280 PRIORITIES WITH OUR AGING 5672 03:28:12,280 --> 03:28:17,240 POPULATION AND OBVIOUSLY WE HOPE 5673 03:28:17,240 --> 03:28:18,480 THAT ARPAH WILL BE AN INTEGRAL 5674 03:28:18,480 --> 03:28:19,760 PART OF SOLVING SOME OF THESE 5675 03:28:19,760 --> 03:28:20,680 ISSUES THAT WE HAVE. 5676 03:28:20,680 --> 03:28:21,120 >>THANK YOU. 5677 03:28:21,120 --> 03:28:24,200 AND LIKEWISE. 5678 03:28:24,200 --> 03:28:24,800 PLEASE DO NOT HESITATE TO REACH 5679 03:28:24,800 --> 03:28:25,120 OUT TO US. 5680 03:28:25,120 --> 03:28:26,520 WE WOULD LOVE NOTHING MORE THAN 5681 03:28:26,520 --> 03:28:27,840 TO DEVELOP A STRONG PARTNERSHIP 5682 03:28:27,840 --> 03:28:32,480 SO WE CAN EXCHANGE IDEAS AND 5683 03:28:32,480 --> 03:28:33,720 ACTIVITIES AND EVERYTHING. 5684 03:28:33,720 --> 03:28:34,440 >>SURE THING. 5685 03:28:34,440 --> 03:28:36,680 THANK YOU, AGAIN. 5686 03:28:36,680 --> 03:28:38,080 >>THANK YOU. 5687 03:28:38,080 --> 03:28:40,120 >>YES. 5688 03:28:40,120 --> 03:28:41,200 >>ALL RIGHT, THANK YOU ALL. 5689 03:28:41,200 --> 03:28:43,320 NEXT UP NOW WE'LL MOVE ON WITH 5690 03:28:43,320 --> 03:28:46,120 OUR PROGRAM. 5691 03:28:46,120 --> 03:28:49,360 NEXT WILL BE ASKING DR. LUIGI 5692 03:28:49,360 --> 03:28:52,680 FERRUCCI, OUR HEAD OF OUR 5693 03:28:52,680 --> 03:28:54,400 CLINICAL CENTER TO GIVE OUR 5694 03:28:54,400 --> 03:28:56,040 INTRAMURAL PROGRAM REPORT. 5695 03:28:56,040 --> 03:28:57,440 SO LUIGI? 5696 03:28:57,440 --> 03:29:01,680 >>LUIGI FERRUCCI: THANK YOU. 5697 03:29:01,680 --> 03:29:01,840 -- 5698 03:29:01,840 --> 03:29:08,280 [ INAUDIBLE ] 5699 03:29:08,280 --> 03:29:18,880 *6 WORLD EXPERT IN NON CODING -- 5700 03:29:24,160 --> 03:29:27,320 I THINK NEW FRONTIER OF 5701 03:29:27,320 --> 03:29:27,880 GENOMICS. 5702 03:29:27,880 --> 03:29:31,480 AND SHE HAS BEEN REVIEWING VERY 5703 03:29:31,480 --> 03:29:35,920 RECENTLY AND WE SUBMIT THAT ONE 5704 03:29:35,920 --> 03:29:37,040 RESPONSE TO THE REPORT WAS 5705 03:29:37,040 --> 03:29:39,040 ABSOLUTELY POSITIVE AND SHE WILL 5706 03:29:39,040 --> 03:29:42,480 INCLUDE IN HER PRESENTATION SOME 5707 03:29:42,480 --> 03:29:45,080 ANSWER TO THE COMMENT FROM THE 5708 03:29:45,080 --> 03:29:48,320 BOARD OF SCIENTIFIC COUNCIL. 5709 03:29:48,320 --> 03:29:51,880 THE SECOND TALK WILL BE GIVEN 5710 03:29:51,880 --> 03:29:52,760 FROM DR. RANHAN SEN, CHIEF OF 5711 03:29:52,760 --> 03:29:55,160 THE MOLECULAR BIOLOGY AND 5712 03:29:55,160 --> 03:29:56,440 IMMUNOLOGY. 5713 03:29:56,440 --> 03:29:59,600 DR. SEN IS A VERY WELL-KNOWN 5714 03:29:59,600 --> 03:30:01,520 IMMUNOLOGIST. 5715 03:30:01,520 --> 03:30:05,680 HIS WORK ON NF-kB AND 5716 03:30:05,680 --> 03:30:08,320 CONTRIBUTED SUBSTANTIALLY IN THE 5717 03:30:08,320 --> 03:30:14,440 FUNCTION OF THIS VERY IMPORTANT 5718 03:30:14,440 --> 03:30:14,720 SYSTEM. 5719 03:30:14,720 --> 03:30:17,560 IT IS SOMETIMES SLOWLY 5720 03:30:17,560 --> 03:30:20,480 PROGRESSIVELY CONVINCING -- 5721 03:30:20,480 --> 03:30:21,440 ABOUT AGING AND SO I THINK HE 5722 03:30:21,440 --> 03:30:26,480 WILL TALK TO YOU ABOUT SOME 5723 03:30:26,480 --> 03:30:27,760 REALLY GREAT WORK. 5724 03:30:27,760 --> 03:30:35,040 AND AFTER THAT, I WILL GIVE YOU 5725 03:30:35,040 --> 03:30:35,600 SOME DESCRIPTION ABOUT WHAT 5726 03:30:35,600 --> 03:30:37,800 HAPPENED IN THE IP IN THE LAST 5727 03:30:37,800 --> 03:30:38,400 YEAR. 5728 03:30:38,400 --> 03:30:41,240 I WILL TRY TO SHORTEN MY 5729 03:30:41,240 --> 03:30:43,040 PRESENTATION AND GIVEN THE FACT 5730 03:30:43,040 --> 03:30:47,280 WE HAVE ACCUMULATED SOME DELAY. 5731 03:30:47,280 --> 03:30:48,680 WITHOUT HESITATION, I ASK MYRIAM 5732 03:30:48,680 --> 03:30:51,120 GOROSPE TO SHARE HER SLIDES. 5733 03:30:51,120 --> 03:31:01,720 >>MYRIAM GOROSPE: SO THANK YOU 5734 03:31:11,320 --> 03:31:13,280 ALSO SENIOR LEADERSHIP AND 5735 03:31:13,280 --> 03:31:20,000 COUNCIL MEMBERS FOR GIVING ME AN 5736 03:31:20,000 --> 03:31:23,120 OPPORTUNITY TO PRESENT AN UPDATE 5737 03:31:23,120 --> 03:31:27,200 IN THE LABORATORY OF GENETICS 5738 03:31:27,200 --> 03:31:30,440 AND GENOMICS IN OCTOBER 2021. 5739 03:31:30,440 --> 03:31:38,320 AND I'LL START WITH THIS BIC 5740 03:31:38,320 --> 03:31:40,160 PICTURE VIEW OF HOW WE 5741 03:31:40,160 --> 03:31:41,080 CONTRIBUTE TO THE MISSION OF 5742 03:31:41,080 --> 03:31:41,240 THE. 5743 03:31:41,240 --> 03:31:43,800 THIS IA TO REDUCE DELAY AND 5744 03:31:43,800 --> 03:31:46,640 PREVENT ASSOCIATED DISEASE AND 5745 03:31:46,640 --> 03:31:48,240 DISABILITY IN THE LABORATORY OF 5746 03:31:48,240 --> 03:31:53,080 GENETICS AND GENOMICS BY 5747 03:31:53,080 --> 03:31:53,680 CONTRIBUTING TOOLS AAPPROACHS 5748 03:31:53,680 --> 03:31:57,240 AND METHODS AND EXPERTISE OF 5749 03:31:57,240 --> 03:31:59,960 CELL AND MOLEC LABILES WHICH IS 5750 03:31:59,960 --> 03:32:02,200 WHAT WE ARE ALL IN IN LGG. 5751 03:32:02,200 --> 03:32:04,160 SO THE LABORATORY IS COMPRISED 5752 03:32:04,160 --> 03:32:06,560 OF THREE SECTIONS. 5753 03:32:06,560 --> 03:32:09,160 HEADED BY THREE SENIOR 5754 03:32:09,160 --> 03:32:10,120 INVESTIGATORS. 5755 03:32:10,120 --> 03:32:16,800 AND VERY BRIEFLY, WE DON'T 5756 03:32:16,800 --> 03:32:17,000 WANT -- 5757 03:32:17,000 --> 03:32:17,480 [ INAUDIBLE ] 5758 03:32:17,480 --> 03:32:20,840 AS YOU'LL SEE ALL OF US FOCUS 5759 03:32:20,840 --> 03:32:23,920 VERY MUCH ON THE PROCESS OF GENE 5760 03:32:23,920 --> 03:32:24,840 REGULATION, FLOW OF GENETIC 5761 03:32:24,840 --> 03:32:28,360 INFORMATION IN ONE WAY OR 5762 03:32:28,360 --> 03:32:28,680 ANOTHER. 5763 03:32:28,680 --> 03:32:31,240 WE FOCUS ON POST TRANSCRIPTIONAL 5764 03:32:31,240 --> 03:32:33,240 GENE REGULATORY PROCESSES IN 5765 03:32:33,240 --> 03:32:40,560 AGING PARADIGMS AND FOCUSES ON 5766 03:32:40,560 --> 03:32:42,280 TELOMERE MAINTENANCE AND 5767 03:32:42,280 --> 03:32:44,120 TELOMERE FUNCTION. 5768 03:32:44,120 --> 03:32:53,040 WE ALSO HAVE TWO INVESTIGATORS. 5769 03:32:53,040 --> 03:32:55,320 LOOKING AT CHROMATIN REMODELING 5770 03:32:55,320 --> 03:32:59,760 AND REGENERATION AND ANOTHER 5771 03:32:59,760 --> 03:33:02,400 LOOKS AT ONLY DYNAMICS AS WELL 5772 03:33:02,400 --> 03:33:06,880 BUT FOCUSING STRONGLY ON 5773 03:33:06,880 --> 03:33:08,920 COMPUTATIONAL BASIS OF GENE 5774 03:33:08,920 --> 03:33:09,600 REGULATION. 5775 03:33:09,600 --> 03:33:17,480 WE ALSO HAVE ANOTHER JUNIOR 5776 03:33:17,480 --> 03:33:18,080 INVESTIGATOR IN THE LAB, AN 5777 03:33:18,080 --> 03:33:18,560 INDEPENDENT RESEARCH 5778 03:33:18,560 --> 03:33:18,880 COLLABORATOR. 5779 03:33:18,880 --> 03:33:21,600 AND THE HER RESEARCH FOCUSES ON 5780 03:33:21,600 --> 03:33:24,680 OUTCOMES OF SENESCENCE IN THE 5781 03:33:24,680 --> 03:33:30,040 CONTEXT OF AGING, IN PARTICULAR 5782 03:33:30,040 --> 03:33:30,400 ARTHROSCLEROSIS. 5783 03:33:30,400 --> 03:33:32,960 AND THE FINAL GROUP IS LED BY 5784 03:33:32,960 --> 03:33:37,680 THE COMPUTATIONAL GENETICS AND 5785 03:33:37,680 --> 03:33:40,440 COMPUTATIONAL CORE, AND SUPPORTS 5786 03:33:40,440 --> 03:33:45,240 US AND COMPLIMENTS WHAT WE DO 5787 03:33:45,240 --> 03:33:47,240 WITH SUPPORT AND THE CORE OF 5788 03:33:47,240 --> 03:33:49,560 COURSE SUPPORTS MANY PROGRAMS 5789 03:33:49,560 --> 03:33:50,080 ACROSS. 5790 03:33:50,080 --> 03:33:53,800 SO WHAT I'D LIKE TO DO TODAY IS 5791 03:33:53,800 --> 03:33:55,400 TOUCH ON TWO THINGS. 5792 03:33:55,400 --> 03:33:57,000 SWONE GIVE YOU A BRIEF UPDATE OF 5793 03:33:57,000 --> 03:33:58,400 WHAT EACH OF THESE SECTIONS AND 5794 03:33:58,400 --> 03:34:01,200 UNITS HAVE DONE OVER THE PAST 5795 03:34:01,200 --> 03:34:02,520 YEAR SINCE WE WERE REVIEWED. 5796 03:34:02,520 --> 03:34:03,840 AND THEN I'LL CONCLUDE WITH 5797 03:34:03,840 --> 03:34:06,760 SPECIFIC WAYS IN WHICH WE ARE 5798 03:34:06,760 --> 03:34:09,360 ADDRESSING THE VERY HELPFUL AND 5799 03:34:09,360 --> 03:34:12,520 VALUABLE RECOMMENDATIONS AND 5800 03:34:12,520 --> 03:34:12,920 ADVICE. 5801 03:34:12,920 --> 03:34:18,960 SO I'LL START WITH THE PROGRESS 5802 03:34:18,960 --> 03:34:20,400 UPDATES. 5803 03:34:20,400 --> 03:34:21,040 SO WE DON'T HAVE DEDICATED A BIT 5804 03:34:21,040 --> 03:34:24,160 OF TIME OVER THE PAST FEW YEARS 5805 03:34:24,160 --> 03:34:25,240 LOOKING AT DATA. 5806 03:34:25,240 --> 03:34:26,360 OVER THE PAST YEAR, THESE 5807 03:34:26,360 --> 03:34:29,680 EFFORTS HAVE LED TO A NUMBER OF 5808 03:34:29,680 --> 03:34:31,120 PUBLICATIONS. 5809 03:34:31,120 --> 03:34:35,240 ONE OF WHICH IDENTIFIES SUBSETS 5810 03:34:35,240 --> 03:34:36,240 OF mRNAs WHO TRANSLATION AND 5811 03:34:36,240 --> 03:34:41,000 STABILITY ARE CONTROLLED BY TOP 5812 03:34:41,000 --> 03:34:41,160 3. 5813 03:34:41,160 --> 03:34:43,800 IN ANOTHER ARTICLE THEY HAVE 5814 03:34:43,800 --> 03:34:47,720 ESTABLISHED THAT TOP 3 DATA IS 5815 03:34:47,720 --> 03:34:48,640 DISPENSABLE FOR VIOLATES 5816 03:34:48,640 --> 03:34:48,920 REPLICATION. 5817 03:34:48,920 --> 03:34:51,160 THIS IS A POINT THAT HASH MADE 5818 03:34:51,160 --> 03:34:52,760 EARLIER AND THEY BROUGHT 5819 03:34:52,760 --> 03:34:54,360 SUPPLIES TO THIS QUESTION. 5820 03:34:54,360 --> 03:34:56,360 AND IN ANOTHER ARTICLE THEY HAVE 5821 03:34:56,360 --> 03:34:59,440 A CATALOG, TRANSCRIPTION FACTORS 5822 03:34:59,440 --> 03:35:02,360 IMPORTANT FOR HUMAN EMBRYONIC 5823 03:35:02,360 --> 03:35:03,360 STEM CELLS. 5824 03:35:03,360 --> 03:35:06,600 MY OWN LAB CONTINUES TO LOOK AT 5825 03:35:06,600 --> 03:35:08,360 GENE REGULATION, VERY MUCH 5826 03:35:08,360 --> 03:35:10,080 FOCUSED ON REGULATION OF RNA 5827 03:35:10,080 --> 03:35:11,240 FROM THE POINTED OF 5828 03:35:11,240 --> 03:35:16,480 TRANSCRIPTION UNTIL THE RNA IS 5829 03:35:16,480 --> 03:35:17,720 USED FOR SYNTHESIS AND MOST 5830 03:35:17,720 --> 03:35:21,320 FOCUS IS ON THE FACTORS, RNA 5831 03:35:21,320 --> 03:35:25,480 BINDING PROTEINS THAT DRIVE THIS 5832 03:35:25,480 --> 03:35:27,120 POST TRANSCRIPTIONAL MESSENGER 5833 03:35:27,120 --> 03:35:27,560 RNA. 5834 03:35:27,560 --> 03:35:28,920 OVER THE PAST YEAR, WE HAVE MADE 5835 03:35:28,920 --> 03:35:30,920 PROGRESS IN FOUR DIFFERENT AREAS 5836 03:35:30,920 --> 03:35:33,760 OF EFFORT IN THE LABORATORY. 5837 03:35:33,760 --> 03:35:37,640 WE HAVE IDENTIFIED SIGNALING 5838 03:35:37,640 --> 03:35:38,240 PATHWAYS THAT ARE CRITICAL IN 5839 03:35:38,240 --> 03:35:38,880 THE PROCESS OF CELL SENESCENCE 5840 03:35:38,880 --> 03:35:41,480 AND LOOKED AT TISSUE AGING. 5841 03:35:41,480 --> 03:35:44,560 WE ALSO HAVE IDENTIFIED SOME 5842 03:35:44,560 --> 03:35:46,680 LONGER CODING RNAs ESSENTIAL 5843 03:35:46,680 --> 03:35:48,680 FOR MUSCLE REGENERATION AS WELL 5844 03:35:48,680 --> 03:35:50,880 AS MACROPHAGES THAT CHANGE 5845 03:35:50,880 --> 03:35:55,080 ACROSS THE LIFESPAN IN THE 5846 03:35:55,080 --> 03:35:55,320 MUSCLES. 5847 03:35:55,320 --> 03:35:57,320 WE HAVE HAD THE OPPORTUNITY TO 5848 03:35:57,320 --> 03:36:01,760 DO A HISTORICAL REVIEW OF RNAs 5849 03:36:01,760 --> 03:36:05,360 FOR THE PAST 25 YEARS. 5850 03:36:05,360 --> 03:36:06,720 AND RECENTLY WE WERE ABLE TO 5851 03:36:06,720 --> 03:36:13,480 BEGIN TO LOOK AT CIRCULAR 5852 03:36:13,480 --> 03:36:17,280 RN56789s. 5853 03:36:17,280 --> 03:36:20,160 NOT REVIEWED IN 2021 BECAUSE SHE 5854 03:36:20,160 --> 03:36:21,880 HAD JUST MOVED TO THE LGG, BUT 5855 03:36:21,880 --> 03:36:25,880 OVER THE PAST YEAR, HER WORK HAS 5856 03:36:25,880 --> 03:36:30,240 CONTINUED TO BE -- TO MAKE 5857 03:36:30,240 --> 03:36:31,280 EXCITING PROGRESS. 5858 03:36:31,280 --> 03:36:32,560 IN THREE OF THE ARTICLES, SHE 5859 03:36:32,560 --> 03:36:36,000 HAS BEEN ABLE TO IDENTIFY THE 5860 03:36:36,000 --> 03:36:38,680 PROTEIN RAT 1 AS BEING A KEY 5861 03:36:38,680 --> 03:36:40,200 MOLECULAR FACTOR IN MAINTENANCE. 5862 03:36:40,200 --> 03:36:41,960 SHE ALSO DEVELOPED A METHOD THAT 5863 03:36:41,960 --> 03:36:47,240 IS QUITE USEFUL IN BEING ABLE TO 5864 03:36:47,240 --> 03:36:50,240 MEASURE CONVENIENTLY TELOMERE 5865 03:36:50,240 --> 03:36:54,200 DYSFUNCTION AND SHE HAS LOOKED 5866 03:36:54,200 --> 03:37:02,520 AT INTERVENTIONS -- IN SHORT 5867 03:37:02,520 --> 03:37:03,760 TELOMERE SYNDROMES IN HUMANS. 5868 03:37:03,760 --> 03:37:06,880 MOVING ON TO THE TENURED TRACK 5869 03:37:06,880 --> 03:37:08,880 INVESTIGATORS AND LOOKING AT 5870 03:37:08,880 --> 03:37:10,720 EPIGENETIC MECHANISMS OF TISSUE 5871 03:37:10,720 --> 03:37:10,920 AGING. 5872 03:37:10,920 --> 03:37:13,560 THIS IS A PERIOD FOR HER OVER 5873 03:37:13,560 --> 03:37:13,880 THE PAST YEAR. 5874 03:37:13,880 --> 03:37:15,240 AND I'M EXCITED TO TELL YOU THAT 5875 03:37:15,240 --> 03:37:18,160 ONE OF HER MAJOR PROJECTS IN THE 5876 03:37:18,160 --> 03:37:19,680 LAB WHICH LOOKS AT TISSUE 5877 03:37:19,680 --> 03:37:22,160 REGENERATION, LIVER 5878 03:37:22,160 --> 03:37:23,200 REGENERATION,S AS A FUNCTION OF 5879 03:37:23,200 --> 03:37:28,200 AGE IN MUSCLE WITH LOOKING AT 5880 03:37:28,200 --> 03:37:34,680 CHROMATIN CHANGES IS NOW IN 5881 03:37:34,680 --> 03:37:36,680 FINAL STAGE LESS OF REVISION. 5882 03:37:36,680 --> 03:37:38,880 ALSO CONTINUING TO LOOK AT RNA 5883 03:37:38,880 --> 03:37:41,240 DYNAMICS OVER THE PAST YEAR AND 5884 03:37:41,240 --> 03:37:45,800 THIS WORK HAS LED TO ADDITIONAL 5885 03:37:45,800 --> 03:37:48,680 ARTICLES, ONE OF WHICH ALSO I'M 5886 03:37:48,680 --> 03:37:50,560 EXCITED TO SAY CAPTURES A LOT OF 5887 03:37:50,560 --> 03:37:53,840 WORK THEY HAVE DONE OVER THE 5888 03:37:53,840 --> 03:37:58,320 PAST COUPLE OF YEARS IN MOUSE 5889 03:37:58,320 --> 03:38:02,080 MODELS OF AGING LOOKING AT RNA 5890 03:38:02,080 --> 03:38:04,200 DYNAMICS, IN PARTICULAR LOOKING 5891 03:38:04,200 --> 03:38:06,840 AT RNA LENGTH AND USING 5892 03:38:06,840 --> 03:38:10,960 TECHNIQUES SUCH AS SEQUENCING 5893 03:38:10,960 --> 03:38:13,960 WITH A VERY STRONG AND 5894 03:38:13,960 --> 03:38:17,040 CUTTING-EDGE COMPUTATIONAL 5895 03:38:17,040 --> 03:38:19,960 SUPPORT WHICH IS ACTUALLY LED TO 5896 03:38:19,960 --> 03:38:22,640 THE DEVELOPMENT OF SOFTWARE AND 5897 03:38:22,640 --> 03:38:29,440 OTHER APPROACHES IN-HOUSE BY THE 5898 03:38:29,440 --> 03:38:31,440 TEAM. 5899 03:38:31,440 --> 03:38:34,760 LEADING THE PROGRAM, THE NEWEST 5900 03:38:34,760 --> 03:38:36,280 IN THE LGG. 5901 03:38:36,280 --> 03:38:37,480 SHE HAS BEEN DEVELOPING CELL AND 5902 03:38:37,480 --> 03:38:40,320 MOUSE MODELS OF VASCULAR 5903 03:38:40,320 --> 03:38:43,000 SENESCENCE AND IDENTIFYING DRUGS 5904 03:38:43,000 --> 03:38:46,360 THAT TARGET SINESENCE IN THIS 5905 03:38:46,360 --> 03:38:47,080 NICHE. 5906 03:38:47,080 --> 03:38:49,480 SHE ALSO HAD BEEN QUITE BUSY 5907 03:38:49,480 --> 03:38:51,160 OVER THE PAST YEAR AND ONE OF 5908 03:38:51,160 --> 03:38:53,720 THE RECENT STUDIES IN WHICH SHE 5909 03:38:53,720 --> 03:38:56,880 HAS LOOKED AT SINGLE CELL 5910 03:38:56,880 --> 03:39:00,000 POPULATIONS IN THE 5911 03:39:00,000 --> 03:39:03,400 ARTHROSCLEROSIS NICHE IN MOUSE 5912 03:39:03,400 --> 03:39:04,640 IS NOW AGAIN IN FINAL STAGES. 5913 03:39:04,640 --> 03:39:07,960 SO REVISION AND PLANS TO SEND IT 5914 03:39:07,960 --> 03:39:08,640 BACK IN THE FUTURE. 5915 03:39:08,640 --> 03:39:15,240 AND FINALLY, WE HAVE BEEN QUITE 5916 03:39:15,240 --> 03:39:20,040 BUSY SUPPORTING ALL OF THE 5917 03:39:20,040 --> 03:39:22,040 GROUPS WHILE THE GROUPS IN. 5918 03:39:22,040 --> 03:39:24,680 THIS IA BY PROVIDING DIVERSE 5919 03:39:24,680 --> 03:39:26,360 OMICS DATA BY COORDINATING DATE 5920 03:39:26,360 --> 03:39:29,400 TA SCIENCE EXPERTISE, BY 5921 03:39:29,400 --> 03:39:33,640 ACQUIRING AND MAINTAINING 5922 03:39:33,640 --> 03:39:35,680 INSTRUMENTS AND SOFTWARE THAT 5923 03:39:35,680 --> 03:39:38,040 ALLOWS US TO BUILD MUCH OF THE 5924 03:39:38,040 --> 03:39:38,320 WORK WE DO. 5925 03:39:38,320 --> 03:39:40,280 AND IN SOME CASES, BY WORKING 5926 03:39:40,280 --> 03:39:42,520 WITH US WITH INDIVIDUAL GROUPS 5927 03:39:42,520 --> 03:39:45,480 TO SET UP SPECIFIC PROJECTS THAT 5928 03:39:45,480 --> 03:39:47,800 REQUIRE EXPERTISE THAT WE DON'T 5929 03:39:47,800 --> 03:39:49,840 HAVE IN OUR OWN GROUPS. 5930 03:39:49,840 --> 03:39:53,480 AND THEY ARE ABLE TO VERY 5931 03:39:53,480 --> 03:39:55,360 QUICKLY HELP US DEVELOP METHODS 5932 03:39:55,360 --> 03:39:58,800 AND APPROACH THAT IS WE CAN USE. 5933 03:39:58,800 --> 03:40:01,240 SO THIS IS THE UPDATE OVER THE 5934 03:40:01,240 --> 03:40:02,960 PAST YEAR BY ALL OF THE TEAMS 5935 03:40:02,960 --> 03:40:05,240 THAT COMPRISE THE LGG. 5936 03:40:05,240 --> 03:40:06,760 AND SO WHAT I'D LIKE TO DO IN 5937 03:40:06,760 --> 03:40:08,320 THE REMAINING FEW MINUTES IS 5938 03:40:08,320 --> 03:40:12,000 TELL YOU HOW WE ADDRESSED THE 5939 03:40:12,000 --> 03:40:13,560 RECOMMENDATIONS AND ADVICE FROM 5940 03:40:13,560 --> 03:40:14,760 THE BSC. 5941 03:40:14,760 --> 03:40:20,320 SO THE BSC PROPOSED OR SUGGESTED 5942 03:40:20,320 --> 03:40:22,240 THAT MORE VERIFICATION OF 5943 03:40:22,240 --> 03:40:24,120 FINDINGS AND MODELS IN PATIENT 5944 03:40:24,120 --> 03:40:25,960 SAMPLES AND WE HAVE TAKEN THIS 5945 03:40:25,960 --> 03:40:30,240 ADVICE VERY SERIOUSLY. 5946 03:40:30,240 --> 03:40:32,600 WE HAVE ADDITIONAL SENESCENCE 5947 03:40:32,600 --> 03:40:33,680 MODELS WE ARE BEGINNING TO 5948 03:40:33,680 --> 03:40:37,000 PUBLISH, INCLUDING MODELS OF 5949 03:40:37,000 --> 03:40:39,520 SENESCENCE SIGNALING AND 5950 03:40:39,520 --> 03:40:40,040 TELOMERE ATTRITION. 5951 03:40:40,040 --> 03:40:42,840 SO THESE ACTUALLY INCLUDING 5952 03:40:42,840 --> 03:40:44,640 MOUSE MODELS OF SENESCENCE. 5953 03:40:44,640 --> 03:40:47,560 AND WE ARE ALSO VERY KEEN ON 5954 03:40:47,560 --> 03:40:51,200 FOLLOWING THE ADVICE OF 5955 03:40:51,200 --> 03:40:53,040 BRANCHING OUT AND EXPANDING INTO 5956 03:40:53,040 --> 03:40:55,520 PATIENT SAMPLES AND WE ARE 5957 03:40:55,520 --> 03:41:00,560 TEAMING UP WITH THE LARGE 5958 03:41:00,560 --> 03:41:02,440 ENTERPRISE AT NIA. 5959 03:41:02,440 --> 03:41:04,720 WE HAVE BEEN LOOKING AT MUSCLE 5960 03:41:04,720 --> 03:41:10,720 AND SKIN IN THIS SPACE AND IN 5961 03:41:10,720 --> 03:41:14,840 OTHER EFFORTS, WE ARE LOOKING AT 5962 03:41:14,840 --> 03:41:15,640 LIVER FROM PATIENTS AS A 5963 03:41:15,640 --> 03:41:17,360 FUNCTION OF AGE AND WE HAVE 5964 03:41:17,360 --> 03:41:20,080 BEEN, AS I MENTI MENTIONED EARL, 5965 03:41:20,080 --> 03:41:26,440 LOOKING AT ALS SAMPLES FROM 5966 03:41:26,440 --> 03:41:28,840 HUMAN BIOPSIES AND NECROPSY. 5967 03:41:28,840 --> 03:41:32,040 TO ILLUSTRATE THIS POINT, THIS 5968 03:41:32,040 --> 03:41:36,760 IS A PROJECT THAT SEEKS TO 5969 03:41:36,760 --> 03:41:39,760 CATALOG CHANGES ACROSS THE HUMAN 5970 03:41:39,760 --> 03:41:41,920 LIFESPAN USING A VERY HEALTHY 5971 03:41:41,920 --> 03:41:43,040 COHORT OF INDIVIDUALS OF 5972 03:41:43,040 --> 03:41:46,160 DIFFERENT AGES FROM 20S TO THEIR 5973 03:41:46,160 --> 03:41:46,680 80s. 5974 03:41:46,680 --> 03:41:48,320 AND A NUMBER OF TISSUES HAVE 5975 03:41:48,320 --> 03:41:51,440 BEEN COLLECTED IN THIS STUDY. 5976 03:41:51,440 --> 03:41:53,960 IN THIS CASE WE LOOKED AT SKIN 5977 03:41:53,960 --> 03:41:56,040 BIOPSIES COLLECTED FROM THE 5978 03:41:56,040 --> 03:41:58,280 PARTICIPANTS FROM WHICH WE 5979 03:41:58,280 --> 03:41:59,120 OBTAINED FIBROBLASTS AND THEN 5980 03:41:59,120 --> 03:42:03,200 COLLECT RNA, WHICH WE ARE NOW 5981 03:42:03,200 --> 03:42:04,360 STUDYING AND PROTEINS THAT WAS 5982 03:42:04,360 --> 03:42:06,560 STUDIED IN THE ARTICLE THAT WE 5983 03:42:06,560 --> 03:42:08,160 LISTED A FEW MONTHS AGO. 5984 03:42:08,160 --> 03:42:10,000 AND HERE ANALYSIS OF PROTEINS 5985 03:42:10,000 --> 03:42:12,200 LED US TO IDENTIFY SPECIFIC 5986 03:42:12,200 --> 03:42:15,000 PATHWAYS THAT WERE CHANGING AS A 5987 03:42:15,000 --> 03:42:16,680 FUNCTION OF AGING IN THIS 5988 03:42:16,680 --> 03:42:17,400 COHORT. 5989 03:42:17,400 --> 03:42:24,680 THE BSC ALSO INDICATED THAT WE 5990 03:42:24,680 --> 03:42:27,480 SHOULD BEGIN TO DESCRIBE MORE 5991 03:42:27,480 --> 03:42:28,680 TRANSLATIONAL STUDIES TO MAKE 5992 03:42:28,680 --> 03:42:30,880 OUR EFFORTS IN THIS SPACE MORE 5993 03:42:30,880 --> 03:42:31,480 IMPACTFUL. 5994 03:42:31,480 --> 03:42:35,000 WE ARE ALSO TAKING THIS 5995 03:42:35,000 --> 03:42:37,320 RECOMMENDATION TO HEART. 5996 03:42:37,320 --> 03:42:42,200 WE HAVE WORKED WITH IN STUDIES 5997 03:42:42,200 --> 03:42:52,680 LED BY OTHERS LOOKING AT NOVEL 5998 03:42:52,680 --> 03:42:55,800 THINGS ELIMINATES SENESCENCEIS 5999 03:42:55,800 --> 03:42:57,120 AND TRACK INHABITORS TO CREATE 6000 03:42:57,120 --> 03:43:02,000 DRUGS THAT ONE CAN EXPLOIT AND 6001 03:43:02,000 --> 03:43:03,400 ADDITIONAL EFFORTS ARE ONGOING. 6002 03:43:03,400 --> 03:43:06,280 ONE OF THESE STUDIES TO 6003 03:43:06,280 --> 03:43:09,640 ILLUSTRATE THIS POINTED SO AFTER 6004 03:43:09,640 --> 03:43:12,040 CAUSING CELL DAMAGE IN 6005 03:43:12,040 --> 03:43:17,280 FIBROBLASTS AND OTHER CELLS, IS 6006 03:43:17,280 --> 03:43:18,200 THE CELL RESPONSE INCLUDES 6007 03:43:18,200 --> 03:43:19,960 ACTIVATION OF THE KINASE SAR? 6008 03:43:19,960 --> 03:43:22,840 THAT CELL IS MORE LIKELY TO 6009 03:43:22,840 --> 03:43:24,280 UNDERGO SENESCENCE. 6010 03:43:24,280 --> 03:43:27,720 BUT IF SARIS INHIBITED OR IS 6011 03:43:27,720 --> 03:43:29,080 SILENCERRED OR OTHERWISE 6012 03:43:29,080 --> 03:43:30,680 IMPAIRED, THAT CELL IS MORE 6013 03:43:30,680 --> 03:43:32,600 LIKELY TO UNDERGO APOPTOSIS AND 6014 03:43:32,600 --> 03:43:37,640 WE CAN TEST THESE DRUGS IN 6015 03:43:37,640 --> 03:43:38,320 PRE-CLINICAL PROD ELSE SUCH AS 6016 03:43:38,320 --> 03:43:38,600 THIS ONE. 6017 03:43:38,600 --> 03:43:40,320 THIS IS A MOUSE IN WHICH 6018 03:43:40,320 --> 03:43:42,320 SENESCENCE IS TRYING TO APPLY 6019 03:43:42,320 --> 03:43:42,880 INJECTION. 6020 03:43:42,880 --> 03:43:45,040 TREATMENT WITH THESE TWO 6021 03:43:45,040 --> 03:43:46,960 INHIBITORS TP1 AND 2 CAUSE 6022 03:43:46,960 --> 03:43:50,400 NUMBER OF SENESCENCE CELLS TO 6023 03:43:50,400 --> 03:43:59,560 DECREASE AS YOU CAN SEE IN THIS 6024 03:43:59,560 --> 03:43:59,760 SLIDE. 6025 03:43:59,760 --> 03:44:02,640 THE BSC ALSO ENCOURAGED FOR 6026 03:44:02,640 --> 03:44:05,240 OTHER SUPPORT PROGRAM AND IN 6027 03:44:05,240 --> 03:44:06,880 PARTICULAR THE DEVELOPMENT OF 6028 03:44:06,880 --> 03:44:08,960 ADDITIONAL MODELS. 6029 03:44:08,960 --> 03:44:11,680 AND WE ARE VERY THANKFUL TO THE 6030 03:44:11,680 --> 03:44:15,880 OFFICIAL SCIENTIFIC DIRECTOR 6031 03:44:15,880 --> 03:44:17,920 WHICH HAS COMMITTED PEOPLER 6032 03:44:17,920 --> 03:44:21,240 ADDITIONAL FUNDS TO STUDY 6033 03:44:21,240 --> 03:44:25,760 SENESCENCE AND MODELS AS WELL AS 6034 03:44:25,760 --> 03:44:28,600 BY CREATION OF AN ADDITIONAL 6035 03:44:28,600 --> 03:44:31,520 POSTBAC POSITION FOR MOUSE WORK. 6036 03:44:31,520 --> 03:44:33,240 MOUSE MODELS THAT WE ARE 6037 03:44:33,240 --> 03:44:34,960 ADOPTING AND DEVELOPING INCLUDE 6038 03:44:34,960 --> 03:44:40,600 A MODEL WHICH WE ARE TESTING THE 6039 03:44:40,600 --> 03:44:43,520 GINGER NONE A DRUG AND OTHER 6040 03:44:43,520 --> 03:44:46,120 INHIBITORS AND OF TEADB AND I'LL 6041 03:44:46,120 --> 03:44:48,600 USE MY LAST SLIDE TO ILLUSTRATE 6042 03:44:48,600 --> 03:44:49,120 THIS POINT. 6043 03:44:49,120 --> 03:44:53,240 IN ANOTHER RECENT ARTICLE, WE 6044 03:44:53,240 --> 03:44:58,040 DISCOVERED THAT SENESCENT CELLS 6045 03:44:58,040 --> 03:45:02,000 EXPRESS BOTH TRKB AND BDNF. 6046 03:45:02,000 --> 03:45:05,000 AND THIS PARADIGM IS ONE THAT WE 6047 03:45:05,000 --> 03:45:07,320 THOUGHT WAS ON THE -- 6048 03:45:07,320 --> 03:45:08,880 RESTRICTED. 6049 03:45:08,880 --> 03:45:09,640 BUT SENESCENCE ACQUIRED THIS 6050 03:45:09,640 --> 03:45:10,800 PHENOTYPE AS WELL. 6051 03:45:10,800 --> 03:45:15,520 AND IN FACT, IF THIS AUDIO CRIN 6052 03:45:15,520 --> 03:45:17,240 OR RESPONSE IS IMPAIRED IN ANY 6053 03:45:17,240 --> 03:45:18,560 WAY, THOSE CELLS ARE MORE LIKELY 6054 03:45:18,560 --> 03:45:20,320 TO DIE THROUGH APOPTOSIS. 6055 03:45:20,320 --> 03:45:25,360 AND SO WE CAN USE INHIBITORS OF 6056 03:45:25,360 --> 03:45:26,960 TRKB IN PARTICULAR TO TEST THE 6057 03:45:26,960 --> 03:45:29,240 POSSIBILITY OF INTERFERING WITH 6058 03:45:29,240 --> 03:45:31,960 THE SENESCENCE PROCESS IN THIS 6059 03:45:31,960 --> 03:45:34,200 MANNER. 6060 03:45:34,200 --> 03:45:39,400 AND SO HERE TWO INHIBITORS TO 6061 03:45:39,400 --> 03:45:42,200 BLOCK TRKB ACTIVITY. 6062 03:45:42,200 --> 03:45:46,040 THIS WILL INJECT -- IN THREE 6063 03:45:46,040 --> 03:45:47,600 MONTHS AND AS I CAN SEE IN 6064 03:45:47,600 --> 03:45:51,160 KEEPING IN LINE WITH LIVER, THE 6065 03:45:51,160 --> 03:45:53,760 NUMBER OF SENESCENCE CELLS 6066 03:45:53,760 --> 03:45:55,120 DECLINE AS A FUNCTION OF 6067 03:45:55,120 --> 03:45:58,440 ADMINISTRATION OF THE DRUG. 6068 03:45:58,440 --> 03:45:59,840 THE FINAL RECOMMENDATION FOR 6069 03:45:59,840 --> 03:46:03,120 WHICH WE ARE SUPER GRATEFUL TO 6070 03:46:03,120 --> 03:46:06,440 THE BSC IS THAT A STAFF 6071 03:46:06,440 --> 03:46:09,640 SCIENTIST BIOINFOMATIC EXPERT BE 6072 03:46:09,640 --> 03:46:11,720 ADDED TO THE LAB. 6073 03:46:11,720 --> 03:46:15,320 SO WESTERN ABLE TO RECRUIT 6074 03:46:15,320 --> 03:46:15,880 DR. CHRISTINA MASON -- SO WE 6075 03:46:15,880 --> 03:46:18,680 WERE ABLE TO RECRUIT -- SHE 6076 03:46:18,680 --> 03:46:21,520 JOINEDIS 2022 AND SHE ALREADY 6077 03:46:21,520 --> 03:46:22,400 ENRICHED THE PROGRAMMING IN 6078 03:46:22,400 --> 03:46:23,880 MANY, MANY DIFFERENT WAYS. 6079 03:46:23,880 --> 03:46:27,720 SO WITH THIS, I WILL THANK THE 6080 03:46:27,720 --> 03:46:29,920 GROUP THAT I'M SO EXCITED TO BE 6081 03:46:29,920 --> 03:46:32,560 A PART OF AND SO PROUD OF 6082 03:46:32,560 --> 03:46:33,200 WORKING WITH. 6083 03:46:33,200 --> 03:46:37,640 AND I WILL THANK ALL OF YOU FOR 6084 03:46:37,640 --> 03:46:38,280 YOUR ATTENTION AND END HERE. 6085 03:46:38,280 --> 03:46:41,400 THANK YOU. 6086 03:46:41,400 --> 03:46:42,040 >>THANK YOU. 6087 03:46:42,040 --> 03:46:44,640 GIVEN THE FACT THAT WE ARE LATE, 6088 03:46:44,640 --> 03:46:48,080 WHY DON'T WE GO ON AND SEE THE 6089 03:46:48,080 --> 03:46:49,720 OTHER PRESENTATION AND THEN 6090 03:46:49,720 --> 03:46:55,280 PEOPLE CAN ASK THEIR QUESTIONS. 6091 03:46:55,280 --> 03:47:03,320 >>OKAY. 6092 03:47:03,320 --> 03:47:06,920 >>RAB JAN YOU CAN START SHARING 6093 03:47:06,920 --> 03:47:08,000 YOUR SCREEN. 6094 03:47:08,000 --> 03:47:11,040 >>RANHAN SEN: OKAY, I WILL. 6095 03:47:11,040 --> 03:47:15,040 IS THAT VISIBLE AND I CAN BE 6096 03:47:15,040 --> 03:47:19,520 HEARD? 6097 03:47:19,520 --> 03:47:19,800 >>YES. 6098 03:47:19,800 --> 03:47:20,440 >>THANK YOU VERY MUCH FOR THE 6099 03:47:20,440 --> 03:47:22,560 KIND INTRODUCTION. 6100 03:47:22,560 --> 03:47:23,960 GOOD AFTERNOON COUNCIL MEMBERS 6101 03:47:23,960 --> 03:47:27,400 AND NIA LEADERSHIP AND OF COURSE 6102 03:47:27,400 --> 03:47:31,560 ALL OF OUR COLLEAGUES WITH THE 6103 03:47:31,560 --> 03:47:31,720 NIA. 6104 03:47:31,720 --> 03:47:32,600 IT'S MY PRIVILEGE TODAY TO 6105 03:47:32,600 --> 03:47:34,400 INTRODUCE TO YOU THE LABORATORY 6106 03:47:34,400 --> 03:47:36,720 OF MOLECULAR BIOLOGY AND 6107 03:47:36,720 --> 03:47:39,520 IMMUNOLOGY WHICH IS A PART OF 6108 03:47:39,520 --> 03:47:40,320 THE INTRAMURAL RESEARCH PROGRAM 6109 03:47:40,320 --> 03:47:42,040 OF THE NATIONAL INSTITUTE ON 6110 03:47:42,040 --> 03:47:43,440 AGING. 6111 03:47:43,440 --> 03:47:50,600 AT THE MOMENT, WE ARE SIX 6112 03:47:50,600 --> 03:47:51,000 INVESTIGATORS. 6113 03:47:51,000 --> 03:47:54,040 SUNG IS A TENURE-TRACK 6114 03:47:54,040 --> 03:47:55,600 INVESTIGATOR INTERESTED IN 6115 03:47:55,600 --> 03:47:56,760 TRANSCRIPTIONAL REGULATION. 6116 03:47:56,760 --> 03:47:59,480 AND THE OTHER FIVE OF US ARE 6117 03:47:59,480 --> 03:48:00,880 TENURED SENIOR INVESTIGATORS 6118 03:48:00,880 --> 03:48:02,560 THAT HEAD OUR INDEPENDENT 6119 03:48:02,560 --> 03:48:05,000 SECTIONS OF WHICH I WILL TALK 6120 03:48:05,000 --> 03:48:08,480 ABOUT IN THE NEXT FEW MINUTES. 6121 03:48:08,480 --> 03:48:14,160 A DEPUTY LAB CHIEF AND ALL OF US 6122 03:48:14,160 --> 03:48:17,680 ARE INTIMATELY INVOLVED IN EACH 6123 03:48:17,680 --> 03:48:19,680 OTHER'S PROGRAMS WITHIN THE LAB. 6124 03:48:19,680 --> 03:48:23,560 AND I WILL OFTEN REFER TO IT IN 6125 03:48:23,560 --> 03:48:26,840 SHORT AS LMBI. 6126 03:48:26,840 --> 03:48:29,040 THE RESEARCH PROGRAMS SHARE THE 6127 03:48:29,040 --> 03:48:33,480 GOALS OF ELUCIDATING MOLECULAR 6128 03:48:33,480 --> 03:48:34,040 AND CELLULAR MECHANISMS TO 6129 03:48:34,040 --> 03:48:36,800 REGULATE IMMUNITY AND THEREBY 6130 03:48:36,800 --> 03:48:38,680 UNDERSTAND THE DECLINE IN 6131 03:48:38,680 --> 03:48:38,920 RESPONSES. 6132 03:48:38,920 --> 03:48:42,120 AS YOU ALL KNOW, THE COVID 6133 03:48:42,120 --> 03:48:44,520 PANDEMIC OVER THE LAST FEW YEARS 6134 03:48:44,520 --> 03:48:47,760 HAS REALLY HIGHLIGHTED AGAIN THE 6135 03:48:47,760 --> 03:48:52,400 NEED TO UNDERSTAND AND 6136 03:48:52,400 --> 03:48:53,680 AMELIORATE THE AGE ASSOCIATE 6137 03:48:53,680 --> 03:48:57,880 SAID IMMUNE DYSFUNCTION IN 6138 03:48:57,880 --> 03:48:58,120 HUMANS. 6139 03:48:58,120 --> 03:49:00,680 GIVEN THE NEW SYSTEM IS VERY 6140 03:49:00,680 --> 03:49:04,040 BROAD-BASED, I HAVE A SLIDE TO 6141 03:49:04,040 --> 03:49:06,480 SHARE WITH YOU TO GIVE YOU 6142 03:49:06,480 --> 03:49:07,880 ASTHENIES OUR INVESTIGATORS THAT 6143 03:49:07,880 --> 03:49:11,640 ARE INVOLVED IN MANY ASPECTS OF 6144 03:49:11,640 --> 03:49:11,920 IMMUNITY I. 6145 03:49:11,920 --> 03:49:14,920 SO IN THE BACKGROUND HERE, WE 6146 03:49:14,920 --> 03:49:15,520 START WITH IMMUNE DEVELOPMENT 6147 03:49:15,520 --> 03:49:20,240 AND THIS COULD BE IMMUNE CELLS 6148 03:49:20,240 --> 03:49:22,120 OF THE INNATE IMMUNE SYSTEM OR 6149 03:49:22,120 --> 03:49:22,600 ADAPTIVE IMMUNE SYSTEM. 6150 03:49:22,600 --> 03:49:24,960 ONCE THESE CELLS EXIST IN THE 6151 03:49:24,960 --> 03:49:26,000 ORGANISM THEY ARE THERE TO 6152 03:49:26,000 --> 03:49:27,960 MOUNTAIN IMMUNE RESPONSE SHOULD 6153 03:49:27,960 --> 03:49:30,920 THE ORDER OF THEM BE FACED WITH 6154 03:49:30,920 --> 03:49:32,160 SUCH A NEED. 6155 03:49:32,160 --> 03:49:34,280 THAT IMMUNE RESPONSE THEN LEADS 6156 03:49:34,280 --> 03:49:36,720 TO SO-CALLED EFFECTOR FUNCTIONS. 6157 03:49:36,720 --> 03:49:39,680 THOSE ARE FUNCTIONS MEDIATED 6158 03:49:39,680 --> 03:49:42,000 BOTH BY SOLUBLE MEDIATORS OR BY 6159 03:49:42,000 --> 03:49:44,840 THE CELLS THEMSELVES THAT TRY TO 6160 03:49:44,840 --> 03:49:46,920 GET RID OF THE INVADING PATHOGEN 6161 03:49:46,920 --> 03:49:50,440 OR THE DANGER THAT THE ORGANISM 6162 03:49:50,440 --> 03:49:51,040 FACES. 6163 03:49:51,040 --> 03:49:54,880 ADAPTIVE IMMUNITY IN PARTICULAR, 6164 03:49:54,880 --> 03:49:59,440 HAS THE EXTREMELY IMPORTANT 6165 03:49:59,440 --> 03:50:00,680 PROPERTY OF BEING ABLE TO 6166 03:50:00,680 --> 03:50:01,200 DEVELOP MEMORY. 6167 03:50:01,200 --> 03:50:04,800 AND MEMORY IS THE BASIS FOR ALL 6168 03:50:04,800 --> 03:50:06,920 VACCINATION AND ALSO THE REASON 6169 03:50:06,920 --> 03:50:09,240 WHY ONCE INFECTED WITH ONE 6170 03:50:09,240 --> 03:50:11,880 PATHOGEN ONE IS LESS SUSCEPTIBLE 6171 03:50:11,880 --> 03:50:14,120 TO THAT SAME PATHOGEN LATER ON. 6172 03:50:14,120 --> 03:50:16,560 AND FINALLY, THE IMMUNE RESPONSE 6173 03:50:16,560 --> 03:50:23,920 HAS TO BE REGULATED. 6174 03:50:23,920 --> 03:50:28,400 TOO MUCH OF AN IMMUNE RESPONSE 6175 03:50:28,400 --> 03:50:30,280 LEADS TO IMMUNITY AND TOO LITTLE 6176 03:50:30,280 --> 03:50:37,120 OF IMMUNE RESPONSE LEADS TO 6177 03:50:37,120 --> 03:50:37,640 IMMUNODEFICIENCY. 6178 03:50:37,640 --> 03:50:38,760 THERE IS A SILTS BALANCE THAT 6179 03:50:38,760 --> 03:50:39,240 THE IMHUGE SYSTEM HAS TO 6180 03:50:39,240 --> 03:50:39,800 ACHIEVE -- SUBTLE BALANCE. 6181 03:50:39,800 --> 03:50:40,840 OUR INVESTIGATORS ADDRESS MANY 6182 03:50:40,840 --> 03:50:45,040 OF THE THESE ASPECTS OF IMMUNITY 6183 03:50:45,040 --> 03:50:45,880 IN THEIR INDIVIDUAL RESEARCH 6184 03:50:45,880 --> 03:50:46,120 PROGRAM. 6185 03:50:46,120 --> 03:50:48,440 FOR THE PRESENTATION THIS 6186 03:50:48,440 --> 03:50:53,360 AFTERNOON, I THOUGHT I WOULD 6187 03:50:53,360 --> 03:50:53,960 FOCUS ON THE RECENT ADVANCES 6188 03:50:53,960 --> 03:50:57,360 MADE BY THREE OF OUR 6189 03:50:57,360 --> 03:51:01,240 INVESTIGATORS, MA -- AND ALSO 6190 03:51:01,240 --> 03:51:05,360 GIVE OFF A SENSE OF WHAT THE 6191 03:51:05,360 --> 03:51:05,960 THREE OF US DO AND HOPE TO GIVE 6192 03:51:05,960 --> 03:51:09,720 YOU THEIR UPDATE IN THE NEXT 6193 03:51:09,720 --> 03:51:15,840 TIME WE PRESENT TO THE COUNCIL. 6194 03:51:15,840 --> 03:51:19,880 NOW AT THIS POINT, SUN'S LAB 6195 03:51:19,880 --> 03:51:21,400 JUST PUBLISHED THE DEVELOPMENT 6196 03:51:21,400 --> 03:51:24,880 AND USE OF AN EXTREMELY VALUABLE 6197 03:51:24,880 --> 03:51:25,320 REAGENT. 6198 03:51:25,320 --> 03:51:26,840 MA'S LAB WORKS ON THE 6199 03:51:26,840 --> 03:51:30,280 TRANSCRIPTION FACTOR NF-kB T 6200 03:51:30,280 --> 03:51:32,560 IS CENTRAL EVOLVED IN 6201 03:51:32,560 --> 03:51:36,880 ESSENTIALLY ALL IN FLAM TORY 6202 03:51:36,880 --> 03:51:37,240 RESPONSES. 6203 03:51:37,240 --> 03:51:41,960 SO SHE HAS GENERATED IN MICE, 6204 03:51:41,960 --> 03:51:43,160 THESE REPORTER ALLELES OF TWO OF 6205 03:51:43,160 --> 03:51:45,600 THE DIFFERENT FAMILY MEMBERS OF 6206 03:51:45,600 --> 03:51:48,760 THE NF-kB FAMILY. 6207 03:51:48,760 --> 03:51:51,840 IN THIS CASE, RAD A PROTEIN IS 6208 03:51:51,840 --> 03:51:53,520 TAGGED WITH THE GFB. 6209 03:51:53,520 --> 03:51:55,200 THE REL IS TAGGED WITH A 6210 03:51:55,200 --> 03:51:57,160 DIFFERENT COLORED MARKER. 6211 03:51:57,160 --> 03:52:00,200 SHE HAS SHOWN THESE FUSION 6212 03:52:00,200 --> 03:52:01,040 PROTEINS DO NOT EFFECT 6213 03:52:01,040 --> 03:52:02,080 DEVELOPMENT IN THE MOUSE SO THEY 6214 03:52:02,080 --> 03:52:08,000 ARE EXPRESSED IN ALL CELLS. 6215 03:52:08,000 --> 03:52:10,560 AND YOU CAN THEN BREED A MOUSE 6216 03:52:10,560 --> 03:52:11,160 THAT HAS AN ALLELE FUSED TO A 6217 03:52:11,160 --> 03:52:13,320 GREEN TO ONE THAT HAS A WELL 6218 03:52:13,320 --> 03:52:15,800 FUSED TO A RED FLUORESCENT 6219 03:52:15,800 --> 03:52:18,200 PROTEIN TO GENERATE DOUBLE 6220 03:52:18,200 --> 03:52:18,800 EXPRESSERS WHERE ONE ALLELE OF 6221 03:52:18,800 --> 03:52:25,160 EACH OF THESE PROTEINS IS 6222 03:52:25,160 --> 03:52:25,400 CHECKED. 6223 03:52:25,400 --> 03:52:26,000 REALLY BRIEFLY A SENSE OF WHAT 6224 03:52:26,000 --> 03:52:27,320 CAN BE ACHIEVED FROM THESE 6225 03:52:27,320 --> 03:52:27,560 ANIMALS. 6226 03:52:27,560 --> 03:52:29,200 SO THE FIRST TIME IN PRIMARY 6227 03:52:29,200 --> 03:52:32,600 CELLS, YOU CAN FOLLOW THE 6228 03:52:32,600 --> 03:52:33,720 ABUNDANCE OF SPECIFIC PROTEINS 6229 03:52:33,720 --> 03:52:35,040 BECAUSE THEY HAVE BEEN EXPRESSED 6230 03:52:35,040 --> 03:52:36,640 FROM THE ENDOGENOUS LOCUS. 6231 03:52:36,640 --> 03:52:39,440 YOU CAN TAKE A TISSUE, PURIFY 6232 03:52:39,440 --> 03:52:41,120 THE CELLS OF INTEREST AND 6233 03:52:41,120 --> 03:52:42,520 MEASURE THE LEVELS OF THE 6234 03:52:42,520 --> 03:52:45,880 PROTEIN BECAUSE THESE ARE FUSION 6235 03:52:45,880 --> 03:52:46,960 PROTEINS THAT EXPRESS. 6236 03:52:46,960 --> 03:52:49,600 WE CAN ALSO ASSAY IN THE CELLS 6237 03:52:49,600 --> 03:52:54,320 THE PRESENCE OF 6238 03:52:54,320 --> 03:52:54,720 HOMOHETERODIMERS. 6239 03:52:54,720 --> 03:52:55,640 HOW MUCH VED COUPLED WITH GREEN 6240 03:52:55,640 --> 03:52:58,360 OR HOW MUCH GREEN IS BY ITSELF, 6241 03:52:58,360 --> 03:52:58,640 ET CETERA. 6242 03:52:58,640 --> 03:53:02,760 AND FINALLY ONE CAN ISOLATE 6243 03:53:02,760 --> 03:53:04,480 CELLS FROM THE MICE AND 6244 03:53:04,480 --> 03:53:05,640 STIMULATE THEM IN CULTURE 6245 03:53:05,640 --> 03:53:09,240 BECAUSE THE TRANSCRIPTION FACTOR 6246 03:53:09,240 --> 03:53:11,600 IS INVOLVED IN RESPONSE TO EXOG 6247 03:53:11,600 --> 03:53:13,920 FLUS OR ENDOGENOUS DANGER 6248 03:53:13,920 --> 03:53:15,640 SIGNALS AND FOLLOW THE KINETICS 6249 03:53:15,640 --> 03:53:17,120 AND ASK WHAT HAPPENS TO EACH OF 6250 03:53:17,120 --> 03:53:20,280 THESE KINDS OF PROTEINS WHEN A 6251 03:53:20,280 --> 03:53:23,360 CELL IS STIMULATED? 6252 03:53:23,360 --> 03:53:26,640 SO THE DEVELOPMENT OF THIS 6253 03:53:26,640 --> 03:53:29,080 EXTREMELY IMPORTANT REAGENT AND 6254 03:53:29,080 --> 03:53:31,840 ITS APPLICATION TO ONE 6255 03:53:31,840 --> 03:53:35,200 BIOLOGICAL PROBLEM, F NCAPA B 6256 03:53:35,200 --> 03:53:36,680 ACTIVATION WAS PUBLISHED BY A 6257 03:53:36,680 --> 03:53:39,560 GROUP IN CELL REPORTS, TO 6258 03:53:39,560 --> 03:53:42,320 CONSIDERABLE INTEREST FROM THE 6259 03:53:42,320 --> 03:53:43,280 EXTRAMURAL COMMUNITY AND 6260 03:53:43,280 --> 03:53:45,800 HIGHLIGHTED IN OUR OWN LOCAL 6261 03:53:45,800 --> 03:53:48,200 PUBLICATION, THE NIH CATALYST, 6262 03:53:48,200 --> 03:53:55,440 AS A STUDY OF SOME IMPORTANCE. 6263 03:53:55,440 --> 03:53:58,680 THE DOCTOR WHO HEADS THE 6264 03:53:58,680 --> 03:53:59,240 IMMUNOREGULATION SECTION HAS 6265 03:53:59,240 --> 03:54:01,920 BEEN INTERESTED IN THAT 6266 03:54:01,920 --> 03:54:04,160 INTERFACE BETWEEN HOW THE NEW 6267 03:54:04,160 --> 03:54:07,360 SYSTEM IS REGULATED SO AS NOT TO 6268 03:54:07,360 --> 03:54:09,720 BECOME TOO MUCH OR NOT TO BE TOO 6269 03:54:09,720 --> 03:54:09,960 LITTLE. 6270 03:54:09,960 --> 03:54:11,440 BUT IN THE SET OF EXPERIMENTS 6271 03:54:11,440 --> 03:54:15,120 I'M GOING EMPHASIZE THIS 6272 03:54:15,120 --> 03:54:19,440 AFTERNOON, IS THIS ANALYSIS 6273 03:54:19,440 --> 03:54:20,480 WHERE THIS SECTION BEGAN TO 6274 03:54:20,480 --> 03:54:24,880 STUDY THE POTENTIAL ROLE OF 6275 03:54:24,880 --> 03:54:25,560 ADAPTIVE IMMUNE CELLS IN THE 6276 03:54:25,560 --> 03:54:27,920 CONTEXT OF ALZHEIMER'S DISEASE 6277 03:54:27,920 --> 03:54:31,560 MOUSE MODELS. 6278 03:54:31,560 --> 03:54:32,440 AND THE THRUST OF THE FIRST 6279 03:54:32,440 --> 03:54:34,680 PAPER THAT WAS PUBLISHED LAST 6280 03:54:34,680 --> 03:54:37,040 YEAR, OR NOW TWO YEARS AGO, IS 6281 03:54:37,040 --> 03:54:38,800 THAT IN THIS PARTICULAR MODEL 6282 03:54:38,800 --> 03:54:41,680 WHICH FOR THOSE OF YOU WHO 6283 03:54:41,680 --> 03:54:43,600 STUDIED THESE AS A TRIPLE 6284 03:54:43,600 --> 03:54:45,240 TRANSGENIC MODEL OF AD IN THE 6285 03:54:45,240 --> 03:54:48,360 MOUSE, YOU CAN SEE IN THE 6286 03:54:48,360 --> 03:54:52,120 NORMAL, CONTEXT OF THE TRIPLE 6287 03:54:52,120 --> 03:54:53,680 TRANSGENIC, YOU HAVE PLATS SHOWN 6288 03:54:53,680 --> 03:54:55,560 IN THE GREEN AS EXPECTED 6289 03:54:55,560 --> 03:54:57,720 ACTIVATED MICROGLIA SHOWN IN THE 6290 03:54:57,720 --> 03:54:59,880 RED OVER HERE, BUT WHEN THIS 6291 03:54:59,880 --> 03:55:02,400 GENETIC MODEL IS MOVED INTO THE 6292 03:55:02,400 --> 03:55:05,600 BACKGROUND OF A MOUSE THAT DOES 6293 03:55:05,600 --> 03:55:06,000 NOT HAVE B CELLS. 6294 03:55:06,000 --> 03:55:08,560 IT HAS EVERY OTHER KIND OF 6295 03:55:08,560 --> 03:55:10,640 IMMUNE CELL PRESENT INCLUDING 6296 03:55:10,640 --> 03:55:13,000 THE ADAPTIVES IMMUNE T-CELLS, 6297 03:55:13,000 --> 03:55:15,680 THOSE MICE HAVE SUBSTANTIALLY 6298 03:55:15,680 --> 03:55:20,320 REDUCED A DATA BLACKS AND 6299 03:55:20,320 --> 03:55:21,720 ACTIVATED MICROGLIA. 6300 03:55:21,720 --> 03:55:25,360 SO CONCLUDING FROM THESE 6301 03:55:25,360 --> 03:55:28,080 OBSERVATIONS, B CELLS ARE 6302 03:55:28,080 --> 03:55:30,480 INTIMATELY INVOLVED IN THE 6303 03:55:30,480 --> 03:55:34,200 PROGRESSION AND MANIFESTATION OF 6304 03:55:34,200 --> 03:55:36,720 THE PHENOTYPES OF AD IN THIS 6305 03:55:36,720 --> 03:55:37,840 MOUSE MODEL. 6306 03:55:37,840 --> 03:55:40,840 AND THEIR FUTURE WORK WILL TRY 6307 03:55:40,840 --> 03:55:43,240 TO DISSECT WHAT IS ACTUALLY 6308 03:55:43,240 --> 03:55:43,880 GOING ON. 6309 03:55:43,880 --> 03:55:47,280 THE RESULTS SO FAR SHOW THAT A 6310 03:55:47,280 --> 03:55:50,080 KIND OF IMMEAN CELL IS 6311 03:55:50,080 --> 03:55:53,240 INTIMATELY INVOLVED. 6312 03:55:53,240 --> 03:55:55,360 AND FINALLY THE THIRD RESULT 6313 03:55:55,360 --> 03:56:00,400 THAT I WILL ELABORATE ON TO SOME 6314 03:56:00,400 --> 03:56:01,760 EXTENT, IS DEVELOPED BY A LAB 6315 03:56:01,760 --> 03:56:05,520 WHO HEADS UP THE LYMPHOCYTE 6316 03:56:05,520 --> 03:56:08,240 SECONDS AND FOR MANY YEARS HAS 6317 03:56:08,240 --> 03:56:10,040 BEEN THE DRIVER OF STUDYING 6318 03:56:10,040 --> 03:56:12,320 HUMAN IMMUNITY AND HOW IT 6319 03:56:12,320 --> 03:56:14,320 CHANGES WITH AGE IN OUR 6320 03:56:14,320 --> 03:56:16,080 INSTITUTE, IN OUR INTRAMURAL 6321 03:56:16,080 --> 03:56:17,240 PROGRAM. 6322 03:56:17,240 --> 03:56:21,640 AND IN THIS CASE, HE HAS LOOKED 6323 03:56:21,640 --> 03:56:23,760 AT THE SO-CALLED ALPHA BETA 6324 03:56:23,760 --> 03:56:26,280 T-CELL RECEPTOR REPERTOIRE. 6325 03:56:26,280 --> 03:56:27,760 LET ME JUST GIVE ONE SENTENCE OR 6326 03:56:27,760 --> 03:56:30,720 TWO SENTENCE UPDATE OF WHAT THE 6327 03:56:30,720 --> 03:56:32,000 IMPLICATION OF THIS IS. 6328 03:56:32,000 --> 03:56:34,240 NOW IT HAS BEEN PROPOSED FOR 6329 03:56:34,240 --> 03:56:35,880 MANY YEARS, MOSTLY BASED ON 6330 03:56:35,880 --> 03:56:38,640 CROSS SECTIONAL STUDIES EVEN IN 6331 03:56:38,640 --> 03:56:39,960 MICE, THAT ONE OF THE REASONS 6332 03:56:39,960 --> 03:56:42,000 FOR THE IMMUNE DECLINE THAT 6333 03:56:42,000 --> 03:56:45,280 OCCURS WITH AGE IS BECAUSE THERE 6334 03:56:45,280 --> 03:56:48,280 AREN'T CELLS THERE THAT WOULD 6335 03:56:48,280 --> 03:56:49,320 RECOGNIZE THE POTENTIAL ANTIGEN 6336 03:56:49,320 --> 03:56:51,640 OR PATHOGEN WHEN IT COMES INTO 6337 03:56:51,640 --> 03:56:53,400 THE ORGANISM. 6338 03:56:53,400 --> 03:56:56,880 AND THIS IS BECAUSE THE LARGE 6339 03:56:56,880 --> 03:56:58,040 RANDOMLY ASSORTED REPERTOIRE OF 6340 03:56:58,040 --> 03:57:00,800 B-CELL RECEPTORS AND T-CELL 6341 03:57:00,800 --> 03:57:02,720 RECEPTORS, THE ANTIBODIES OF THE 6342 03:57:02,720 --> 03:57:04,480 T-CELL RECEPTORS IN THE CASE OF 6343 03:57:04,480 --> 03:57:08,120 T-CELLS, HAVE REDUCED IN THEIR 6344 03:57:08,120 --> 03:57:08,400 COMPLEXITY. 6345 03:57:08,400 --> 03:57:10,960 AND SO, THIS IS A HYPOTHESIS 6346 03:57:10,960 --> 03:57:14,760 THAT HAS BEEN AROUND FOR A 6347 03:57:14,760 --> 03:57:14,960 WHILE. 6348 03:57:14,960 --> 03:57:20,240 AND DIRECTLY TESTED THIS USING 6349 03:57:20,240 --> 03:57:22,160 THE INVALUABLE RESOURCE OF THE 6350 03:57:22,160 --> 03:57:24,240 LONGITUDINAL STUDY ON AGING TO 6351 03:57:24,240 --> 03:57:27,640 LOOK WITHIN INDIVIDUALS OF 6352 03:57:27,640 --> 03:57:31,320 DIFFERENT AGES SEPARATED BY NINE 6353 03:57:31,320 --> 03:57:31,800 YEARS. 6354 03:57:31,800 --> 03:57:34,280 SO 15 MALES SEPARATED BY NINE 6355 03:57:34,280 --> 03:57:37,640 YEARS ACROSS THE AGING SPECTRUM. 6356 03:57:37,640 --> 03:57:40,040 15 FEMALES. 6357 03:57:40,040 --> 03:57:43,000 PURIFIED CD4 AND CD8 MEMORY 6358 03:57:43,000 --> 03:57:45,200 CELLS, BEING THE HALLMARK OF 6359 03:57:45,200 --> 03:57:47,840 ADAPTIVE IMMUNITY. 6360 03:57:47,840 --> 03:57:48,960 FIGURED OUT WHAT THEIR 6361 03:57:48,960 --> 03:57:50,000 COMPLEXITY OF THE T-CELL 6362 03:57:50,000 --> 03:57:53,200 RECEPTOR ALPHA AND BETA CHANGES 6363 03:57:53,200 --> 03:57:53,600 USING RNA-SEQ. 6364 03:57:53,600 --> 03:57:55,760 AND THE RESULTS ARE VERY 6365 03:57:55,760 --> 03:57:59,840 BEAUTIFULLY SUMMARIZED ON THIS 6366 03:57:59,840 --> 03:58:02,360 RIGHT PANEL SHOWING THE 6367 03:58:02,360 --> 03:58:05,600 DIVERSITY OF THESE CELLS IS MUCH 6368 03:58:05,600 --> 03:58:06,280 HIGHER IN YOUNGER INDIVIDUALS 6369 03:58:06,280 --> 03:58:09,240 AND NOW GIVES YOU A NUMBER FOR 6370 03:58:09,240 --> 03:58:12,520 THE RATE AT WHICH THIS DIVERSITY 6371 03:58:12,520 --> 03:58:12,920 REDUCES WITH AGE. 6372 03:58:12,920 --> 03:58:19,560 SO YOU WANT TO FIGURE OUT HOW 6373 03:58:19,560 --> 03:58:22,800 MANY FEWER WIDELY DIVERSELY 6374 03:58:22,800 --> 03:58:24,240 EXPRESSING T-CELL RECEPTORS AS A 6375 03:58:24,240 --> 03:58:28,120 PRESENTS AS A FUNCTION OF AGE IN 6376 03:58:28,120 --> 03:58:28,360 HUMANS. 6377 03:58:28,360 --> 03:58:35,680 HE DOES THIS FOR CD4 AND CD8. 6378 03:58:35,680 --> 03:58:38,040 SO WITH THOSE THREE EXAMPLES 6379 03:58:38,040 --> 03:58:41,000 WANT I WANT TOED TO EMPHASIZE IS 6380 03:58:41,000 --> 03:58:47,000 GIVE YOU ASCENSUS OF THE RANGE 6381 03:58:47,000 --> 03:58:49,600 OF OUR ENTERPRISE FROM OUR 6382 03:58:49,600 --> 03:58:50,720 MECHANISTIC STUDIES GOING 6383 03:58:50,720 --> 03:58:53,600 THROUGH TO MOUSE MODELS AND 6384 03:58:53,600 --> 03:58:57,000 PHYSIOLOGICAL SITUATIONS AS 6385 03:58:57,000 --> 03:58:58,040 DIVIDED FROM THE KIND OF 6386 03:58:58,040 --> 03:59:01,240 EXPERIMENT I SHOWED YOU FROM THE 6387 03:59:01,240 --> 03:59:03,680 OTHER LAB, ALL THE WAY TO HUMAN 6388 03:59:03,680 --> 03:59:06,880 IMMUNITY AND THE IMPLICATIONS OF 6389 03:59:06,880 --> 03:59:08,520 T-CELL RECEPTOR REPERTOIRE 6390 03:59:08,520 --> 03:59:12,240 DECLINE IN LEADING TO IMMUNE 6391 03:59:12,240 --> 03:59:15,120 DYSFUNCTION WITH AGE. 6392 03:59:15,120 --> 03:59:16,920 THE OTHER THREE INVESTIGATORS 6393 03:59:16,920 --> 03:59:19,280 HAVE CORRESPONDINGLY INTERESTING 6394 03:59:19,280 --> 03:59:21,120 RESEARCH PROGRAMS SO DR. GEAR 6395 03:59:21,120 --> 03:59:25,680 HEART, HER LAB IS SPECIFICALLY 6396 03:59:25,680 --> 03:59:27,600 LOOKING AT THE ANTIBODY IN A 6397 03:59:27,600 --> 03:59:29,880 DIFFERENT CONTEXT. 6398 03:59:29,880 --> 03:59:32,960 WHAT HAPPENS IN THE B CELLS IN 6399 03:59:32,960 --> 03:59:33,160 AGING. 6400 03:59:33,160 --> 03:59:36,720 HOW IS HIGH AFFINITY ANTIBODIES 6401 03:59:36,720 --> 03:59:37,760 GENERATED DURING IMMUNE 6402 03:59:37,760 --> 03:59:38,040 RESPONSES? 6403 03:59:38,040 --> 03:59:41,160 IS THERE A ROLE FOR ANTIBODIES 6404 03:59:41,160 --> 03:59:42,120 IN ARTHROSCLEROSIS? 6405 03:59:42,120 --> 03:59:44,240 AND THE LATEST PROJECT IN THE 6406 03:59:44,240 --> 03:59:46,480 LAB LOOKS AT CHANGES IN 6407 03:59:46,480 --> 03:59:48,240 HEMATOPOIETIC STEM CELLS THAT 6408 03:59:48,240 --> 03:59:51,320 MIGHT LEAD TO REDUCED ANTIBODY 6409 03:59:51,320 --> 03:59:54,080 DIVERSITY WITH AGE. 6410 03:59:54,080 --> 03:59:55,960 DR. MICHAEL'S SECTION IS 6411 03:59:55,960 --> 03:59:56,840 STUDYING REP DECLARATION STRESS. 6412 03:59:56,840 --> 03:59:58,560 AND WE TAKE REPLICATION STRESS. 6413 03:59:58,560 --> 04:00:01,320 THIS IS REPLICATION AS IN DNA 6414 04:00:01,320 --> 04:00:03,000 REP SITUATION DURING THE CELL 6415 04:00:03,000 --> 04:00:03,400 CYCLE. 6416 04:00:03,400 --> 04:00:07,680 WE THINK THIS IS AN EXTREMELY 6417 04:00:07,680 --> 04:00:08,360 IMPORTANT AREA THAT SYNERGIZES 6418 04:00:08,360 --> 04:00:13,160 WITH IMMUNITY BECAUSE ONE OF THE 6419 04:00:13,160 --> 04:00:14,400 FUNDAMENTAL PRINCIPLES OF 6420 04:00:14,400 --> 04:00:17,760 ADAPTIVE IMMUNITY IS A SO-CALLED 6421 04:00:17,760 --> 04:00:22,000 PHENOMENON OF CLONAL SELECTION. 6422 04:00:22,000 --> 04:00:25,320 IN A NAIVE INDIVIDUAL YOU HAVE A 6423 04:00:25,320 --> 04:00:26,640 LARGE DIVERSITY CELLS THAT COULD 6424 04:00:26,640 --> 04:00:29,280 POTENTIALLY RECOGNIZE MANY 6425 04:00:29,280 --> 04:00:29,840 DIFFERENT KINDS OF ANTIGEN. 6426 04:00:29,840 --> 04:00:31,360 THESE HAVE BEEN GENERATED 6427 04:00:31,360 --> 04:00:34,200 AGNOSTIC OF WHAT ANTIGEN HUMAN 6428 04:00:34,200 --> 04:00:36,520 LIFE OR HUMAN ORGANISM MIGHT 6429 04:00:36,520 --> 04:00:36,800 FACE. 6430 04:00:36,800 --> 04:00:41,120 BUT WHEN SUCH AN ORGANISM COMES 6431 04:00:41,120 --> 04:00:44,320 ALONG, FULL OF ANTIGENS, 6432 04:00:44,320 --> 04:00:46,080 ANTIGEN-SPECIFIC CELLS, SOME 6433 04:00:46,080 --> 04:00:48,680 LIMITED, VERY LIMITED NUMBER OF 6434 04:00:48,680 --> 04:00:50,760 SELECTED AND CLONALLY EXPANDED 6435 04:00:50,760 --> 04:00:53,280 GO THROUGH 8, 10, 12 ROUNDS OF 6436 04:00:53,280 --> 04:00:55,840 DIVISION TO CREATE A POOL OF 6437 04:00:55,840 --> 04:00:57,440 CELLS THAT CAN MOUNT A GOOD 6438 04:00:57,440 --> 04:00:57,800 IMMUNE RESPONSE. 6439 04:00:57,800 --> 04:01:00,720 AND MICHAEL'S LAB LOOKS AT THE 6440 04:01:00,720 --> 04:01:04,120 STRESS THAT IS INVOLVED DURING 6441 04:01:04,120 --> 04:01:06,320 THIS CELL DIVISION AND DURING 6442 04:01:06,320 --> 04:01:08,160 DNA REPLICATION. 6443 04:01:08,160 --> 04:01:09,320 AND THEY HAVE IDENTIFIED THAT 6444 04:01:09,320 --> 04:01:13,880 EARLY REPLICATING REGIONS OF THE 6445 04:01:13,880 --> 04:01:15,240 CHROMOSOME USE A DIFFERENT 6446 04:01:15,240 --> 04:01:18,720 SUBSET OF PROTEINS TO SENSE A 6447 04:01:18,720 --> 04:01:20,920 STRESS TO THE NUCLEOSOME, A 6448 04:01:20,920 --> 04:01:24,280 STRESS TO THE REPLISOME, EXCUSE 6449 04:01:24,280 --> 04:01:27,920 ME, BLOCKED BECAUSE OF SOME DANA 6450 04:01:27,920 --> 04:01:30,080 DAMAGE WHICH REVENTS REPLICATION 6451 04:01:30,080 --> 04:01:30,920 TO TAKE PLACE. 6452 04:01:30,920 --> 04:01:33,840 AND MY OWN PROGRAM HAS THREE 6453 04:01:33,840 --> 04:01:36,760 MAJOR COMPONENTS TO UNDERSTAND 6454 04:01:36,760 --> 04:01:38,680 MOLECULAR MECHANISM OF CELL 6455 04:01:38,680 --> 04:01:40,600 SPECIFIC GENE EXPRESSION, WHICH 6456 04:01:40,600 --> 04:01:42,600 WE DO IN ANALYSIS OF DEVELOPMENT 6457 04:01:42,600 --> 04:01:44,920 AND THE EXPRESSION OF 6458 04:01:44,920 --> 04:01:45,400 IMMUNOGLOBULIN. 6459 04:01:45,400 --> 04:01:46,840 HEAVY CHAIN LOCUS. 6460 04:01:46,840 --> 04:01:48,440 WE ARE INTERESTED IN STUDYING 6461 04:01:48,440 --> 04:01:51,800 GENE REGULATION BY NF-kB, AN 6462 04:01:51,800 --> 04:01:55,760 AREA WE SYNERGIZE AND COMPLIMENT 6463 04:01:55,760 --> 04:01:57,240 MIA'S PROGRAM. 6464 04:01:57,240 --> 04:01:59,720 AND FINALLY A PART, INTEGRAL 6465 04:01:59,720 --> 04:02:05,120 PART OF THE HUMAN IMMUNE STUDIES 6466 04:02:05,120 --> 04:02:07,440 THAT WAS MENTIONED JUST A FEW 6467 04:02:07,440 --> 04:02:07,760 MINUTES AGO. 6468 04:02:07,760 --> 04:02:11,800 I WOULD LIKE TO CONCLUDE, 6469 04:02:11,800 --> 04:02:14,480 THOUGH, WITH A BIT OF SELF 6470 04:02:14,480 --> 04:02:16,240 REALIZATION THAT OCCURRED TO US 6471 04:02:16,240 --> 04:02:18,160 ABOUT 6-8 MONTHS AGO. 6472 04:02:18,160 --> 04:02:20,040 AND THIS IS IT. 6473 04:02:20,040 --> 04:02:23,240 EVEN THOUGH EACH OF OUR 6474 04:02:23,240 --> 04:02:24,040 INVESTIGATORS HAD THEIR OWN 6475 04:02:24,040 --> 04:02:27,040 RESEARCH PROGRAMS THAT THEY 6476 04:02:27,040 --> 04:02:30,720 WERE -- HAD BEEN FOLLOWING UP, 6477 04:02:30,720 --> 04:02:34,440 IT TURNS OUT THAT THERE WERE 6478 04:02:34,440 --> 04:02:37,520 ASPECTS THAT WERE POTENTIALLY 6479 04:02:37,520 --> 04:02:39,600 SHARED THAT WE WERE NOT USING TO 6480 04:02:39,600 --> 04:02:40,960 OUR ADVANTAGE AS MUCH AS WE 6481 04:02:40,960 --> 04:02:41,280 COULD. 6482 04:02:41,280 --> 04:02:45,960 SO FOR EXAMPLE, MIA AND MYSELF, 6483 04:02:45,960 --> 04:02:48,600 HAD BEGUN TO LOOK AT MICROGLIAL 6484 04:02:48,600 --> 04:02:50,040 GENE EXPRESSION FROM THE 6485 04:02:50,040 --> 04:02:53,840 PERSPECTIVE OF NF-kB 6486 04:02:53,840 --> 04:02:54,800 ACTIVATION. 6487 04:02:54,800 --> 04:03:00,160 WE -- BUT AT THE SAME TIME -- 6488 04:03:00,160 --> 04:03:00,720 THEY DEVELOPED MODELS IN THE 6489 04:03:00,720 --> 04:03:01,800 ROLE OF B CELLS. 6490 04:03:01,800 --> 04:03:05,040 WE STUDIED B CELLS FOR A LONG 6491 04:03:05,040 --> 04:03:08,240 TIME, AS HAS DR. GEAR HEART'S 6492 04:03:08,240 --> 04:03:08,400 LAB. 6493 04:03:08,400 --> 04:03:10,720 NOW MIA'S LAB IS LOOKING AT CD8 6494 04:03:10,720 --> 04:03:14,480 CELLS IN THIS CONTEXT IN THESE 6495 04:03:14,480 --> 04:03:15,320 MODELS. 6496 04:03:15,320 --> 04:03:18,200 SO WE THOUGHT THIS IS THE PRIME 6497 04:03:18,200 --> 04:03:21,080 OPPORTUNITY FOR US NOT ONLY TO 6498 04:03:21,080 --> 04:03:24,200 DRIVE OUR OWN PROGRAMS BUT TO 6499 04:03:24,200 --> 04:03:26,640 COME TOGETHER IN A WAY TO 6500 04:03:26,640 --> 04:03:29,120 UNDERSTAND, TO BRING OUR 6501 04:03:29,120 --> 04:03:30,040 COMPLEMENTARY INTERESTS AND 6502 04:03:30,040 --> 04:03:33,240 EXPERTISE IN IMMUNITY AND 6503 04:03:33,240 --> 04:03:36,480 INFLAMMATORY GENE EXPRESSION TO 6504 04:03:36,480 --> 04:03:37,680 UNDERSTAND INFLAMMATORY 6505 04:03:37,680 --> 04:03:41,680 INTERACTIONS IN AD RELATED 6506 04:03:41,680 --> 04:03:42,360 DEMENTIAS. 6507 04:03:42,360 --> 04:03:43,840 WE HAVE NOW COME TOGETHER TO 6508 04:03:43,840 --> 04:03:45,080 FOCUS ON A LIMITED NUMBER OF 6509 04:03:45,080 --> 04:03:50,720 MODELS WHERE WE CAN BRING TO 6510 04:03:50,720 --> 04:03:54,760 FOCUS OUR INTERESTS IN THE 6511 04:03:54,760 --> 04:03:56,800 INTERMISSION, BE THAT 6512 04:03:56,800 --> 04:03:59,280 INVESTIGATORS HERE, OUR INTEREST 6513 04:03:59,280 --> 04:04:01,000 IN B-CELL OR T-CELLS TO 6514 04:04:01,000 --> 04:04:03,360 COORDINATE AND COORDINATELY 6515 04:04:03,360 --> 04:04:06,240 STUDY THE POTENTIAL ROLE OF 6516 04:04:06,240 --> 04:04:07,800 IMMUNITY. 6517 04:04:07,800 --> 04:04:10,160 INNATE OR ADAPTIVE. 6518 04:04:10,160 --> 04:04:12,440 AND ITS ROLE IN AGE RELATED 6519 04:04:12,440 --> 04:04:12,680 DEMENTIA. 6520 04:04:12,680 --> 04:04:16,120 SO I CERTAINLY AM VERY EXCITED 6521 04:04:16,120 --> 04:04:17,920 ABOUT THE POSSIBILITIES THAT ALL 6522 04:04:17,920 --> 04:04:20,560 SIXER OF US CAN CONTRIBUTE TO 6523 04:04:20,560 --> 04:04:24,320 THIS STORY AND BE ABLE TO 6524 04:04:24,320 --> 04:04:27,400 HOPEFULLY CLEARLY DELINEATE THE 6525 04:04:27,400 --> 04:04:30,000 POSSIBLE ROLLS OF INNATE AND 6526 04:04:30,000 --> 04:04:33,200 AADAPTIVE IMMUNITY DURING THE 6527 04:04:33,200 --> 04:04:35,720 NEURODEGENERATIVE DISEASES. 6528 04:04:35,720 --> 04:04:39,720 FINALLY, THE LABORATORY ALSO 6529 04:04:39,720 --> 04:04:46,880 OVER SEAS THE IRB, INTRAMURAL 6530 04:04:46,880 --> 04:04:48,320 PROGRAM, OVERSEEN HERE BY HUANG. 6531 04:04:48,320 --> 04:04:53,240 AND I GIVE YOU A SENSE OF OUR 6532 04:04:53,240 --> 04:04:54,760 THREE WONDERFUL PERSONNEL THAT 6533 04:04:54,760 --> 04:05:00,120 RUN THE CORE, SERVICE THE ENTIRE 6534 04:05:00,120 --> 04:05:03,200 IRB -- AND THE IDEA OF THE 6535 04:05:03,200 --> 04:05:05,800 VARIOUS INSTRUMENTATIONS WE HAVE 6536 04:05:05,800 --> 04:05:09,760 AVAILABLE, NOT JUST FOR THE USE 6537 04:05:09,760 --> 04:05:13,440 OF NIA BUT THE ENTIRE IRB. 6538 04:05:13,440 --> 04:05:16,160 WITH THAT I'LL STOP AND SEE IF 6539 04:05:16,160 --> 04:05:19,040 THERE IS ANY QUESTIONS. 6540 04:05:19,040 --> 04:05:20,320 THANK YOU VERY MUCH FOR YOUR 6541 04:05:20,320 --> 00:00:00,000 ATTENTION.